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Abstract 
Introduction 
The childhood onset retinal dystrophies comprise a clinically and molecularly 
heterogeneous group of disorders. To date, sixteen genes have been implicated in the 
pathogenesis of the spectrum of disorders comprising Leber Congenital Amaurosis 
(LCA) and Early Onset Retinal Dystrophy (EORD), accounting for approximately 
70% of cases. Although a wide range of phenotypes have been observed within this 
spectrum, some genotype – phenotype associations are reported. Further detailed 
genotype – phenotype studies will be important for expanding our understanding of 
the effects of mutations in these genes on patients and their families. Our knowledge 
of the phenotypic effects of mutations in other genes implicated in childhood onset 
retinal dystrophies, such as the bestrophinopathies, continues to expand.     
 
Purpose 
To undertake detailed phenotypic studies into subjects with molecularly identified 
childhood onset retinal dystrophies, and to describe novel phenotypes. 
 
Methods 
Affected subjects and their families were recruited from Moorfields Eye Hospital to 
an ongoing Study into childhood onset retinal dystrophies. Subjects were examined 
clinically and those that were historically recruited to the Study were invited back for 
further phenotypic analyses, if their molecular cause was identified. Genetic analysis 
4 
was performed using a variety of methods including DNA microarray analysis, 
autozygosity mapping, direct sequencing and whole exome sequencing.  
 
Results 
Between August 2008 and August 2011, 201 subjects from 186 families were 
recruited into the Childhood Onset Retinal Dystrophy Study, and categorised into 2 
cohorts: cohort 1 - the generalised retinal dystrophies, comprising 177 subjects (166 
families); and cohort 2 – subjects with a macular phenotype, comprising 24 subjects 
(20 families). The molecular cause was identified in 34.5% of subjects in cohort 1 and 
25% of subjects in cohort 2. RDH12 accounted for 28% of mutations in cohort 1, 18% 
had mutations in CEP290, and 13% had mutations in RPE65. The subjects in cohort 2 
with autosomal recessive bestrophinopathy all had bi-allelic mutations in BEST1. The 
phenotype associated with the different genes identified was expanded, and focused 
on those genes with limited reports of the phenotype, such as SPATA7, LRAT, RGR 
and BEST1. The phenotype associated with a gene not previously identified in human 
EORD, TUB, was studied, and the features associated with a novel macular phenotype 
named Benign Yellow Dot Dystrophy were characterised. 
  
Conclusions 
This study has expanded and refined our understanding of the phenotypes associated 
with mutations in genes that cause childhood onset retinal dystrophies, and has 
identified a novel phenotype. This work will allow accurate prognostic and genetic 
counselling to affected families, and provides phenotypic information that will be 
important in ascertaining disorders that may be suitable for clinical trials of novel 
therapies.  
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1.0 Introduction 
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1.1 History and epidemiology of Leber 
Congenital Amaurosis and Early 
Onset Retinal Dystrophy 
 
Following the invention of the ophthalmoscope by Helmholtz in 1851, van Trigt in 
1853 reported the first authenticated case of pigmentary degeneration of the retina, 
but it was Donders in 1855 who devised the name Retinitis Pigmentosa [1, 2]. This 
term is rather a misnomer as this is not a predominantly inflammatory condition. Von 
Graefe, who identified the condition to be a pigmentary retinal degeneration with a 
hereditary component, subsequently made the first detailed description of the disease 
[3]. In fact, these inherited retinal dystrophies (historically known as ‘tapeto-retinal 
degenerations’) are a range of conditions characterised by progressive familial night 
blindness (nyctalopia) with severe visual field constriction, eventual diminution of the 
central vision, and attenuation of the electroretinal response [4]. The genetic aspects 
of this range of conditions have excited a great deal of interest and have generated an 
enormous amount of literature that has uncovered a wide underlying genetic 
heterogeneity.  
 
Although the majority of these conditions are inherited in an autosomal recessive 
manner, other inheritance patterns are also present, including autosomal dominant, 
sex-linked and mitochondrial inheritance. Classification of these disorders is 
progressively moving towards one based upon their underlying genetic cause, 
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however the historical ‘umbrella’ terms under which they are known are continuing to 
be used. The research carried out towards this thesis is based upon these inherited 
retinal dystrophies, in particular those with a childhood onset, which are collectively 
known as the ‘Early Onset Retinal Dystrophies’, of which Leber Congenital 
Amaurosis represents the most severe form. 
 
 
1.1.1 Genetics of inherited retinal dystrophies 
Inherited retinal dystrophies affect millions of people worldwide; dozens of different 
types of diseases are included in this set of conditions and more than 190 genes have 
been identified as the cause for one or another form of inherited retinal disease. One 
group of these conditions is retinitis pigmentosa (RP). The heterogeneity associated 
with RP includes genetic heterogeneity (many different genes that may cause the 
same disease phenotype), allelic heterogeneity (many different disease-causing 
mutations in the same gene), phenotypic heterogeneity (different mutations in the 
same gene that may cause different diseases) and clinical heterogeneity (the same 
mutation in different individuals that may cause a different clinical picture) [5]. RP is 
a generic name that covers the retinal dystrophies that comprise of loss of 
photoreceptors and pigmentary retinal deposits, the most common type being 
primarily a rod photoreceptor degeneration that may progress to involve cone 
photoreceptors. These, therefore, present with nyctalopia and visual field constriction. 
The age of onset of RP can be variable. Most RP begins in adolescence or early 
adulthood, but there are later onset forms that may begin at or after mid-life. 
Childhood onset forms fall under the umbrella term ‘early onset retinal dystrophies’ 
(EORD). 
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RP may occur alone, as non-syndromic RP without any other clinical findings, or as 
syndromic or systemic RP with other neurosensory disorders, developmental 
abnormalities or other complex clinical phenotypes. Such syndromes include Usher 
syndrome (RP with congenital or early onset deafness) and Bardet Biedl syndrome 
(RP with renal disease, polydactyly, obesity and developmental delay).  
 
There are autosomal dominant, autosomal recessive and X-linked forms of 
inheritance, as well as rare mitochondrial and digenic forms of RP [6, 7]. 
Traditionally, simplex RP is considered to be predominantly autosomal recessive in 
inheritance with unaffected carrier parents. However some of these cases will 
represent new (de novo) autosomal dominant mutations, or in males, may represent 
X-linked RP, where there is no known family history. It tends to typically begin in the 
first decade, but milder forms exist. There is a higher incidence in consanguineous 
families [8]. Autosomal dominant forms are usually the mildest of all, with some 
cases starting after the age of 50, however there are childhood onset forms that 
display autosomal dominant inheritance, such as those associated with mutations in 
the gene CRX [9]. X-linked forms start early and are often associated with myopia; 
they are usually recessive in inheritance, caused predominantly by mutations in RPGR 
or RP2 [10]. The rare mitochondrial mutations have mostly been found in RP 
associated with other neurological and systemic dysfunction, such as with 
sensorineural deafness, or ataxia and dementia, or in Kearns Sayre syndrome [11-13].    
 
However, the genetics of this group of conditions is much more complicated than this, 
as alluded to above. Many genes can cause more than one form of disease – such as 
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mutations in Rhodopsin, which usually cause autosomal dominant RP, but in which 
rare mutations have been identified to cause recessive RP [7]. In addition, mutations 
in a single gene very commonly cause different phenotypes, such as in those with 
RPE65 mutations [14, 15]. Such complexity in these conditions has led to a huge 
international body of research into the underlying genetic causes and phenotypes of 
the inherited retinal dystrophies. 
 
 
1.1.2 History of Leber Congenital Amaurosis 
Theodore Karl Gustav von Leber (1840 – 1917), an eminent ophthalmologist and 
ocular pathologist, who studied under von Helmholtz, Ludwig and von Graefe, and 
who later became Professor of Ophthalmology in Berlin (1867 – 1870), and then in 
Heidelberg (1890 – 1910), was the first clinician to establish ophthalmological 
thought on the ‘tapeto-retinal degenerations’ [4]. He considered these conditions to be 
primary dystrophies of the retina, which included retinitis pigmentosa with and 
without pigment, retinitis punctata albescens, chorioretinal degenerations and 
scleroses such as gyrate atrophy and central papillary sclerosis, as well as congenital 
night blindness without ophthalmoscopic abnormalities. He thought that the 
underlying pathology in these conditions lay in the pigmentary epithelium, the 
‘tapetum nigram’, or black carpet. In 1869 and 1871, through his role as consultant 
oculist of the Ilvesheim Asylum for the Blind, Leber described a disease which he 
called ‘pigmentary retinopathy with congenital amaurosis’ (now known as Leber 
Congenital Amaurosis) in which, in the majority of cases, there was congenital 
blindness or development of blindness within the first year of life [2, 16, 17]. In his 
later writings, he distinguished two types: the first, a congenital form in which 
19 
blindness occurred in the first year of life; and the second, a juvenile form which 
manifested itself between the first year and puberty, that did not always entail 
blindness, but in which usually a severe degree of visual failure was observed [2, 4].  
 
Leber’s original description of the condition was of ‘bilateral blindness, with coarse 
nystagmus, some retention of the pupillary reflexes and the eventual appearance of 
pigmentary and degenerative changes in the fundi’ [4]. He recognised that the 
condition was familial (identified in 44.8% of the families he initially described) and 
observed a higher rate of consanguinity within these affected families (24.1% of his 
series), thus inadvertently describing an autosomal recessive inheritance pattern. 
Children usually presented at birth or within the first few months of life with very 
poor or absent vision, a coarse ‘roving’ nystagmus, photophobia, poor pupil 
responses, and a habit of pushing a fist or fingers into the orbit, a sign later described 
as the ‘oculo-digital sign’ of Franceschetti (cited in [2]). Initially the fundi appeared to 
be normal, which could remain the case in the first few months of life, but soon 
various polymorphic lesions were observed, the most typical being small white dots in 
the periphery of the fundus, followed later by pigmentation, which at first could look 
like ‘salt and pepper’ pigmentary change, but which later could become more typical 
of the bone-corpuscular pigmentation seen in the pigmentary retinopathy described by 
Mooren in 1867 (cited in [4]). The optic disc became pale and the retinal vessels 
attenuated, with atrophy of the retinal pigment epithelium. The milder cases were not 
necessarily associated with nyctalopia or severely constricted visual fields, but instead 
may have had severely irregular contraction of the visual fields with some reduced 
vision detectable within parts of the remaining fields [17]. In the infantile, or juvenile 
form, the vision was described by Leber to fail seriously by the 6th or 7th year of life, 
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and blindness to be complete before the age of 30 years; ophthalmoscopic 
examination at first was often normal, but from the age of 8 years, a more typical 
pigmentary degeneration was observed.  
 
Although a few reports were published following Leber’s initial paper, the spectrum 
of conditions were rarely recognised and remained neglected until the advent of 
electroretinography, when it was established that many cases of blindness in infants, 
often previously presumed to be of central origin, were due to a retinal dysplasia [2, 
18]. A number of authors identified these individuals to have an absent electrical 
retinal response, reported in up to 92% of cases, suggesting that this is an imperative 
finding in congenital amaurosis [19, 20]. Subsequent studies further delineated 
characteristics associated with this condition such as keratoglobus, corneal 
opacification, cataract and photophobia [20, 21].  
 
An extensive study by Alström and Olson, of 175 cases in Sweden, which they termed 
heredo-retinopathia congenitalis, monohybrida recessiva autosomalis, described in 
detail the longitudinal clinical and hereditary features of the disease and, in particular, 
hypothesised that this is a ‘uniform condition with a monohybrid, autosomal recessive 
mode of inheritance and complete manifestation’ [21]. They estimated the frequency 
of the condition to be 3 in 100 000, and also noted a higher rate of consanguinity 
among affected families. Waardenburg and Schappert-Kimmijser subsequently 
proposed that the condition may be genetically heterogeneous, following the study of 
a family in which the parents, who met in an asylum for the blind and who were both 
affected with LCA, had unaffected children [22]. Their conclusion was that Lebers 
amaurosis ‘may be the result of homozygositism for different recessive genes’. 
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A variety of terms have been used to describe this condition, including: amaurosis 
congenita, dysgenesis neuro-epithelialis retinae, heredo–retinopathia congenitalis, 
retinal aplasia and tapeto-retinal dysplasia [19-21, 23]. However, the condition has 
subsequently, and more uniformly, become known as Leber Congenital Amaurosis 
(LCA) and is considered to be the most severe form of a spectrum of disorders known 
as the Early Onset Retinal Dystrophies (EORDs).  
 
 
1.1.3 Epidemiology 
LCA is rare, with a population frequency of between 1 in 30 000 and 1 in 81 000, 
accounting for at least 5% of all inherited retinopathies and approximately 20% of all 
children attending schools for the blind [24]. In the UK in 2000, retinal and macular 
dystrophies accounted for 14% of children registered with severe visual impairment 
or blindness (62/439 individuals), with LCA accounting for 15, and rod cone 
dystrophy (retinitis pigmentosa) or cone rod dystrophy accounting for 17 of these 
[25]. It is predominantly inherited in an autosomal recessive manner and consequently 
the condition is more prevalent in consanguineous families and in those families who 
are not known to be consanguineous, but who have a common ancestor [26]. To date, 
16 genes have been implicated in the pathogenesis of LCA and EORD, demonstrating 
the genetic heterogeneity associated with this group of conditions. These will be 
explored further in this study. 
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1.1.4 Spectrum of clinical features 
LCA and EORD are considered to be a ‘purely’ ocular spectrum of conditions, 
characterised by a constellation of four clinical features: early severe visual loss, 
nystagmus, sluggish pupils and an unrecordable ERG [24]. Traditionally, the 
classification of this spectrum of disorders has been based upon clinical 
characteristics. It is universally accepted that Leber Congenital Amaurosis represents 
the most severe end of this spectrum of conditions. However, early onset retinal 
dystrophy (EORD), early onset severe retinal dystrophy (EOSRD), severe early 
childhood onset retinal dystrophy (SECORD) and juvenile retinitis pigmentosa are all 
terms that are found in the literature to describe those progressive childhood retinal 
dystrophies that present at a slightly later age. Essentially these terms are describing 
the same clinical entities, but they have the potential of creating confusion about the 
exact diagnoses in these families. It is likely, in the future, that these terms will be 
superceded, and that the conditions will be named according to their causative gene, 
which should help avoid confusion from such descriptive terms.  
 
Although LCA occurs from birth or the first few months of life, the term EORD (the 
most frequently used term for this spectrum of conditions) is reserved for those rod-
cone dystrophies that have an infantile onset but which may have less nystagmus, 
better vision, normal pupil reactions but a severely attenuated ERG. Some of the 
genes associated with LCA have been identified to also cause the less severe 
phenotype of EORD [27]. In general, phenotypic variability exists for these 
conditions with respect to the retinal appearance, refractive error, symptomatology 
and age of symptom onset (such as photophobia and photophilia) and the oculodigital 
sign. The associated features of keratoconus (postulated to occur due to genetic, 
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traumatic or toxic factors), cataract, microphthalmia, ptosis and enophthalmos may 
also be variable. 
 
The range of retinal appearances include a normal retina, mild retinal vessel 
attenuation, macular ‘coloboma’, macular pigmentation, retinal bone spicule 
pigmentation, nummular pigmentation, ‘salt and pepper’ appearance, white retinal 
spots, preservation of the para-arteriolar retinal pigment epithelium and a Coat’s like 
appearance [24]. There have been some genotype-phenotype associations, and these 
shall be explored in subsequent sections. 
 
An ‘LCA-like ocular phenotype’ occurs in a number of syndromes that may initially 
present without the systemic features, but which may dominate the phenotype later in 
life. These include Alström syndrome, Batten disease, Joubert syndrome, Senior-
Løken syndrome and peroxisomal disorders [28]. Subjects with these conditions were 
excluded from this study. 
 
For the purposes of this study, LCA is defined as a severe early onset retinal 
dystrophy with absent or very poor vision from birth or the first few months of life, 
nystagmus, sluggish or ‘amaurotic’ pupillary responses, a variable retinal appearance 
and an un-recordable electroretinogram. EORD is defined as poor vision with 
infantile or early childhood onset below five years of age, with less nystagmus (if 
present at all), reduced vision, normal pupil reactions and a severely attenuated 
electroretinogram. 
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1.2 Retinal Structure and Function 
 
It is thought that the first anatomical description of the eye was by Democrites (c.460-
370 BC), who described it as two ‘coats’, filled with a homogenous fluid; there was 
no lens and the optic nerve was hollow [29]. Aristotle (384-322 BC) described it as a 
spherical organ with three layers, filled with a homogeneous fluid, connected to the 
brain by three tubes, one of which connected with a similar tube from the other eye. 
This was probably the first description of the optic chiasm. Galenus (130-200 AD), 
the most renowned physician in Roman times, considered the eye to have seven 
layers, and was the first to recognise the retina. He described it as an extension of the 
optic nerve, which nourished the vitreous humour and the lens. After this time there 
was a hiatus in scientific discovery and few new ideas regarding ocular anatomy were 
proposed. Although Vesalius (1514-1564), a Belgian academic considered to be the 
‘Father of Anatomy’, vastly expanded the understanding of the human body, he made 
limited contributions to ocular anatomy. He described the retina as ‘a tunic, which we 
compare to a net which is detached from the substance of the optic nerve’. It was not 
until the 17th century, when Van Leeuwenhoek, the inventor of the microscope, 
discovered the retinal photoreceptors. With newer microscopic techniques, the 
anatomy of the retina was further elucidated. 
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1.2.1 Ultrastructural and microscopic structure of the 
retina 
The retina forms the innermost layer of the wall of the eye, with the choroid and 
sclera forming the middle and outer layers respectively. It lines the entire posterior 
portion of the eye, except at the optic nerve head, and extends anteriorly to end 360o 
circumferentially at the ora serrata. The outer pigmented layer (the retinal pigment 
epithelium) and inner neurosensory layer of the retina are embryologically derived 
from the neuroectoderm. The macula, demarcated by the supra-temporal and infra-
temporal branches of the central retinal artery and vein, forms the anatomical centre 
of the retina and is responsible for central vision. The centre of the macula is the 
fovea centralis (Figure 1).  
 
 
Figure 1 – Gross anatomy of a normal retina, right eye. 
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The neurosensory retina is transparent, which allows the underlying retinal pigment 
epithelium (RPE) to be visible. There is a potential space between these two layers, 
but they remain tightly attached to each other at the optic disc and the ora serrata. The 
retinal blood supply is derived from branches of the ophthalmic artery. In severe 
retinal dysfunction, the retinal arterioles may appear attenuated, the RPE may look 
abnormal and there may be retinal pigmentation of varying patterns. 
 
Based upon light microscopic findings, the retina is comprised of 10 layers which, 
from the inner to the outer surface, are as follows: the internal limiting membrane 
(formed by the Müller cell end plates that separate the retina from the vitreous), the 
nerve fibre layer (predominantly comprised of ganglion cell axons), the ganglion cell 
layer, the inner plexiform layer (comprising the synapses between ganglion cells and 
amacrine cells), the inner nuclear layer (comprised of the nuclei of the amacrine cells, 
bipolar cells and horizontal cells), the outer plexiform layer (comprised of the 
synapses between the horizontal cells and the photoreceptor cells), the outer nuclear 
layer (nuclei of the photoreceptor cells), the external limiting membrane (formed at 
the bases of the photoreceptor inner segments), the photoreceptor layer (inner and 
outer segments of the photoreceptors) and the retinal pigment epithelium (Figure 2). 
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Figure 2 – Schema of the layers of the retina, adapted from [30].  
 
1.2.1.1 Photoreceptor cells 
The photoreceptor (PR) cells are predominantly made up of rods and cones; there are 
approximately 120 million rods and 60 million cones in each human retina. A third 
class of photoreceptor, the photosensitive ganglion cell, is involved in the regulation 
of circadian rhythms and the pupillary response. Rods function best in dim light and 
are responsible for producing images of varying shades of black and white; cones 
function better in bright light and are responsible for colour vision and resolution of 
fine detail. Rods are absent at the fovea, rising in number towards the retinal 
periphery, with their highest density at 20o eccentricity; cones are most dense at the 
fovea, and their numbers decrease at the retinal periphery [31]. Each PR cell is 
comprised of photoreceptor elements and a cell body containing the nucleus, which 
makes contact with the dendrites of the bipolar cells via a synaptic terminal, termed 
the spherule or the pedicle in rods and cones, respectively. 
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The photoreceptor portion of the rods and cones is anatomically divided into an inner 
segment (IS) and outer segment (OS). The IS contains cellular organelles and 
connects with the cell body. Its main function is to provide ATP for sodium-
potassium pumps. The outer segments (OSs) interdigitate with the RPE cells and are 
considered to be modified sensory cilia, which are structures present in many aspects 
of sensation. In rods, the OS contains the photosensitive pigment rhodopsin, within 
membrane-bound lamellae, or discs, stacked tightly along the microtubule-based 
axoneme. These discs are unconnected to the plasma membrane. The axoneme is 
derived from and anchored to the cell via the basal body and enters the OS via the 
transition zone (or the ‘connecting cilium’) (Figure 3) [32]. A separate structure, also 
arising from the basal body, the ciliary rootlet, extends into the inner segments, 
through the cell body and into the synapse. The rootlet serves to anchor the cilium to 
the cell and functions as a channel for proteins destined for the outer segment. The 
outer segment and its cytoskeleton, including the rootlet, basal body and axoneme, are 
collectively called the ‘photoreceptor sensory cilium complex’, and have been 
implicated in the pathogenesis of a number of retinal dystrophies [33].  
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Figure 3 – Rod Photoreceptor. Adapted from [32]. 
 
The cone outer segment is conical, and considerably wider than a rod at its base, 
tapering down to a rounded tip. The membranes of the transversely arranged discs are 
continuous with the outer plasma membrane, which is arranged as a series of 
invaginations. Thus, unlike the rods, the laminae of the discs are continuous with the 
extracellular space, although the photosensitive pigments continue to be incorporated 
into the disc membranes. Cones also possess a connecting cilium, a photoreceptor 
sensory cilium complex and inner segment similar to the rods (Figure 4).  
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Figure 4 – Comparison of cone and rod photoreceptor anatomy. A – mammalian cone 
photoreceptor; B – mammalian rod photoreceptor. Adapted from [34]. 
 
Light absorption within the OSs of both rods and cones is achieved by pigments, 
known as opsins, which are G-protein coupled receptors that require a bound 
chromophore to absorb photons. There are 3 types of cones, each with sensitivity to a 
specific wavelength of light, depending on its iodopsin pigment: L cones (these 
absorb long wavelengths of light), M cones (which absorb medium wavelength light) 
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and S cones (which absorb short wavelength light). PR cells maintain a roughly 
constant length by continually generating new OSs from their base while 
simultaneously releasing mature OSs, that are engulfed and phagocytosed by the RPE 
[35]. 
 
1.2.1.2 Neural cells 
The retinal nerve cells include the bipolar, ganglion, horizontal and amacrine cells. 
The bipolar cells are entirely contained within the retina and are orientated 
perpendicular to the retinal surface. They connect the PRs to the ganglion cells, and 
are post-synaptic to the PRs. There are many different types of bipolar cells, which 
are named according to their synaptic connections. These include rod bipolar cells, 
which connect several rod cells to 1-4 ganglion cells; diffuse bipolar cells, which 
connect many cone cells to many ganglion cells; and midget bipolar cells, which 
connect a single cone cell to a single midget ganglion cell, and thus provide a direct 
pathway from a cone to a single optic nerve fibre.  
 
The ganglion cells are multi-polar and have dendrites that synapse with the bipolar 
cells and amacrine cells. The non-myelinated axons become the nerve fibre layer 
within the retina and converge at the optic disc to become the optic nerve fibres, 
which become myelinated after exiting the globe via the lamina cribrosa. The 
ganglion cells are the second order neurons in the visual pathway, and in most of the 
retina they form a single layer. However, from the periphery of the retina to the 
macula there may be as many as 10 layers; but these then decrease in number towards 
the fovea, where they are absent.  
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The horizontal cells are the laterally inter-connecting neurons within the outer 
plexiform layer. They are multipolar and have one long and several short processes 
that run parallel to the retinal surface. Those that are associated with cones have short 
processes that synapse with several cone pedicles; those associated with rods have 
short processes synapsing with 10-12 rod spherules. The long processes make contact 
with distant rods and cones, and with bipolar cells. They function in an inhibitory 
manner: following light excitation of the PRs, horizontal cells release an inhibitory 
neurotransmitter, gamma-aminobutyric acid (GABA), that inhibits bipolar cell 
activity some distance away, thus sharpening contrast and increasing spatial 
resolution.  
 
The amacrine cells have long processes that radiate widely horizontally, and synapse 
with one another and with the dendrites of ganglion cells and axons of bipolar cells; 
they comprise the inner plexiform layer. There are many types of amacrine cells that 
each release a specific neurotransmitter – up to 30 different types are reported [36]. 
Their functions are variable but still incompletely resolved, and include: a role in 
generating contextual effects for the responses of the retinal ganglion cells, such as 
‘centre surround’ antagonism and motion detection; vertical signal integration, such 
that they communicate across some, if not all of the inner plexiform layer, carrying 
ON information into OFF layers and vice versa; specific cell types that may be 
stimulated by bipolar cells, and in turn stimulate the ganglion cells; and modulation of 
PR signals. Amacrine cell function is the subject of much current investigation. 
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1.2.1.3 Supporting cells 
The retinal supporting cells, comprised of Müller cells, are similar to other neuroglial 
cells. They fill up most of the neural retina that is not occupied by the neurons. Müller 
cell bodies lie in the inner nuclear layer and project processes in both directions to 
form the inner limiting membrane (at the vitreous surface of the neural retina) and the 
external limiting membrane (between the PRs and the Müller cells).  Müller cells have 
been identified to possess a number of functions including: homeostatic and metabolic 
support of the retinal neurons; control of the composition of the extracellular matrix; 
trophic and anti-oxidative support; regulation of the blood retinal barrier; regulation 
of the synaptic activity within the inner retina; ‘guiding’ of light through the inner 
retina to minimise light scattering; and modulation of neuronal activity [37].  
 
 
1.2.2 The retinal pigment epithelium 
The retinal pigment epithelium (RPE) is a monolayer of cells lying beneath the 
neurosensory retina, whose apical membrane lies adjacent to the PR OSs, and 
basolateral membrane is in contact with Bruch’s membrane [38]. In tangential section, 
the cells are hexagonal. The apical ends of the cell show multiple microvilli that 
project between and surround the PR OSs. The adjacent cell membranes are bound 
together in the basal region by the zonula adherens and in the apical region by the 
zonula occludens. These are formed by tight junctions that maintain the blood retinal 
barrier. The cytoplasm of RPE cells contains numerous melanin granules that extend 
into the microvilli, a well-developed Golgi apparatus and endoplasmic reticulum, and 
multiple lysosomes and phagosomes. The apical microvilli continually erode the PR 
OSs, the RPE cells phagocytose the resultant debris and lysosomes break down the 
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contents of the phagosomes to produce lipofuscin granules. The RPE has a wide range 
of functions including phagocytosis of photoreceptor OSs; absorption of light to 
reduce the effects of photo-toxicity; repair of DNA, proteins and lipids; transport of 
nutrients and ions between the retina and the choriocapillaris, including retinoids 
essential to the visual cycle; regeneration of 11-cis retinal during the visual cycle; 
secretion of growth factors and factors necessary for maintenance of the structural 
integrity of the retina and choriocapillaris; and maintenance of the blood retinal 
barrier [35, 38]. Dysfunction of the RPE is implicated in a number of retinal 
dystrophies and in age related retinal degenerations.   
  
 
1.2.3 The phototransduction cascade 
Visual phototransduction is the process by which photons of light are converted to an 
electrical signal within the eye, via G-protein coupled receptors within the PRs called 
opsins that are bound to the chromophore 11-cis retinal. 11-cis retinal is a derivative 
of all-trans retinol (a vitamin A analogue), which is obtained through the diet. The 
chromophore is bound to the opsin by a Schiff base bond, and when exposed to a 
photon of light, undergoes photoisomerisation to all-trans retinal, which changes the 
conformation of the opsin G-protein coupled receptor. This initiates a signal cascade 
that eventually results in hyperpolarisation of the PR cell. 11-cis retinal is 
subsequently regenerated via a process known as the ‘visual cycle’ in rods and cones 
but there is evidence to suggest that an additional, alternative visual cycle for cones 
also exists.  
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PRs are maintained in a depolarised state in the absence of a stimulus. A high density 
of sodium-potassium pumps allows the cell to maintain a steady concentration of Na+ 
and K+. In scotopic conditions, cyclic guanosine monophosphate (cGMP) gated Na+ 
channels remain open, allowing a continuous influx of Na+ into the cell, which keeps 
it depolarised at around -40 mV. This is known as the dark current. Depolarisation of 
the cell leads to the opening of voltage gated Ca2+ channels and the subsequent 
increase in intracellular Ca2+ levels causes release of the neurotransmitter glutamate, 
which hyperpolarises ON-bipolar cells and depolarises OFF-bipolar cells. In photopic 
conditions, PRs hyperpolarise to a potential of -60 mV; this ‘switching off’ of the 
depolarised state leads to a signal cascade that activates the neural pathway, as 
follows. When a photon of light reaches the PR, photoisomerisation of 11-cis retinal 
to all-trans retinal causes a change to the opsin binding site (Figure 5 – B, 
phototransduction cascade). Thus, rhodopsin (in rods) or cone opsin absorbs a photon 
of light and undergoes a conformational change to its active form, metarhodopsin II 
[39, 40]. Metarhodopsin II binds to transducin, a G protein within the membrane of 
the discs, and there is an exchange of guanosine triphosphate (GTP) for guanosine 
diphosphate (GDP). This leads to activation of phosphodiesterase (PDE), which 
hydrolyses cGMP to GMP. The reduction of cGMP leads to closure of Na+ channels, 
which causes hyperpolarisation of the cell due to the on-going potassium current via 
non-gated K+ channels. Hyperpolarisation of the cell leads to closure of voltage gated 
Ca2+ channels, causing a reduction in intracellular Ca2+. Subsequent reduction in 
glutamate release results in depolarisation of ON-bipolar cells and hyperpolarisation 
of OFF-bipolar cells.   
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Deactivation of the phototransduction cascade occurs by activation of guanylate 
cyclase activating protein in response to falling Ca2+ levels. This activates guanylate 
cyclase, which converts GTP to cGMP and reopens Na+ channels. Metarhodopsin II is 
deactivated: recoverin, a Ca2+ bound protein is normally bound to rhodopsin kinase 
when Ca2+ is present; when Ca2+ levels fall during phototransduction, it dissociates 
from recoverin, rhodopsin kinase is released and metarhodopsin II is phosphorylated 
to its inactive state metarhodopsin III, which reduces its affinity for transducin. 
Arrestin binds to metarhodopsin III, completely deactivating it, and the dark current is 
restored. Metarhodopsin III dissociates into opsin and all-trans retinol [41]. All-trans 
retinol subsequently enters the visual cycle (see section 1.2.4), and opsin binds with 
regenerated 11-cis retinal to reform the visual pigment [42]. Proteins involved in 
phototransduction are synthesised in the inner segments of the photoreceptors and are 
then translocated through the connecting cilium to the outer segments. However, there 
is evidence that cones may be able to regenerate cone pigment using the Müller cells 
in the alternative visual cycle (see Section 1.2.4).  
 
 
1.2.4 The visual cycle 
When photoactivated chromophore-bound opsin releases the toxic aldehyde all-trans 
retinal in the photoreceptor OS, it is converted to all-trans retinol by a number of 
retinol dehydrogenases, including RDH8, RDH12 and RETSDR1 (a cone specific 
dehydrogenase) [43, 44] (Figure 5 – A, retinoid, or visual, cycle). All-trans retinol is 
then removed from the OS and transferred to the RPE across the interphotoreceptor 
matrix (IPM), facilitated by interphotoreceptor binding protein (IRBP), where it then 
can be recycled to 11-cis retinal via a series of steps, as follows. All-trans retinol is 
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first esterified by lecithin retinol acyltransferase (LRAT) to form all-trans retinyl 
esters; the retinoid isomohydrolase activity of RPE65 then acts on the retinyl ester 
substrates to form 11-cis retinol; retinol dehydrogenases, predominantly RDH5, but 
also RDH11, facilitated by RLBP1 [43] [45], then oxidise 11-cis retinol to produce 
11-cis retinal, which is transported out of the RPE cell by IRBP into the photoreceptor 
OSs where it combines with opsin to re-form visual pigment [41].  
 
 
Figure 5 – Processes in human rod and RPE cells. Adapted from [46]. A – Retinoid or 
Visual cycle; B – phototransduction cascade; C – ciliary transport.    
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In addition to this ‘classical’ visual cycle, a cone-specific ‘alternative’ visual cycle 
exists to provide cones with an additional privileged source of 11-cis retinol, which 
they can utilise to regenerate cone pigment [40, 41, 47]. The existence of this 
additional pathway was proposed following observations that cones recover their 
sensitivity following bleach much more quickly than rods, and that cones cannot be 
completely saturated even in bright light [48]. This pathway is likely to occur in 
Müller cells as it has been observed that they are able to take up all-trans retinal and 
release 11-cis retinol, which cones are able to gain access to via 11-cis retinol 
dehydrogenase activity, which is not present in rods [49]. The proposed alternative 
pathway is likely to occur as follows. After photolysis, all-trans retinal is reduced to 
all-trans retinol in cone outer segments, which is released and transported across the 
interphotoreceptor matrix (IPM), possibly by IRBP, to the Müller cells [41]. Here, 
bound to cellular retinol binding protein, all-trans retinol is isomerised to 11-cis 
retinol, which is then released into the IPM. It is then transported to cone 
photoreceptor inner segments, possibly utilising IRBP, and moves freely to the OS. 
Here, it is oxidised to 11-cis retinal by an unknown 11-cis retinol dehydrogenase 
and/or utilising a retinal – retinol redox coupling reaction to regenerate pigment [43, 
50].     
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1.3 Techniques for Phenotyping 
 
The phenotyping techniques utilised to assess the effects of specific mutations on 
ocular structure and function in this study include many that are used in routine 
clinical practice such as visual acuity testing, assessment of colour vision deficiencies 
and of refractive error, visual field testing, electrodiagnostic testing and retinal 
imaging modalities such as optical coherence tomography and fundus 
autofluorescence imaging. These are reviewed in this chapter. More specialised tests 
utilised in the investigation of specific genetic subtypes will be described in the 
appropriate chapters. 
 
 
1.3.1 Visual Acuity 
There are references in antiquity suggesting that the ‘sharpness of vision’ could be 
measured by the ability to resolve double stars, and from the 17th century by Daça de 
Valdes, who described a method based on the ability to resolve mustard seeds, but the 
first convincing arguments for the standardisation of vision tests were not made until 
1843 by Kuechler, who developed 3 vision charts to avoid memorisation. 
Unfortunately these did not gain popularity. In 1854 Jaeger published near vision 
reading plates and in 1861 Donders proposed a measurement of the ‘sharpness in 
vision’ while undertaking his studies on refraction and accommodation. A year later 
his co-worker Herman Snellen published his standardised acuity charts that soon 
became adopted worldwide.      
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Visual acuity is a measure of the ability to discriminate two stimuli separated in 
space. It is measured at high levels of illumination and at high contrast, and although 
it reflects only a small part of an individuals’ visual performance, it is traditionally the 
most widely used measure to describe the functional capacity of the eye.  
 
Snellen notation is the most frequently used when measuring acuity. It consists of 
black letters (‘optotypes’) on a white, brightly lit background, each of which subtends 
an angle of 5 minutes of arc and the space between each optotype subtends 1 minute 
of arc. Conventional test charts contain about 10 lines of letters in a progression of 
sizes, each designated by the distance at which the overall height of the letters on that 
line continues to subtend 5 minutes of arc, with the width of each ‘limb’ of the letter 
subtending 1 minute of arc. The acuity is recorded as a ‘fraction’ in which the 
numerator is the recording distance (in meters or feet), and the denominator is the 
distance at which the letter subtends the standard visual angle of 5 minutes of arc. 
Thus, on the 6/6 line (20/20 in feet), the letters subtend an angle of 5 minutes of arc 
when viewed at 6 m, and on the 6/12 line (20/40), the letters subtend an angle of 10 
minutes of arc when viewed at 6 m, or 5 minutes of arc when viewed at 12 m.  
 
Snellen charts, however, posed a number of problems including the observation that 
the optotypes are not related to each other by geometric progressions in size, and that 
there are different numbers of letters per line. Thus, other charts have been developed, 
such as the Bailey-Lovie (or ETDRS) chart [51]. In this chart, LogMAR notation is 
used, which provides a measure of visual acuity known as the Logarithm of the 
Minimal angle of Resolution (LogMAR). The sizes of the letters progress 
systematically in geometric progression, each letter carries a value of 0.02 LogMAR 
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and there are 5 letters per line (Figure 6). Thus, each line represents a change in acuity 
by 0.1 LogMAR and acuity doubles every third line. 0.00 LogMAR is equivalent to 
6/6 Snellen acuity and 1.0 LogMAR is equivalent to 6/60 Snellen acuity. The Snellen 
fraction can also be converted to the minimum angle of resolution, and the base-10 
logarithm of this (LogMAR) determined [52]. This has allowed the standardisation of 
measurements such as counting fingers and hand movements to be denoted as 2.0 
LogMAR and 3.0 LogMAR respectively. Perception of light (PL) and Nil Perception 
of Light (NPL) vision are arbitrarily denoted as 5.0 LogMAR and 6.0 LogMAR 
respectively [53]. Both the Snellen and Bailey-Lovie charts rely on the literacy of the 
subject being tested, and require the detection, resolution and recognition of the 
letters, and then the relaying of this information to the examiner. 
 
 
Figure 6 – ETDRS visual acuity chart. LogMAR acuity scale is on the right and 
equivalent Snellen acuity on the left. 
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1.3.1.1 Visual acuity testing in children 
In young children and infants, the above methods are not possible. Letter matching 
tests in which the child can point to letters on a key card once they recognise the letter 
they are shown, most closely relate to the Bailey-Lovie test. Examples of these 
include the Sheridan Gardiner test, the Sonksen-Silver acuity system and Cambridge 
crowding tests, among others. Some tests are ‘pictorial’, where the child is asked to 
name or match the pictures shown to them, such as the Kay Picture Test, although this 
test tends to underestimate the visual acuity. ‘Preferential looking’ may be used to 
estimate the visual acuity in infants and non-verbal children who cannot complete 
letter/picture matching. It is based on the observation that infants would rather look at 
a pattern than a blank stimulus. Such tests include the Teller and the Keeler acuity 
cards, which consist of a series of large grey cards with a central peephole that have a 
black and white grating of specific frequencies on one side. The cards are shown to 
the child and their preference recorded. However, although these tests attempt to 
provide a measure of visual acuity, they do not equate to Snellen vision. The Cardiff 
Acuity test, another example of a preferential looking test, uses ‘vanishing optotypes’ 
which consist of pictures with increasingly fine outlines that are correspondingly 
difficult to see. In the youngest infants (from age 3 months), the objective is to 
determine whether they have the ability to steadily fixate and follow an object, and at 
the same time assess if they have any nystagmus or a manifest strabismus. Another 
crude method of assessing acuity is to measure the optokinetic response in an infant, 
which should be present before age 3 months. This can be performed using an OKN 
drum or tape. 
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1.3.2 Colour Vision 
There are a number of tests available that test colour vision, most of which have been 
designed to assess inherited, rather than acquired, colour vision defects. Some are 
designed to detect more subtle colour deficiencies and may be more appropriate in the 
research setting. In the clinical setting, the Ishihara pseudoisochromatic test plates and 
Hardy Rand Rittler tests are the most widely available and the easiest to use to screen 
for colour vision deficits. 
 
1.3.2.1 Ishihara Pseudoisochromatic Plates 
The Ishihara Test (Handaya, Tokyo, Hongo Harukicho, 1917) was designed to detect 
protan (red) and deutan (green) colour vision deficiencies and has high sensitivity and 
specificity. There are a number of editions: the full 38-plate edition, an abridged 24-
plate edition and a 14-plate edition for quick screening. In all editions the first plate is 
a ‘test plate’; there are up to 20 numerical plates to screen for red-green colour 
deficiencies; and 4 plates to distinguish between protan and deutan deficiencies 
(Figure 7 – A). Errors on three or more of the numerical plates indicate a red-green 
colour vision deficit, with a small chance of misdiagnosing the deficit (2%); five or 
more errors signify certain red-green deficit [54]. However, specificity of the plates 
designed to distinguish between the colour deficits is reduced in 30%-40%. In 
addition, Ishihara test plates do not detect tritan defects. Nevertheless, it is a useful 
screening test in the clinical setting due to its speed and ease of use.  
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1.3.2.2 Hardy Rand Rittler Pseudoisochromatic Plates 
The Hardy Rand Rittler test not only allows the identification of protan and deutan 
colour defects, but it is also able to test for tritan (blue) defects [54]. It is almost as 
sensitive and specific as the Ishihara test, and has the additional benefit of being able 
to test younger children who do not yet know numbers, but who can identify shapes. 
It can distinguish between the different colour axes, and grade the defects into mild, 
moderate and severe. Aside from the 4 introductory plates, there are 4 red-green 
screening plates that identify a definite red-green colour deficit if errors are made on 3 
or 4 of these; and there are 2 tritan screening plates (Figure 7 – B). Depending on the 
number of subsequent plates that are read incorrectly (of which there are 14), the 
colour vision deficit can be described as mild, moderate or severe.  
 
 
Figure 7 – Tests of Colour Vision. A – Ishihara pseudoisochromatic plates; B – Hardy 
Rand Rittler pseudoisochromatic plates. 
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1.3.2.3 Other tests of colour vision 
The Nagel anomaloscope was introduced in 1907 and incorporates a Maxwellian view 
spectroscope in which the field of view is split into two halves, one that is illuminated 
by monochromatic yellow (589 nm), and the other that is illuminated by a mixture of 
monochromatic red (670 nm) and green (546 nm) wavelengths. The subject first 
makes several exact colour matches by adjusting both the red-green mixture ratio and 
the luminance of the yellow test field. In a second step the examiner sets the red-green 
mixture ratio and the subject ascertains whether an exact match can be made, by 
altering the luminance of the yellow test field. Normal trichomats precisely match the 
colours within a small range of red-green mixture ratios. As protanopes and 
deuteranopes have only one photopigment in the spectral range that is provided by the 
instrument, they are able to match any red-green mixture ratio with yellow by 
adjusting the luminance of the yellow comparison field. Protanomalous trichromats 
obtain matching ranges with an excess of red and deuteranomalous trichromats obtain 
matches with an excess of green in the matching field. A scale is used to record 
readings with a red-green x-axis and yellow y-axis [55, 56]. 
 
The Farnsworth-Munsell 100 hue test is a hue discrimination test in which the subject 
is required to arrange small coloured caps according to hue, lightness and saturation. 
All the colours are presented at the same time and the subject asked to arrange them in 
what they perceive to be a natural order. The results are plotted on a polar diagram 
representing the 85 hues of the test, and a score for each colour cap is plotted on the 
radial line of the polar diagram representing the numbered cap [55]. This test is useful 
for moderate or severe colour vision deficiency. 
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1.3.3 Refractive Error 
The refractive power of the eye is determined by four factors and their interactions: 
corneal steepness, depth of the anterior chamber, power of the lens (determined by its 
thickness and curvature) and axial length of the eye. In situations of refractive error, 
or ametropia, the error may be spherical or there may be astigmatism. In simple 
myopia, an image is formed in front of the retina (in essence the myopic eye has an 
optical system too powerful for its axial length) and in hypermetropia, the image 
forms behind the retina. Thus, spherical corrective lenses must be placed in front of 
the eye in order for the retinal image to fall on to the retina. In simple astigmatism, 
light rays do not fall on to one point on the retina due to variations in the curvature of 
the cornea or lens at 2 different meridians that are perpendicular to each other. Thus, 
correction is required for both meridians. Determination of the refractive error can be 
achieved by objective or subjective techniques; automated techniques are also 
possible, but these tend to be reserved for the screening of refractive errors. In 
children, objective measurement of the refractive error may be achieved under 
cycloplegic or non-cycloplegic conditions using retinoscopy.  
 
Most retinoscopes use a ‘streak’ projection, which allows a straight beam of light to 
be shone through the pupil; the projected streak illuminates an area of the retina that 
reflects back towards the examiner. When this beam of light is moved in a sweeping 
motion, the reflected light will also move in a direction that reflects the refractive 
status of the eye: it can move in the same direction as the sweeping movement (‘with’ 
motion) or in the opposite direction to the sweeping movement (‘against’ motion). 
When the light fills the pupil and does not move, a point of ‘neutrality’ is reached. By 
using corrective lenses placed in front of the subjects’ eye, the ‘with’ or ‘against’ 
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movement can be neutralised (plus lenses are placed if a ‘with’ movement is seen, 
minus lenses are placed if a ‘plus’ movement is seen). This gives a measure of the 
refractive error. The movement is measured in the 2 principle astigmatic meridians, 
which are at 90o to each other; thus when measuring refraction, the power in both axes 
needs to be measured, and the refraction recorded as a spherical optical power in one 
meridian, with a cylinder placed at the meridian 90o to it. The dioptric equivalent of 
the distance at which the examiner is working must be removed from the spherical 
power in order to determine the actual refractive error (usually +1.5 dioptres for a 
working distance of 67 cm). 
 
Ideally, refraction should be measured with accommodation relaxed, which in a co-
operative older subject may be possible by sustained fixation at a distance target 
during testing. However, in children such co-operation is often not possible, and 
accommodation can vastly affect the accuracy of measurement. In this situation, 
cycloplegia is necessary to fully relax accommodation, with the use of cycloplegic 
drops such as guttae cyclopentolate 0.5% (if below 1 year of age) or guttae 
cyclopentolate 1% (older than 1 year).  
 
 
1.3.4 Psychophysical testing - Perimetry 
Testing of the visual field can be achieved using either kinetic stimuli (kinetic 
perimetry), eg with the Goldmann Perimeter, or static stimuli (static perimetry). Both 
of these methods of perimetry rely upon sustained fixation on a central target, which 
can be challenging in children and in subjects with reduced central vision, such as 
those with retinal dystrophies.  
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1.3.4.1 Kinetic Perimetry 
In kinetic perimetry a moving stimulus of known luminance and size is presented at 
various points in the visual field from an area outside the boundary of visual 
perception towards fixation. The patient indicates when the target is first seen, and the 
perimetrist plots this point. When successive points have been plotted they can be 
‘joined’ together, producing a line of equal threshold sensitivity, known as the 
‘isopter’. Successive isopters may be plotted using stimuli that vary according to size 
and light intensity.  
 
The most common type of manual kinetic perimeter is the Goldmann perimeter, 
which consists of a spherical bowl, whose luminescence at 31.5 asb is precisely 
controlled to allow constant retinal light adaptation, and a self-illuminated projection 
arm that allows the presentation of different stimuli. Assessment of maintained 
fixation is achieved by the perimetrist monitoring the subject’s eye through a 
telescope while projecting moving spots of constant size and fixed contrast from the 
periphery into the centre. The size and intensity of the test stimulus is set using four 
levers – one that determines size and three for intensity. Roman numerals denote 
stimulus size (I-V): size I (with no interposed intensity filters) is the standard 
maximum stimulus, equivalent to 1,000 asb in intensity; increasing intensity is 
simulated by switching to larger stimulus sizes so that changing from size I to V is the 
equivalent of a 100-fold increase in intensity. Arabic numbers (1-4) denote the 
stimulus intensity: as the numbers increase, the stimulus intensity increases by 0.5 log 
units; position 4 is unfiltered. A letter is also used to indicate intensity (a-e); each stop 
increases the stimulus intensity by 1 dB from a to e, with e being unfiltered. The third 
stimulus lever has 3 positions; furthest to the right has no filter and it is in this 
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position that this lever is usually kept. The standard stimulus is size I with filters fully 
off, and is represented as I4e. The test requires considerable skill of the perimeter to 
map the visual field, and due to this, and the potential of prolonged testing time, there 
can be significant interobserver variability in the results obtained from Goldmann 
perimetry. Testing of the visual field using the Goldmann perimeter should be 
performed using both dynamic and static methods, and aside from mapping isopters 
as described above, it is important to map any scotomata that may be present within 
the field, for example in subjects with retinal dystrophies. The original Goldmann 
Field Analyser was manufactured by Haag-Streit (Bern), but this is no longer in 
production; automated kinetic perimeters have now superseded the original manual 
versions.  
 
The progression of visual field abnormalities in RP has been investigated using the 
Goldmann perimeter, and visual field defects have been categorised into four different 
patterns: progressive concentric loss of the visual field; field loss beginning in the 
superior visual field and progressing to an arcuate scotoma; a complete or incomplete 
peripheral ‘ring scotoma’ that can break through into the periphery; and ‘end stage’ 
visual field defects in which only a small central visual field is retained, with possible 
additional peripherally preserved islands of vision [57]. The plotting of Goldmann 
visual fields may be quite challenging and requires a skilled and experienced 
perimetrist. In addition, in these subjects an appropriate period of light adaptation is 
required before testing commences, the test-retest variability is high and nystagmus 
can add to the variability of the results [58]. 
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1.3.4.2 Static Perimetry 
In static perimetry stationary stimuli are presented at defined points in the visual field. 
Although static perimetry can be measured using manual techniques including with 
the Goldmann perimeter, most static perimetry is carried out now using automated 
techniques using machines such as the Humphrey Visual Field Analyser (Carl Zeiss 
Meditech, Dublin, CA, USA). The benefit of automated perimetry is that both the 
stimulus presentation and the recording of patient’s results can be standardised, with 
more detailed, reproducible, quantitative results that do not require a skilled 
perimetrist. The presented stimulus at a given point in the visual field changes in 
intensity until the sensitivity of the eye at that point is found. Testing involves the use 
of threshold or suprathreshold algorithms at a choice of degrees of eccentricity of the 
visual field, either monocularly or binocularly. In a full threshold strategy, a 
suprathreshold stimulus is presented at each location based on the threshold values 
determined from prior points. The intensity is decreased at fixed 4 dB increments until 
the stimulus is no longer seen, and then increased at fixed 2 dB increments until it is 
seen again. The threshold value is the intensity of the last stimulus seen at that 
location. This algorithm can take some time, and requires cooperation and 
concentration. The suprathreshold strategies are screening tests and are quick to 
perform, and calculate the threshold adjusted for age by measuring a few 
predetermined points using a 4-6 dB step. 
 
1.3.4.3 Perimetry in children 
Visual field testing in children can be challenging as it relies upon the child’s 
cooperation, which can be hampered by fatigue, a lack of concentration and a lack of 
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comprehension of the test. In older children automated techniques may be 
successfully performed. However, in younger children testing often relies upon 
confrontation techniques using interesting colourful targets presented in the peripheral 
visual field that the child will make a saccadic movement to see. 
 
 
1.3.5 Additional psychophysical tests 
Detailed psychophysical tests may be used to investigate rod and cone function, such 
as dark adapted perimetry, dark adapted spectral sensitivities and cone critical flicker 
fusion tests. These tests are not used routinely and tend to be reserved for the research 
setting. They were used in the LRAT subjects in this study and will be explained 
further in chapter 4.6. 
 
 
1.3.6 Electrophysiology 
The objective measure of visual pathway function is achieved through visual 
electrophysiological testing, and such testing is fundamental to the diagnosis of all 
retinal dystrophies. It allows the assessment of the nature and severity of visual 
dysfunction, which may or may not be evident through clinical ocular examination. It 
is particularly useful in children, in whom subjective measures of visual dysfunction 
may not be accurate or possible. The main test armamentarium includes: the electro-
oculogram (EOG), which measures retinal pigment epithelium (RPE) function, and its 
relationship with the rod photoreceptor; the full-field electro-retinogram (ERG), 
which measures the massed retinal response to light, and is a measure of 
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photoreceptor and inner nuclear layer function; the pattern electro-retinogram 
(PERG), which arises from retinal ganglion cell function and can give a measure of 
the macular function; and the visual evoked potential (VEP), which measures the 
function of the intracranial visual pathways. The International Society for Clinical 
Electrophysiology of Vision (ISCEV) regularly publishes minimum standards (and 
updates) to establish standardised worldwide protocols for electrophysiological 
examinations (http://www.iscev.org/standards/). 
 
1.3.6.1 The ISCEV standard Electro-Oculogram 
In this test, changes in the electrical potential across the RPE are measured during 
successive periods of dark and light adaptation [59]. The difference in electrical 
potential between the cornea and the posterior pole of the eye is known as the 
standing potential. This potential is generated by the RPE and it changes in response 
to the background retinal illumination. When switching to darkness, the potential 
continues to decrease for 8-10 minutes; there is then an initial fall in the standing 
potential over 60-75 seconds when the retina is subsequently illuminated (the fast 
oscillation), and then a slower but larger rise over 7-14 minutes (the light response). 
These changes are generated by changes in permeability of ion channels across the 
RPE basal membrane, which are (in part) encoded by the Bestrophin-1 (BEST1) gene. 
 
When measuring the EOG, the amplitude of the standing potential is measured in the 
dark, and then again at its maximum amplitude in the light, with electrodes placed at 
the medial and lateral canthi. This is done by the patient making fixed 30o lateral eye 
movements during a period of 20 minutes dark adaptation, and then again during a 15 
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minute period of light adaptation. Eye movements are made every 1-2 seconds for 10 
seconds every minute. The ratio of the maximum (peak) amplitude in the light to the 
minimum (trough) amplitude in the dark is expressed as the ‘Arden’ ratio (EOG light 
rise or light/dark ratio) and a normal EOG light rise is greater than 175%. This test is 
relatively difficult to perform and may not be possible in children below the age of 10 
years. The principal use for the EOG in clinical practice is in the diagnosis of 
Bestrophin related conditions. It may also be used in inflammatory conditions of the 
choroid and retina. 
 
1.3.6.2 The ISCEV standard Electro-Retinogram 
The full field ERG (ffERG) represents the combined electrical activity of different 
cells of the retina to uniform illumination. This is measured using corneal electrodes 
and an integrating sphere, the Ganzfeld bowl, to deliver stimuli with whole field 
illumination. The ISCEV standard specifies 5 responses: (1) dark adapted 0.01 ERG 
(rod response); (2) dark adapted 3.0 ERG (combined rod-cone response); (3) dark 
adapted 3.0 oscillatory potentials; (4) light adapted 3.0 ERG (cone response); and (5) 
light adapted 3.0 flicker (30Hz flicker) [60]. An additional ‘maximal’ ERG is also 
undertaken in the dark adapted state. Measurements are taken with pupils 
pharmacologically dilated, and dark adapted ERGs are measured after 20 minutes 
dark adaptation, and light adapted ERGs after 10 minutes light adaptation. For the 
‘maximal’ ERG, an 11 cd.s.m-2 flash is presented in the dark adapted state. The 
stimuli presented to attain the other responses range from a dim white flash of 0.01 
cd.s.m-2 (dark adapted 0.01 ERG) to a bright white flash of 3.0 cd.s.m-2 on a dark 
adapted background (dark adapted 3.0 ERG) or 30 cd.s.m-2 background luminance 
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(light adapted 3.0ERG). In the 3.0 flicker ERG the same 3.0 cd.s.m-2 stimulus is 
presented at a rate of 30 stimuli per second (30Hz), on an illuminated background.  
 
The maximal ERG has an (negative) a-wave, the initial 8-10ms of which 
predominantly reflects rod photoreceptor hyperpolarisation. The subsequent (positive) 
b-wave is generated post-receptorally, secondary to depolarisation of the ON-bipolar 
cells. The oscillatory potentials are small oscillations on the ascending limb of the b-
wave and are thought to arise from the amacrine cells. Rod system dysfunction will be 
seen as a reduction in the rod specific ERG b-wave, but this is generated in the inner 
nuclear layer so does not localise disease to the photoreceptors themselves. The 
maximal response a-wave does allow localisation as it is predominantly driven by rod 
photoreceptor function. If the rod response is poor, it could reflect either an ON-
bipolar abnormality or poor rod photoreceptor function, so the bright flash maximal 
response in the dark adapted state needs to be measured. If it is a bipolar problem then 
the a-wave will be normal or near normal (an ‘electronegative’ ERG); if it is a rod 
photoreceptor problem then both the a and b waves will be reduced.  
 
A cone-specific waveform, generated at the inner retinal level, is recorded when the 
30Hz flicker is presented on a rod-suppressing background (in the light adapted state). 
The single flash cone response allows better localisation within the retina, with the 
photopic a-wave reflecting cone photoreceptor and OFF-bipolar cell 
hyperpolarisation, and photopic b-wave reflecting post-phototransduction activity. As 
the ERG is a massed retinal response, disease isolated to one part of the retina, eg the 
macula, will have a normal ERG. 
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1.3.6.3 Other electrodiagnostic tests 
ISCEV have published standards on a number of other electrodiagnostic tests [61-63].  
 
The Pattern ERG (PERG) assesses the retinal response to a contrast-reversing 
stimulus such as a black and white checkerboard, when the eyes are fixated centrally, 
and provides information regarding macular and retinal ganglion cell function [61]. 
The PERG waveform consists of a small initial negative waveform of 35 ms peak 
time (N35), followed at 45-60 ms by a large positive waveform (P50) and then a large 
negative component at 90-100 ms (N95). This is a ‘transient’ response that is 
complete before the next contrast reversal. The amplitudes of the PERG are measured 
from the peaks to the troughs of the waveform. The N95 component arises in relation 
to the retinal ganglion cells; the P50 component reflects macular function. In contrast 
to the ff-ERG, the PERG is a local response to the area that is covered by the stimulus 
image, and thus can sensitively indicate macular dysfunction. It can also be used in 
conjunction with the visual evoked potential in order to differentiate a central retinal 
abnormality from optic pathway dysfunction, when the VEP is abnormal.   
 
The visual evoked potentials (VEP) provide diagnostic information regarding the 
functional integrity of the visual system. They are the visually evoked 
electrophysiological signals obtained from electroencephalographic activity of the 
visual cortex that are recorded from the scalp overlying this area [62]. They are used 
to assess the intracranial visual pathways, in particular the optic nerves and chiasm. 
ISCEV have published a range of stimuli and recording conditions including: pattern 
reversal VEPs and pattern onset/offset VEPs, both elicited by checkerboard stimuli 
with large 1o (60 minutes of arc) and small 0.25o (15 minute) check sizes; and flash 
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VEPs, elicited by a brief luminance increment, a flash, which subtends a visual field 
of at least 20o. Pattern reversal is used for most clinical situations, pattern onset/offset 
is useful to assess for malingering and in patients with nystagmus, and flash VEPs are 
used if there is poor cooperation, very poor vision levels or poor optics that make the 
use of pattern stimuli difficult.         
 
1.3.6.4 Electrodiagnostic testing in children 
Electrodiagnostic testing can be essential in the visual assessment and diagnosis of 
children with visual dysfunction, and can provide an indication of vision levels in 
non- or pre-verbal children. In very young or premature children it may not be 
possible to apply adult protocols, and as such they may require non-standard 
protocols. Most paediatric patients can be tested without anaesthesia or sedation, 
which is the preferred situation as anaesthesia carries a small risk and also may alter 
the VEP measurements. Although corneal electrodes may be applied, most young 
children (particularly between age 3 months to 5 years) will not tolerate them. In these 
situations, infra-orbital skin electrodes, close to the rim of the lower eyelid, may be 
used, but consideration must be taken into the variety of physical and physiological 
factors that can interfere with readings obtained in this manner [64]. Some 
laboratories advocate the recording of both the ERG and VEP concurrently, using 
skin electrodes [65]. In this situation, an estimate of gross retinal function (from the 
ERG) and macular pathway function (from the VEP) in a single recording session 
lasting 30-40 minutes can be achieved. In LCA, 56% show an un-recordable ERG or 
VEP; and in 44% no recordable ERG activity is detected but a small, degraded flash 
VEP is detectable, suggesting some residual retinal and visual pathway function. [66].       
57 
1.3.7 Optical Coherence Tomography 
Optical coherence tomography (OCT) has become a standard tool in the field of 
ophthalmology and is a non-invasive method of imaging in which reflected light is 
used to produce detailed cross sectional and 3-dimensional images of the retina and 
anterior segment. Initial work relied upon low coherence interferometry to reflect 
light from biological tissues, which gives ‘time of flight’ information that in turn, 
yields spatial information about tissue microstructure [67]. The time of flight ‘delay’ 
from the reflective boundaries and backscattering sites in the tissue being imaged 
allows the longitudinal location of the reflective sites to be determined. Multiple 
longitudinal axial scans are performed to acquire a 2-dimensional map of the sample.  
 
Multiple generations of OCT imaging techniques have since been developed. In the 
early time-domain OCT (TD-OCT), a series of longitudinal cross sections 
perpendicular or in the coronal plane to the retinal surface were acquired over time, 
giving depth information and an image resolution of 10-15 µm, but imaging speed 
was limited by the need for the reference mirrors to move mechanically. TD-OCT 
acquires approximately 400 axial scans (A scans) per second. More recently, 
advances have been made regarding image resolution – particularly by the 
development of high-resolution OCT – and in imaging speed, signal to noise ratio and 
sensitivity, in ultra-high resolution OCT or spectral domain OCT (SD-OCT), which 
can achieve a resolution of 2-3 µm [68, 69].  In SD-OCT, the reference mirror 
remains stationary and the OCT image is obtained either by using a spectrometer as a 
detector or by varying the narrowband wavelength of the light source over time 
(swept source). Different echo time delays of light, which produce different 
frequencies of fringes in the interference spectrum are measured and then a Fourier 
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transform (a mathematical procedure that extracts the frequency spectrum of a signal) 
is applied [70]. This method allows measurement of all echoes of light from different 
delays simultaneously, which dramatically increases speed and sensitivity. Motion 
artefact is diminished by the increased speed of image acquisition, and 3-dimensional 
images can be obtained that can give ‘volume scans’ of the retina. 
 
The SPECTRALIS® OCT HRA + OCT imaging system (Heidelberg Engineering, 
Heidelberg, Germany), can obtain images 100 times faster than time-domain OCT 
(http://www.heidelbergengineering.com/international/products/spectralis/technology/s
pectral-domain-oct/) [71]. 40 000 A scans are acquired per second, and it can combine 
high resolution, high speed SD-OCT images with, among other modalities, fundus 
autofluorescence imaging. Image quality is improved by the use of confocal scanning 
laser ophthalmoscopy (cSLO), which uses laser light to illuminate the retina instead 
of a white light. Figure 8 illustrates a normal eye imaged using the Spectralis OCT. 
 
 
Figure 8 – Normal sd-OCT image. Adapted from [72]. Retinal layers are labelled as 
follows: ILM – Internal Limiting Membrane; NFL – Nerve Fibre Layer; GCL – 
Ganglion Cell Layer; IPL – Inner Plexiform Layer; INL – Inner Nuclear Layer; OPL 
– Outer Plexiform Layer; ONL – Outer Nuclear Layer; ELM – External Limiting 
Membrane; IS/OS – Inner segment / Outer segment junction; RPE – Retinal Pigment 
Epithelium; Choroid. 
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1.3.8 Fundus Autofluorescence Imaging 
The retinal pigment epithelium (RPE), a polygonal monolayer of cells between the 
neurosensory retina and Bruch’s membrane (which separates the RPE from the 
vascular choroid layer), has a number of vital functions, of which the phagocytic role 
is essential to the renewal of photoreceptors. Phagocytosed outer segment tips are 
digested in the extensive phagolysosomal system within the RPE cell, and solubilised 
waste material is transported across the basal in-foldings of the RPE cell into the 
choriocapillaris. With age, there is an accumulation of lipofuscin pigment, a storage 
material that accumulates as a result of cell senescence in post-mitotic cells such as 
neurons, retina and muscles [73]. In the RPE, lipofuscin ‘granules’ accumulate as a 
result of incomplete degradation of photoreceptor outer segment discs, with 
subsequent incomplete release of degraded material [74]. However, lipofuscin also 
accumulates as a result of a number of retinal disease processes such as age related 
macular degeneration and certain inherited retinal dystrophies such as Best disease 
and Stargardt disease [75, 76]. 
 
Lipofuscin possesses the phenomenon of ‘autofluorescence’ – the ability of a 
substance to emit light of a particular wavelength when illuminated by light of a 
different wavelength. There are at least 10 different fluorophores (fluorescent 
compounds) that accumulate within lipofuscin granules in the RPE [77]. One 
prominent fluorophore is the bisretinoid A2E (N-retinyl-N-retinylidene ethanolamine), 
which has toxic properties that may interfere with normal cell function by inhibition 
of lysosymal degradative capacity, loss of membrane integrity and phototoxicity [78].  
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In vivo recording of RPE autofluorescence as an index of lipofuscin accumulation can 
give important clues to the pathogenesis and progress of different retinal diseases. The 
first fundus spectrophotometer that could exhibit retinal autofluorescence in vivo 
demonstrated that fundus fluorescence has a broad emission spectrum between 500nm 
to 750nm, with a peak at 630nm and optimal excitation of 510nm [79]. This 
fluorescence is highest at 7o to 15o from the fovea and decreases towards the 
periphery, and it was confirmed that lipofuscin is the dominant source of 
autofluorescence within the retina. In order to address the issues of limitations due to 
the low intensity of the autofluorescence signal and interference from the crystalline 
lens, a fundus autofluorescence imaging system using a confocal scanning laser 
ophthalmoscope was developed [80]. In this system, a focused low power laser beam 
is swept across the fundus, and the confocal nature of the optics ensures that the 
reflectance and fluorescence are derived from the same optical plane. In order to 
reduce background noise and enhance image contrast, a series of several single fundus 
autofluorescence images are recorded, and a mean image (of 4-16 frames) is obtained 
after correction of eye movement during image acquisition. Consequently in 
situations where there is high eye movement, such as nystagmus, fundus 
autofluorescence image quality may be diminished or not possible. The Heidelberg 
Retinal Angiograph (HRA; Heidelberg Engineering, Germany) is the predominant 
commercially available device for measuring fundus autofluorescence, and at the time 
the work towards this thesis was carried out, the standard images obtained were of a 
30o field, but a wider field was possible with a 55o lens. This technology has been 
combined with SD-OCT imaging, and other retinal imaging modalities [81] in the 
widely used SPECTRALIS® OCT HRA + OCT imaging system (Heidelberg 
Engineering, Heidelberg, Germany).  
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During fundus autofluorescence imaging in normal fundi the optic nerve head and 
retinal vessels appear dark due to the absence of the RPE and absorption by blood 
respectively (Figure 9). In the macula, autofluorescence in the fovea is reduced due to 
absorption by luteal pigments (lutein and zeaxanthin), and increases in the parafovea, 
but this is still of relative decreased intensity compared to the diffuse background 
signal in more peripheral retina [80]. This may be due to increased melanin and 
decreased lipofuscin granules in central RPE cells. Abnormal fundus autofluorescence 
signals may be due to either increased or decreased amounts or compositions of 
fluorophores in the RPE cytoplasm, or due to the presence of autofluorescent or 
absorbing material anterior to the RPE [82]. Autofluorescence is increased with RPE 
dysfunction and decreased when there is loss of photoreceptors. Media opacity within 
the cornea, lens or vitreous may also reduce the quality of the recorded image.  
 
 
Figure 9 – Normal Fundus Autofluorescence image, right eye.     
62 
1.3.9 Fundus Imaging 
The unique optical properties of the eye allow visualisation of the retina. The earliest 
ophthalmoscope was invented based upon principles put forward by Purkinje in 1823, 
and reinvented by Babbage in 1845 [83]. Von Helmholtz reinvented the direct 
ophthalmoscope again, in 1851, and Gerloff achieved the first useful photographic 
recording of the retinal blood vessels in 1891. Reports regarding the first fundus 
cameras vary: Dimmer in 1905, working with the Zeiss company developed a reflex 
free fundus camera; in 1910 a fundus camera was developed by Gullstrand; and in 
1925 the Zeiss-Nordenson camera became a widely used fundus camera. 
Modifications to the imaging techniques led to the development of stereoscopic 
fundus imaging [84] and now, high-resolution digital fundus photography is the 
routine method by which the retina is photographed. 
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1.4 Techniques for Molecular Analysis 
 
The genetic heterogeneity underlying LCA and EORD makes the process of 
identifying causative mutations in these families challenging. Various techniques have 
been utilised over time to refine genetic loci, determine gene sequences and identify 
mutations in causative genes. The history and principles of the available techniques 
will be described in this chapter. 
  
 
1.4.1 Linkage 
Present understanding of human genetics owes much to the Austrian monk Gregor 
Mendel who, in 1865, presented and published the results of his breeding experiments 
on garden peas [85]. Unfortunately these went largely unnoticed until 1900 when his 
work was rediscovered 16 years following his death, after scientists began to conduct 
experiments that upheld his principles of inheritance: the Law of Uniformity, the Law 
of Segregation and the Law of Independent Assortment. However, they also 
discovered situations that represented deviations from these principles. The Law of 
Independent Assortment refers to the observation that members of different pairs of 
genes segregate to offspring independently of one another. However, studies on pea 
plants by Bateson, Saunders and Punnett in 1905 revealed that not all crosses yielded 
results that reflected the law of independent assortment [86]. Looking at the inherited 
features of flower colour (purple and red) and pollen grain shape (long and round) 
they identified that there was a connection, or coupling, of these traits in successive 
generations when plants were inbred. Subsequent work by Thomas Morgan on ‘eye 
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colour, body colour, wing mutations and the sex factor for femaleness in Drosophila’ 
unearthed the concept of genetic linkage, in which he concluded that when two genes 
are closely associated on the same chromosome, they do not assort independently [87, 
88]. He observed that during meiosis ‘homologous chromosomes twist around each 
other, but when the chromosomes separate (split) the split is in a single plane’ and 
thus for short genetic distances ‘original materials will…be more likely to fall on the 
same side of the split, while remoter regions will be as likely to fall on the same side 
as the last, as on the opposite side’. Thus, he concluded that during this crossing over, 
there is exchange of genetic material between homologous chromosomes. The linkage 
of the different traits was felt to be dependent upon the linear chromosomal distance 
between these traits.  
 
Morgan’s student, Alfred Sturtevant, was the first to use this hypothesis to create a 
genetic map, though not based on physical distance on chromosomes, but rather on 
the proportion of ‘crossovers’ (or recombination events) as an index of the distance 
between any two factors [89]. He proposed that the greater the distance between 
linked genes, the greater the chance that non-sister chromatids would cross over in the 
region between the genes. By calculating the number of recombinants, a measurement 
of the distance between genes could be made. This distance, defined as the distance 
between genes for which 1% of the products of meiosis is recombinant, is known as 
the Centimorgan. The relationship between linkage map units and physical length is 
not linear. Some chromosome regions appear to be prone to recombination, so called 
‘hot spots’, and recombination tends to occur more frequently during meiosis in 
women than men. 
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Linkage analysis has proven to be an extremely valuable tool in the mapping of genes. 
The method involves the study of disease segregation with polymorphic ‘markers’ 
from each chromosome. Eventually a marker will be identified that co-segregates with 
the disease more often than would be expected by chance, such that the marker and 
disease loci are linked. The underlying principle involves the use of likelihood ratios, 
the logarithms of which are known as LOD scores (logarithm of the odds): the LOD 
score Z is equal to the logarithm of the odds that the loci are linked divided by the 
logarithm of the odds that they are not linked. This uses the recombination frequency 
(θ), which is the frequency with which a single cross over event will take place 
between two genes during meiosis. In reality, the LOD score is calculated for 
different recombination frequencies providing a maximum likelihood estimate for the 
recombination frequency (θmax) at which the greatest LOD score is observed (Zmax) 
[90]. It is generally agreed that a LOD score of +3 or more is confirmation of linkage, 
as it indicates 1000 to 1 odds that the linkage being observed did not occur by chance, 
and a LOD score less than -2 excludes linkage. It is possible to calculate maximum 
likelihood estimates for multiple loci at a time and therefore to place disease loci on a 
map of ordered genetic marker loci. 
 
 
1.4.2 Genetic Markers 
Historically there have been a number of different types of DNA marker. These DNA 
polymorphisms can serve as a set of markers that are sufficiently numerous and 
adequately spaced across the entire genome to allow a whole-genome search for 
linkage. They have the advantage of being able to be typed by the same technique and 
their chromosomal location can be determined using radiation hybrid mapping or by 
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searching the genome for a match to the polymerase chain reaction (PCR) (see section 
1.4.3) primer used to score the marker. 
 
1.4.2.1 Restriction Fragment Length Polymorphisms 
The first polymorphisms to be discovered were restriction fragment length 
polymorphisms (RFLPs). These usually form as a result of single base pair changes in 
DNA sequences and lead to the removal or, less commonly, the introduction of a 
recognition site for a restriction enzyme. This causes an increase or decrease in the 
length of restriction fragments, which can be detected by the altered mobility of 
different sized fragments on gel electrophoresis (see section 1.4.4). A difference in 
number or size of fragments between individuals tested indicates a polymorphism in 
the restriction site of the enzyme used. Initially RFLPs were typed by preparing 
Southern blots from restriction digests of the test DNA and hybridisation with 
radioactive probes – a procedure that was cumbersome and time consuming, requiring 
a large amount of sample DNA. Unfortunately RFLPs are limited by their low 
informativeness.  
 
1.4.2.2 Microsatellites 
With the advent of the PCR (see section 1.4.3), a novel class of short tandem repeat 
(STR) polymorphisms, or microsatellites, was discovered, which were highly 
informative for linkage analysis. These are dinucleotide, trinucleotide or 
tetranucleotide sequences, such as (CA)n or (GATA)n, that can be repeated between 
10 to 100 times, and that tend to occur in non-coding regions of DNA throughout the 
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genome. They are multi-allelic, which increases the probability that an individual is 
heterozygous for these markers, allowing paternal and maternal alleles to be 
distinguished [90]. On each side of the repeat unit are flanking regions that can be 
used to develop locus-specific primers to amplify the microsatellites by PCR. This 
allows amplification of alleles whose sizes differ by integral repeat units. A 
fluorescent nucleotide precursor can be incorporated into the PCR products, which are 
denatured and then size-fractionated by gel electrophoresis (see section 1.4.4). 
Microsatellites are useful genetic markers because they tend to be highly 
polymorphic. The reason for this is that they are prone to high rates of mutation due to 
‘replication slippage’ during DNA replication – there is incorrect pairing of the 
nucleotide repeats of the two complementary strands during DNA replication. 
Microsatellites have formed an essential tool in genome mapping.  
 
1.4.2.3 Single nucleotide polymorphisms 
The newest generation of markers are single nucleotide polymorphisms (SNPs). A 
SNP is a DNA coding variation occurring commonly in a population in which two 
sequence alternatives (called ‘alleles’) exist, with the frequency of the least abundant 
allele in the population being at least 1%. There is a difference of a single nucleotide 
between members of a biological species or paired chromosomes. Approximately 
two-thirds of SNPs are cytosine (C) to thymine (T) variations. These are bi-allelic and 
occur in coding and non-coding regions. In coding regions, a SNP can be 
synonymous, where the amino acid sequence remains unchanged, or non-
synonymous, where the amino acid sequence is altered. The combinations of SNPs in 
regulatory regions, as well as amino acid coding SNPs, have a substantial influence 
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on inter-individual differences. Within different populations in the human species 
there are different variations such that a SNP allele that is common in one 
geographical or ethnic group may be much more rare in another group. SNPs are the 
genetic marker with the highest abundance in the genome and occur with a frequency 
of around 1 in every 1000 base pairs. Although they are not as polymorphic (and 
therefore individually less powerful as a marker) as microsatellites because they are 
bi-allelic, their high frequency within the genome makes them extremely useful for 
genome wide studies. An international consortium of academic and industrial partners 
has generated a public database of millions of SNPs, known as ‘dbSNP’, available 
through the National Center for Biotechnology Information 
(http://www.ncbi.nlm.nih.gov/SNP/index.html). There are a number of other SNP 
databases available including the OMIM database and the International HapMap 
Project (http://hapmap.ncbi.nlm.nih.gov/), the SNP Consortium (TSC) [91], the 1000 
genomes databases (http://browser.1000genomes.org/index.html) and the Exome 
Variant Server (http://evs.gs.washington.edu/EVS/). 
 
 
1.4.3 Polymerase Chain Reaction 
Since its advent in the mid-1980s, the polymerase chain reaction (PCR) has 
revolutionised molecular genetics by allowing the rapid cloning and analysis of DNA 
[92, 93]. It has become a robust and extremely sensitive technique, enabling 
amplification of minute amounts of target DNA even from tissues or cells that are 
badly degraded. The wide range of applications of PCR, including DNA cloning for 
sequencing, functional analysis of genes, diagnosis, genetic linkage analysis, 
detection and diagnosis of infectious diseases, and in forensic science, have prompted 
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the development of a variety of PCR approaches, many of which have arisen due to 
the need to optimise efficiency and specificity.  
 
PCR may be used to permit selective amplification of a specific target of DNA, of 
known sequence, within a heterogeneous collection of DNA sequences – often the 
starting DNA is total genomic DNA from a particular tissue. Thus the target DNA is 
typically a tiny fraction of the starting DNA. PCR amplification involves the use of 
oligonucleotide primers that flank the DNA segment to be amplified, and subsequent 
repeated cycles of heat denaturation of the DNA, annealing of the primers to their 
complementary sequences, and extension of the annealed primers with a DNA 
polymerase enzyme. The custom designed primers (amplimers), optimally 18-25 
nucleotides in length, are specific for sequences flanking the target sequence. They 
hybridise to opposite strands of the target sequence and are orientated so that 
polymerisation occurs between the amplimers, effectively doubling the amount of that 
DNA segment. Further exponential accumulation of the target DNA sequence occurs, 
as the extension products are capable of further amplification, thus each successive 
cycle theoretically doubles the amount of DNA synthesised in the previous cycle.    
 
PCR is carried out in reaction volumes of 10-200 μl, in small reaction tubes (0.2-0.5 
ml volumes) using a thermal cycler. The components required for the successive 
reactions that take place during PCR amplification include: a DNA template that 
includes the target region to be amplified; two oligonucleotide primers that are 
complementary to the 3’ ends of the sense and anti-sense strands of the DNA target; a 
DNA polymerase such a Taq polymerase which is heat stable and has an optimum 
temperature of approximately 70o C [94]; the four deoxynucleoside triphosphates 
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(dNTPs), nucleotides containing triphosphate groups, dATP, dCTP, dGTP and dTTP; 
a buffer solution; and cations such as magnesium and potassium. Each cycle consists 
of 3 steps: a denaturation step at 94-98oC for 20-30 seconds during which the DNA 
template is melted and single stranded DNA molecules are generated; an annealing 
step for 20-40 seconds at a temperature 3-5o below the Tm of the primers used; and an 
elongation step that is time and temperature specific to the DNA polymerase being 
used, during which dNTPs are added together to complement the DNA template, in a 
5’ to 3’ direction. In total, 20-40 cycles are utilised. There may be an initialisation 
step for 1-9 minutes before the start of the cycles if the DNA polymerase requires heat 
activation; and there is usually a final elongation step at 70-74o for 5-15 minutes after 
the last PCR cycle to ensure that any remaining single stranded DNA is fully 
extended. To determine whether the correct PCR fragments were generated, agarose 
gel electrophoresis is used to separate the DNA fragments, and a molecular marker – 
a DNA ladder – is run alongside the products to determine the size of the fragments.    
 
 
1.4.4 Agarose Gel electrophoresis 
Agarose gel is a 3-dimensional matrix formed by helical agarose molecules in 
supercoiled bundles with channels and pores through which biomolecules can pass. 
Gel electrophoresis allows the separation of a population of DNA by the application 
of an electrical field - the negatively charged phosphate backbone of DNA molecules 
will migrate towards the positively charged anode. The rate of molecular migration 
depends on a number of factors including: the size of the DNA molecules (smaller 
molecules travel faster than larger molecules); the concentration of the gel (typically 
the higher the percentage of gel, the slower the DNA will migrate); the voltage of the 
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current applied (the higher the voltage, the faster the molecules migrate); the ionic 
strength of the buffer used; and the concentration of the intercalating dye such as 
ethidium bromide. A 0.8% gel allows good resolution of large 5-10 kB DNA 
fragments while a 2% gel gives good resolution of smaller 0.2-1 kB fragments. Buffer 
solutions are used during electrophoresis to reduce pH changes due to the electrical 
field, the most common being Tris/Acetate/EDTA (TAE). 
 
The gel is cast in molten form in trays, with combs that, when removed form wells, 
once the gel has set. DNA samples are loaded into each well, with a dye such as 
bromphenol blue, and a DNA ladder is loaded into the first well that allows estimation 
of the molecular weight of the DNA samples. The dye co-migrates with the DNA 
during electrophoresis. When stained with ethidium bromide, and once the gel has 
been run, it is viewed under a UV light and an image of the gel can be taken with a 
camera, which can be printed.  
 
Agarose gel electrophoresis may be used in a number of applications including 
analysis of PCR products, separation of DNA for extraction and purification, 
estimation of DNA molecular size after restriction digestion and separation of 
restricted DNA or RNA during Southern or Northern blotting respectively.  
 
 
1.4.5 DNA sequencing  
DNA sequencing, the process of determining the nucleotide order of a given DNA 
fragment, was pioneered by Frederick Sanger using the dideoxy sequencing, or chain 
termination, method [95]. At the time that the work towards this thesis was being 
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carried out, Sanger sequencing was the most abundantly used method of DNA 
sequencing. Since then, newer techniques involving large-scale automated genome 
analyses, such as Next Generation Sequencing (see section 1.4.9), have come to the 
fore. These will be discussed in subsequent sections. 
 
In the dideoxy direct sequencing method, single-stranded DNA is used as a template 
to create a new complementary DNA strand in vitro using oligonucleotide primers 
(specific to the region of interest), a suitable DNA polymerase, the four dNTPs, and a 
small proportion of one of the four analogous dideoxynucleotides (ddNTPs: ddATP, 
ddCTP, ddGTP, ddTTP). The ddNTPs are closely related to the normal dNTPs 
utilised during PCR, but they differ in that they lack a hydroxyl group at the 3’ and 2’ 
carbon positions. Although a ddNTP can be incorporated into the growing DNA chain 
by forming a phosphodiester bond between its 5’ carbon atom and the 3’ carbon atom 
of the previously incorporated nucleotide, the lack of a hydroxyl group at its 3’ carbon 
atom prevents a further phosphodiester bond to form in this position. This leads to 
termination of DNA chain synthesis at this point. As the incorporation of a ‘chain 
terminating’ nucleotide is a random process, there will be a mixture of DNA 
fragments of different lengths that terminate in their respective ddNTP. 
 
Fragments that differ in size may be size fractionated on a denaturing polyacrylamide 
gel, which contains a denaturing agent that ensures that the DNA strands remain 
single stranded. Although Sanger sequencing originally utilised radioactive labelling 
with manual interpretation of data, this technique was superseded by the use of 
fluorescent labels incorporated into the ddNTPs [96]. As the DNA passes through a 
fixed point in the gel, a laser detects and records a fluorescence signal, which is 
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specific for the particular ddNTP that each DNA fragment terminates in. The 
sequence is read in the form of intensity profiles, known as chromatograms, for each 
of the differently coloured fluorophores. The interpreted sequence can be used to infer 
a polypeptide, and can be stored in a computer database. Automated DNA sequencers 
historically used slab acrylamide gels, but newer generation high throughput 
sequencers use capillary electrophoresis [97], where the DNA samples migrate 
through very thin long glass capillary tubes containing gel, allowing for a higher 
degree of throughput and accuracy. Examples include the ABI and Illumina 
platforms, which can sequence approximately 1 million bases per day.  
 
 
1.4.6 DNA Microarrays 
DNA microarrays can be used to rapidly measure the expression of a large number of 
genes simultaneously or to genotype multiple regions of a genome [98-102]. These 
‘DNA chips’ consist of a number of DNA ‘spots’ attached to a solid surface. In a 
standard microarray, probes are synthesised and attached to a solid surface, such as 
glass or silicone, by a covalent bond to a chemical matrix (Affymetrix chip). Some 
platforms utilise microscopic beads instead of the large solid support (Illumina), and 
other microarrays can be constructed by the direct synthesis of oligonucleotide or 
peptide probes on solid surfaces. The original technology involved the utilisation of 
light directed combinatorial chemical synthesis – semiconductor based 
photolithography – to enable the synthesis of hundreds of thousands of compounds in 
precise locations on a chip, so that a target molecule labelled with a fluorescent dye 
that was incubated with the chip could hybridise to the probes. Using combined laser 
confocal fluorescence scanning the molecular binding events at individual sites on the 
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array were measured [98]. By generating an array consisting of oligonucleotides 
complementary to sub-sequences of a target sequence, the identity of the target 
sequence could be determined, its amount measured and differences detected between 
the target and a reference sequence [100]. The use of microarrays is now widespread 
and there are a diverse range of applications, including sequencing to compare 
hundreds of different genes assayed simultaneously, detection of gene expression of 
many genes in parallel, utilisation of genetic markers to identify pathogenic organisms 
and analysis of sequence specificity of RNA- or protein-DNA interaction.   
 
 
1.4.7 Autozygosity Mapping 
Autozygosity, a form of homozygosity, is the appearance of two copies of a DNA 
segment that are identical by descent, such that they have a common origin (contrary 
to being introduced into the genetic pool of a population independently, which is 
known as identity by state) [103]. In autosomal recessive disease, the probability that 
each parent is a carrier of a mutated recessive allele will depend on the carrier 
frequency in the general population. This tends to be very low due to selective 
pressure against these highly morbid alleles. However, in the consanguineous setting, 
the probability of one parent being a carrier is not independent of the other. For 
example, first cousin parents will share 1/8th of their genome, substantially increasing 
the risk of autozygosity of a disease allele, and therefore the occurrence of a recessive 
disorder, in their offspring. 
 
The concept of disease gene identification using mapping strategies that analyse 
autozygous regions in consanguineous families with recessive diseases was conceived 
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by Lander and Botstein [104]. They suggested that by searching regions that are 
consistently homozygous by descent, a recessive disease gene could be mapped in an 
affected child from a consanguineous marriage. They calculated that the fraction of a 
child’s genome that is homozygous by descent is 1/4, 1/16 and 1/64 for sibling, first 
cousin and second cousin marriages, respectively. Using RFLPs they mapped areas of 
homozygosity in affected offspring, searching for regions in which adjacent RFLPs 
were homozygous. They used the hypothesis that affected individuals of 
consanguineous families would be homozygous for markers residing within the region 
surrounding the disease locus, which are therefore linked to the causative gene, and 
thus that these regions of homozygosity may be searched for the causative gene.  
 
Autozygosity mapping became more practical with the discovery of multiple highly 
polymorphic microsatellite repeat markers spread throughout the genome, allowing 
genome-wide association studies looking for linkage [105]. Subsequently, the 
International Hap Map Project provided a genome wide set of SNPs to tag variation 
throughout the genome (http://hapmap.ncbi.nlm.nih.gov/). While each SNP has far 
less power to detect a homozygous chromosomal segment than a microsatellite 
marker, it is both their high frequency and their ability to detect a heterozygous 
region, and hence exclude linkage, that suggested their potential use in autozygosity 
mapping [106]. Widespread genome-wide SNP studies have been made possible 
through the availability of microarrays incorporating a large set of SNPs.  
 
These ‘SNP-chips’ are now commercially available from a number of companies. Our 
laboratory used the Affymetrix SNP Chip, and earlier generations incorporated up to 
10,000 SNPs, with newer versions incorporating 1,000,000 SNPs. The farther 
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removed the common ancestor is from the parents of the proband, the more 
opportunity for cross over events to have occurred during meiosis to generate their 
gametes, and thus a greater chance that the ancestral haplotype is broken. Therefore, a 
higher density of SNPs is required to capture an autozygous block when the parents 
are more distantly related. The analysis is performed following a single hybridisation 
reaction with one individual’s DNA. Results are produced as a spreadsheet of SNP 
allele calls. The largest detected regions of homozygosity may be sorted according to 
genetic size, chromosome, and genetic location on the chromosome, number of 
homozygous SNPs in a run, number of ‘no calls’ in the run and whether the results 
reach statistical significance. The autosomal recessive gene locus could reside in any 
of the statistically significant homozygous regions detected and a number of tools 
exist to facilitate the subsequent search for candidate genes [103]. 
 
 
1.4.8 APEX Microarray 
Another microarray-based method designed to rapidly screen for known mutations in 
a DNA sample is the Arrayed Primer Extension (APEX) technique [107, 108]. In this 
technique, a detection primer anneals to the target nucleic acid immediately adjacent 
to a variable nucleotide position. A DNA polymerase is used to specifically extend the 
3’ end of the primer with a labelled nucleotide analogue complementary to the 
nucleotide at the variable site. In essence, the APEX reaction is a sequencing reaction 
on a solid support.   
 
An ‘LCA chip’ has been designed that uses APEX technology to enable screening for 
a large number of known LCA variants and SNPs [109]. This DNA microarray 
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incorporates 5’ modified sequence specific oligonucleotides arrayed on a glass slide, 
so that their 3’ ends are immediately adjacent to the variable site. Target nucleic acids 
that have been prepared by PCR and then fragmented, are annealed to the 
oligonucleotides on the slide, followed by sequence specific extension of the 3’ ends 
of the primers with dye labelled ddNTPs using a DNA polymerase. The process is 
rapid, taking 4 hours from sample preparation to analysis. As further LCA variants are 
discovered, the chip can be ‘updated’, making this technology a high volume, cost 
effective screening tool for known variants in this genetically heterogeneous 
condition. Asper Biotech Ltd (Tartu, Estonia) have commercialised this LCA chip (as 
well as many others) and utilise their Genorama Genotyping Software to detect 
and analyse variants in both the sense and antisense strand, and thus provide one or 
two variants in the disease gene in informative samples 
(http://www.asperbio.com/asper-ophthalmics/leber-congenital-amaurosis-lca-genetic-
testing). Currently, this chip analyses 780 variants in 15 genes.  
 
The efficiency and efficacy of the LCA chip was analysed by Henderson et al. who 
identified one or two mutations in 46% of LCA and 24% of early onset retinal 
dystrophy patients [110]. The authors identified that overall, the chip is informative in 
around one third of patients, concluding that it is a sensitive technique with a low call 
failure rate, thus providing an excellent first pass screening tool for LCA. However, a 
number of anomalies between the chip and direct sequencing results were identified, 
including false-positive results in AIPL1, a false-negative result in CRB1 and a 
relatively high call failure rate in certain SNPs, although these were on a par with the 
difficulties encountered with direct sequencing techniques.  
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1.4.9 Next generation sequencing 
At the time that the work towards this thesis was being carried out, next-generation 
sequencing (NGS) technologies were in their infancy. They are now in the forefront 
of biological research, reaching unparalleled levels of sequencing capacity. As this 
technology was used by our laboratory and collaborators at the UCL Genetics 
Institute to identify the genetic cause in one patient in this study, the principles of 
NGS will be described here.  
 
A number of different DNA sequencing platforms have now been generated and 
several commercial next-generation DNA sequencing systems are available, such as 
the Roche 454 Genome Analyzers (Roche Diagnostics Corp., West Sussex, UK) 
(http://454.com/products/technology.asp), the Illumina NGS platforms (Illumina Inc., 
California, USA) (http://www.illumina.com/technology/next-generation-
sequencing.html), the Applied Biosystems SOLiD™ Genetic Analyzers 
(http://www.lifetechnologies.com/uk/en/home/life-science/sequencing/next-
generation-sequencing/solid-next-generation-sequencing.html) by Life Technologies 
(Thermo Fisher Scientific Inc., Massachusetts, USA), and the Ion Torrent™ platform, 
also by Life Technologies (http://www.lifetechnologies.com/uk/en/home/brands/ion-
torrent.html). The data obtained from NGS depends heavily on the high quality 
reference sequences produced by the Human Genome Project [111]. The major 
advantage of NGS technologies is the ability to process millions of sequence reads 
simultaneously, a technique known as massively parallel sequencing. This vastly 
reduces the required number of instruments and personnel compared to Sanger-type 
DNA capillary sequencers, and significantly accelerates the rate of data collection for 
DNA sequencing – current machines are capable of sequencing an entire genome 
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within a couple of weeks. This is likely to be accelerated further, with time, such that 
whole genome sequencing could be achieved within hours to days. Another important 
difference is that NGS technologies are derived from fragment libraries rather than 
depending on vector based cloning, which significantly speeds up the sequencing 
process. The read lengths are shorter: 35-250 base pairs (bp) for NGS compared to 
650-800 bp for capillary sequencers. Finally, there is a significant reduction in the 
costs for NGS: in 2013 it cost approximately $5,000 USD to sequence the entire 
genome of one person [112]. With time this will undoubtedly reduce further. 
 
All NGS platforms first require the construction of a ‘library’ of the DNA to be 
sequenced before the sequencing process that follows. The processes involved in the 
construction of this library begin with random shearing of genomic DNA into 200-
500 bp fragments of different sizes by sound waves, and subsequent ligation by DNA 
ligase of customised synthetic DNA linkers known as adapters, that are covalently 
linked to the end of the DNA fragments [112]. These adapters are universal sequences 
that are specific to each platform, which can be used in later steps to polymerase-
amplify the fragments. The libraries are quantitated very precisely before they go on 
to the amplification process in order to obtain the correct amount of sequence data 
after amplification has occurred. Each of these synthetic library fragments is 
amplified by a few PCR cycles on a solid surface (either a bead or a flat silicone 
derived surface, depending on the platform used) that already has covalently bound 
adapters attached to the surface. These are complementary to the adapters that have 
been attached to the fragments. The amplification of the library fragments on the flow 
cell surface leads to the generation of clusters of fragments, all of which have 
originated from a single fragment.  
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In the Illumina® platform (Illumina Inc., California, USA), which was used in this 
study, the amplified fragments generate clusters by a method known as ‘bridge 
amplification’. In this process the denatured fragment on the flow cell surface anneals 
to an adapter bound to the fixed surface during the first annealing cycle, forming a 
‘bridge’, following which the first extension cycle occurs from the bound and 
annealed adapter using the fragment as a template. This generates 2 strands in a 
bridge which are then denatured in the second cycle, followed by second cycle 
annealing and then second cycle extension. This process occurs around 35 times and 
generates clusters of amplified fragments, which are foci for subsequent sequencing.  
 
Once the clusters have been generated, there is chemical ‘release’ of fragment ends 
that carry the same adapter, and denaturation of the fragments to single strands. There 
is subsequent ligation of a complementary synthetic DNA sequencing primer to the 
linear single stranded cluster DNAs, which provides a free 3’-OH group, which can 
be extended in subsequent stepwise sequencing reactions (see below). The sequencing 
occurs in a direction from the free end down to the surface of the chip. The clusters 
can be regenerated by another amplification process, with release of the other end of 
the bridged fragment, followed by ligation of a second primer and then sequencing. In 
this manner, ‘paired end reads’ are used to generate the sequence. These reads are 
paired with one another during the alignment step of the data analysis process, which 
provides an overall higher certainty of placement than would occur with a single end 
read of the same length.  
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The sequencing method utilised by Illumina® is known as massively parallel 
‘sequencing by synthesis’, in that following the incorporation of each base during 
sequencing there is an imaging step to identify the incorporated nucleotide at each 
cluster. This is achieved by using a process known as reversible dye terminator 
sequencing: all four nucleotides, each with a specific fluorescent label, are provided 
by the fluidics of the instrument into the flow cell; the nucleotide is incorporated 
adjacent to the sequencing primer by a polymerase and is detected by the optics of the 
sequencer; the nucleotide has a ‘block’ incorporated into it at the 3’-OH position of 
the ribose sugar such that a second adjacent nucleotide can only be incorporated after 
steps in which the previous nucleotide is ‘unblocked’ and the fluorescent group is 
cleaved off and washed away. This prevents additional nucleotide incorporation 
reactions by the polymerase. Therefore, the overall series of steps occurs in the 
following sequence: a. the nucleotide becomes added by the polymerase; b. 
unincorporated nucleotides are washed away; c. the flow cell is imaged on both 
surfaces to identify each cluster that is reporting a fluorescent signal; d. the 
fluorescent groups are chemically cleaved, and e. the 3’-OH group is chemically 
cleaved [112]. This series of steps is repeated for up to 150 nucleotide additions, after 
which the second read preparations begin (for reading from the opposite end). To read 
from the opposite end of each fragment cluster (paired end read technology) the 
synthesised strands are removed by denaturation, the clusters are regenerated by 
limited bridge amplification, opposite ends of the fragments are released from the 
flow cell surface and the fragments are primed with the reverse primer. Sequencing 
can then proceed in the opposite direction, as above. 
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The technique of whole genome sequencing can be refined by using a method called 
‘hybrid capture’ to specifically capture exome sequences (the ‘coding’ regions of 
DNA) from a whole genome library by generating synthetic probes specifically for all 
of the exons in which one is interested. These probes are ‘biotinylated’ and adhere to 
fragments of interest. The DNA is purified using magnetic beads that allow the 
specific capture of fragments of interest and the remaining fragments are washed 
away. These fragments can then be sequenced. The process is known as ‘whole 
exome sequencing’ (WES). 
  
The interpretation of the vast amounts of data generated by NGS employs complex 
bioinformatics. The raw sequencing reads need to be aligned to the reference genome 
and the data require ‘cleaning up’ in order to remove duplicates, correct local 
misalignments and calculate quality scores. The number of SNP ‘calls’ is very 
important as this evaluates whether there is adequate and accurate coverage of the 
genome, which will subsequently allow investigators to reliably call true variants as 
variants. Not only is the coverage important (ie the percentage of the genome that has 
been sequenced), but so is the read depth (the number of times the genome base has 
been read) eg 10x, 30x.  
 
The advent of NGS has revolutionised biological research, with significant increases 
in data-production capacity and significant lowering of costs. WES technologies are 
being superseded by whole genome sequencing as costs are falling, which have the 
added benefit of enabling identification of copy number variants and variants in non-
coding regions. At present the technology is being utilised in a research setting but as 
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costs become further reduced, this technology will have a tremendously important 
impact in the clinical setting.  
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1.5 Genetics of Leber Congenital 
Amaurosis and Early Onset Retinal 
Dystrophy  
  
Since Donders’ and Leber’s earliest descriptions of Leber Congenital Amaurosis 
(LCA) and the Early Onset Retinal Dystrophies (EORDs), it has become apparent that 
these are a highly heterogeneous group of disorders, both in terms of their molecular 
causes and in their phenotypes. In recent years, until the work towards this thesis was 
completed, the global effort at elucidating the genetic causes of these conditions had 
led to the discovery of 16 different genes, and an additional locus, that contribute to 
the pathogenesis of LCA and EORD. All of the genes, bar one (CRX) display an 
autosomal recessive inheritance pattern. The LCA9 locus had been known for some 
time, but the causative gene at this locus was only identified after this study was 
completed. The wide genetic heterogeneity reflects the different roles of these genes, 
which have a number of functions, including: photoreceptor structure and 
development; retinal function such as phototransduction and the visual cycle; 
transport across the photoreceptor cilium; chaperone functions; and some, as yet, 
unknown functions (Figure 10). There is considerable overlap of the genes that lead to 
LCA and EORD. The variability of the ocular phenotype can relate to the underlying 
molecular cause, but it can also vary between and within families affected by the 
same genetic variants. Typical phenotypes are associated with only a handful of 
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genes. Genotype-phenotype association studies are therefore particularly important 
for widening our understanding of these heterogeneous disorders. 
 
This chapter examines each gene or genetic locus that, until the work towards this 
thesis was completed, have been implicated in the pathogenesis of LCA and EORD. 
A description of the published phenotypes associated with variants in these genes is 
also included. The genes are described in the historic order that they or their loci were 
identified.  
 
 
 
 
Figure 10 – Spatial representation of 14 different LCA / EORD genes and their 
putative roles. Adapted from [46]. AIPL1 predominantly locates to the rod outer 
segments; CRB1 is located in the Müller cell membrane; CEP290, TULP1, RPGRIP1 
and Lebercillin are involved in protein transport through the cilia; RDH12 and 
IMPDH1 are located in the photoreceptor outer segments; LRAT and RPE65 are in 
the membranes of the endoplasmic reticulum of the RPE. 
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1.5.1 GUCY2D (LCA1) 
Following both linkage analysis and homozygosity mapping in 5 unrelated families of 
North African origin, the locus for the putative LCA1 gene was identified in 1995 on 
the short arm of chromosome 17 [113]. The causative gene was subsequently 
identified as the retinal guanylate cyclase 2D gene (RetGC, GUCY2D) (MIM 
600179), located at chromosome 17p13.1 [114]. GUCY2D encodes a human 
photoreceptor specific guanylate cyclase located in the photoreceptor (PR) outer 
segments (OSs), which catalyses the conversion of guanosine triphosphate (GTP) to 
cyclic 3’5’-guanosine monophosphate (cGMP), a key process involved in the 
restoration of PRs to their dark adapted state following excitation by light [115]. 
Mutations in this gene may lead to a state of constant hyperpolarisation of rod and 
cone PR plasma membranes due to the constant closed state of cGMP gated cation 
channels [116]. This leads to a situation equivalent to constant light exposure, in 
which PR cGMP levels do not return to the levels present in the dark adapted state. 
 
Mutations in GUCY2D account for about 11% of cases of LCA and EORD but the 
proportion can vary depending on the ethnic origin of the cohorts studied [109, 110, 
115, 117-124]. There is a higher prevalence of GUCY2D mutations in Mediterranean 
populations. A Mediterranean ancestry was present in 70% of all GUCY2D mutations 
in one LCA cohort [115]. The phenotype associated with mutations in GUCY2D is 
one of severe visual loss from birth (light perception or counting fingers vision), 
roving eye movements, pendular nystagmus, severe photophobia, high hypermetropia 
of +7.00 dioptre sphere (DS) or greater, a normal fundus appearance at birth and an 
un-recordable ERG [115, 120, 124]. The normal fundus appearance may progress 
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with age with the development of pigment migration into the retina and macular 
atrophy. Some patients may show little progression until adult life [120, 122]. 
 
Heterozygous GUCY2D mutations have also been associated with an autosomal 
dominant cone-rod dystrophy (CORD6), with affected individuals displaying 
characteristic macular atrophy and marked loss of cone function, with minimal loss of 
rod function on electroretinography [125-127]. The GUCY2D mutations that lead to 
autosomal dominant cone-rod dystrophy target exon 13 and have been identified to 
target codons 837, 838 and 839 specifically [128].  
 
Functional analysis of recessive missense mutations in GUCY2D in LCA subjects 
demonstrates location-specific effects of the mutations [129]. Missense mutations 
affecting the catalytic domain lead to severely impaired cGMP (basal activity), 
GCAP-1 and GCAP-2 (guanyl cyclase activating proteins) activity, and when these 
mutant cyclases are co-expressed with wild type alleles, the activity of the wild type 
allele is severely reduced, suggesting a dominant negative effect of mutations in the 
catalytic domain. However, in missense mutations affecting the extracellular domain 
there is no effect on basal cGMP activity, but GCAP-1 and GCAP-2 activity is 
reduced by 50%, suggesting that mutations in the extracellular domain moderately 
reduce cyclase activity. Therefore, with mutations in the catalytic domain, and not the 
extracellular domain, the dominant negative effect is expected to reduce GUCY2D 
function in heterozygotes with recessive mutations.  
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1.5.2 RPE65 (LCA2)  
In 1993 an evolutionarily conserved RPE-specific retinol binding protein receptor, 
with a molecular weight of 65kD, was identified and its expression was demonstrated 
to occur prior to the appearance of the photoreceptor outer segments during retinal 
development in rats [130]. Cloning and characterization of the protein revealed the 
533 amino acid structure [131]. The chromosomal locus of the relevant gene was 
subsequently mapped to 1p31 using fluorescence in situ hybridisation [132]. The 
human RPE65 (MIM 180069) gene structure was characterised in 1995 and comprises 
14 coding exons, spanning 20kB [133].     
 
Subsequent studies identified RPE65 as the isomerohydrolase, within the RPE, 
involved in the conversion of all-trans retinyl esters to 11-cis retinol during the visual 
cycle [134-136]. The substrate for this hydrolysis-isomerisation process is provided 
by the preceding step of the visual cycle in which lethicin acyl transferase (LRAT) 
converts all-trans retinol to all-trans retinyl ester. Despite RPE65 expression being 
predominantly in the RPE, studies have identified that it is also expressed in 
mammalian cone, but not rod, photoreceptors [137]. The exact role of RPE65 in cones 
is unknown. It is evident from animal models and from investigation of the phenotype 
in humans with RPE65 deficiency that cones have an alternative source of 
chromophore. Cones utilise an additional pathway to recycle retinoids that involves 
Müller cells [41, 43, 138]. In this alternative cycle, all-trans retinol leaves the cone 
outer segments and, instead of being transported to the RPE, is transported to the 
Müller cells, where it is converted to 11-cis-retinol, and subsequently transported to 
the cone OSs, where it is converted to 11-cis-retinal [139]. Rods, on the other hand, 
are entirely dependent on RPE65 in the RPE to recycle chromophore. This may 
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explain why patients with bi-allelic mutations in RPE65 have evidence of residual 
cone function but absent rod function. 
 
Recent studies using zebrafish, which have cone-dominant retinas, have characterized 
the isomerohydrolase likely to be involved in the cone visual cycle [138]. The 
identified protein, named RPE65c, shares 78% sequence homology with zebrafish 
RPE65a, the orthologue of human RPE65, and contains the key residues responsible 
for RPE65 enzyme activity. Immunohistochemistry has identified that RPE65c 
expression occurs in the Müller cells and inner retina, but not RPE, and that the 
chromosomal location of RPE65c is different to RPE65a. Further studies will be 
necessary to identify the human orthologue of RPE65c, it’s role in the visual cycle in 
humans and potential disease involvement.  
 
Several RPE65 animal models have been characterised, including the naturally 
occurring murine Rpe65rd12 [140] and canine Briard dog models [141, 142], and the 
genetically engineered Rpe65-/- knockout mouse model [143]. These animal models 
have been useful in studies of the underlying biochemical, genetic, functional and 
pathological role of RPE65, and in the development of novel therapeutic strategies. 
The retinal degeneration 12 (rd12) mouse has a naturally occurring homozygous 
nonsense mutation in the mouse orthologue of human RPE65, Rpe65, and shows 
small lipid-like droplets in the RPE from 3 weeks of age [140]. Over time these 
droplets grow larger in size and are associated with rod OS shortening and 
degeneration. Electrophysiological evidence of rod degeneration is evident as early as 
3 weeks of age, however histopathological examination suggests a slower retinal 
degeneration. The phenotype in these mice resembles, to some extent, that which is 
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seen in fundus albipunctatus, a condition caused predominantly by mutations in 
RDH5. The Rpe65-/- knockout mouse was described prior to the discovery of the rd12 
mouse [143]. The visual changes observed in these mice are restricted to rod 
dysfunction, as observed by an abolished rod ERG, with relatively spared cone 
function, thus supporting the hypothesis of an alternative cone system visual cycle. A 
slow retinal degeneration is evident as the retinal anatomy is relatively normal from 
birth, but from 7 weeks of age some loss of density of the rod outer segment discs is 
seen. By 15 weeks the outer segments are short, with inclusions present in the RPE. 
The PR nuclear layers also degenerate slowly. Rhodopsin, 11-cis-retinal and 11-cis-
retinyl esters are not present in Rpe65-/- mice, and there is an over-accumulation of 
all-trans-retinyl esters in the RPE, supporting the hypothesis that RPE65 is essential in 
the isomerisation step within the visual cycle.    
 
The naturally occurring Briard dog has a homozygous 4 nucleotide deletion in RPE65 
and has a phenotype similar to humans affected with mutations in this gene [141, 144-
146], with severe nyctalopia, a normal retina to up to 4 years of age and a severe rod-
cone dystrophy on electroretinography, with better preservation of cone function [141, 
142, 144]. Ultrastructural studies in the RPE of these dogs identify large lipid-like 
inclusions in the central and tapetal retina [145]. Smaller lysosomal inclusions in the 
RPE cytoplasm were detected, as well as disorganisation of the rod outer segments. 
The cone OSs and inner retinal structures were better preserved.  
 
The above animal models harbour mutations in RPE65 that render the function of the 
protein ‘null’. However, of the published RPE65 mutations to date, approximately 
50% are missense variants, and bi-allelic null mutations are extremely rare. Some 
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missense mutations may encode proteins that have residual enzymatic activity [147]. 
In ‘hypomorphic’ mutations, a milder phenotype may exist (see below), and studies 
using knock-in animal models for particular mutations, such as for the R91W Rpe65 
mutation, have been conducted to determine the effect of such missense mutations 
when compared to null mutations [147]. 
 
The overall mutation frequency of RPE65 in early onset retinal dystrophy is around 
6% [24]. The first families to be reported with RPE65 mutations were identified using 
single stranded conformation analysis (SSCA) and harboured a variety of mutations 
including missense, splice site and rearrangements [148-150]. The phenotypes in 
these families also varied, with diagnoses including LCA and EORD to different 
degrees of severity. With further reports of RPE65 retinopathy, the phenotypic 
variability associated with mutations in this gene has been highlighted, with affected 
individuals displaying a wide spectrum of severity, age of onset and progression [27, 
151-157]. The diagnoses range from ‘classical’ LCA, with very severe early onset 
visual loss from birth, through to autosomal recessive RP, with a later age of onset 
and a milder clinical picture. A variety of mutational mechanisms have been 
described (missense, nonsense, insertion – deletion mutations and splicing 
abnormalities) in a variety of combinations. 
 
The ‘classical’ phenotype of RPE65 retinopathy is described as severe visual 
impairment of infantile onset, with nystagmus, nyctalopia, photophilia, visual field 
constriction and an absence of photophobia. The fundus is either normal or 
hypopigmented (a ‘blonde fundus’) with visible choroidal vessels and little to no 
intra-retinal pigmentation [152, 154, 155]. Atrophic macular changes may be present 
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and retinal ‘white dots’ have also been described [14, 154, 156]. The ERG is either 
undetectable or shows severe rod dysfunction with possible residual cone function in 
the young [151, 153-155]. Children may have poor but useful vision in early life such 
that they may be able to attend normal school, however there can be significant 
deterioration in VA by the second decade and some retention of peripheral islands of 
vision into the third decade [151]. In some, however, only rudimentary peripheral 
visual fields are maintained [157]. Colour vision is severely affected across all axes, 
but in those in whom colour vision can be tested, the disturbance appears to 
predominantly affect the tritan axis [27, 153, 155]. A range of refractive errors have 
been documented, however in a report of 10 RPE65 patients, 50% had myopia or 
myopic astigmatism [158]. This group demonstrated absent or very low fundus 
autofluorescence in EORD due to RPE65 mutations. OCT studies have demonstrated 
loss of the central PR layer in young patients, and foveal and extrafoveal outer nuclear 
layer (ONL) thinning corresponding to rod photoreceptor loss [159]. The ONL 
thinning is more prominent inferior to the fovea, however the extent of OCT changes 
is variable. In older subjects (as described in a patient age 43 years), severe retinal and 
RPE thinning may be present, corresponding to the areas of RPE atrophy seen on 
ophthalmoscopy [158]. 
 
Although there is no specific genotype – phenotype association, the presence of 
milder phenotypes suggests hypomorphic allelic function. Marlhens first reported a 
correlation between the severity of disease and the type of RPE65 mutation in a 
compound heterozygote with two missense mutations and a mild clinical picture with 
slow progression [160]. In their series of 20 RPE65 individuals identified from 453 
retinal dystrophy patients, Thompson et al. described one individual with ‘nyctalopia 
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at age 3 years, a diagnosis of RP by age 20 and small islands of residual vision at age 
58’ who had a compound heterozygous mutation (Y79H/E95Q) [151]. Lorenz et al. 
described one subject with a homozygous p.P25L missense mutation who had best 
corrected visual acuities of 6/6 at age 5 and 6/9 at age 7 years [161]. He had reduced 
dark adaptation at age 3, an absence of nystagmus, hypopigmented fundi, and a small 
macular reflex. Goldmann kinetic perimetry at age 6 was normal to the V4e and III4e 
targets, but to the I4e target demonstrated slight constriction. Two-colour threshold 
perimetry detected predominantly cone mediated scotopic responses, and in the 
photopic state, cone responses were 1.5 log units below normal. Fundus 
autofluorescence was low but detectable, and OCT by age 7 showed outer retinal 
thinning. The ERG rod responses were severely impaired but cone mediated 
responses were detectable, albeit with 30% reduced amplitudes. These reports provide 
a convincing case for RPE65 hypomorphic variants causing a milder phenotype. 
Recently a knock-in mouse model with the R91W missense mutation was 
characterised which has comprehensively demonstrated the functional differences in 
the production of 11-cis-retinal and rhodopsin compared to Rpe65 null mutations 
[147]. 
 
The phenotypic heterogeneity associated with RPE65 mutations is further 
complicated by a report of a patient with ‘fundus albipunctatus’ harbouring a 
compound heterozygous RPE65 mutation [15]. In addition, there have been reports of 
heterozygote carriers displaying multiple hard drusen at the posterior pole and mid-
peripheral retina, in some patients associated with rod ERG and dark-adapted 
threshold perimetry dysfunction [154, 157]. 
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1.5.3 SPATA7 (LCA3)  
The LCA3 locus was identified through the analysis of a large consanguineous Saudi 
Arabian family with LCA [162]. Using homozygosity mapping the LCA3 locus was 
mapped to chromosome 14q24, but no obvious positional candidate genes were 
apparent in the identified region. In 2009, after further fine mapping of this region in 
this and other linked families, SPATA7 (MIM 609868) was identified as the causative 
gene [163].  
 
First cloned in 2003 from the rat testis, SPATA7 (spermatogenesis associated protein 
7) cDNA was also found to be expressed in the human testis [164]. In humans, 
SPATA7 consists of 12 exons and maps to chromosome 14q31.3. It encodes a 599 
amino acid protein with one transmembrane domain but no known functional domains 
[163]. In the mouse, Spata7 is expressed in multiple retinal layers including the inner 
segments of photoreceptors, inner nuclear layer and ganglion cell layer. The protein 
appears to be important in retinal function rather than development. Of the two known 
isoforms of SPATA7, isoform 1 is predominantly expressed in neuronal tissues 
including the retina, cerebellum and whole brain [165] and isoform 2 in the testis 
[166]. The exact function of SPATA7 remains to be identified.    
 
The incidence of SPATA7 mutations in LCA and EORD is around 2-3% [165, 166]. 
At the time that this study was conducted the limited phenotypic data available 
suggested that mutations in SPATA7 are associated with a severe LCA-like 
phenotype, but that less severe phenotypes also occur. The affected individuals in the 
original Saudi Arabian family, homozygous for a p.R108X mutation, had poor vision 
from birth, nystagmus, hypermetropic astigmatism and a non-recordable ERG [163]. 
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The same mutation was identified in a Dutch male with poor vision and nystagmus 
from birth who, at the age of 6 years, had retinal pigmentation and peripheral 
chorioretinal atrophy. A less severe phenotype was described in a 7 year old 
Portuguese female harbouring a homozygous nonsense mutation, p.R395X, who had 
juvenile onset RP with early onset nyctalopia, 6/6 visual acuity, an absence of 
nystagmus, severely constricted visual fields to the central 5o and undetectable ERGs. 
A diffuse hypopigmented parafoveal annulus was present. Another patient in this 
series, a male of French Canadian ancestry with a homozygous frameshift SPATA7 
mutation, p.Q465fsX505, carried a diagnosis of juvenile onset RP. He had normal 
vision in childhood, but developed nyctalopia and nystagmus. By age 55 years he had 
advanced retinal pigmentation and maculopathy, with a flat ERG. From their panel of 
134 LCA patients, Perrault et al. identified 4 families harbouring SPATA7 mutations, 
three of which were functionally ‘null’ [166]. All were of European ancestry and had 
a typical LCA phenotype. Photophobia was an initial feature, but by age 3 years all 
had nyctalopia. The retinae were normal initially but gradually developed a ‘salt and 
pepper’ appearance with vascular attenuation, retinal atrophy and typical fundus 
features of RP. There was complete absence of autofluorescence by adulthood. This 
group postulated that due to the expression profile of SPATA7, there may be an effect 
on male infertility, however their only male patient was not of child-bearing age. 
Mutations in SPATA7 thus may be associated with LCA or childhood onset rod cone 
dystrophy. 
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1.5.4 AIPL1 (LCA4)  
In 2000, linkage analysis in a Pakistani LCA family, in whom mutations in the nearby 
GUCY2D gene had been excluded, led to the identification of a separate LCA locus, 
termed LCA4, located on chromosome 17p13 [167]. The AIPL1 (aryl hydrocarbon 
receptor-interacting protein-like 1) gene (MIM 604392) was subsequently identified 
as the causative gene at this locus in the original LCA4 family [168]. 
 
The AIPL1 protein was named due to its similarity (49% identity) to the human aryl 
hydrocarbon receptor (AhR) interacting protein, AIP [168]. It is comprised of 384 
amino acids, and contains a 34-amino acid motif, that contains 3 tetratricopeptide 
repeats, that are present in proteins with nuclear transport or protein chaperone 
activity [169]. In situ hybridisation studies in rats and mice have shown Aipl1 
expression in the pineal gland and mouse photoreceptors [168]. In humans, AIPL1 is 
expressed in the pineal gland, and in the inner segments and outer plexiform layers of 
the rod photoreceptors in the central and peripheral retina [170]. It is not detected in 
cone photoreceptors in the mature retina. It is, however, expressed in both rod and 
cone photoreceptors of the developing retina, with may explain why there is severe 
and early rod and cone dysfunction in LCA patients with AIPL1 mutations [171].  
 
Early functional studies of AIPL1 have sought clues from the AIPL1 homologue AIP 
(aryl hydrocarbon receptor activated protein 9), which shares 49% identity and 69% 
similarity with AIPL1, and which in turn shares identity with the immunophilin co-
chaperones FKBP (FK506-binding protein) 51 and FKBP52 [172]. The results of such 
studies indicate that these molecules are components of cytosolic heterocomplexes 
[170], which play various functional roles. The ligand-induced transcriptional activity 
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of the AhR (aryl hydrocarbon receptor) is enhanced by AIP, which both stabilizes the 
cytosolic levels and modulates the intracellular localisation of the AhR. Thus the role 
of AIP is to regulate the nuclear translocation and transactivation of the AhR.  
 
AIPL1 interacts and aids with the farnesylation of proteins [173, 174]. Farnesylation 
is a 3-step prenylation process in which post-translational modification occurs at the 
c-terminus of a number of proteins. In the first step, a farnesyl group is covalently 
attached to the protein, in the cytosol. These farnesylated proteins are then targeted to 
the endoplasmic reticulum (ER) in step two, where proteases remove the last 3 amino 
acid residues. In step three, carboxymethylation of the proteins occurs in the ER. The 
farnesylated proteins are subsequently transported to their target membranes. AIPL1 
plays a role in at least one of these steps. The farnesylation process enhances protein-
membrane interactions and protein-protein interactions, and is important for the 
maintenance of the retinal and photoreceptor cytoarchitecture.  
 
Knock down mouse models of Aipl1, in which there is hypomorphic AipL1 function, 
have identified AIPL1 as a chaperone for the biosynthesis of phosphodiesterases in 
rod photoreceptors [175]. AIPL1 is probably also required for the normal 
development of cone photoreceptors. This study has refuted the findings of previous 
studies that AIPL1 is involved in protein farnesylation. In these hypomorphic Aipl1 
mutant retinas, the retinal degeneration occurred more slowly, and by 8 months of age 
half of the photoreceptors were lost and the inner and outer segments were shortened. 
In Aipl1-/- knockout mice photoreceptors initially develop normally, but once outer 
segments begin to develop, the rod and cone photoreceptors degenerate rapidly, in a 
light independent state, and in a process that is mediated by the destabilization of the 
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rod phosphodiesterase holoenzyme [176]. The mechanism by which AIPL1 affects 
the stability of the phosphodiesterase heterotrimer is unknown. AIPL1 and the 
molecular chaperones Hsp70 and Hsp90, may interact in regulating the production of 
phosphodiesterase [177].  
 
The role of AIPL1 in cone photoreceptor viability has been recently investigated 
using a transgenic mouse in which human AIPL1, under the control of a rod specific 
promoter, was expressed in an Aipl1-/- knockout mouse model [178]. This group 
hypothesized that the cone degeneration observed in Aipl1-/- mice may be due to an 
indirect ‘bystander effect’ due to rod photoreceptor death, or due to a direct role of 
AIPL1 in cones. Their findings demonstrated that cone photoreceptors degenerate 
more slowly in mice rescued by the transgenic expression of human AIPL1 in rods 
compared to the Aipl1-/- knockout, and that there is rescue of rod function. In addition 
to this, structural defects were seen in the surviving cones including thinner and 
shorter outer segments with disorganisation of the disc membranes. In the absence of 
AIPL1, the lack of cone function is due to the drastic destabilization of the cone PDE6 
subunits, as observed by the highly reduced levels of cone PDE6 in the transgenic 
mice. This study demonstrates that AIPL1 is required for cone function and survival 
but that in the presence of viable rods there is a reduced rate of cone degeneration.  
 
The incidence of AIPL1 mutations in LCA and EORD is 5.3% [24]. The original 
LCA4 family was subsequently identified to harbour the homozygous variant 
p.Trp278X [167, 168]. This has subsequently been identified to be the most common 
mutation associated with AIPL1 disease reported in both the homozygous and 
compound heterozygous states [179, 180]. One compound heterozygous subject 
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harbouring the variants p.Trp278X and p.Gly122Arg has been described with a milder 
phenotype, suggesting that the p.Gly122Arg variant acts as a hypomorphic allele 
[179]. 
 
The phenotype associated with AIPL1 mutations is typical of LCA, with severe visual 
loss from birth or within the first few months of life, nystagmus and nyctalopia [167, 
168, 179-183]. Visual acuity ranges from between 6/120 to no light perception [181, 
183]. There is predominantly a hypermetropic refractive error. Keratoconus and 
cataract are common [167, 179-181]. Characteristic fundus features include a 
maculopathy and pigmentary retinopathy. However, the severity of these features may 
be variable, and in some cases, age related. In the youngest patients, below 3 years of 
age, the retina may appear normal [180, 181]. The mildest maculopathy is described 
as an indistinct foveal reflex while the most severe appear as macular ‘colobomatous’ 
lesions. A pigmentary retinopathy over the age of 3 years is universal. Fundus 
autofluorescence imaging may show a hyperautofluorescent fovea with a 
hypoautofluorescent surrounding annulus or show complete lack of autofluorescence, 
corresponding with severe macular atrophy [179, 180]. 
 
 
1.5.5 Lebercilin (LCA5)  
The LCA5 locus was mapped to chromosome 16q11-16 in 2000, through linkage 
analysis of a consanguineous family belonging to the Old Order River Brethren, a 
religious isolate originating from Switzerland which emigrated to America in the 
1750s [184]. Three retina specific genes were excluded as the disease-causing gene in 
three affected members of this kindred. A second consanguineous family from 
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Pakistan was subsequently described in 2003 that also mapped to this region [185]. 
However, it was not until 2007 that the causative gene, LCA5 or lebercilin (MIM 
611408), was identified through homozygosity mapping of these two, and 4 other, 
families linking to the same region [186].  
 
LCA5 encodes a 697 amino acid ciliary protein containing 4 regions that are predicted 
to form coiled coils, a feature that is shared with some other ciliary proteins [186]. 
Lebercilin is expressed widely in human tissues. Murine in situ hybridisation studies 
have demonstrated that lebercilin expression occurs during embryogenesis and it is 
present in the eye, inner ear, kidney, central and peripheral nervous systems, gut and 
the ciliated epithelium of the nasopharynx, trachea and lungs. In adult mice, 
expression is confined to the retinal photoreceptors. Immunohistochemical studies of 
ciliated cells have localised lebercilin to the ciliary axoneme at the base of primary 
cilia. In the eye it is localized to the connecting cilium and basal bodies of 
photoreceptor cells, in particular to the axonemal microtubules of the connecting 
cilium. Proteins that interact with lebercilin exist as an ‘interactome’ that consists of 
24 proteins, many of which are associated with microtubules and/or have centrosomal 
or ciliary functions. This interactome specifically interacts with the intraflagellar 
transport (IFT) machinery that is involved in protein transport through the 
photoreceptor cilia [187]. A defect in IFT results in the failure of outer segment 
formation, causing photoreceptor degradation. 
 
The phenotype associated with LCA5 mutations is one with severe visual loss from 
birth, nystagmus, nyctalopia and an unrecordable ERG [184-186, 188-191]. Subjects 
are highly hypermetropic, have poor colour vision and pupillary responses. Visual 
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acuity ranges from 0.20 to light perception, and kinetic perimetry may detect only a 
small central area of retained vision. Anterior segments are normal, except in one 
recent report, which identified affected individuals with keratoconus and spoke-like 
cataracts [191]. Macular atrophy is a striking and frequent finding; in its mildest form, 
this may appear as mild perifoveal atrophy, but with age the atrophic macula becomes 
pigmented and takes on the appearance of a macular staphyloma [185]. Funduscopy 
in the youngest subjects shows widespread RPE atrophy and white dots, or a ‘salt and 
pepper’ pigment distribution [185]. With age, RPE atrophy becomes more 
widespread, bone spicule pigmentation or a ‘salt and pepper’ fundus may be seen and 
there is arteriolar attenuation [184, 185, 188, 189, 191]. There is a low 
autofluorescence signal corresponding to the macular atrophy [190]. OCT shows 
disorganized and abnormal retinal lamination eccentric to the fovea, that takes on a 
‘bilaminar’ appearance, with loss of the photoreceptor and outer nuclear layers, 
suggestive of retinal remodeling [190]. At the fovea the photoreceptor layer may be 
retained, although the IS/OS junction may be ill defined, and the foveal ONL 
thickness reduced, suggestive of loss of cones. Although lebercilin is expressed in a 
number of tissues, there have been no reports of extraocular abnormalities in LCA5 
mutations. One subject with LCA5 retinopathy died from asphyxia and the authors 
propose that there may be a connection between the cause of death and the presence 
of lebercilin in the ciliated epithelial cells of the bronchi [189].    
 
 
1.5.6 RPGRIP1 (LCA6) 
LCA6 was identified through studies investigating the molecular pathogenesis of the 
retinitis pigmentosa GTPase regulator (RPGR) gene, mutations in which account for 
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up to 60% of X-linked RP, and which are also implicated in X-linked cone, and X-
linked cone-rod dystrophy [192-196]. Yeast two-hybrid experiments, which allow the 
identification of the interacting partners of a particular gene by investigating the 
modular nature of transcription factors, were performed for RPGR by 3 independent 
groups in 2000 [197-199].  
 
At that time, as the only identified mutations within RPGR were located within its 
RCC1-homolgous domain (RHD), Roepman et al utilized RPGR and RHD in two-
yeast hybrid studies to identify several novel and retina-specific gene products that 
were alternatively spliced from the same gene that was localized to chromosome 
14q11 [199]. They named them RP GTPase regulator-interacting protein 1 (RPGIP1) 
isoforms and identified that they each contain an RPGR interacting domain at the C 
terminal and have stretches of coiled coil domains that share homology with proteins 
involved in vesicular transport. In human and bovine rod photoreceptor outer 
segments these proteins co-localise with RPGR. Mutations in RPGR lead to impaired 
interaction between these two proteins, suggesting that they could be candidate genes 
for RP. They suggested that RPGRIP1 might belong to a family of proteins that play a 
role in vesicular-transport and have neurone-specific function. 
 
Concurrently, Boylan et al identified the RPGR interacting protein RPGRIP1 [197]. 
They identified two human RPGRIP1 orthologues, which are expressed in the retina 
and testis. They also mapped the RPGRIP1 gene to 14q11.  Studies of murine retinal 
cDNA also identified an RPGR interacting protein that, in contrast to the views of 
Roepman et al., was exclusively localised to the photoreceptor connecting cilium 
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[198]. The authors concluded that RPGRIP1 is involved in regulating protein 
transport to or from the OS, through the connecting cilium. 
 
RPGRIP1 (MIM 605446) was first identified as a cause of LCA in 2001 [200]. 
Subsequent studies have determined the prevalence of RPGRIP1 mutations in LCA to 
be 4.2% [24]. The phenotype associated with null mutations in RPGRIP1 is typical of 
LCA and consists of severe visual loss and nystagmus from early childhood [200]. 
Nyctalopia and photoaversion are uncommon [182, 201]. Visual acuity is poor and 
ranges between 20/100 to no light perception [183, 200, 201], and hypermetropic 
refractive errors predominate [182, 183]. The retinal appearance is variable; being 
described as normal, unassociated with pigment, having circumferential bone spicule 
pigment or having drusen-like deposits [182, 200]. Vascular attenuation is widespread 
and macular atrophy, if present, may be seen by the third decade [200, 201]. There 
has been one report of 4 families diagnosed with cone rod dystrophy and mutations in 
RPGRIP1, in which the affected individuals had poor vision, colour blindness and 
severe photophobia from childhood, with variable fundus changes consisting of 
‘granularity’ in the retina, macular degeneration and a bull’s eye maculopathy [202].  
 
 
1.5.7 CRX (LCA7)  
The cone-rod homeobox (CRX) gene (MIM 602225) was the third gene to be 
identified in the pathogenesis of LCA [9]. It is a member of the highly conserved 
orthodenticle-related (otx) family of homeobox genes, encoding a 299 amino acid 
protein with a molecular mass of 32kDa [203]. This gene was first identified in the 
mouse retina and was found to be expressed in developing and mature photoreceptor 
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cells. It is required for the differentiation of photoreceptor outer segments and is 
essential for photoreceptor cell survival [204].  
 
CRX acts synergistically with neural retinal leucine zipper (NRL) in transactivating 
Rhodopsin [205]. It also regulates the expression of several other photoreceptor 
specific proteins including rhodopsin, the cone opsins, interphotoreceptor retinoid-
binding protein, N-phosphodiesterase, and arrestin. Both NRL and CRX can 
independently induce rhodopsin promoter activity but the leucine zipper of NRL 
interacts with CRX and this leads to the establishment and maintenance of 
photoreceptor function [206]. 
 
In 2002 the human and murine gene structure of CRX was characterised [207]. Human 
CRX has a molecular mass of 25Kb and is comprised of 6 exons, while murine crx is 
15Kb and comprises 4 exons. Both share an evolutionarily conserved promoter 
containing OTX/CRX and SP1/AP1 binding sites that lead to two different transcripts 
that are conserved in both species. The human gene has an additional human specific 
promoter that leads to 5 further transcripts.  
 
The otx family of homeobox genes includes PAX6, OTX1 and OTX2, which are also 
essential to ocular development [208]. The homeodomain of human CRX has 88%, 
86% and 88% identity to mouse OTX1, OTX2 and drosophila otd homeodomains 
respectively, and 60% identity to the homeodomain of other OTX-related proteins 
such as Ptx1/Potx [203]. The conserved sequences lie in the OTX tail at the carboxyl 
terminus and in other regions of these proteins. Animal studies have demonstrated 
that crx-/- mice fail to develop photoreceptor outer segments and have a thin outer 
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nuclear layer, while crx+/- mice develop short outer segments early in development, 
which eventually grow to the same length as those in wild type mice [209].  
 
Pathogenic mutations in CRX were first identified in autosomal dominant cone rod 
dystrophy [204, 210]. Subsequently, a patient with LCA was identified with a 
heterozygous CRX mutation in whom the second mutation was not found [9]. Until 
that time, it had been considered that LCA was exclusively inherited in an autosomal 
recessive manner. However, in the report by Freund et al. the identification of only 
one heterozygous variant left open the possibility that these changes represented de 
novo mutations in autosomal recessive disease, in which a second mutation was not 
found, or that this was a de novo mutation in autosomal dominant disease. The parents 
of the affected patient did not carry the mutations and had normal phenotypes, 
suggesting the latter scenario. Subsequent studies have expanded the phenotype of 
LCA associated with mutations in CRX, and suggest that the condition is 
predominantly inherited in an autosomal dominant manner [211-219].  
 
Phenotypic variability has been described within the cohorts of patients screened and 
identified with CRX mutations, who have diagnoses of autosomal dominant cone rod 
dystrophy and LCA [211, 212]. CRX mutation frequency in LCA is reported to be 1% 
[24]. The phenotype is typical of LCA, with poor vision from birth or early infancy, 
roving nystagmus, nyctalopia, constricted visual fields and undetectable ERGs. Visual 
acuity loss is usually very severe, ranging from between counting fingers to no light 
perception vision, although there have been some reports of better vision [217, 218]. 
At a younger age the retina may be normal or have a granular appearance, with RPE 
atrophy and white spots [211, 212, 215]. At this age the macula can appear irregular, 
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granular or atrophic, with RPE atrophy [211, 213-216, 219]. At an older age there 
may be varying degrees of pigment clumping that may be confined to the retinal 
periphery, with widespread RPE atrophy [211, 212, 217, 218]. In addition, there is 
severe macular atrophy, which can appear colobomatous [212, 213, 216].  
 
In keeping with the autosomal dominant nature of inheritance, almost all of the LCA-
associated CRX mutations identified to date have been in the heterozygous state. 
Unaffected parents have been reported to not carry the mutation, indicating that de 
novo mutations occur relatively frequently in CRX associated LCA [9, 212, 214-216, 
220]. It has been proposed, however, that the heterozygous mutations identified in 
these subjects may be explained by the presence of an unidentified mutation on the 
other CRX allele, in autosomal recessive disease, or that there may be a mutation on 
another gene that would suggest digenic inheritance [221]. To date, all but one 
mutation has been identified in the final exon of CRX. Missense mutations 
predominantly affect the homeodomain (a region of the protein comprising 20% of all 
amino acid residues) and frame shift mutations generate premature stop codons and 
predominantly affect the OTX domain (encoded by the final exon). Only one family 
has been described with a null mutation affecting the first exon of CRX [220]. In this 
family the p.Pro9(1-bpins) mutation was heterozygous in both the proband, who had 
LCA and other systemic abnormalities, and in the unaffected father. In this family, a 
number of possibilities arise: if the condition is inherited in an autosomal dominant 
manner, it is likely to be incompletely penetrant; the father may display mosaicism 
and hence not display the retinal phenotype; the condition could be inherited in an 
autosomal recessive manner in which the second CRX allele was not identified; or that 
CRX is not the causative gene in this family [221]. 
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There is only one report of a homozygous CRX mutation in a family with LCA that 
could suggest autosomal recessive inheritance [222]. Although the proband, who was 
from a non consanguineous family, had features consistent with LCA and carried the 
homozygous mutation p.W90R, the parents carried the mutation in the heterozygous 
state and they subsequently developed visual symptoms later in life and had signs of 
photoreceptor degeneration. It has therefore been proposed that in this family, a ‘semi 
dominant’ mode of inheritance exists in which the phenotype is severe in the 
homozygous state and milder in the heterozygous state [221].  
 
 
1.5.8 CRB1 (LCA8)  
The 1q31-q32.1 locus was identified by linkage analysis in a large Dutch family with 
autosomal recessive retinitis pigmentosa (ARRP) and preserved para-arteriolar retinal 
pigment epithelium (PPRPE) in 1994 (RP12) [223]. The causative gene was 
subsequently identified as the crumbs homologue 1 gene (CRB1) (MIM 604210), so 
called due to homology to the Drosophila Crumbs (CRB) protein [224]. The CRB 
proteins are highly conserved throughout evolution and were first characterised in 
Drosophila melanogaster [225]. CRB is required to maintain epithelial cell polarity, 
and is located in the zonula adherens, a cell-cell adherens junction located at the 
apical surface of cells of epithelial origin, including photoreceptor cells in Drosophila 
and vertebrates, and vertebrate Müller glial cells [226, 227]. CRB is also required for 
the morphogenesis and maintenance of the vertebrate and invertebrate retina [228]. In 
the adult mouse retina, Crb1 is present in the apical region of all retinal epithelial 
cells, the rod and cone photoreceptors and Müller glial cells.  
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The CRB1 gene consists of 4,361 base pairs, comprising 11 exons, and encodes a 
1,376 amino acid protein [224]. RT-PCR analysis identified CRB1 expression in 
human neural retina and brain, but not in the RPE or any other extra-ocular structures. 
The predicted protein sequence consists of a signal peptide, 19 EGF-like domains, 3 
laminin A G-like domains and a C-type lectin domain.  
 
The phenotype associated with mutations in CRB1 is variable. First described in 1982, 
autosomal recessive RP with relative preservation of the RPE adjacent to and under 
retinal arterioles (RP12) has now been reported in a number of families [229]. This 
condition is characterised by early onset progressive visual field constriction, 
hypermetropia, nystagmus, optic nerve head drusen, vascular sheathing and RP with 
preserved para-arteriolar RPE (PPRPE) (MIM 600105). CRB1 mutations are also 
associated with LCA and EORD, with a prevalence of 7-13% in this group of 
disorders [53, 124, 230, 231]. In addition, CRB1 mutations have been detected in 
subjects with RP without PPRPE [232], in asymptomatic subjects with pigmented 
paravenous chorioretinopathy [233] and in RP subjects who developed a Coats-like 
exudative vasculopathy, characterised by peripheral retinal telangeictasia and 
extravascular yellow sub-retinal lipid exudation, that may progress to an exudative 
retinal detachment [53, 230]. 
 
The phenotype in subjects with LCA or EORD that harbour mutations in CRB1 is 
particularly distinctive. In a large series, CRB1 mutations were identified in 12% of 
subjects with LCA, EORD and ARRP [53]. The condition is clinically progressive, 
with visual acuity at counting fingers or worse by the fourth decade. Hypermetropia is 
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common. Widespread sub-retinal white dots and macular atrophy occur from infancy, 
with characteristic deep nummular pigmentation at the level of the RPE developing by 
later childhood. This may become more extensive with age, and PPRPE, particularly 
associated with peripheral retinal telangeictasia, is highly suggestive of CRB1-related 
disease. OCT imaging characteristically identifies retinal thickening around the foveal 
pit and disorganised retinal lamination with coarse outer and inner zones, resembling 
the normal immature retina [234]. Preservation of the retinal layers has been 
identified in younger patients, but at an older age there may be coarse retinal 
lamination and loss of the outer limiting membrane or atrophy of the macula with loss 
of the central macular volume, suggesting that the retinal changes may not represent a 
developmental abnormality but that there is loss of the normal architecture over time 
[53]. Intra-retinal cysts have additionally been described as a common feature in LCA 
and EORD associated with mutations in CRB1. 
 
 
1.5.9 LCA9 locus  
The LCA9 locus was identified in a study of a large consanguineous Pakistani family 
with LCA in 2003 [235]. The affected family members displayed typical features of 
LCA, with widespread pigmentation in the retina, retinal white spots, optic disc pallor 
and macular staphyloma. Linkage analysis in this family identified a 10 cM region of 
autozygosity between the markers D1S1612 and D1S228 on chromosome 1p36. This 
region contains at least 5.7 Mb of DNA and, at the time of identification of this locus, 
contained around 50 genes. For many years the causative gene at this locus remained 
unidentified, and a number of techniques were utilised, including candidate gene 
screening in an attempt to identify the gene. At the time that the work presented in 
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this thesis was being carried out, the causative gene at the LCA9 locus had not been 
identified.  
 
However, in 2012, the gene nicotinamide nucleotide adenylyltransferase (NMNAT1) 
was identified simultaneously by 4 different groups, using exome sequencing, as the 
causative gene at the LCA9 locus [236-239]. NMNAT1 (MIM 608700) encodes a 279 
residue protein that plays an important role in NAD+ biosynthesis, in that it catalyses 
the formation of NAD+ from nicotinamide mononucleotide (NMN) and ATP [239]. It 
is a well-conserved protein with embryonic lethality in knockout mice and death in 
null mutations in Drosophila melanogaster.  NMNAT1 is also necessary for cell 
signaling and DNA metabolism [236]. Subjects with NMNAT1 mutations have a 
severe LCA phenotype but have normal general health [237]. The retinal appearance 
is characterised by severe macular atrophy and pigmentation, with scattered 
peripheral retinal pigmentation [236, 237]. Vision is severely reduced to between 
counting fingers and nil light perception.  
 
 
1.5.10 CEP290 (LCA10)  
In 2006, linkage analysis in a consanguineous French Canadian LCA family with four 
affected siblings identified a region on chromosome 12q21-q22 containing fifteen 
genes including CEP290 (MIM 610142) [240]. This gene had recently been identified 
to cause Joubert syndrome-related disorders [241]. Sequencing of all 53 exons and 
splice junctions in this family identified only one synonymous sequence variant in 
exon 21 that was predicted to have an effect on exon splicing [240]. However, RT-
PCR analysis in one of the affected siblings did not identify aberrant splicing of exon 
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21. Subsequent RT-PCR analysis of the entire CEP290 mRNA identified an aberrant 
splice product, and sequencing identified that a 128bp cryptic exon had been inserted 
between exons 26 and 27, that had introduced a stop codon immediately downstream 
of exon 26. Further sequencing of the genomic DNA identified a mutation in the 
intronic sequence (c.2991+1655A>G) that created a strong splice donor site and 
which had inserted the cryptic exon into the CEP290 mRNA. In a subsequent screen 
of 76 unrelated LCA families, this intronic mutation was identified in 4 patients in the 
homozygous state and in 12 patients in the heterozygous state. In the 12 heterozygous 
patients, the second mutation was identified in CEP290, confirming the autosomal 
recessive inheritance pattern with this gene. 
 
Further CEP290 mutations in families with Joubert syndrome-related disorders and 
Senior Loken syndrome were identified and the protein was characterised [242]. 
CEP290 encodes centrosomal protein 290 (also known as nephrocystin 6, NPHP6), 
spans 55 exons, and 93.2kb on human chromosome 12q21.32. This is a multi-domain 
protein found in the centrosomes and nuclei of renal epithelial cells and in the cilia of 
retinal photoreceptors. The rd16 mouse, which has early onset retinal dystrophy and 
absent olfactograms, suggesting anosmia, was found to harbour an 897bp in-frame 
deletion in Cep290 which led to the formation of truncated CEP290 [243, 244]. 
Murine CEP290 is similar to human CEP290 and localises to the centrosomes of 
dividing cells and the connecting cilium of photoreceptors. It is present in complex 
with other centrosomal and microtubule based transport proteins including RPGR, 
RPGRIP, dynactin subunits, kinesin subunit KIF3A, Ŋ-tubulin, centrin and ATF [242, 
243], and has a role in the regulation of intracellular protein trafficking. In this mouse 
model, the misrouting and redistribution of phototransduction proteins leads to 
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photoreceptor degeneration; the connecting cilia themselves do not show any obvious 
structural abnormalities.  
 
A detailed study of the single cell green alga with 2 flagella, chlamydomonas 
reinhardtii, in which most of CEP290 is deleted, identified that CEP290 forms part of 
a complex linking the flagellar membrane to microtubules in the transition zone, and 
regulates the entry of proteins into the cilium [245]. The transition zone is a short 
region of the cilium between the basal body and the axonemal microtubules where the 
triplet microtubules of the basal body transition into the axonemal doublets [246].  
 
The phenotype associated with mutations in CEP290 varies from isolated blindness 
(LCA) to the lethal Meckel-Gruber syndrome (MKS) [247, 248]. Other partially 
overlapping, yet distinct, disorders caused by CEP290 mutations include Joubert 
syndrome-related disorders and Senior Løken syndrome [241, 249, 250]. The 
phenotype in the original French Canadian family was typical of LCA, with blindness 
or severe visual impairment from birth, roving nystagmus from 6 weeks, high 
hyperopia, the oculodigital sign, keratoconus and cataract [240]. The retinal 
appearance ranges from looking normal in infancy, to one with vascular attenuation, a 
mottled RPE, intra-retinal white dots, a salt and pepper appearance, and subsequent 
specular pigmentary retinal degeneration with or without nummular pigmentation in 
adulthood [240, 251, 252]. The macular appearance is also variable and may be 
normal, show a blunt foveal reflex, have a bull’s eye appearance or late geographic 
atrophy [251, 253]. A milder phenotype, in which the vision was 20/40 at best, was 
reported in a family with a CEP290 mutation that induces exon skipping [254]. OCT 
imaging studies have described preservation of the outer nuclear layer at the central 
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macula in the first few decades of life, with an age related centrifugal thinning of this 
layer when extending into the perifoveal area [253, 255]. The PR inner segment / 
outer segment junction is poorly defined in the central macula and is invisible in the 
periphery. The demonstration that in cone rich areas (ie the fovea) there is normal 
photoreceptor lamination without thinning and a detectable RPE, leads this group to 
suggest that CEP290 patients may be amenable to cone photoreceptor targeted 
therapeutic strategies. AF imaging has revealed a hyperautofluorescent ring around 
the macula [252].  
 
Cilia are essential for many different cell types and are highly conserved organelles. 
The extensive presence of cilia throughout the body may account for the wide range 
of phenotypes associated with mutations in genes that encode ciliary proteins. The 
olfactory system contains sensory neurons that terminate in dendritic knobs 
containing basal bodies, from which numerous sensory cilia that compartmentalise the 
signaling molecules required for odour detection, project towards the nasal mucosa 
[244]. Olfactory investigation in CEP290 mutation has identified severe dysfunction 
in one family with LCA, and reduced electro-olfactogram responses in rd16 mice, 
demonstrating anosmia. The mechanism of this olfactory dysfunction is due to the 
altered ciliary localisation of olfactory G proteins in the olfactory sensory neurons. In 
addition to this, abnormal respiratory cilia in the nasal epithelial cells of CEP290 
LCA patients, which are short, rarefied and possess abnormalities of several axonemal 
components, has been described [256]. These findings suggest an additional role of 
CEP290 in the development of respiratory cilia in addition to photoreceptor cilia. 
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Mutations in CEP290 are reported to represent the most common cause of LCA in 
European cohorts, comprising up to 30% of cases [24, 119, 240, 251, 252, 257]. 
However, the incidence of CEP290 mutations in other cohorts worldwide is almost 
zero [258-260].  The majority of mutations described in CEP290 are protein 
truncating, caused by nonsense or frame-shift mutations [247]. The most frequent 
variant, a probable founder mutation, is the intronic variant c.2991+1655A>G 
described in the original French Canadian family, which accounts for up to 89% of 
CEP290 mutations in Northern European cohorts [24, 251, 252]. It was hypothesised 
that in CEP290 related LCA, there is a small amount of functioning residual wild type 
protein, resulting in a dosage-dependent mechanism with sufficient residual CEP290 
activity for normal cerebellar and renal function but not for photoreceptor function; 
and that loss of function from both alleles leads to Joubert syndrome [240]. However, 
this hypothesis has since been debated as families with truncating mutations on both 
alleles have been identified with LCA [251]. The c.2991+1655A>G mutation had 
been considered to lead solely to LCA, but there have now been reports of LCA 
families who carry this mutation who have additional renal dysfunction [252].  
 
CEP290 disease remains a highly heterogenous condition and there is no clear-cut 
correlation between genotype and clinical expression. In general, mutations leading to 
Joubert syndrome-related disorders tend to cluster in the second half of the gene, 
while there is a more homogeneous distribution to the mutations segregating with 
LCA, Senior Løken syndrome and MKS [247]. This clinical variability may be due to 
second-site modifier alleles that encode proteins that also comprise the ciliary 
proteome. Variants in genes such as AHI1 (associated with Joubert syndrome-related 
disorders), TMEM67 (associated with a number of clinical phenotypes) and NPHP4 
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(associated with nephronophthisis and Senior Løken Syndrome) may affect the 
interaction and function of CEP290. Conversely, variants in CEP290 may affect the 
phenotype caused by mutations in other ciliary genes.   
 
 
1.5.11 IMPDH1 (LCA11)  
Mutations in the IMPDH1 gene (MIM 146690) were initially identified in autosomal 
dominant retinitis pigmentosa [261, 262]. In a subsequent screen of different retinal 
phenotypes, 2 subjects with pathogenic heterozygous variants in IMPDH1, one with 
LCA and the other with EORD, were identified [263]. One child was diagnosed with 
LCA at 8 months of age as he did not fix or follow and had roving nystagmus. He had 
hypotonia and developmental delay. His retina showed diffuse RPE mottling, no 
pigment and an identifiable macular reflex. The second child had nyctalopia and 
reduced peripheral visual fields, and was diagnosed with an early onset retinal 
dystrophy phenotype at age 33 months. Her vision was 20/40 and she had moderate 
hypermetropia. Her fundus was de-pigmented, with vascular attenuation and optic 
nerve pallor. Both mutations were considered de novo, and may lead to an inheritance 
pattern consistent with autosomal dominant inheritance. IMPDH1 associated LCA is 
extremely rare, and has not been identified in other studies worldwide of LCA 
screening [118, 119, 124, 201, 252, 258-260]. 
 
IMPDH1, found on chromosome 7q32.1, encodes inosine monophosphate 
dehydrogenase type 1 (IMPDH1), a highly conserved, widely expressed, 
housekeeping gene [263, 264]. It catalyses the rate limiting step of de novo guanine 
synthesis by oxidizing inosine monophosphate to xanthosine-5’-monophosphate with 
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reduction of nicotinamide adenine dinucleotide (NAD). Humans have 2 IMPDH 
genes: 1 and 2. Although IMPDH1 is found in many tissues, its expression is highest 
in the retina, particularly the inner segments [264]. These retina specific isoforms may 
explain why mutations in IMPDH1 restrict the phenotype to the retina.  
 
 
1.5.12 RD3 (LCA12)  
Following the identification of Rd3 gene in the RD3 mouse, which has early onset 
retinal degeneration, the first family with RD3 associated LCA was discovered [265]. 
Mutations in RD3 (MIM 180040) are an extremely rare cause of LCA and by the time 
that work towards this thesis had been completed, this was the only family to be 
reported with an RD3 mutation.  
 
Human RD3 is located on chromosome 1q32.1, and encodes a 22 KDa protein with 2 
putative coiled coil domains that are presumed to be protein interaction sites. In the 
mouse, Rd3 is preferentially expressed in the retina, with increased expression in 
early post-natal development. The exact function of RD3 is not completely 
understood. It is known to co-localise and interact with guanylate cyclases 1 and 2 
(GC1 and GC2) in the rod and cone photoreceptors of normal mice, and one study 
proposed that it mediates the export of GC1 (encoded by GUCY2D) from the 
endoplasmic reticulum to endosomal vesicles, playing a crucial role in the stable 
expression and in the photoreceptor membrane trafficking of GC1 and GC2 [266]. 
Subsequent studies have proposed that RD3 inhibits GUCY2D activity and may play 
a role in retinal maturation [267]. 
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The phenotype described in the original RD3 family, a consanguineous family of 
Indian origin, is typical of LCA, with poor vision from birth, nystagmus, macular 
atrophy, RPE mottling and both macular and peripheral pigmentation [265].  
 
Since the work towards this thesis was carried out, further families with RD3 
mutations have been identified [268, 269]. A multiply consanguineous Kurdish family 
with 6 affected individuals was studied in detail, and found to have a typical LCA 
phenotype with poor vision from birth (never better than 1.12 logMAR) that 
deteriorated with age to light perception, severe nystagmus, photosensitivity, sluggish 
pupils, and a low hypermetropic refractive error that progressed to myopia [268]. The 
fundus appearance below 2 years was normal, but progressed to one with attenuated 
vessels, a reduced macular reflex that eventually became atrophic and a mottled 
peripheral retina by the third decade with bone spicule pigmentation. The OCT 
showed severely disorganised photoreceptor and RPE layers and a very poor 
autofluorescence signal was attained. The GVF was severely reduced to less than 20 
degrees and the ERG was un-recordable.  
 
A subsequent worldwide collaborative study has identified 7 further families, from 
574 LCA families, giving a prevalence of 1.21% [269]. Photoaversion and low, if any, 
hypermetropia were common findings, with visual acuity reaching counting fingers, at 
best. In addition to the most frequent features of LCA, these patients had macular 
abnormalities ranging from ‘rearrangement’ to atrophy, little to no retinal 
pigmentation, and RPE atrophy with a salt and pepper fundus.  
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All human RD3 mutations to date cluster in exon 2, and six of 9 families described are 
of Mediterranean origin, suggesting mutations ‘hotspots’ or an ancient founder 
mutation in this region. The phenotype bears strong resemblance to that associated 
with mutations in GUCY2D, also more common in Mediterranean populations, and it 
has been recommended that LCA patients with a cone rod phenotype who have 
moderate to no hypermetropia, and are of Mediterranean origin, should have RD3 
screening prior to the screening of other cone related LCA genes such as GUCY2D, 
CEP290 or RPGRIP1 when searching for the causative gene [269].  
 
 
1.5.13 RDH12 (LCA13)  
The first human RDH12 (MIM 608830) mutation was identified in 3 consanguineous 
Austrian families with early onset retinal dystrophy, following microarray analysis 
that identified a region that overlapped with the region containing the putative LCA3 
gene [270]. This region contained 29 genes and RDH12 was selected as a candidate 
gene due to its location in the retina and role as a retinol dehydrogenase that was 
proposed to function in the visual cycle. All three families harboured the same 
c.677A>G variation, suggesting a founder mutation for retinal dystrophy in Western 
Austria. Concurrently, screening of a panel of unrelated LCA subjects in France 
identified a significant subset (4.1%) of patients with a range of mutations in RDH12 
[271]. The mutation spectrum in this gene was further expanded through a screening 
of 1011 autosomal recessive retinal dystrophy patients, at a prevalence of 2.2%, and 
haplotype analysis in the original LCA3 family excluded RDH12 as the causative gene 
in this locus [272]. 
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RDH12, located on chromosome 14q23.3, encodes a 35KDa protein, retinol 
dehydrogenase 12, which is a member of the short chain alcohol dehydrogenase / 
reductase superfamily that catalyse the transformation of retinol to retinal [273]. This 
family of enzymes has been the subject of much study and the specific role of RDH12 
in the visual cycle remains to be elucidated. RDH12 is localised to the inner segments 
of both rod and cone photoreceptors and has dual substrate specificity in that it can 
utilise both cis- and trans- retinoids as substrates [273], and it is also active against 
medium chain aldehydes [274]. The RDH12-/- knock out mouse has a milder 
phenotype than in human RDH12 mutations, suggesting that the role of murine 
RDH12 is different to humans [275]. In this knock out mouse however, dark 
adaptation is slower and all-trans-retinal accumulation occurs after excessive 
bleaching, albeit less than in the RDH8-/- mouse, suggesting that RDH12 contributes 
less to all-trans-retinal reduction than RDH8. However, RDH12-/- mice are more 
susceptible to light induced apoptosis, suggesting that RDH12 has an important role 
in photoreceptor protection from all-trans-retinal accumulation during excessive 
illumination.   
 
There are separate visual cycles in rods and cones. In the rod visual cycle, RDH12 
appears to function with, but contributes less than, RDH8 in the reduction of all-trans-
retinal in the photoreceptor [276].  In cones, some all-trans-retinal is transported out 
to Müller cells, isomerised to 11-cis-retinol, and then transported to cones for 
oxidation to 11-cis-retinal [48, 277].  Whether RDH12 plays a role in this process 
remains to be elucidated. Since the work towards this thesis was carried out, an 
additional role for RDH12 in rods has been hypothesised to be in the protection of 
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inner segment organelles against aldehyde toxicity caused by intracellular leakage of 
all-trans-retinal and other aldehydes, originating from the outer segments [44].   
 
The phenotype associated with human RDH12 mutations is of an early onset retinal 
dystrophy with symptoms beginning in the first few years of life, progressing to legal 
blindness by the second to third decade [270-272]. This is a severe progressive rod 
cone dystrophy, with widespread RPE atrophy, pronounced intra-retinal pigmentary 
deposition, attenuation of blood vessels and severe macular atrophy, with extinction 
of the ERG as early as 5 years old. The phenotype has been further described in a 
number of studies, and RDH12 mutations represent a significant cause of LCA and 
EORD worldwide [278-284].  
 
 
1.5.14 LRAT (LCA14)  
Mutations in the Lecithin Retinol Acyl Transferase (LRAT) gene (MIM 604863) were 
first identified in individuals with early onset retinal dystrophy [285]. Located on 
chromosome 4q31.2, and comprising of 3 exons, LRAT encodes a 230 amino acid, 
25KDa protein, which is expressed in a number of foetal and adult tissues including 
the RPE and liver [286, 287]. Its function in the RPE, and other tissues, is to transfer 
an acyl group from lecithin to all-trans-retinol (vitamin A), derived from the 
photoreceptors or the circulation, to generate all-trans-retinyl esters, a crucial step of 
the visual cycle.  
 
The Lrat-/- mouse develops normally but shows slow degeneration of the retina [288]. 
At 6-8 weeks of age its rod outer segments are 35% shorter than wild type mice but 
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the other neuronal layers are normal. The RPE is devoid of all-trans-retinol and all-
trans-retinyl esters, the photoreceptors have no functional rhodopsin and the photopic 
and scotopic ERGs demonstrate severely attenuated rod and cone function at an early 
age. Similar to the Rpe65-/- mouse, the Lrat-/- mouse does not produce 11-cis-retinal 
[289]. Both of these models show slow degeneration of rods and failure of cone 
opsins to traffik appropriately to the outer segments, leading to rapid cone 
degeneration.  
 
The human phenotype of LRAT mutations is that of a severe early onset retinal 
dystrophy, with onset of nyctalopia and reduced vision in the first few years of life 
[26, 285, 290, 291]. Only 8 patients have been reported to date. Of the limited 
phenotypic information available, the retina can vary from looking normal to one with 
vascular attenuation, peripheral retinal mottling and bone spicule pigmentation. 
Moderate to marked hypermetropia and visual field constriction to between 10-30 
degrees is reported, and the ERG demonstrates a severe rod cone dystrophy. 
 
Since the work toward this thesis was completed, a further family with EORD and a 
homozygous mutation in LRAT has been described [292], as well as two families of 
Dutch descent with a homozygous frame shift mutation in LRAT who have a 
phenotype consistent with retinitis punctata albescens, usually caused by mutations in 
RLBP1 [45]. These subjects had relatively good vision (6/9.5 or better), nyctalopia 
and normal visual fields. The fundus showed few to numerous white dots in the mid-
periphery. The ERG demonstrated reduced or non-recordable scotopic responses after 
standard and prolonged dark adaptation, and normal or slightly reduced photopic 
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responses, in keeping with retinitis punctata albescens. This finding, therefore, further 
expands the phenotype associated with mutations in LRAT.  
 
 
1.5.15 TULP1 (RP14)  
Following identification of a recessive mutation in tub in the tubby mouse, which 
causes progressive retinal and cochlear degeneration and maturity onset obesity with 
insulin resistance and impaired glucose tolerance [293-295], mutations in genes 
encoding other members of the Tubby-like protein (TULP) family were sought. 
TULP1 (Tubby-like protein 1) is a member of this family, in which to date, 5 
members have been identified: TUB, TULP1, TULP2, TULP3 and TUSP (TULP4) 
[296-298]. TULP1 (MIM 602280) mutations in humans were first identified following 
mapping to the RP14 locus on chromosome 6q21 in two large Dominican kindreds 
with a severe retinal phenotype consistent with early onset retinal degeneration [299]. 
Concurrently, screening of TULP1 in large panels of autosomal recessive RP families 
identified further pathogenic variants [300, 301].  
 
TUB maps to chromosome 11p15.4 and TULP1 to 6p21.3, which maps to the RP14 
locus identified in autosomal recessive RP [296]. Both TUB and TULP1 have a 90% 
shared amino acid identity, and the members of the TULP family of proteins share a 
highly conserved c-terminal ‘tubby’ domain that is capable of highly selective binding 
to specific phosphoinositides [302, 303]. The tubby-like proteins are present in a wide 
range of species and show distinct expression in a number of tissues. Murine studies 
using in situ hybridisation and immunohistochemistry have identified the cell specific 
expression of these proteins within the retina: TUB is expressed throughout the retina, 
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with its highest expression in the ganglion cell layer and photoreceptors; TULP1 is 
expressed exclusively in the photoreceptors, localising predominantly to the inner 
segments, connecting cilium perikarya and terminals; TULP2 shows no retinal 
expression; and there is moderate expression of TULP3 in the inner nuclear and 
ganglion cell layers [304, 305]. 
 
It is suggested that the primary site of action of the tubby family of genes is in 
neuronal cells, including hypothalamic, sensory and differentiating neurones [306], 
and that TULP1 plays a role in intracelluclar trafficking in the inner segments and at 
the photoreceptor synapse [307]. In Tulp1-/- mice, the photoreceptor cells degenerate, 
rod and cone opsins mislocalise and vesicles containing rhodopsin accumulate, 
suggesting that Tulp1 plays a role in protein transport through the connecting cilium 
between the inner and outer segments. Further studies have identified that absence of 
Tulp1 leads to photoreceptor synapse malformation that precedes photoreceptor 
degeneration, and therefore that Tulp1 is essential for photoreceptor synapse 
development and in photoreceptor function and survival [308].  
 
The phenotype associated with human mutations in TULP1 has been well documented 
and appears to be solely ocular. One of the original multiply consanguineous 
Dominican kindreds, with 16 affected members, was closely phenotyped, and the 
pedigree traced back to 2 founders born in the 1800s [309]. Disease onset was in early 
childhood with nyctalopia (as young as 10 months), poor vision (no better than 1.00 
LogMAR), reduced colour vision, nystagmus and myopia. Kinetic visual field testing 
in the young demonstrated preservation of the peripheral field, but older subjects had 
only preserved ‘islands’ of vision. Psychophysical testing with dark-adapted 
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perimetry demonstrated no rod function and markedly reduced cone function, which 
subsequently deteriorated. The ERG was undetectable. In the first decade, the retina 
displayed vascular attenuation and minimal pigmentation. By the 2nd and 3rd decades, 
yellow deposits were seen in the macula with bone spicule pigmentation from the 
arcades to the periphery. By the 5th decade, subjects developed a ‘bull’s eye’ 
maculopathy and peripheral retinal pigmentation. The optic discs showed a ‘waxy 
pallor’. These individuals were otherwise in good health, were not obese and had 
normal hearing and balance. A similar phenotype has been described by a number of 
other authors [258, 310-314]. Fundus autofluorescence imaging has identified an 
annulus of increased perifoveal autofluorescence, and OCT imaging has shown 
abnormal lamination, with complete loss of the outer nuclear layer and inner segment 
outer segment junction [311]. Only in one study did patients predominantly have a 
hypermetropic refractive error [258]. Mutations in TULP1 appear to be more common 
in families from the Middle East and in South East Asia. At the time the research 
towards this study began, no reports of human TUB mutations were published. We 
have since identified the first mutations in the human TUB gene causing retinal 
dystrophy (see chapter 4.4). 
 
 
1.5.16 RGR (RP44)  
The retinal pigment epithelium G protein-coupled receptor (RGR) is an intracellular 
membrane bound protein located in RPE cells and Müller cells, and plays a role in the 
visual cycle [315]. It had been proposed that RGR functions in an ‘alternative’ visual 
cycle that is dependent upon light, in which it regenerates 11-cis-retinal from all-
trans-retinal during periods of light exposure [316]. However, experiments have 
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shown that RGR accelerates rhodopsin regeneration by inducing isomerohydrolase 
activity and accelerating the conversion of retinyl esters to 11-cis-retinal in a process 
that is independent of light levels [317]. The exact role of RGR in the regulation of 
the visual cycle continues to be investigated. Radu et al. recently identified that RPE 
cells respond to light by mobilising all-trans retinyl esters, and that RGR mediates this 
mobilisation [318]. In addition, in the dark, in vitro studies show that RGR inhibits 
LRAT and all-trans-retinyl ester hydrolase, and that this inhibition is reversed in the 
light.    
 
RGR  (MIM 600342), located on chromosome 10q23, comprises 7 exons [315]. 
Although extremely rare, mutations in RGR have been identified as a cause of retinitis 
pigmentosa [319]. A missense mutation, c. 196A>C, p.Ser66Arg, was identified in the 
homozygous state in 5 affected siblings of one RP family, suggesting a recessive 
inheritance pattern. The age of onset of symptoms was not reported, however vision 
in the 4th and 5th decades was severely reduced (to less than 1.00 LogMAR), with 
severe visual field constriction and severe rod cone dysfunction demonstrated by the 
ERG. The retina displayed diffuse depigmentation of the RPE, including the macula, 
with vascular attenuation and peripheral pigmentation. A second family with a 
heterozygous RGR mutation comprising a 1 base pair insertion, p.Gly275, in 2 
affected siblings, suggested a dominant inheritance pattern. Vision in the 7th decade 
was reduced but better than in the recessive family, and the ERG was severely 
attenuated. One further family with the p.Ser66Arg mutation was recently reported 
with a severe childhood onset phenotype progressing to perception of light vision, 
macular RPE changes, peripheral retinal degeneration, RPE atrophy and bone spicule 
pigmentation by the 4th decade [292]. Further screening of RGR in a range of inherited 
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retinal dystrophies has failed to find any other pathogenic variants, confirming that 
RGR mutations are a rare cause of early onset retinal dystrophy [320, 321].         
 
 
1.5.17 IQCB1 / NPHP5  
In 2011, mutations in NPHP5 (IQCB1) (MIM 609237) were first reported in a number 
of non-syndromic LCA families [250, 322]. This gene was previously identified to be 
the predominant causative gene in individuals with Senior Løken syndrome, an oculo-
renal syndrome characterised by nephronophthisis and LCA [323]. Located on 
chromosome 3q13.33, and comprising 15 exons, it encodes the ciliary protein 
nephrocystin-5, which localises to the connecting cilium of photoreceptors and the 
primary cilia of renal epithelial cells. NPHP5 has been shown to interact with NPHP6 
(also known as CEP290), and mutations in the genes encoding these proteins are 
associated with LCA [324]. Knockdown of both of these genes in zebrafish leads to 
similar phenotypes with both ocular and systemic manifestations. 
 
Screening of IQCB1 in a panel of 225 LCA patients identified 11 with pathogenic 
mutations, 7 of whom were subsequently diagnosed with Senior Løken syndrome, and 
4 of whom had ‘isolated’ LCA, giving a prevalence of 2% of isolated LCA in this 
cohort [322]. Concurrently, the screening of NPHP5 in an enriched panel of 276 LCA 
probands identified 9 pathogenic mutations, 2 of which developed nephronophthisis 
in the second decade, giving a prevalence of 2.5% of ‘isolated’ LCA in this cohort 
[250]. The authors report that there is a highly variable age of onset of renal failure in 
IQCB1 mutations, so all these patients will require lifelong screening for renal 
dysfunction.  
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The ocular phenotype in these subjects is typical of LCA, and there is little disparity 
between those with ‘isolated’ LCA and Senior Løken syndrome. There is significant 
and progressive loss of vision from birth, with pendular nystagmus, high hyperopia 
and an undetectable ERG [250, 322, 325]. The retina shows prominent diffuse RPE 
atrophy and vascular attenuation. OCT imaging demonstrates preservation of the 
outer nuclear layer only at the fovea and a disorganised inner segment outer segment 
line. Overall the phenotype is suggested to be similar to other ciliopathies such as that 
caused by mutations in CEP290. The preservation of cone photoreceptor nuclei in 
both NHPH5 and NHPH6 mutations, albeit with abnormal inner and outer segments, 
has lead to the proposal that these subjects may be good candidates for cone-directed 
gene augmentation therapy [326].   
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1.6 Aims and Objectives 
 
1.6.1 Aims  
1. To recruit probands with childhood onset retinal dystrophies, and family 
members, into 2 cohorts of the Childhood Onset Retinal Dystrophy Study: 
a. Subjects with Leber Congenital Amaurosis (LCA), Early Onset Retinal 
Dystrophy (EORD) and early onset rod-cone or cone-rod dystrophies 
b. Subjects with Childhood Onset macular phenotypes;  
 
2. To use information gathered from phenotypic studies to understand the natural 
history and heterogeneity of the condition(s) in order to help provide prognostic 
and genetic counselling to affected families;  
 
3. To identify novel phenotypes of childhood onset retinal dystrophies.  
 
 
1.6.2 Objectives 
 
1. To undertake detailed phenotypic studies of affected subjects with mutations in 
specific genes in order to explore, expand and refine our understanding of the 
phenotypes associated with variants in these genes;  
 
2. To obtain blood samples for DNA extraction for molecular analysis of probands 
and family members in order to identify causative mutation(s);  
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3. To work with colleagues to identify mutations in known and newly identified 
genes in the two cohorts, using a variety of molecular techniques. 
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2.0 Materials and Methods  
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2.1 Ethics / Patient selection 
 
2.1.1 Ethical Approval  
Ethical approval for this study, entitled ‘A Clinical Trial and Genetic Investigation of 
Childhood Retinal Dystrophies’ was previously granted by the Moorfields Local 
Research Ethics Committee (REC) in December 2004, REC reference number 
MOOA1005. This study is also known as the ‘Childhood Onset Retinal Dystrophy 
Study’, and will be referred to as such from this point on. A number of amendments 
had been made and approved by the REC prior to this author’s involvement in the 
study, and the ethical approval was extended to 2012. Following this date, new ethical 
approval was sought and this study was incorporated into a larger study held at 
Moorfields Eye Hospital (MEH) and University College London (UCL) entitled ‘A 
Genetic Study of Inherited Retinal Eye Disease’. Ethical approval for this study was 
granted by the National Research Ethics Committee Camden and Islington REC 
Office, REC reference number 12/LO/0141, on 30th January 2012.  
 
 
2.1.2 Patient Selection 
There were two separate cohorts of patients that were recruited to this study. A few 
different approaches to patient ascertainment were utilised, as described below.   
 
The first, and largest cohort, were those patients and families where the proband had a 
generalised retinal dystrophy, which predominantly included subjects who carried a 
diagnosis of Leber congenital amaurosis (LCA), early onset retinal dystrophy 
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(EORD), childhood onset rod-cone dystrophy, childhood onset cone-rod dystrophy 
and childhood onset cone dystrophy. Any patients with symptoms or signs suggesting 
syndromic involvement were excluded.  
 
The second cohort of patients had childhood onset signs that predominantly involved 
the macular region of the retina, and in particular included patients with a phenotype 
similar to Best disease and a newly recognised phenotype with drusen – like yellow 
deposits at the macula. 
 
Patients and their families were predominantly recruited into the Childhood Onset 
Retinal Dystrophy Study from the paediatric and adult retina clinics at Moorfields Eye 
Hospital NHS Foundation Trust, London, UK and Great Ormond Street Hospital for 
Children NHS Foundation Trust, London, UK. Some patients were referred by 
Ophthalmologists or Geneticists from other hospitals, both nationally and 
internationally, who were aware of the study. Some of these families were then 
invited to take part in the study by a postal invitation if they were not able to attend 
MEH.  
 
There is a large database of families with inherited retinal diseases at MEH that spans 
over a 40-year period. The Inherited Eye Disease (IED) Database, keeps a log of these 
patients and their families, along with their genetic mutations, where known. This 
database includes all families with inherited retinal diseases, regardless of diagnosis, 
age of disease onset or inheritance pattern. DNA of patients held in this database is 
stored at the Institute of Ophthalmology, UCL. Mr Robert Henderson and Mr Phillip 
Moradi, who were the research fellows involved in the Childhood Onset Retinal 
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Dystrophy study between 2004-2006 and 2006-2008 respectively, had previously 
recruited some of these families and had logged them into the IED database. A record 
of these ‘historic’ subjects was kept in a Microsoft Access (Microsoft, Washington, 
USA) database, to which this author had access while conducting the study.  
 
Other researchers within the Genetics Unit were investigating patients who carried a 
diagnosis of autosomal recessive retinitis pigmentosa (ARRP). Several panels of 
DNA were screened for mutations in EORD genes by them, which included patients 
with ARRP but whose symptom onset, when later probed, was identified to have 
begun in childhood, before the age of 5 years. These subjects and their families were 
subsequently recruited into the Childhood Onset Retinal Dystrophy study and invited 
to attend for further phenotyping. These subjects will be clearly identified in this 
thesis.   
 
 
2.1.3 Consent 
Patients and their families were consented to enter this study using approved consent 
forms for adults and children (Appendix 7.1.2, 7.1.3, 7.1.4). Patient information 
sheets had been previously prepared, and included information about the study 
(Appendix 7.1.1). For those patients or families that were not seen and consented at 
MEH, a letter was sent out by post, inviting them into the study. Along with the letter, 
Patient Information sheets, consent forms, letters to their GP / local hospital and blood 
collecting tubes were also provided, so that they could have their blood samples taken 
locally and subsequently returned by post.  
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2.2 Phenotyping 
 
All phenotyping in this study was performed at Moorfields Eye Hospital (MEH), 
London, UK or at the Institute of Ophthalmology, University College London (UCL), 
London, UK. 
 
 
2.2.3 Clinical History 
All subjects recruited into the study underwent detailed questioning from them or 
their parents regarding age of onset and course of symptoms, functional level of 
vision, presence and age of onset of nystagmus, nyctalopia, photophobia, 
photoattraction, visual field deficits, colour vision deficits and history of eye poking 
or rubbing. Information regarding the past ocular history including any glasses wear, 
presence of strabismus and previous ocular surgery or amblyopia therapy was sought. 
An enquiry regarding the past medical history was made, in particular any systemic 
illnesses or previous or on going investigations such as those looking into renal, 
neurological or endocrine dysfunction. These may have included radiological imaging 
and haematological or biochemical investigations, and was undertaken to ensure that 
no patients with syndromic associations were included. Birth and developmental 
histories were taken, including any maternal problems encountered during pregnancy, 
and ages that developmental milestones were met. Any current or historical use of 
medications was recorded. A full pedigree, including ethnicity and family history of 
consanguinity, was also taken.   
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2.2.4 Clinical Examination 
2.2.4.1 Visual Acuity 
Where possible, best corrected LogMAR visual acuity (VA) was obtained using the 
ETDRS vision chart at 4 metres. If this was not possible, the best corrected Snellen 
VA was measured and converted to a LogMAR scale. The Snellen VA was initially 
measured at 6 metres, but if subjects were unable to view the chart at this distance, it 
was brought closer to 2 metre or 1 metre viewing distances. If at this distance the 
chart was not detectable, VA was recorded in the following step-wise denominations: 
detection of counting fingers (CF), the LogMAR equivalent of which was recorded as 
2.0; detection of hand movements (HM), the LogMAR equivalent of which was 
recorded as 3.0; perception of light (PL), the LogMAR equivalent of which was 
recorded as 5.0; or no perception of light (NPL), the LogMAR equivalent of which 
was recorded as 6.0 [52, 53]. Best-corrected VA (BCVA) was measured monocularly 
in the right eye (RE) and left eye (LE) respectively, and with both eyes open (BEO). 
 
In infants and younger children VA was measured by orthoptic colleagues using age 
appropriate methods and recorded or converted into LogMAR equivalent as above. If 
the baby or infant was not able to undergo this assessment, its ability to fixate and / or 
follow a light target was recorded, and documentation made as to whether this 
fixation was central, steady and maintained.  
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2.2.4.2  Colour vision 
Colour vision testing was performed on subjects with VA of CF or better. Where 
possible, this was done using the Hardy Rand Rittler (HRR) pseudoisochromatic 
plates (Richmond Products Inc., New Mexico, USA) or the Ishihara 
pseudoisochromatic plates (Kanehara and Co. Ltd., Tokyo, Japan) in standard room 
lighting. Subjects were tested with both eyes open for each of these tests. The plates 
were held 60 cm away from the patient at a perpendicular angle to the line of sight. 
The plates are intended to be presented for 4 seconds at a time, but in this study they 
were presented for longer if necessary, to account for poor vision and nystagmus, 
which could influence the speed at which the subjects could respond. The subject was 
required to identify the shape and position of the symbol (for the HRR test), or the 
number (Ishihara test), on the plate presented to them; an immediate response was 
required. A point was given for each correctly identified plate. 
 
The HRR test began with the presentation of the first four demonstration plates: if 
these were identified correctly, testing was continued; if not, testing was abandoned. 
The 6 screening plates (plate numbers 5-10) were then presented; if all were identified 
correctly the subject was recorded as having normal colour vision and the test was 
complete. If the first two screening plates (plate numbers 5 and 6) were incorrect, the 
subject was identified to have a defect in the tritan axis (a blue-yellow defect), and 
was subsequently shown the tritan axis grading plates (plate numbers 21-24). If plates 
21 and 22 were failed, a moderate tritan defect was recorded; if plates 23 and 24 were 
failed a severe tritan defect was recorded. If the last four screening plates (plate 
numbers 7-10) were incorrect, the subject was identified to have a defect in the 
protan-deutan axis (red-green defect), and was subsequently shown the plates to grade 
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deficiencies on these axes (plate numbers 11-20). Failure to identify only plates 11-15 
indicated a mild protan and deutan deficiency; failure to identify plates 16-18 
indicated a moderate protan and deutan deficiency; failure to identify plates 19-20 
indicated a severe protan and deutan deficiency. Subjects’ responses were recorded on 
the HRR scoring sheet that was supplied with the test. 
 
Ishihara colour plate testing began with presentation of the first plate (the ‘test plate’). 
If this was correctly identified, the subsequent plates with numbers were presented 
and the number of correct plates that were identified was recorded. If none of these 
subsequent plates were correctly identified, the subject was shown the ‘hidden digits’ 
plates. This test is designed to assess protan and deutan defects; it is not designed to 
identify tritan defects, and it is not able to quantify the red-green defect. 
 
In a subset of subjects, more detailed colour vision assessment was performed using 
additional tests; these will be described in the appropriate chapters.    
2.2.4.3 General Ocular Examination 
The ocular examination involved assessment of nystagmus, in which the character, 
direction, velocity and amplitude were recorded. Any ocular motility abnormalities 
and manifest strabismus measured by the cover – uncover test were recorded. 
Pupillary examination was performed in scotopic conditions using a bright white light 
source and reactions recorded as being normal or abnormal; abnormal pupils were 
recorded as being sluggish, non-reactive and with or without the presence of a relative 
afferent pupil defect.  
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Slit lamp biomicroscopy (Haag-Streit, Switzerland) was used to examine the anterior 
segments for corneal changes and lenticular opacities in those old enough to tolerate 
the examination. Funduscopy was performed after the instillation of guttae 
tropicamide 1% and guttae phenylephrine 2.5% or of guttae cyclopentolate 0.5% (if 
less than 1 year old) or 1% (older than 1 year) and guttae phenylephrine 2.5% into 
each eye. Indirect (non contact) methods using slit lamp biomicroscopy and a Volk® 
Super Field NC® lens (Volk Optical Inc., Ohio, USA) were used if the subject could 
cooperate. Otherwise, indirect ophthalmoscopy using a Keeler Vantage Indirect 
Ophthalmoscope (Keeler Ltd., Windsor, UK), and a 20 dioptre Nikon lens (Nikon, 
Japan) or a 28 dioptre Volk® Double Aspheric lens (Volk Optical Inc., Ohio, USA) 
was performed. Recordings were made regarding retinal appearance including the 
vasculature, macular appearance and optic disc appearance. 
 
An assessment of the patients’ refractive status was made if the refraction was not 
previously available. In infants and small children this was performed by cycloplegic 
refraction using neutralising lenses, by Professor Anthony Moore (ATM), Miss Dev 
Borman (ADB) or optometric colleagues 
 
Data from the clinical examination were recorded using a phenotyping form that had 
been prepared by Mr Robert Henderson, a previous research fellow who lead the 
Childhood Onset Retinal Dystrophy Study between 2004-2006, and entered into an 
Excel spreadsheet. 
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2.2.5 Fundus Autofluorescence Imaging 
Fundus autofluorescence imaging (FAF) was performed using the Heidelberg 
Spectralis® HRA + OCT (Heidelberg Engineering GmbH, Heidelberg, Germany) 
machine, with viewing module version 5.1.2.0, in those patients old enough to 
cooperate with the test. This was performed at a viewing angle of 30o, centred on the 
fovea, using blue laser autofluorescence imaging, in each eye. An excitation 
wavelength of 488 nm was used and emitted light was detected above 500 nm. 
Several frames were taken and the signal averaged using in-built software. Due to 
nystagmus and photophobia, the quality of the FAF images obtained was frequently 
poor. 
 
 
2.2.6 Optical Coherence Tomography 
Optical Coherence Tomography (OCT) was performed using the Heidelberg 
Spectralis® HRA + OCT machine (Heidelberg Engineering GmbH, Heidelberg, 
Germany), with viewing module version 5.1.2.0, in those subjects old enough to 
cooperate with the test. The scanning protocol included a horizontal linear scan 
centred on the fovea and a ‘volume’ scan (19 B-scans, 20o x 15o) also centred on the 
fovea, for each eye. Sd-OCT data were analysed qualitatively. HEYEX software 
interface (version 1.6.2.0, Heidelberg Engineering GmbH, Heidelberg, Germany) was 
used for any measurements taken. Due to nystagmus and fixation difficulties, the 
images obtained were frequently not ideal. 
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2.2.7 Psychophysical testing: Goldmann visual fields 
Goldmann visual field (GVF) testing was performed on subjects who were old enough 
to understand the test and if their VA was CF or better. This was a difficult test to 
perform for many subjects, as it required sustained central fixation that was often 
quite difficult to achieve due to poor central vision and nystagmus. It was performed 
more frequently in subjects without nystagmus and in those who had better levels of 
concentration and central fixation.  
 
The perimeter was calibrated according to the manufacturer’s instructions. The testing 
conditions were prepared prior to the subject being positioned for testing: the 
appropriate lens for central 30o field assessment was selected by calculating the 
spherical equivalent if the cylinder was 1.00 dioptre or less, with an age appropriate 
addition incorporated; the perimeter paper was locked into place within the machine; 
the patients’ ability to press the buzzer was assessed, and if not possible, an 
alternative method of response was used such as tapping on the table or a verbal 
response; the subjects’ chin rest was moved into place and their ability to maintain 
central fixation with the testing eye and with the fellow eye covered was ascertained; 
testing was performed with the room lights turned off. 
 
Perimetry was performed beginning with the V4e isopter; if this was easily visible 
testing was repeated with the III4e and I4e targets. Subjects were asked to fixate on 
the central dark fixation target; eyes were tested monocularly. Testing of the 
peripheral field was performed without correction; for the central 30o a lens was used. 
Peripheral visual field testing was performed before central visual field testing. Static 
targets were first presented for 1 second in a variety of positions in the visual field in 
141 
order to assess areas of visual field loss and to familiarise the subject with the test. 
Kinetic targets were then presented by using the pantograph handle to move the 
stimulus from a non-seeing area into a seeing area at 3-5o per second, in all meridians. 
The subject was instructed to indicate when they first saw the target and a mark was 
made on the perimeter paper; once all the meridians had been tested, the points were 
‘joined up’ to map the isopter. The central 30o was plotted by repeating the test with 
the appropriate lens. If any scotomata were found, they were mapped by moving the 
target from the centre of the scotoma out and the subject was instructed to indicate 
when they could see it. An attempt was made to map the physiological blind spot by 
this method as well, using the appropriate lens. Throughout testing the subjects’ 
fixation was monitored using the telescope. Both eyes were examined in this manner. 
 
 
2.2.8 Colour fundus photography 
Fundus photography was performed using a Topcon TRC 501A retinal camera 
(Topcon Corporation, Tokyo, Japan). Composite images were created using i2k 
Retina™ technology (DualAlign™ LLC, New York, USA). 
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3.3 Genetic Methods 
 
3.3.1 Extraction of DNA 
Blood samples were collected from the proband and other affected family members, 
unaffected siblings and parents, where available. For those family members that were 
not available for sampling on the day of visit, blood sampling tubes, a letter and 
consent form were sent by post for the samples to be taken locally and then returned 
back to the Genetics Unit at Moorfields Eye Hospital, London. 
 
Two 9 ml EDTA (Vacutainer) tubes of peripheral venous blood were obtained per 
person. In young children a topical anaesthetic cream, EMLA 5% (AstraZeneca, 
Macclesfield, UK), which contains lidocaine 2.5% and prilocaine 2.5%, was applied 
to the skin for 1 hour prior to venepuncture. Once the samples were obtained they 
were labelled, stored at 4oC, and logged on to the Moorfields Inherited Eye Diseases 
(IED) database. 
 
DNA was extracted by the department core facility at the Department of Genetics, 
Institute of Ophthalmology, UCL, using the Nucleon BACC-2 genomic DNA kit (GE 
Healthcare Life Sciences, Buckinghamshire, UK), or the Puregene DNA extraction kit 
(Invitrogen, Paisley, UK), as per manufacturers’ instructions. Extracted DNA was 
stored at 4oC if intended for immediate use, or at -20oC for longer-term storage.   
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3.3.2 Genotype identification strategies 
The identification of the genetic variants in individuals affected with LCA or EORD 
was achieved using different techniques. As a first pass screen, APEX analysis was 
used; based on the phenotype, some probands underwent candidate gene screening 
using the polymerase chain reaction (PCR) and direct Sanger sequencing; this 
technique was also used to screen genes in enriched ‘panels’ of patients in whom the 
causative gene had not been found to date; autozygosity mapping was utilised for 
some families in which there was a history of consanguinity; and next generation 
sequencing was utilised in a family in whom all the above techniques had failed to 
identify the causative mutation. In our laboratory a number of researchers were 
investigating different inherited retinal diseases, with different phenotypic 
characteristics. The Inherited Eye Disease (IED) database provided subjects that were 
included in a variety of ‘panels’, which were investigated by a number of different 
researchers. As such, in a collaborative manner, different members of the group 
performed some of the genotyping for the subjects described in this study. This will 
be indicated in the relevant chapters.   
 
3.3.2.1 DNA microarray using the Asper LCA chip  
APEX analysis using the Asper LCA chip (Asper Biotech Ltd., Tartu, Estonia) was 
used to analyse DNA of subjects with LCA or EORD as a first pass screen for 
mutations known to cause LCA. In total, 104 subjects from this cohort were analysed 
using this method. 3.5 μg of concentrated DNA was sent to Asper Ophthalmics for 
analysis using this DNA chip. The technology and methods have previously been 
described [109].  
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3.3.2.2 Polymerase chain reaction and candidate gene sequencing 
Oligonucleotide primers were designed for amplification and subsequent Sanger 
sequencing of the following genes: CEP290, TULP1, RGR, and BEST1. The Ensembl 
genome database (http://www.ensembl.org/index.html) was used to obtain the 
reference sequence, and primers were designed by hand or by utilising the Primer 3 
Software (http://biotools.umassmed.edu/bioapps/primer3_www.cgi.). Primer 
sequences are provided within the Appendix (Chapter 7.2). Oligonucleotide primers 
were ordered and manufactured by Sigma Life Science (Sigma – Aldrich Co. Ltd., 
Dorset, UK) or by Eurofins Genomics (Ebersberg, Germany). The primers were re-
suspended, and concentrated stock solutions were prepared as per the manufacturer’s 
instructions (http://www.sigmaaldrich.com/technical-
documents/articles/biology/handling-guidelines-for-dna-and-rna-
oligonucleotides.html). All polymerase chain reactions (PCRs) were performed in a 
total volume of 30 μl and performed on a PTC200DNA engine thermal cycler (Bio-
Rad Laboratories Inc., Hemel Hempstead, UK) equipped with a heated lid, which 
negated the need for the overlay of mineral oil in the PCR tube to prevent 
evaporation.  
 
 
Table 1 outlines the components that a typical 30 μl PCR reaction consisted of.  
PCR Reagents Volume (μl) Final Concentration 
Buffer * 
Enhancer (100%) 
dNTPs (25mM) 
Forward Primer (100pmol) 
Reverse Primer (100pmol) 
Moltaq: Taq polymerase (5U/μl) 
Template DNA (100ng/μl) 
Sterile H20 
3.00 
0.30 
0.24 
0.20 
0.20 
0.20 
1.00 
24.86 
1X 
10% 
200 μM 
20 pmol 
20 pmol 
0.5-2.5 unit 
100 ng 
 
Total PCR Volume 30  
 
Table 1 - PCR reagents for each 30 μl PCR reaction.  
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Buffer, dNTPs and Moltaq were all supplied by VH Bio (VH Bio Ltd., Gateshead, 
UK). The buffer contained a final concentration of 1.5mM of MgCl2, however in 
order to optimise the specificity of primer annealing, extra MgCl2 was occasionally 
used. A negative control with no DNA was always included in each experiment. The 
standard PCR cycling programme was carried out under the following general 
conditions: 
 
1.   Initial denaturation:  94oC  2 minutes 
2. a.  Denaturation   94oC  30 seconds 
2. b. Annealing   50-70oC 30 seconds             35 cycles 
2. c. Extension   72oC  45 seconds 
3.  Final extension  72oC  7 minutes 
4.  Hold     10oC 
 
PCR conditions were varied slightly according to: (i) the primer annealing 
temperature, which was generally taken to be approximately 2oC lower than the 
lowest Tm of the two primers, and (ii) the expected length of the amplified product. A 
gradient PCR was used when the primer annealing temperatures had not yet been 
optimised. This was performed at a range of temperatures based upon the Tm of the 
two primers. 
 
Visualisation of the PCR products was generally performed on a 1% agarose gel, 
although this concentration was dependent upon the size of the expected PCR 
product. A 2% agarose gel was prepared by adding 2 grams of agarose (Bioline, 
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London, UK) to 100 ml of 1x Tris Acetate EDTA (Eppendorf, Germany) and heated 
in a microwave oven for 2 minutes. Before the gel was set, and once it had cooled to 
less than 60oC, 5 μl of Ethidium Bromide (at 10 mg/ml) was added. The gels were 
poured into pre-prepared gel trays that contained combs to create wells and allowed to 
cool. Once set, they were placed into a gel buffer tank containing TAE buffer. A size 
marker was loaded into the first well of each row – usually 5 μl of HyperLadder IV 
(Bioline, London, UK), and then 5 μl of the PCR product plus 2 μl of loading dye 
(containing bromphenol blue and glycerol) was loaded into each successive well. Gels 
were run for 30 minutes at 100 mV and then checked under a UV light.  
 
The correct sized PCR products were purified in order to remove excess buffer, 
dNTPs and primers, using Montage PCR cleanup (purple) plates, as per standard 
protocols (Millipore, Watford, UK). PCR products were sequenced directly by using 
the ABI Big Dye terminator kit version 3.1 (Life Technologies, California, USA) in a 
total volume of 10 μl. Table 2 outlines the components that a typical 10 μl Big Dye 
sequencing PCR consisted of. 
  
Sequencing PCR Reagents Volume (μl) 
Sequencing buffer (5x) 
Forward or Reverse Primer (10pmol) 
PCR product 
BigDye Terminator 
Sterile H20 
2.50 
1.00 
1.00 
0.50 
5.00 
Total PCR volume 10 
 
Table 2 – Reagents and volumes for each 10 μl sequencing reaction using Big Dye 
Terminator. 
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The sequencing reaction performed was as follows:  
1.     96oC  2 minutes 
2. a.    96oC  10 seconds 
2. b.   50oC  5 seconds                           24 cycles 
3.    60oC  4 minutes 
4.  Hold   4oC   
 
Following the sequencing reaction the mixture was purified using Montage 
sequencing cleanup (blue) plates, as per standard protocols (Millipore, Watford, UK), 
and run on the Applied Biosystems 3730 DNA sequencer. Analysis of the 
electropherograms was performed by hand using the Lasergene software package 
(Version 8.1) (DNASTAR, Wisconsin USA). Any mutations that were identified were 
confirmed bi-directionally and family members were checked for segregation of the 
mutation. Any novel missense mutations were checked in at least 100 control DNA 
chromosomes via ethnically matched DNA samples and the European Collection of 
Cell Cultures (ECACC) (https://www.phe-
culturecollections.org.uk/collections/ecacc.aspx). Missense mutations were analysed 
using a number of mutation prediction software programmes, namely: ‘Sorting 
Intolerance from Tolerance’ (SIFT) (http://sift.jcvi.org/) and the PolyPhen-2 
algorithm (http://genetics.bwh.harvard.edu/pph2/index.shtml). SIFT results are 
reported to be tolerant if the tolerant index is at least 0.05, or intolerant if the tolerant 
index is less than 0.05. PolyPhen-2 appraises mutations as benign, possibly damaging, 
or probably damaging based on the false positive rate of the model. Novel splice site 
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mutations were analysed using an in silico analysis programme available at 
www.fruitfly.org.  
 
3.3.2.3 Autozygosity Mapping  
Autozygosity mapping was performed in a number of consanguineous families in 
order to identify regions of autozygosity that would be predicted to contain the 
putative causative gene defect in that family. Families were selected to undergo 
autozygosity mapping if previous molecular analysis did not identify the causative 
mutation, if they had a high level of consanguinity (second cousin parent families 
were considered to be more informative), and if there was sufficient high quality 
DNA available for this technique. Samples were sent from our laboratory by Dr 
Mackay (DSM), Dr Sergouniotis (PIS) or Dr Davidson (AED) to the University of 
Manchester where they were analysed using the Affymetrix GeneChip® SNP array 
6.0 (Affymetrix, California, USA). The Affymetrix SNP array 6.0 contains 1.8 
million markers of genetic variation, with more than 906 000 SNPs and more than 
946 000 probes for copy number variant detection [327]. Detailed methodology for 
genotyping using the GeneChip® array has been described previously [328]. 
 
The GeneChip® DNA Analysis Software (GDAS version 3; Affymetrix, California, 
USA),AutoSNPa software [329] and an alternative method of analysis [327] was used 
by Dr Mackay, Dr Davidson or Dr Sergouniotis to call SNPs for genome-wide 
autozygosity scans. The Microsoft Excel (Microsoft, Washington, USA) programme 
was used to detect regions with a shared haplotype. These regions were assorted 
according to size (up to the 10 largest homozygous regions were determined) and 
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candidate genes known to be associated with retinal diseases were selected within 
these regions. Subsequent positional gene sequencing and mutation analysis was 
performed for probands in candidate genes based upon the above methods.  
 
3.3.2.4 Next Generation Sequencing 
Exome capture and high-throughput sequencing was undertaken in one patient from a 
consanguineous family, by Dr Mackay and Dr Davidson, in collaboration with 
colleagues at the UCL Genetics Institute. The method has been previously described 
[327]. Whole exome sequencing was undertaken using the Agilent SureSelect38 Mb 
Human All Exon Kit and the HiSeq2000 Sequencer (Illumina Inc., California, USA). 
Average sequencing depth on target was 43, with 78.4% of the targeted region being 
covered by a read depth of 10x [330]. Calls with minor allele frequencies greater than 
0.5% in the 1000 genomes dataset (http://www.1000genomes.org/) were filtered, 
based upon the prior belief that RP-related mutations are rare. Homozygous, 
presumed loss-of-function mutations were prioritised in this family.  
 
 
3.3.3 Bioinformatics 
A Microsoft Access (Microsoft, Washington, USA) database had been set up prior to 
the onset of this study in which recruited patients were stored, with some clinical data 
recorded within it. In addition, Microsoft Excel (Microsoft, Washington, USA) was 
used to record the patients recruited into the study. Pedigrees were drawn using 
Cyrillic 2.1 (FamilyGenetix Ltd., Oxford, UK). Composite images of fundus 
photographs were generated using i2k Retina™ technology (DualAlign™ LLC, New 
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York, USA). DNA sequencing analysis was performed using the Lasergene software 
package  (version 8.1) (DNA Star Inc., Wisconsin USA). 
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4.0 Results   
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4.1 Overview of study 
 
4.1.1 Study period and Patient recruitment  
Subjects and their families were recruited to the Childhood Onset Retinal Dystrophy 
Study between August 2008 and August 2011. An electronic database in Microsoft 
Excel (Microsoft, Washington, USA) was kept of all families recruited during this 
period and categorised into the two separate cohorts of patients. Subjects were 
predominantly recruited from the paediatric and adult retina clinics at Moorfields Eye 
Hospital, London, UK and Great Ormond Street Hospital for Children, London, UK. 
A cohort of subjects were referred to the study by other Ophthalmologists or 
Geneticists who were aware of the study; in a sub-group of these subjects the 
genotype had been identified prior to their recruitment into the study. Access was 
available to the database that had been created and maintained by previous researchers 
involved in the Childhood Onset Retinal Dystrophy Study, so that subjects who had 
been recruited prior to August 2008 could be invited to attend for further phenotyping, 
when necessary. The data presented in this chapter represent the results obtained from 
these two cohorts of subjects recruited between August 2008 and August 2011. Any 
results identified in these subjects after this study period was complete are not 
included. Some of the subjects investigated according to genotype that are presented 
in subsequent chapters may have been recruited prior to this study period but were 
recalled for phenotyping. These subjects will be indicated in the relevant chapters.  
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4.1.2 Demographics and Diagnoses  
Between August 2008 and August 2011, 201 subjects from 186 families were 
recruited into the Childhood Onset Retinal Dystrophy Study. The cohort comprising 
the generalised retinal dystrophies consisted of 177 subjects from 166 families 
(Cohort 1). The cohort comprising subjects with a macular phenotype consisted of 24 
subjects from 20 families (Cohort 2). The results from these two cohorts will be 
presented separately.  
 
4.1.2.1 Cohort 1 
Of the 177 subjects in Cohort 1, 102 were male and 75 were female. The diagnoses in 
these subjects were made based upon their clinical histories, clinical examination and 
electrophysiological data, where available. Subjects diagnosed with LCA had absent 
or very poor vision from birth or within the first few months of life, nystagmus, 
sluggish pupillary responses and an undetectable ERG. Those diagnosed with EORD 
had a later onset of visual symptoms, in infancy or early childhood (less than 5 years 
of age), less nystagmus (if present at all), variably reduced vision, normal pupil 
reactions and a severely attenuated ERG. A diagnosis of rod-cone dystrophy 
(synonymous with retinitis pigmentosa) or cone-rod dystrophy was made in children 
with age of onset of 5 years or older, if there was ERG evidence of the class of 
photoreceptor that was predominantly involved, or if there was clinical evidence to 
suggest first rod (rod-cone) or cone (cone-rod) involvement. Those with only cone 
involvement, on ERG or clinical examination, were diagnosed with a cone dystrophy.  
EORD comprised the largest number of subjects at 96 (90 families), followed by LCA 
at 67 subjects (63 families), rod-cone dystrophy at 8 subjects (8 families), cone-rod 
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dystrophy at 3 subjects (3 families) and cone dystrophy at 3 subjects (3 families) 
(Table 3). In one family with two affected individuals harbouring the same mutation, 
symptom onset differed between these individuals, resulting in one carrying a 
diagnosis of EORD and one of rod-cone dystrophy (Family 40). All subjects with 
cone dystrophy had symptom onset below 5 years of age, and ERG confirmation of 
cone dysfunction but relatively normal rod function.   
 
Diagnosis Number of Subjects Number of families 
Early Onset Retinal Dystrophy 96 90 
Leber Congenital Amaurosis 67 63 
Rod-Cone Dystrophy 8 8 
Cone-Rod Dystrophy 3 3 
Cone Dystrophy 3 3 
Total 177 167 
 
Table 3 - Diagnoses of subjects recruited into Cohort 1 of the Childhood Onset 
Retinal Dystrophy Study, Aug 2009 – Aug 2011. One family is counted twice as there 
were two diagnoses within this family.   
4.1.2.2 Cohort 2 
Of the 24 subjects in cohort 2, 9 were male and 15 were female. Their diagnoses were 
made based upon their clinical examination and electrophysiological tests, where 
available. Two diagnoses comprised this cohort of subjects: 6 subjects (6 families) 
with autosomal recessive bestrophinopathy (ARB) and 18 subjects (14 families) with 
a newly recognised phenotype termed ‘yellow dot dystrophy’ (Table 4). 
 
Diagnosis Number of Subjects Number of Families 
Autosomal Recessive Bestrophinopathy 
(ARB) 6 6 
Yellow Dot Dystrophy 18 14 
Total 24 20 
 
Table 4 - Diagnoses of Subjects recruited into Cohort 2 of the Childhood Onset 
Retinal Dystrophy Study, Aug 2009 – Aug 2011. 
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4.2 Overview of Study: overall 
molecular findings 
 In this chapter the results from the molecular analyses undertaken in this Study, using a variety of techniques, will be presented. These techniques included APEX Array using the Asper Chip, direct sequencing of candidate genes, autozygosity mapping with subsequent positional candidate gene screening and exome sequencing for subjects in Cohorts 1 and 2.      
4.2.1 LCA Chip results for Cohort 1  
Of the 177 subjects in Cohort 1, the DNA of 104 subjects (from 102 families) was 
sent from UCL to be analysed across the LCA Chip (Asper Ophthalmics, Tartu, 
Estonia). The diagnoses in these subjects were as follows: LCA 47 subjects (45 
families); EORD 51 subjects (51 families); rod-cone dystrophy 3 subjects (3 
families); cone dystrophy 2 subjects (2 families); cone-rod dystrophy 1 subject (1 
family). Not all subjects with LCA or EORD were sent for LCA chip analysis as they 
may have belonged to a sibling group, their phenotype may have suggested a 
particular gene and so they were pre-selected for candidate gene screening, the 
proband may not have provided a blood sample, or there was an insufficient amount 
of good quality DNA available for chip analysis. The reasons that subjects with rod-
cone, cone-rod and cone dystrophies were screened using this technique were that 
later on in the study additional funding became available to screen more families 
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across the chip, so 2 subjects suggestive of a very early onset condition were 
screened; in addition, in 4 subjects their original diagnosis of EORD was revised to 
rod-cone dystrophy after further interrogation of symptoms and signs; and in 2 
subjects the fundus appearance was similar to that seen in subjects with known LCA / 
EORD genes.  
 
Screening for known disease associated variants in families from UCL, using the 
LCA chip, identified 29 subjects (from 29 families) with either 2 variants 
(homozygous or compound heterozygous) or with 1 variant only. This resulted in an 
overall variant identification rate by the LCA chip for the subjects sent from UCL of 
27.9%. The results of 3 subjects are outstanding.  
 
Of these 29 subjects identified by the LCA chip to harbour variants, 11 (37.9%) had 
two variants identified, of which 5 (17.2% of those identified with variants) were 
homozygous and 6 (20.7% of those identified with variants) were compound 
heterozygous variants. The LCA chip identified 18 subjects (62.1% of those identified 
with variants) to harbour one only variant. LCA was the most frequent diagnosis for 
those subjects who were identified by the chip to harbour any variants. Of the 47 LCA 
subjects sent for chip analysis, 12 (25.5%) were identified to harbour one variant and 
5 (10.6%) to harbour two variants using this method only. Of the 51 EORD subjects 
screened with the chip, 6 (11.8%) were identified to harbour one variant and 6 
(11.8%) were identified to harbour two variants (Table 5).  
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Gene No identified by 
LCA chip 
LCA patients sent for chip 
analysis (n=47) 
EORD patients sent for chip 
analysis (n=51) 
  1 variant 2 variants 1 variant 2 variants 
AIPL1 1 0 0 1 0 
CEP290 9 5 2 0 2 
CRB1 4 1 0 1 2 
GUCY2D 5 4 1 0 0 
LCA5 1 1 0 0 0 
MERTK 1 0 0 0 1 
RDH12 2 0 0 2 0 
RPE65 2 0 1 1 0 
RPGRIP1 2 1 0 1 0 
SPATA7 1 0 1 0 0 
TULP1 1 0 0 0 1 
Total 29 12 (25.5%) 5 (10.6%) 6 (11.8%) 6 (11.8%) 
 
Table 5 - Breakdown of LCA chip results for samples sent from UCL by gene, 
diagnosis and number of variants identified. 
 
The most frequent gene identified by the LCA chip for subjects sent from UCL was 
CEP290, which accounted for 31.0% of the genes identified by this method, but this 
was only in 8.7% of all subjects sent for analysis with the chip (Figure 11). The most 
frequent mutation identified was the common CEP290 intronic variant 
c.2991+1655A>G, p.Cys998X, occurring in 6 of 40 (15.0%) alleles identified by the 
LCA chip for the UCL cohort of subjects. 
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Figure 11 - Results of Cohort 1 subjects sent for LCA Chip analysis. Outstanding 
results are included in ‘unknown’ group. 
 
 
For those subjects in whom only one variant was found using the chip (12 LCA and 6 
EORD subjects), the second variant was investigated using direct sequencing where 
funding was available. Of these, in 6 LCA and 4 EORD subjects who underwent a 
screen in search of the second allele (in AIPL1, CEP290, GUCY2D, LCA5, RDH12 
and RPE65), direct sequencing identified the second variant in 3 LCA subjects (in 
CEP290 and LCA5) and in 4 EORD subjects (in AIPL1, RDH12 and RPE65). This 
search failed to identify the second allele in one subject with a CEP290 mutation 
found by the chip, and 2 with a GUCY2D mutation found by the chip. No subjects 
with rod-cone dystrophy, cone-rod dystrophy or cone dystrophy who were screened 
across the LCA chip were identified to harbour pathogenic variants by chip analysis.  
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In 5 additional subjects, the LCA chip was used by the referring hospital to identify 
the disease causing mutations; these subjects were recruited into the study and stored 
on the IED database. Two of these five subjects were invited to attend Moorfields Eye 
Hospital for phenotypic investigations and they will be described further in 
subsequent chapters (Table 6).  
 
Subject Gene Variant 1 
(identified by 
Asper Chip) 
Variant 2 (identified 
by Asper Chip) 
Location of 
referring 
hospital 
Invited for 
further 
phenotyping? 
4 CEP290 c.2991+1655A>G, 
p.Cys998X 
[240] 
Not found Poland No 
12 CEP290 c.4723A>T, 
p.Lys1575X [251] 
c. 4966G>T, 
p.Glu1656X [240] 
Cape Town, 
South Africa 
No 
19 CRB1 c.2555T>C 
p.Ile852Thr [124] 
c.3427delT 
p.Cys1143AlafsX67 
[331] 
Firenze, Italy No 
28 LRAT c.525T>A, 
p.Ser175Arg [285] 
c.525T>A, 
p.Ser175Arg [285] 
Manchester, 
UK 
Yes 
47 RGR c.196A>C, 
p.Ser66Arg [319] 
c.196A>C, 
p.Ser66Arg [319] 
Rovereto, 
Italy 
Yes 
 
Table 6 – Subjects identified with variants using the LCA chip by referring hospital.  
 
 
4.2.2 Molecular diagnoses identified in this Study 
Of the subjects recruited into this study between August 2008 and August 2011, the 
causative gene was identified in 67 subjects (63 families) using a number of 
strategies. The proportions by gene and diagnoses are described below. 
 
4.2.2.1 Molecular Diagnoses for Cohort 1 
For the subjects in Cohort 1, a molecular diagnosis was obtained in 61 subjects (57 
families) (34.5%) in total, using the following strategies: LCA APEX analysis (29 
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subjects from UCL, 5 subjects from elsewhere); direct sequencing of candidate genes 
to identify one or two variants by different researchers (AIPL1 – 2 subjects, CEP290 – 
2 subjects, LCA5 – 2 subjects, LRAT – 1 subject, RDH12 – 17 subjects, RPE65 – 7 
subjects, SPATA7 – 1 subject, TULP1 – 1 subject); autozygosity mapping using the 
SNP6 chip followed by positional candidate gene screening (2 subjects: 1 LCA5, 1 
RDH12) and exome sequencing (1 subject, CRB1). No molecular diagnosis was 
obtained for 116 subjects (65.5%) (109 families), which includes those families in 
whom the chip results are outstanding (Figure 12). 
 
 
Figure 12 - Genotypes of all subjects identified with variants in Cohort 1.  
 
 
Of the 61 subjects in cohort 1 in whom the causative gene was identified, 12 subjects 
(19.7%) (12 families) had only one variant identified and 49 subjects (80.3%) (45 
families) had both variants identified. The most frequent gene identified in cohort 1 
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was RDH12, comprising 28% of all genes identified. In the subjects who only 
underwent direct sequencing or exome sequencing, and not Asper chip analysis (27 of 
61 subjects identified with a molecular cause), molecular analysis identified both 
variants in all (AIPL1 – 1 subject, CRB1 – 1 subject [exome sequencing], LCA5 – 1 
subject, LRAT – 1 subject, RDH12 – 15 subjects, RPE65 – 6 subjects, SPATA7 – 1 
subject, TULP1 – 1 subject). Of these, 19 (70.4%) were homozygous and 8 (29.6%) 
were compound heterozygous mutations. These compound heterozygous mutations 
were only identified in CRB1, RDH12 and RPE65; the attributed diagnoses are 
indicated in Table 7. The most frequent gene to affect subjects with LCA was 
CEP290 and for subjects with EORD was RDH12. No mutations were identified for 
any of the subjects who carried a diagnosis of cone-rod dystrophy or cone dystrophy 
(Table 7). 
 
Gene Total No 
Patients 
EORD 
(n=96) 
LCA 
(n=67) 
Rod-Cone 
Dystrophy 
(n=8) 
Cone-Rod 
Dystrophy 
(n=3) 
Cone 
Dystrophy 
(n=3) 
AIPL1 2 1 1 0 0 0 
CEP290 11 2 9 0 0 0 
CRB1 6 4 1 1 0 0 
GUCY2D 5 0 5 0 0 0 
LCA5 2 0 2 0 0 0 
LRAT 2 2 0 0 0 0 
MERTK 1 1 0 0 0 0 
RDH12 17 14 0 3 0 0 
RGR 1 1 0 0 0 0 
RPE65 8 5 3 0 0 0 
RPGRIP1 2 1 1 0 0 0 
SPATA7 2 0 2 0 0 0 
TULP1 2 2 0 0 0 0 
Total 61 33 24 4 0 0 
 
Table 7 - Genotype for Cohort 1 with breakdown according to diagnosis. 
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The complete list of variants identified, with method of identification and researcher who identified them, are listed in Table 8. 
 
Subject 
No. 
Family 
No. 
Diagnosis Gene Mutation 
Type 
Allele 1 
Nucleotide change 
Allele 1 
Protein change 
MethodPerson identifying Allele 2 
Nucleotide change 
Allele 2 
Protein change 
MethodPerson identifying 
1  1 LCA AIPL1 Hom c.487C>T p.Gln163X Direct seq – novela c.487C>T p.Gln163X Direct seq – novela 
2  2 EORD AIPL1 Comp het c.834G>A p.Trp278X Asper c.190G>A p.Gly64Arg Direct seq - noveld 
3  3 LCA CEP290 Comp het c.3175_3176insA p.Ile1059fs Asper not found not found  
4  4 LCA CEP290 Comp het c.2991+1655A>G p.Cys998X Asper (Poland) not found not found  
5  5 LCA CEP290 Comp het c.2991+1655A>G p.Cys998X Asper not found not found  
6  6 EORD CEP290 Comp het c.2991+1655A>G p.Cys998X Asper c.4723A>T p.Lys1575X Asper 
7  7 LCA CEP290 Comp het c.4723A>T p.Lys1575X Asper c.712G>T p.Glu238X Direct seq - novelg 
8  8 LCA CEP290 Hom c.5668G>T p.Gly1890X Asper c.5668G>T p.Gly1890X Asper 
9  9 LCA CEP290 Comp het c.4723A>T p.Lys1575X Asper c.6079delG p.Glu2027LysfsX5 Direct seqf 
10  10 EORD CEP290 Comp het c.2991+1655A>G p.Cys998X Asper c.5668G>T p.Gly1890X Asper 
11  11 LCA CEP290 Comp het c.2991+1655A>G p.Cys998X Asper c.1066-1G>A splice site Asper 
12  12 LCA CEP290 Comp het c.4723A>T p.Lys1575X Asper (SA) c. 4966G>T p.Glu1656X Asper (SA) 
13  13 LCA CEP290 Comp het c.2991+1655A>G p.Cys998X Asper not found not found  
14  14 LCA CRB1 Comp het c.2401A>T p.Lys801X Asper not found not found  
15  15 EORD CRB1 Comp het c.2843G>A p.Cys948Tyr Asper not found not found  
16  16 Rod-cone CRB1 Comp het c.3655C>T p.Gln1219X Exome c.1312T>C p.Cys438Arg Exome 
17  17 EORD CRB1 Comp het c.2555T>C p.Ile852Thr Asper c. 3307G>A p.Gly1103Arg Asper 
18  18 EORD CRB1 Comp het c.2555T>C p.Ile852Thr Asper c.2843G>A p.Cys948Tyr Asper 
19  19 EORD CRB1 Comp het c.2555T>C p.Ile852Thr Asper (Italy) c3427delT p.Cys1143AlafsX67 Asper (Italy) 
20  20 LCA GUCY2D Het c.2302C>T p.Arg768Trp Asper not found not found  
21  21 LCA GUCY2D Comp het c.2302C>T p.Arg768Trp Asper c.307G>A p.Glu103Lys Asper 
22  22 LCA GUCY2D Het c.121C>T p.Leu41Phe Asper not found not found  
23  23 LCA GUCY2D Het c.2943delG p.Ser981SerfsX39 Asper not found not found  
24  24 LCA GUCY2D Het c.2849C>T p.Ala950Val Asper not found not found  
25  25 LCA LCA5 Hom c.439_449dup p.Glu151X Direct seq - novelb; SNP6 c.439_449dup p.Glu151X Direct seq - novelb; SNP6 
26  26 LCA LCA5 Comp het c.835C>T p.Gln279X Asper c.3G>A p.Met1Ile Direct seq - noveld 
27  27 EORD LRAT Hom c.316G>A p.Ala106Thr Direct seq - novelc c.316G>A p.Ala106Thr Direct seq - novelc 
28  28 EORD LRAT Hom c.525T>A p.Ser175Arg Asper (Manchester) c.525T>A p.Ser175Arg Asper (Manchester) 
29  29 EORD MERTK Hom c.2214delT p.Cys738TrpfsX31 Asper c.2214delT p.Cys738TrpfsX31 Asper 
30  30 EORD RDH12 Hom c.609C>A p.Ser203Arg Direct seq - noveld c.609C>A p.Ser203Arg Direct seq - noveld 
31  31 EORD RDH12 Hom c.609C>A p.Ser203Arg Direct seq - noveld c.609C>A p.Ser203Arg Direct seq - noveld 
32  31 EORD RDH12 Hom c.609C>A p.Ser203Arg Direct seq - noveld c.609C>A p.Ser203Arg Direct seq - noveld 
33  32 EORD RDH12 Hom c.146C>A p.Thr49Lys Direct seqd c.146C>A p.Thr49Lys Direct seq - noveld 
34  33 EORD RDH12 Hom c.601T>C p.Cys201Arg Direct seqd c.601T>C p.Cys201Arg Direct seqd 
35  34 Rod-cone RDH12 Comp het c.481C>T p.Arg161Trp Direct seq - noveld c.714insC p.Val238fsX34 Direct seq - noveld 
36  35 EORD RDH12 Comp het c.57_60del p.Pro20delfs Asper c.506G>A p.Arg169Gln Direct seq - noveld 
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37  36 EORD RDH12 Hom c.379G>T p.Gly127X Direct seqd c.379G>T p.Gly127X Direct seqd 
38  37 EORD RDH12 Comp het c.481C>T p.Arg161Trp Direct seq - noveld c.806_810del5bp p.Ala269fsX5 Direct seqd 
39  38 EORD RDH12 Comp het c.806_810del5bp p.Ala269fsX5 Asper c.209G>A p.Cys70Tyr Direct seq - noveld 
40  39 EORD RDH12 Hom c.146C>T p.Thr49Met Direct seqd c.146C>T p.Thr49Met Direct seqd 
41  40 EORD RDH12 Hom c.619A>G p.Asn207Asp Direct seq - noveld c.619A>G p.Asn207Asp Direct seq - noveld 
42  40 Rod-cone RDH12 Hom c.619A>G p.Asn207Asp Direct seq - noveld c.619A>G p.Asn207Asp Direct seq - noveld 
43  41 EORD RDH12 Hom c.601T>C p.Cys201Arg Direct seqd c.601T>C p.Cys201Arg Direct seqd 
44  42 EORD RDH12 Hom c.454T>A p.Phe152Ile Direct seq - noveld; SNP6 c.454T>A p.Phe152Ile Direct seq - noveld; SNP6 
45  43 Rod-cone RDH12 Hom c.601T>C p.Cys201Arg Direct seqd c.601T>C p.Cys201Arg Direct seqd 
46  44 EORD RDH12 Comp het c.448+1G>A splice site Direct seq - noveld c.698insGT p.Val233ValfsX45 Direct seq - noveld 
47  45 EORD RGR Hom c.196A>C p.Ser66Arg Asper (Italy) c.196A>C p.Ser66Arg Asper (Italy) 
48  46 LCA RPE65 Hom c.1451G>A p.Gly484Asp Asper c.1451G>A p.G484D Asper 
49  46 LCA RPE65 Hom c.1451G>A p.Gly484Asp Direct seqe c.1451G>A p.Gly484Asp Direct seqe 
50  47 EORD RPE65 Comp het c. 131G>A p.Arg44Gln Asper c. 1024T>C p.Tyr342His Direct seq - novele 
51  48 LCA RPE65 Comp het c.257C>A p.Thr86Asn Direct seq - novele c.760G>A p.Glu254Lys Direct seq - novele 
52  49 EORD RPE65 Comp het c.1543C>T p.Arg515Trp Direct seqe c.1067dupA p.Asn356Lysfs*8 Direct seq - novele 
53  50 EORD RPE65 Hom c.353G>A p.Arg118Lys Direct seq - novele c.353G>A p.Arg118Lys Direct seq - novele 
54  51 EORD RPE65 Comp het c.11+5G>A cryptic splice site Direct seqe c.245G>A p.Arg82Lys Direct seq - novele 
55  52 EORD RPE65 Comp het c.1087C>A p.Pro363Thr Direct seqe c.1418T>A p.Val473Asp Direct seqe 
56  53 EORD RPGRIP1 Comp het c.1447C>T p.Gln483X Asper not found not found  
57  54 LCA RPGRIP1 Comp het c.1447C>T p.Gln483X Asper not found not found  
58  55 LCA SPATA7 Hom c.253C>T p.Arg85X Direct seqd c.253C>T p.Arg85X Direct seqd 
59  56 LCA SPATA7 Hom c.961dupA p.Pro321ThrfsX5 Asper c.961dupA p.Pro321ThrfsX5 Asper 
60  57 EORD TULP1 Hom c.1511_1521del p.Leu504fsX140 Asper c.1511_1521del p.Leu504fsX140 Asper 
61  57 EORD TULP1 Hom c.1511_1521del p.Leu504fsX140 Direct seqf c.1511_1521del p.Leu504fsX140 Direct seqf 
 
Table 8 - Genetic variants identified in cohort 1 including method and researcher identifying the variant.  
a. Dr Tan, b. Dr Davidson, c. Dr Ocaka, d. Dr Mackay, e. NGRL, f. Miss Dev Borman, g. Centre for Nephrology and metabolic disorders; 
Abbreviations: No. – Number, LCA – Leber Congenital Amaurosis, EORD – Early Onset Retinal Dystrophy, Hom – Homozygous, Comp het – 
Compound Heterozygous, Seq – sequencing, SA – South Africa, SNP6 – autozygosity mapping. 
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4.2.2.2 Cohort 2 
Molecular analysis was performed for the ARB subjects of cohort 2 in the Bestrophin-
1 (BEST1) gene and genotype identified for all six subjects. Dr Davidson, University 
of Manchester, identified the variants in subjects 1-4 of this cohort and Miss Dev 
Borman (ADB) identified the variants in subjects 5 and 6 of this cohort. The 
phenotype and genetic variants will be discussed in the ARB chapter (Chapter 4.7). 
No molecular investigations have been carried out in the Yellow Dot Dystrophy group 
of subjects to date. 
 
 
4.2.3 Diagnosis by Gene – Cohort 1 
4.2.3.1 AIPL1 
Mutations in AIPL1 were identified in 2 subjects in this cohort (Subjects 1 and 2); 1 
by the LCA chip (only one variant was identified), and 1 by direct sequencing by Dr 
Tan, UCL. In the subject in whom the Asper chip identified one variant, Dr Mackay, 
UCL, identified the second variant by direct sequencing. One subject carried a 
diagnosis of LCA and one of EORD. The phenotype associated with AIPL1 mutations 
in this cohort will be discussed in chapter 4.3. 
 
4.2.3.2 CEP290 
CEP290 was the most frequent gene identified in subjects with LCA (affecting 13.4% 
of subjects with LCA) and in the subjects who were screened across the LCA chip 
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(identified in 31.0% of subjects sent for LCA chip analysis from UCL). The most 
frequent mutation identified was the common intronic variant, c.2991+1655A>G, 
p.Cys998X, occurring in 6 of 40 (15.0%) alleles identified by the LCA chip. This 
variant is reported to be the most common LCA variant, identified in up to 26% of 
LCA cases in North Western European populations, but it has a much lower incidence 
in other populations [247]. All but one of the subjects identified with variants in 
CEP290 in this cohort (Subjects 3 – 13) were of European origin; the one subject who 
was not was from South Africa although he is presumed to be of British and Dutch 
descent. The genotype-phenotype associations for CEP290 will be discussed briefly 
in chapter 4.3. 
 
4.2.3.3 CRB1 
Mutations in CRB1 comprised 9.8% of those identified with mutations in this cohort 
(Subjects 14 - 19) and the strategies used to identify them included screening using 
the LCA chip (5 subjects) and exome sequencing (1 subject). This patient (Subject 16) 
had been screened across the LCA chip prior to exome sequencing, but no variants 
were identified. The compound heterozygous mutations in CRB1 identified in this 
subject (c.3655C>T, p.Q1219X and c.1312T>C, p.C438R) were excluded from the 
1000 genomes project and exome variant server, and were considered to be novel.  
The phenotype associated with CRB1 mutations in this cohort will be discussed 
briefly in chapter 4.3. 
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4.2.3.4 GUCY2D 
GUCY2D mutations were identified in 5 subjects in cohort 1, all via the LCA chip 
(Subjects 20 – 24). All 5 subjects carried a diagnosis of LCA. The chip identified two 
variants in only one subject, but one variant in 4 subjects. Direct sequencing of 
GUCY2D was performed by Dr Ocaka, UCL, in 2 of these four subjects, which did 
not identify a second variant. These two subjects had no other affected family 
members and no family history of consanguinity. GUCY2D has been identified to 
segregate both in an autosomal dominant and a recessive manner [114, 126-128]; it 
may be postulated that in this cohort the identification of only one variant in GUCY2D 
could suggest an autosomal dominant inheritance pattern with a possible de novo 
mutation in these individuals. However, this is unlikely to be the case as all dominant 
mutations in GUCY2D have been identified, to date, to cluster in 3 particular codons, 
837, 838 and 839 [128]. These were not implicated in any of the GUCY2D subjects 
identified in this study. The genotype-phenotype associations of GUCY2D will be 
discussed in chapter 4.3. 
 
4.2.3.5 LCA5 
2 subjects were identified with LCA5 mutations. One subject (Subject 25) had 
undergone autozygosity mapping due to her consanguineous ancestry, which 
identified a region of homozygosity in which LCA5 resided. Positional gene screening 
was carried out, which identified the c.439_449dup, p.Glu151X variant in the 
homozygous state. The molecular analysis in this family was performed by Dr 
Davidson, UCL. The other subject (Subject 26), identified with compound 
heterozygous mutations in LCA5, had one variant identified by the Asper chip and the 
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other variant by direct sequencing by Dr Mackay, UCL. The phenotypes in these 
individuals will be briefly discussed in chapter 4.3. 
 
4.2.3.6 MERTK 
A homozygous mutation in MERTK was identified in one subject by the Asper chip 
(Subject 29). This subject carried a diagnosis of EORD. The phenotype associated 
with this MERTK variant will be discussed in chapter 4.3.  
 
4.2.3.7 RDH12 
RDH12 was the most frequently identified gene, comprising 27.8% of the genes 
identified in cohort 1 (Subjects 30 – 46). All 17 subjects identified with RDH12 
mutations underwent direct sequencing by Dr Mackay, which identified both alleles in 
15 of 17 (88.2%) subjects, and one allele in 2 subjects, both of whom had one allele 
identified by the LCA chip. The reason for the high proportion of subjects with 
RDH12 mutations in this series is that the distinctive phenotype associated with 
RDH12 mutations had recently been described [278], and the majority of these 
subjects were selected for RDH12 screening based upon their phenotype. A number of 
novel mutations were identified. These subjects were combined with those with 
RDH12 mutations that were identified and phenotyped by the previous research 
registrar, Mr Phillip Moradi, and published [284]. The genotype-phenotype 
associations for RDH12 identified in this study will be discussed in chapter 4.3.  
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4.2.3.8 RPE65 
Mutations in RPE65 were identified in 13.1% of the subjects in whom a molecular 
diagnosis was identified (Subjects 48 – 55). The Asper chip identified variants in 2 
subjects, but the majority of the RPE65 variants were identified by direct screening at 
the National Genetics Reference Laboratory (NGRL) in Manchester, part of the 
Central Manchester University Hospitals NHS Foundation Trust, UK, who at the time 
of conducting this study, provided a clinical service in which molecular analysis of 
RPE65 was performed using direct screening. The subjects were selected for RPE65 
screening based upon their history and clinical features, and referred directly to the 
NGRL, who identified variants in 7 of the 8 subjects with mutations in RPE65 
ascertained in this study. 6 of these variants were novel. The phenotype associated 
with mutations in RPE65 will be discussed in chapter 4.3.  
 
There was one RPE65 subject who displayed hypomorphic features (Subject 52), and 
he was a compound heterozygote, as were 5 of the 7 families identified with RPE65 
mutations. However, he was the only subject to harbour a duplication on one allele, 
c.1067dupA, p.Asn356Lysfs*8, which occurs beyond halfway in the transcript. His 
other variant, c.1543C>T, p.Arg525Trp occurs late in the transcript, and in silico 
analysis suggests that it is damaging (SIFT) or probably damaging (PolyPhen2). It is 
presumed that his mutation leads to some functional protein product. However, 
comparison of the location of these variants to the other milder cases reported in the 
literature, which have occurred much earlier in the transcript, do not identify any true 
correlation between mutation location and phenotypic severity [151, 161]. 
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4.2.3.9 RPGRIP1 
2 subjects (Subjects 56 and 57) were identified by the Asper chip to harbour only one 
variant each in RPGRIP1. This was the same variant in both subjects, c.1447C>T, 
p.Gln483X. No further molecular screening was carried out in these subjects, and so 
the second variants were not identified. The phenotypes in these individuals will be 
briefly discussed in chapter 4.3.  
 
4.2.3.10 SPATA7, TULP1, LRAT, RGR  
The variants identified in these genes and the associated phenotypes observed will be 
discussed in the appropriate chapters (4.4 – 4.7). 
 
 
4.2.4 Diagnosis by Gene – Cohort 2 
The subjects in cohort 2 who underwent molecular screening all carried a diagnosis of 
autosomal recessive bestrophinopathy. In collaboration with Dr Davidson, University 
of Manchester, the disease-causing variants were identified in BEST1. These subjects 
underwent phenotypic studies at Moorfields Eye Hospital by Miss Dev Borman. The 
findings and associated phenotypes in these subjects will be presented in chapter 4.8. 
 
 
4.2.5 Summary of overview of study 
In total, 201 subjects were recruited into this study, with 177 carrying a diagnosis of a 
generalised retinal dystrophy (cohort 1) and 24 with a macular phenotype (cohort 2). 
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In cohort 1, the LCA chip was used as a ‘first pass screen’ in 104 subjects, which 
identified 1 or 2 variants in known LCA and EORD genes in 29 subjects. The chip 
was more informative for subjects with LCA than EORD. In total, the disease causing 
mutation was identified in 34.5% of subjects in cohort 1, using a variety of techniques 
including APEX analysis, direct sequencing, autozygosity mapping with positional 
candidate screening and exome sequencing. 35.8% of LCA subjects and 34.4% of 
EORD subjects had their genotype identified using these different methods. The 
molecular analysis and detailed phenotyping results will be further considered in the 
subsequent chapters.  
 
In cohort 2, molecular analysis into BEST1 was only carried out for the subjects with 
presumed autosomal recessive bestrophinopathy. Subjects with a macular phenotype 
similar to drusen at the macula did not undergo molecular analysis. The phenotypes of 
the subjects in cohort 2 will be discussed in subsequent chapters. 
 
The molecular techniques utilised in this study were in widespread use at the time that 
the study was conducted. However, with the advent of next generation sequencing 
many of these techniques have been surpassed. The rapid detection of genes using 
whole genome sequencing and exome sequencing is likely to lead to the successful 
identification of the molecular cause in the majority of patients with LCA and EORD, 
in whom, in the past, the molecular diagnosis frequently remained unidentified. This 
is a very exciting time in the field of genetics and will hopefully produce translatable 
results that may help develop novel therapeutic techniques in the future. 
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4.3 Genotype - Phenotype Associations 
 
Of the subjects recruited into Cohort 1 of the study a number of causative genes were 
identified using APEX microarray and direct sequencing. These genes have 
previously been identified to cause Leber Congenital Amaurosis (LCA) and Early 
Onset Retinal Dystrophies (EORD). A number of reports have been published 
describing the phenotype associated with these genes. The clinical features associated 
with the following genes in the subjects in cohort 1 will be briefly described here: 
AIPL1, CEP290, CRB1, GUCY2D, LCA5, MERTK, RDH12, RPE65 and RPGRIP1. 
 
 
4.3.1 AIPL1 Genotype - Phenotype association  
Two subjects (Subject 1 and Subject 2) from 2 families in Cohort 1 were identified to 
harbour mutations in AIPL1. The phenotype in both of these subjects was quite 
different, with subject 2 displaying a much milder phenotype. Subject 1 was from a 
consanguineous family from the UAE and was noted to have poor vision and 
nystagmus from 2 months of age, with photophilia. When examined at age 24 months 
he had perception of light vision in both eyes, amaurotic pupils, nystagmus and 
hypermetropia (+6.50 DS in each eye). His fundi at this age were normal. His features 
were consistent with a diagnosis of LCA. Subject 2, from a non-consanguineous 
British Caucasian family, had a much milder phenotype. She only had nystagmus, 
associated with head nodding, from 2 months of age. There were no visual concerns 
otherwise, although she did display photophilia despite her ERG findings. At 26 
172 
normal pupils and a myopic refraction (-8.50 DS in each eye). Aside from mild 
mottling at both maculae, her fundi at this age were otherwise normal (Figure 13 - A 
and B). OCT imaging showed disruption of the photoreceptor layer at the fovea 
(Figure 13 - C and D). An ERG performed at 8 months of age identified marked cone 
dysfunction but normal rod function. Her diagnosis was consistent with EORD, with 
hypomorphic features compared to the usual phenotype associated with mutations in 
AIPL1, which is typically more severe [179-181, 332, 333]. However, the residual 
ERG function demonstrated in subject 2 bears similarities to the very young AIPL1 
subjects with residual rod ERGs that were recently reported, and who may be human 
candidates for gene replacement therapy, which has been identified in animal models 
of AIPL1 disease to show effective photoreceptor rescue [334, 335].      
 
 
Figure 13 - Subject 2, AIPL1, Hypomorphic EORD. A – right eye fundus; B – left eye 
fundus, yellow arrow indicating subtle mottling at fovea; C – OCT right eye; D - OCT 
left eye, yellow arrows indicating disruption of photoreceptor layer. Images taken at 
age 3 years. 
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4.3.2 CEP290 Genotype - Phenotype association  
Eleven subjects from 11 unrelated families in cohort 1 were identified with mutations 
in CEP290 (Subjects 3 -13). Eight subjects were British Caucasian, 2 were half 
British Caucasian and 1 was Polish. None of the CEP290 families had 
consanguineous ancestries. All subjects had poor vision from birth or within the first 2 
months of life, with severe nyctalopia, visual field loss and nystagmus. General health 
was normal in 8 of 11 CEP290 subjects. One subject had Asperger syndrome and no 
renal abnormalities (Subject 3), one had a renal transplant by 12 years of age (Subject 
8) and one had renal cysts by 2.75 years of age (Subject 12).  
 
Visual acuity ranged from between 0.78 LogMAR to nil perception of light (age range 
3 months to 29 years 10 months) (Figure 14). Six of 11 subjects had perception of 
light or nil perception of light vision. In general, the visual acuities observed in 
CEP290 associated retinopathy were poor and appeared to be worse in infancy than in 
the third decade (Figure 14). This change in acuity might be perceived as the vision 
improving over time, however, it is more likely that this apparent improvement 
actually reflects the methods available to measure vision at an early age rather than a 
true improvement in vision. Due to the small number of subjects identified with 
CEP290 mutations in this study, and to the lack of longitudinal data, it is not possible 
to reliably conclude that the vision in subjects with mutations in this gene improve 
with age. 
 
Roving eye movements were present in all subjects and two displayed the oculodigital 
sign. Hypermetropic refractive errors were present in 9 subjects for whom refractive 
data were available, with a spherical equivalent ranging between +5.50 D and +7.25 
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D. Anterior segments and mediae were clear in all but one subject who had 
keratoconus and posterior subcapsular lens opacification in both eyes (Subject 3).  
The fundi were normal at a young age (7 subjects, age range 3 months to 33 months). 
In the third decade the fundi displayed widespread RPE atrophy, bone spicule and 
nummular pigmentary retinopathy and vascular attenuation (4 subjects, age range 20 
years to 29 years 10 months) (Figure 15 - A and B, Subject 10). ERGs, performed in 9 
of 11 subjects, were unrecordable (age range 3 months to 29 years). All but 2 subjects 
carried a diagnosis of LCA; Subjects 6 and 10 had diagnoses of EORD as their onset 
of visual symptoms were in infancy and visual acuities were 1.48 LogMAR (right 
eye) and 1.78 LogMAR (left eye) (Subject 6, age 29 years 10 months) and 0.78 
logMAR in either eye (Subject 10, age 27 years).  
 
The phenotypic findings associated with the CEP290 subjects in this cohort are 
consistent with published reports [252, 255, 336]. Although there is no clear cut 
genotype - phenotype correlation associated with CEP290 mutations, in LCA caused 
by mutations in this gene there is severe rod cone dysfunction with counting fingers or 
worse visual acuity and fundus changes that progress from being normal or having 
minimal peripheral white dots early in life to mid-peripheral nummular and specular 
pigmentation later in life [240, 247]. The identification of cone rich regions with 
corresponding normal OCTs, particularly at the fovea, has led to the suggestion that 
gene therapy may be possible for the restoration of central vision in these subjects 
[255, 337]. 
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Subject, 
Family, 
(Gender) 
Ethnicity Consanguinity Diagnosis Age at 
Onset 
(Weeks) 
Age at 
Exam 
LogMAR 
VA 
RE, LE 
Spherical 
Equivalent 
(Dioptres) 
RE, LE 
General 
Health 
Retina 
3, 3, (M) British Caucasian Nil LCA Birth 21 yr 8 
mth 
1.78, 1.55 Moderate 
hypermetropia 
Asperger Peripheral RPE atrophy 
4, 4, (M) Polish Nil LCA Birth 23 mth NPL, NPL +6.50, +6.25 Normal Normal 
5, 5, (M) British Caucasian Nil LCA 8 18 mth NPL, NPL +6.50, +5.50 Normal Normal 
6, 6, (M) British Caucasian Nil EORD Infancy 29 yr 
10 mth 
1.48, 1.78 Not available Normal Widespread RPE atrophy, 
nummular & BS pigment, 
attenuated vessels  
7, 7, (M) 1/2 British Caucasian,  
1/2 Brazilian 
Nil LCA 6 3 mth NPL, NPL +6.50, +6.50 Normal Normal 
8, 8, (M) British Caucasian Nil LCA 6 20 yr 1.00, 1.00 Not available Renal 
transplant  
Widespread RPE atrophy, 
nummular & BS pigment, 
attenuated vessels 
9, 9, (F) British Caucasian Nil LCA 6 9 mth PL, PL Hypermetropic 
astigmatism 
Normal Normal 
10, 10, (M) British Caucasian Nil EORD Infancy 27 yr 0.78, 0.78 Moderate 
hypermetropia 
Normal ‘typical RP'  
11, 11, (M) British Caucasian Nil LCA 8 13 mth NPL, NPL +6.00, +6.00 Normal Normal 
12, 12, (M) 1/2 British Caucasian,  
1/2 SA Caucasian 
Nil LCA Birth 33 mth FF, FF +7.25, +7.25 Renal cysts Normal 
13, 13, (F) British Caucasian Nil LCA 4 19 mth PL, PL +7.00, +6.50 Normal Normal 
 
Table 9 - Clinical Features of CEP290 subjects in cohort 1.  
F – Female; M – Male; SA – South African; LCA – Leber Congenital Amaurosis; EORD – Early Onset Retinal Dystrophy; yr – years; mth – 
months; VA – Visual Acuity; RE – Right Eye; LE – Left eye; NPL – Nil Perception of Light; PL – Perception of Light; FF – Fixing and 
Following; BS – Bone Spicule; RP – Retinitis Pigmentosa.
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Figure 14 - Graphical representation of age versus visual acuity in CEP290 
retinopathy. In the first decade visual acuity appears to be worse than in the third 
decade. Visual acuities of 5 LogMAR and 6 LogMAR represent perception of light 
and nil perception of light vision, respectively [53]. 
 
 
 
Figure 15 - Subject 10, CEP290, EORD. A – right eye fundus; B – left eye fundus. 
Both fundi show widespread RPE atrophy, vascular attenuation, and peripheral bone 
spicule and nummular pigmentation. Images taken at age 27 years. 
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4.3.3 CRB1 Genotype - Phenotype association  
Six subjects (6 families) in cohort 1 had mutations in CRB1. One subject carried a 
diagnosis of LCA (Subject 14), 4 had EORD (Subjects 15, 17, 18, 19) and 1 had rod 
cone dystrophy (Subject 16). Four of six subjects were British Caucasian, 1 was 
Indian and 1 was Italian. The only subject from a consanguineous family was subject 
16 and he had compound heterozygous mutations in CRB1. All subjects’ general 
health was normal.  
 
The subject with LCA had poor vision from 6 weeks of age with nyctalopia and 
nystagmus. When examined at 4 months he was able to fix and follow, and he had 
bilateral macular atrophy with surrounding pigment. The subjects with EORD had 
poor vision from between 2 years and just below 5 years of age. Two of these subjects 
had nyctalopia and only one had nystagmus, from 10 years of age (Subject 19). Visual 
acuity in the subjects with EORD ranged from between 0.10 LogMAR to nil 
perception of light (age range 11 years 4 months to 53 years). All 4 subjects had 
widespread retinal pigmentation and maculopathy to varying degrees (Figure 16 – A 
and B, Subject 19). Subject 15 had milder retinal pigmentation at age 11 years (Figure 
17 - A and B). Fundus autofluorescence (FAF) in one EORD subject identified a 
dense hyperautofluorescent ring at the macula at age 11 years 4 months (Subject 15) 
(Figure 17 - C and D). Three of 4 subjects had OCT imaging which demonstrated 
thickening of the retina; in 2 subjects there were intra-retinal cysts (Subjects 15 and 
17) (Figure 17 – E and F, subject 15). Subject 16, diagnosed with rod cone dystrophy, 
had poor vision from 6 years and nyctalopia from 10 years of age. His visual acuity 
was 0.78 LogMAR (right eye) and 1.00 LogMAR (left eye) at 23 years of age. His 
fundi also displayed typical features associated with CRB1 mutations, with 
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widespread RPE atrophy, coarse retinal pigmentation and macular thickening (Figure 
18 - A and B). FAF demonstrated hypoautofluorescence at the macula and OCT 
imaging did not identify macular oedema (Figure 18 – C to F). ERGs performed in 4 
of 6 CRB1 subjects identified severe photoreceptor dysfunction with more severe rod 
than cone involvement (Subjects 14 – 17, age range 4 months to 23 years). In 3 
subjects there was a hypermetropic refractive error with the spherical equivalent 
ranging between +1.88 D and +8.00 D.   
 
These phenotypic observations correlate with the published phenotype associated with 
mutations in CRB1, which in infants is characterised by retinal white dots and macular 
atrophy but in later childhood is associated with deep nummular pigmentation, 
preservation of the para-arteriolar RPE, peripheral telangiectasia, increased retinal 
thickness and macular atrophy [53, 230, 233, 331]. Additionally there may be an 
exudative retinal detachment, secclusio pupillae and secondary glaucoma. OCT 
imaging in CRB1 mutations typically displays retinal thickening, disorganised and 
coarse retinal lamination, loss of the outer limiting membrane with age and intra-
retinal cysts [53, 234].  
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Figure 16 - Subject 19, CRB1. Diagnosis EORD. A – right eye fundus; B – left eye 
fundus. Fundi display dense macular atrophy and peripheral nummular pigmentation. 
Images taken at age 12 years. 
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Figure 17 - Subject 15, CRB1, EORD. A – right eye fundus; B – left eye fundus. 
Fundi demonstrate mild disease with peripheral nummular retinal pigmentation 
(yellow arrows); C – right eye FAF; D – left eye FAF. FAF imaging shows dense 
hyperautofluorescence at the foveas; E – right eye OCT displaying macular 
thickening and intra-retinal fluid, central retinal thickness 496 microns; F – left eye 
OCT displaying macular thickening and intra-retinal fluid, central retinal thickness 
243 microns. Images taken at age 11 years. 
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Figure 18 - Subject 16, CRB1. Diagnosis rod-cone dystrophy. A – right eye fundus; B 
– left eye fundus. Fundi display dense macular atrophy and pigmentation; C – right 
eye autofluorescence; D – left eye autofluorescence. Dense hypoautofluorescence 
corresponding with the macular atrophy; E – right eye OCT, demonstrating severe 
disruption of the photoreceptor layer (yellow arrow) and disrupted retinal lamination. 
Images taken at age 21 years. 
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4.3.4 GUCY2D Genotype - Phenotype association  
In five subjects (5 families) in Cohort 1, GUCY2D was identified as the causative 
gene (Subjects 20 – 24). Three of 5 subjects were British Caucasian, 1 was Turkish 
and one was Khazakstani. All 5 had been diagnosed with LCA, with poor vision 
beginning between birth and 2 months of age. All had roving nystagmus and 2 had 
photoaversion. Visual acuity in the two oldest subjects was better than in the three 
younger subjects: perception of light to nil perception of light in subjects 21, 22 and 
24 (age range 10 months to 42 months) and 0.8 LogMAR to 1.76 LogMAR in 
Subjects 20 and 23 (ages 16 years 4 months and 10 years 5 months respectively). 
Three subjects were hypermetropic with a spherical equivalent between +1.00 D and 
+8.00 D. However, Subject 22 was myopic with a spherical equivalent of -13.0 D. 
This is not in keeping with the published phenotype associated with GUCY2D 
mutations [114, 115, 338].  
 
The fundi were normal in 4 subjects, who were examined between 10 months and 16 
years of age (Subjects 20, 21, 23 and 24) (Figure 19 - A and B, Subject 20). However, 
in Subject 22 there was a diffuse pigmentary retinopathy, which was not in keeping 
with the published GUCY2D phenotype. The ERG was unrecordable in 4 of 5 
GUCY2D subjects; in Subject 20 there was severe cone rod dysfunction at age 17 
years.  
  
The phenotype in Subject 22 was not typical of GUCY2D mutations. This subject’s 
mother and maternal aunt had mild RP, thus it is possible that the inheritance pattern 
in this family is autosomal dominant. The mutation identified in this family has been 
reported in the heterozygous state in another family with LCA from Tunisia, but the 
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fundus appearance in this family was not clearly described to allow a detailed 
comparison with the subject in the present study [115]. In addition, Perrault et al. 
described hyperopia, while Subject 22 had myopia. It remains possible therefore, that 
another gene may contribute to the disease in this family, which has, as yet, not been 
identified.  
 
 
Figure 19 - Subject 20, GUCY2D. A – right eye fundus; B – left eye fundus. Both 
fundi appear normal. Images taken at age 16 years. 
  
 
4.3.5 LCA5 Genotype - Phenotype association  
Two subjects in cohort 1 were identified with LCA5 mutations (Subjects 25 and 26). 
One was British Caucasian from a consanguineous family (Subject 25) and the second 
subject was from a non-consanguineous family of unknown ethnicity (Subject 26).  
Both were diagnosed with LCA, with poor vision and nystagmus from birth or early 
infancy. General health was normal. Visual acuity was measured at perception of light 
(Subject 25, age 18 years and 6 months) and 1.1 LogMAR (Subject 26, age 8 years 
and 6 months).  
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The fundus appearances were different between the two subjects. Subject 25 had 
atrophy at the macula, which Subject 26 did not (Figure 20 – A to D). Although both 
had peripheral RPE atrophy, Subject 26 had additional white dots in the periphery, 
which Subject 25 did not. ERGs had not been performed in these subjects. As the 
number of LCA5 families ascertained in this study were small, it is not possible to 
make a general conclusion about the LCA5 phenotype. However, these two subjects 
were included in a publication with a number of LCA5 families ascertained 
worldwide, in which the clinical diagnoses were heterogeneous and the fundi 
frequently displayed white dots in the periphery, widespread RPE atrophy and some 
preserved peripheral islands of normal RPE that may indicate a potential for therapy 
at a very young age [339].  
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Figure 20 - Subject 25, LCA5: A – right eye; B – left eye. Dense macular atrophy and 
peripheral RPE atrophy. Images taken at age 18.5 years. Subject 26: C – right eye 
with white dots in the periphery; D – left eye. Images taken at age 8.5 years.    
4.3.6 MERTK Genotype - Phenotype association  
Only one subject was identified in cohort 1 with mutations in MERTK and a diagnosis 
of EORD (Subject 29). This subject was from a multiply consanguineous family from 
the UAE, which had 5 affected members in 2 successive generations. Subject 29 had 
poor vision and nyctalopia from 4 years of age, and no nystagmus. Visual acuity at 5 
years and 4 months was 0.18 LogMAR in either eye, with a myopic refractive error of 
-4.63 D and -7.13 D spherical equivalent in the right and left eyes, respectively. Her 
retina appeared normal at this age (Figure 21 - A and B). FAF demonstrated a ring of 
hyperautofluorescence at the fovea, which corresponded to the retained photoreceptor 
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layer at the fovea seen on OCT imaging (Figure 21 - C and D). An ERG at age 4 years 
and 3 months demonstrated rod more than cone dysfunction, with sparing of the 
maculae. There were no other affected family members available for examination. 
MERTK subjects have been identified with macular atrophy and RPE depigmentation 
in a ‘bulls eye’ configuration with corresponding hyperautofluorescence, which was 
seen on autofluorescence imaging in the subject in this study [340, 341]. These 
subjects may be amenable to treatment and a clinical trial is currently underway into 
gene therapy for patients with retinal disease due to MERTK mutations 
(https://clinicaltrials.gov/ct2/show/NCT01482195). 
 
 
Figure 21 - Subject 29, MERTK, EORD. A – right eye fundus; B – left eye fundus. 
The fundi appeared normal at age 5 years 4 months; C – right eye fundus 
autofluorescence image demonstrating a ring of herperautofluorescence at the fovea; 
D – left eye OCT image demonstrating retention of the photoreceptor layer at the 
fovea, limits marked by yellow arrows. 
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4.3.7 RDH12 Genotype - Phenotype association  
In total, 17 subjects from 15 families were identified with causative mutations in 
RDH12 (Table 10). All subjects had a diagnosis of either EORD (14 subjects) or rod 
cone dystrophy (3 subjects). Interestingly, the age of symptom onset varied between 
the two affected members of family 40, leading to subject 41 carrying a diagnosis of 
EORD and subject 42 carrying a diagnosis of rod cone dystrophy. Ethnicities were 
diverse, and included British Caucasian, Saudi Arabian, Indian, Pakistani, Kurdish, 
Latvian, and western European families. Symptom onset ranged from infancy to 11 
years of age. Symptoms included poor vision, nyctalopia and visual field constriction. 
4 subjects reported a noticeable deterioration in vision in the third and fourth decades. 
General health was normal in all subjects. Subjects were examined between 6 years of 
age and 52 years of age.  
 
Visual acuity was best preserved at a young age – subject 39 had 0.6 LogMAR vision 
at 6 years of age (Figure 22). However, in general, visual acuity was poor. Only 3 
subjects had 1.0 LogMAR acuity or better. In 11 subjects the acuity ranged between 
hand movements and perception of light. The worst visual acuity was in the oldest age 
at 52 years, however two subjects also had perception of light vision in their fourth 
decade. Due to the small numbers of subjects identified with RDH12 associated 
disease and to the lack of longitudinal data it is not possible to determine how rapidly 
vision deteriorates with time.  
 
Mild hypermetropia was recorded in 3 subjects. Keratoconus was present in 1 subject 
(Subject 31); otherwise anterior segments were normal. Posterior subcapsular lens 
opacification was common, affecting 10 subjects, one of whom had surgery for lens 
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extraction (Subject 41). The fundus appearance was easily recognisable as a severe 
pigmentary retinopathy with yellow macular atrophy, macular pigmentation and 
arteriolar attenuation (Figure 23 - A to D, Table 10). In 3 subjects the severe pigment 
clumping spared the para-arteriolar region. In 3 subjects in whom OCT imaging was 
performed, there was severe thinning of the fovea with debris visible in the 
photoreceptor layer (Figure 24 – C, Subject 35 and Figure 25 – B, Subject 43). In 4 
subjects FAF imaging identified little to no autofluorescence at the macula, in keeping 
with the observed macular atrophy (Figure 24 - B, subject 35). ERGs performed in 4 
subjects were unrecordable.  
 
The phenotypic appearances of the RDH12 subjects in this study were in keeping with 
the published phenotypes which have identified severe retinal pigmentation and 
macular atrophy with very poor vision from early childhood [270, 271, 278, 279, 
282]. These subjects, and those previously recruited into the Childhood Onset Retinal 
Dystrophy Study, were published [284]. 
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Subject, 
Family, 
(Gender) 
Ethnicity Consanguinity Diagnosis Age at 
Onset 
(Years) 
Age at 
Exam 
(Years) 
LogMAR 
VA 
RE, LE 
Retina 
30, 30, (F) Unknown Consanguineous EORD 4 35 HM, HM Pigment clumping, yellow macular atrophy, arteriolar attenuation 
31, 31, (M) Saudi Arabian Consanguineous EORD 2 29 HM, HM Pigment clumping, yellow macular atrophy, arteriolar attenuation 
32, 31, (M) Saudi Arabian Consanguineous EORD <5 23 HM, CF Pigment clumping with para-arteriolar sparing, yellow macular 
atrophy, arteriolar attenuation 
33, 32, (M) British Caucasian Nil EORD 2 34 HM, HM Pigment clumping, macular atrophy and ‘coloboma’, arteriolar 
attenuation 
34, 33, (F) Indian Nil EORD Infancy 33 1.0, 0.78 Pigment clumping with para-arteriolar sparing, yellow macular 
atrophy, arteriolar attenuation 
35, 34, (M) Latvian Nil Rod-cone 10 40 1.78, 1.48 Pigment clumping, yellow macular atrophy, arteriolar attenuation 
36, 35, (F) European Caucasian Nil EORD 1.5 32 PL, PL Pigment clumping, yellow macular atrophy, arteriolar attenuation 
37, 36, (M) Kurdish Nil EORD Infancy 21 2.3, 2.3 Pigment clumping, large bilateral macular atrophic lesions, 
arteriolar attenuation 
38, 37, (M) British Caucasian Nil EORD <5 33 1.3, 1.0 Pigment clumping, yellow macular atrophy, arteriolar attenuation 
39, 38, (M) British Caucasian Nil EORD 4 6 0.6, 0.6 Pigment clumping, macular atrophy, arteriolar attenuation 
40, 39, (F) Indian Nil EORD 1 52 PL, PL Pigment clumping, yellow macular atrophy, arteriolar attenuation 
41, 40, (M) Pakistani Consanguineous EORD 4 27 HM, HM Pigment clumping, macular atrophy, arteriolar attenuation 
42, 40, (F) Pakistani Consanguineous Rod-cone 8 25 HM, HM Pigment clumping, macular atrophy, arteriolar attenuation 
43, 41, (F) Indian Nil EORD 2 20 1.0, 0.78 Pigment clumping with para-arteriolar sparing, yellow macular 
atrophy, arteriolar attenuation 
44, 42, (M) Irish Caucasian Consanguineous EORD 2.5 29 CF, CF Pigment clumping, macular atrophy and ‘coloboma’, arteriolar 
attenuation 
45, 43, (F) Indian Nil Rod-cone 11 30 PL, PL Pigment clumping, large bilateral macular atrophic lesions, 
arteriolar attenuation 
46, 44, (M) ½ British Caucasian, 
½ Portuguese 
Nil EORD 2 8 1.0, 1.3 Moderate pigment clumping, RPE atrophy, atrophic pigmented 
macula arteriolar attenuation 
 
Table 10 – Clinical Features of RDH12 subjects in cohort 1.  
F – Female; M – Male; EORD – Early Onset Retinal Dystrophy; VA – Visual Acuity; RE – Right Eye; LE – Left eye; HM – Hand Movements; 
CF – Counting Fingers; PL – Perception of Light. 
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Figure 22 - Graphical representation of age versus visual acuity in RDH12 
retinopathy. In the first decade visual acuity is markedly better than in the sixth 
decade, however, a variety of acuities are observed in the intervening decades. 
Diagnoses included EORD and rod-cone dystrophy. Visual acuities of 2 LogMAR, 3 
LogMAR, 5 LogMAR and 6 LogMAR represent counting fingers, hand movements, 
perception of light and nil perception of light vision, respectively [52, 53]. 
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Figure 23 - RDH12 subjects with EORD. A – Right eye fundus, Subject 39 age 6 
years; B – Right eye fundus, Subject 38 age 33 years; C – Left eye fundus, Subject 31 
age 29 years; D – Left eye fundus, Subject 40 age 52 years. All subjects display a 
severe pigmentary retinopathy and yellow macular atrophy with pigmentation that 
worsens with age.  
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Figure 24 - Subject 35, RDH12, Rod-cone dystrophy. A – Right eye fundus, age 40 
years displaying severe pigmentary retinopathy and yellow pigmented macular 
atrophy; B – corresponding right eye fundus autofluorescence image displaying only a 
faint autofluorescent signal at the macula; C – OCT image of the right eye displaying 
foveal shallowing (double ended arrow), severe photoreceptor disruption (single 
ended arrow) and an intra-retinal cyst. 
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Figure 25 - Subject 43, RDH12 EORD. A – Left eye fundus, age 20 years displaying 
severe pigmentary retinopathy and yellow pigmented macular atrophy; B – 
corresponding OCT image of left eye displaying foveal shallowing (double ended 
arrow) and severe photoreceptor disruption (single ended arrow).  
 
 
4.3.8 RPE65 Genotype - Phenotype association  
RPE65 mutations were identified in 8 subjects from 7 families in cohort 1. Two 
subjects were British Caucasian, 2 were Syrian, 1 was Indian, 1 Sri Lankan and 1 
from New Zealand with European ancestry; the ethnicity of one subject was unknown 
(Table 11). Three subjects had LCA and 5 had EORD. Those with LCA had poor 
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vision from birth or the first few months of life; those with EORD had symptom onset 
from infancy to 3.5 years of age. Photophilia, in which subjects would stare at lights, 
was universal. Refractive errors ranged from low hypermetropia (+2.00 D spherical 
equivalent) to severe myopia (-12.88 D spherical equivalent), with half of the subjects 
being myopic. Nystagmus was present in 3 subjects and strabismus in 2.  
 
Reduction in visual acuity was variable (Figure 26). In the LCA subjects, visual 
acuity ranged from 0.7 LogMAR at age 4 years and 6 months (Subject 49), to 
perception of light at 33 years (Subject 51). In the EORD subjects, visual acuity 
ranged from 0.00 LogMAR (Subject 52, age 18 years) to 1.3 LogMAR (Subject 50, 
age 2 years and 3 months). Subject 52 was the most mildly affected subject with 
normal visual acuity and full visual fields to confrontation. His only symptom was of 
nyctalopia beginning at 3 years and 6 months of age. He has been diagnosed with 
EORD but shows hypomorphic features. In general, the visual acuity in subjects with 
mutations in RPE65 was better than in other genes associated with retinal dystrophy. 
Although there are limited numbers of subjects with RPE65 retinopathy in this study, 
these data demonstrate that the visual acuity remains stable over the first two decades 
of life, but may deteriorate by the fourth decade, suggesting a therapeutic window of 
opportunity at an early age (Figure 26). 
 
The retina was normal in 3 subjects (Subjects 50, 53 and 55) (Table 11). In the 
remaining 5 subjects there was peripheral RPE atrophy with minimal pigmentation 
(Figure 27 – A and B, Subject 48 and Figure 28 – A, Subject 54). The only subject to 
have any pigment was the oldest subject, Subject 51, in whom the pigmentation was 
nummular and scattered in the peripheral retina at age 33 years, with focal white dots 
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at the macula (Figure 29 - A, arrow). Subject 52, who had hypomorphic disease, had 
only minimal RPE change in the retinal periphery (Figure 30 - A). FAF appearances 
were variable, demonstrating: retained autofluorescence at the fovea (Figure 29 – B, 
Subject 51); a very poor autofluorescence signal at the macula (Figure 28 – B, Subject 
54); and an annulus of hyperautofluorescence at the macula in the hypomorphic 
patient (Figure 30 – C and D, Subject 52). OCT imaging in Subject 54 demonstrated 
retention of the photoreceptor layer at the fovea (Figure 28 – C) and in subject 51 
demonstrated focal loss of the photoreceptor layer (Figure 29 - C). ERGs in 4 subjects 
were unrecordable (age range 1 year to 10 years) and in 3 subjects demonstrated 
severe rod and cone dysfunction (age range 4 years to 18 years), with residual cone 
function detected in 2 subjects (Subjects 52 and 55). 
 
In general, the phenotype displayed in the RPE65 subjects in this cohort are in 
keeping with the published phenotypes associated with RPE65 mutations, which 
describe poor vision from early childhood, localised regions of RPE atrophy, vascular 
attenuation and bone spicule pigmentation [14, 116, 148, 149, 151, 153, 342]. 
Although Subject 52 has EORD, he displays hypomorphic features, which has also 
been identified in RPE65 retinopathy [151, 160, 161]. In these subjects the clinical 
picture is milder, with onset of nyctalopia in the first or second decade, but with 
slower progression of disease, residual islands of vision or full visual fields, and 
residual ERG cone function.  
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Subject, 
Family, 
(Gender) 
Ethnicity Consanguinity Diagnosis Age at 
Onset 
(Years) 
Age at 
Exam 
(Years) 
LogMAR 
VA 
RE, LE 
Spherical 
Equivalent 
(Dioptres) 
RE, LE 
Retina 
48, 46, (M) Syrian Nil LCA Birth 10 0.9, 1.2 -1.63, -1.63 Widespread RPE atrophy 
49, 46, (M) Syrian Nil LCA Birth 4.5 0.8, 0.7 -1.13, -0.88 Peripheral RPE atrophy 
50, 47, (F) British Caucasian Nil EORD 1 2.25 1.3, 1.3 +2.00, +2.00  Normal 
51, 48, (F) New Zealand, 
European Caucasian 
Nil LCA <3 months 33 PL, PL Not available Widespread RPE atrophy, 
scattered nummular pigment, focal 
white macular lesions, PPA 
52, 49, (M) Unknown Nil EORD 3.5 18 0.00, 0.00 0.00, 0.00 Peripheral RPE irregularity 
53, 50, (F) Sri Lankan Nil EORD 2 5.67 0.60, 0.70 Not available Normal 
54, 51, (M) British Caucasian Nil EORD Infancy 11.75 0.8, 0.62 Myopic Peripheral RPE atrophy 
55, 52, (M) Indian Nil EORD 3 months 4 0.78, 0.78  -11.25, -12.88 Normal myopic fundus 
 
Table 11 - Clinical Features of RPE65 subjects in cohort 1.  
F – Female; M – Male; LCA – Leber Congenital Amaurosis; EORD – Early Onset Retinal Dystrophy; VA – Visual Acuity; RE – Right Eye; LE 
– Left eye; PL – Perception of Light.
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Figure 26 - Graphical representation of age versus visual acuity in RPE65 retinopathy. 
Vision remains good in the first two decades and can deteriorate by the fourth decade. 
Visual acuity of 5 LogMAR denotes perception of light vision [53].   
 
Figure 27 - Subject 48, RPE65, LCA. A –right eye fundus; B – left eye fundus images 
demonstrating widespread RPE atrophy and no retinal pigmentation. Images taken at 
age 10 years.   
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Figure 28 - Subject 54, RPE65, EORD. A – right eye fundus. Normal fundus at 
posterior pole with typical features of myopia, but peripheral retina showed RPE 
atrophy (not shown); B – right eye fundus autofluorescence imaging demonstrating 
little / no autofluorescence at the macula; C – right eye OCT image demonstrating 
retention of the photoreceptor layer at the fovea, demarcated by arrows. Images taken 
at age 11 years 9 months. 
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Figure 29 - Subject 51, RPE65, LCA. A – left eye fundus with focal white dots at the 
fovea (arrow) and peripheral RPE atrophy with minimal pigment in the periphery; B – 
left eye fundus autofluorescence image demonstrating minimal retained 
autofluorescence at the macula; C – left eye OCT image demonstrating focal loss of 
the photoreceptor layer at the fovea, delineated by arrows. Images taken at age 33 
years. 
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Figure 30 - Subject 52, RPE65, hypomorphic EORD. A – Right eye fundus; B  - left 
eye fundus. Both fundi are essentially normal with minimal focal RPE change in the 
periphery (yellow arrows); C – right eye fundus autofluorescence image; D – left eye 
fundus autofluorescence image. Autofluorescence images indicate annuli of 
hyperautofluorescence at the maculae. Images taken at age 18 years. 
 
 
 
4.3.9 RPGRIP1 Genotype - Phenotype association  
Two subjects from 2 families in cohort 1 were identified with mutations in RPGRIP1. 
The older subject was diagnosed with EORD as his age of symptom onset was 
described to be in childhood (Subject 56). He was British Caucasian. The younger 
subject had onset of poor vision and nystagmus from 3 months and was diagnosed 
with LCA (Subject 57). She was of Greek origin. Both subjects had very poor vision, 
nyctalopia and nystagmus. Subject 57 had photophilia. General health was normal. 
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Visual acuity was nil perception of light (right eye) and hand movements (left eye) in 
Subject 56, and perception of light in Subject 57. Both subjects were hypermetropic.  
 
In the younger subject, at 2 years of age, the retinal appearances were normal aside 
from minimal pigmentation in the periphery. In the older subject, at 46 years of age, 
there was widespread RPE atrophy and bone spicule pigmentation typical of retinitis 
pigmentosa; the maculae appeared spared (Figure 31 - A and B). An ERG at 2 years 
of age in Subject 57 was unrecordable. The phenotypes observed in these two subjects 
correlate with the published severe phenotype associated with RPGRIP1 mutations, 
which can also display a variable fundus appearance but which have been associated 
with vascular attenuation, a granular appearance to the retina, macular atrophy and 
drusen–like retinal deposits [167, 182, 183, 200, 201]. 
 
 
Figure 31 - Subject 56, RPGRIP1 EORD. A – right eye fundus; B – left eye fundus. 
Widespread RPE atrophy and bone spicule pigmentation with macular sparing. 
Images taken at age 46 years.  
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4.4 SPATA7 Phenotype 
 
SPATA7 was recently identified as the causative gene at the LCA3 locus, and when 
this research was carried out, few studies had been published reporting the phenotype 
associated with this gene [163] [166]. In this study, six families were identified to 
harbour mutations in SPATA7, and their phenotypes were examined in detail. The 
probands of families 1-4 had been recruited into the Childhood Retinal Dystrophy 
Study by Mr Henderson, a previous research fellow, and the probands of families 5 
and 6 were recruited by ADB during the period between Aug 2008 and Aug 2011. In 
total 11 subjects were identified with mutations in SPATA7, age range 4.5 years to 43 
years when examined. The strategies used to identify the SPATA7 variants in these 
families differed and will be described in this chapter. The phenotype of these 
subjects was explored in detail as there had been few descriptions to date regarding 
the SPATA7 phenotype. The results of these phenotypic studies will be presented in 
this chapter, and were published [165]. 
 
 
4.4.1 Clinical History 
All subjects affected by mutations in SPATA7 carried a diagnosis of LCA. Onset of 
poor vision and nystagmus was at birth in 6 of 11 subjects (54.5%), and by 12 weeks 
of age in the remaining subjects. One subject had a milder phenotype (Subject 2). 
Although he had developed nystagmus by 8 weeks of age, he was able to fix and 
follow well at this age, and only developed nyctalopia and visual field constriction 
when older. His symptoms deteriorated from 14 years of age. In 5 of 11 subjects 
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photoaversion was a feature early on in the disease, and in 1 subject (Subject 2) there 
was photophilia. The oculodigital reflex was present from the outset in 7 subjects. 
General health was good in all subjects except the oldest subject, Subject 3 (family 2), 
who had type II diabetes mellitus, auditory dysfunction and reduced fertility due to a 
reduced spermatozoa count, and the two youngest members of family 3 who had renal 
dysfunction (Subject 6) and severe autistic spectrum disorder with auditory 
dysfunction (Subject 7). No other SPATA7 subjects were identified with auditory or 
fertility dysfunction. In particular, Subject 1 had two children and there were no 
problems encountered regarding his fertility prior to having children. 
 
Family 1, with 2 affected subjects, was a non-consanguineous British Caucasian 
family. Families 2-6 were of South East Asian origin; families 2-5 were 
consanguineous and family 6 denied consanguinity (Table 12). There were multiple 
affected individuals in families 1-4 (Family 1: 2 affecteds, Subjects 1 and 2; Family 2: 
4 affecteds, Subject 3 only available; Family 3: 9 affecteds, Subjects 4 – 8 available; 
Family 4: 2 affecteds, Subject 9 only available) and the probands of families 5 
(Subject 10) and 6 (Subject 11) were simplex cases. None of these families were 
knowingly related to each other. 
 
 
4.4.2 Clinical Examination 
Nine of eleven SPATA7 subjects were male. Visual acuity was hand movements or 
worse in all but two subjects (Table 12). Subject 2 had a best corrected visual acuity 
of 0.22 logMAR in the right eye and 0.1 logMAR in the left eye at age 19 years. 
Subject 10 had an unaided visual acuity of 1.08 logMAR in the right eye and 1.48 
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logMAR in the left eye at age 17 years. Colour vision testing was only reliable in 
subject 2, who had a mild blue-yellow defect on HRR testing. In those subjects for 
whom refractive data were available, there tended to be a myopic astigmatism.  
 
Slit lamp examination revealed keratoconus in subject 3 and mild cataract in subjects 
1-3. In all but one patient the fundi had severe, widespread RPE atrophy with minimal 
intra-retinal pigmentation, relative parafoveal preservation, severe vascular 
attenuation and optic disc pallor (Figure 32, Figure 33, Figure 34 and Figure 35 – 
Images A, subjects 1, 2, 5 and 10). In subject 11 the posterior poles appeared to be 
normal and nummular pigmentation was visible in the peripheral retina superiorly. 
Subject 2 additionally had bilateral optic disc drusen.  
 
 
4.4.3 Fundus Autofluorescence Imaging 
Severe nystagmus and photoaversion precluded the acquisition of fundus 
autofluorescence imaging in most subjects however, in 3 subjects a parafoveal 
annulus of hyperautofluorescence was present (subjects 1, 2 and 4) (Figure 32, Figure 
33, Figure 34 and Figure 35 - B). 
 
 
4.4.4 OCT Imaging 
sd-OCT imaging was only possible in subjects 2 and 10 as image acquisition was 
limited due to nystagmus. OCT imaging in these two subjects demonstrated retinal 
thinning and possible preservation of the inner segment outer segment layer at the 
fovea (Figure 33 and Figure 35 – C, indicated by arrows). In subject 2 this 
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corresponded with the centrally preserved visual field on Goldmann perimetry. 
Elsewhere, in both of these subjects, there was loss of the photoreceptor layer, and 
some loss of retinal lamination.  
 
 
 
Figure 32 - Subject 1, Family 1 SPATA7. A – right eye fundus demonstrating 
widespread RPE atrophy, minimal retinal pigmentation, vascular attenuation and 
sparing of the fovea; B – right eye fundus autofluorescence image demonstrating an 
annulus of hyperautofluorescence at the fovea. Images taken at age 21 years. 
 
 
 
206 
 
 
Figure 33 - Subject 2, Family 1 SPATA7. A – right eye fundus demonstrating 
widespread RPE atrophy, minimal retinal pigmentation, vascular attenuation and optic 
disc drusen; B – right eye fundus autofluorescence image demonstrating an annulus of 
hyperautofluorescence at the fovea and optic disc drusen; C – right eye OCT image 
demonstrating loss of retinal lamination but preservation of photoreceptors at the 
fovea, limits delineated by arrows. Images taken at age 19 years. 
 
 
 
 
Figure 34 - Subject 5, Family 3 SPATA7. A – right eye fundus demonstrating 
widespread RPE atrophy, peripheral retinal pigmentation, vascular attenuation and 
sparing of the macula; B – right eye fundus autofluorescence image demonstrating an 
annulus of hyperautofluorescence at the fovea. Images taken at age 29 years. 
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Figure 35 - Subject 10, Family 5, SPATA7. A – right eye fundus demonstrating 
widespread RPE atrophy, minimal retinal pigmentation, vascular attenuation and 
foveal sparing; B – right eye fundus autofluorescence image demonstrating a very 
faint annulus of hyperautofluorescence at the fovea; C – right eye OCT image 
demonstrating loss of retinal lamination but possible preservation of photoreceptors at 
the fovea, limits delineated by arrows. Images taken at age 17 years.    
4.4.5 Psychophysical testing: Goldmann Visual Fields  
Goldmann visual field testing was only reliably performed in Subject 2 and showed 
preservation of less than 10o of the central vision to the V4e target and less than 5o to 
the I4e target (Figure 36). 
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Figure 36 – Goldmann Visual Field, Subject 2, SPATA7. A – Left eye; B – Right eye; 
V4e – blue line; I4e – red line. 
 
 
4.4.6 Electrophysiological Testing 
ISCEV standard ERG testing was performed in Subject 9 at 18 years of age and there 
was no detectable full field or pattern ERG, in keeping with severe bilateral 
photoreceptor dysfunction. In Subjects 1 and 2, ERGs were performed at different 
ages in the first decade using a modified paediatric ERG protocol and skin and DTL 
electrodes; the methods have been described previously [64, 343]. Subject 1 was 
tested first at age 4 years at which time the photopic ERGs were undetectable but rod 
driven ERGs were detected at subnormal amplitudes. By 5 years of age the rod-ERG 
was also undetectable. In contrast, his younger brother, Subject 2, had normal rod 
driven ERG b-wave amplitudes at age 2 years, but undetectable photopic ERGs; by 4 
years of age his rod driven b-wave amplitudes were subnormal; and by 9 years of age 
they were undetectable. This suggests that in these two subjects the condition started 
with predominantly cone dysfunction, progressing to cone – rod dysfunction. In 
Subject 11 ERGs were performed by the hospital that diagnosed his condition in 
India, but the results are not available.  
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Table 12 - Clinical features of SPATA7 subjects. M – Male; F – Female; VA – Visual Acuity; RE – Right eye; LE – left eye; CF – Counting 
fingers. HM – Hand movements; PL – Perception of light; NPL – Nil perception of light. 
Subject 
(Gender) 
Family Ethnicity Consanguinity Age at Onset 
(weeks) 
Age at 
Examination 
(years) 
LogMAR VA 
RE, LE 
General Health 
1 (M) 1 British Caucasian Non-consanguineous 6 21 1.06, CF Good 
2 (M) 1 British Caucasian Non-consanguineous 8 19 0.42, 0.66 Good 
3 (M) 2 Pakistani Consanguineous Birth 43 HM, PL Type II diabetes mellitus 
Auditory dysfunction 
Fertility dysfunction 
4 (M) 3 Pakistani Consanguineous Birth 27 HM, HM Good 
5 (M) 3 Pakistani Consanguineous Birth 29 HM, HM Good 
6 (M) 3 Pakistani Consanguineous Birth 5 PL, PL Mild renal dysfunction 
7 (M) 3 Pakistani Consanguineous 12 4.5 NPL, NPL Autistic spectrum disorder 
Auditory dysfunction 
8 (F) 3 Pakistani Consanguineous Birth 12 NPL, NPL Good 
9 (M) 4 Bangladeshi Consanguineous 8 15 CF, CF Good 
10 (F) 5 Pakistani Consanguineous Birth 17 1.08, 1.48 Good 
11 (M) 6 Indian Non-consanguineous 12 5.5 PL, PL Good 
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4.4.7 Molecular analysis 
The molecular techniques used to identify the families with SPATA7 mutations varied. 
Dr Ocaka and Dr Mackay at UCL carried out the molecular analysis on these families. 
Families 1-3 were identified following the screening of SPATA7 in an enriched panel 
of 141 probands with LCA and EORD that had previously been screened using the 
LCA chip, with no variants identified; Family 4 was identified based upon the 
phenotype; Family 5 was identified through positional gene screening after 
autozygosity mapping; and family 6 was identified via analysis using the LCA chip.  
 
The two affected brothers in Family 1 (Subjects 1 and 2) were identified by direct 
sequencing to harbour novel compound heterozygous variants in SPATA7 as follows: 
Exon 5 c.265_268delCTCA, p.L89KfsX3 and Exon 8 c1227_1229delCAC, 
p.H410del. Segregation analysis in the parents identified the c.265_268delCTCA, 
p.L89KfsX3 variant in the unaffected mother in the heterozygous state, and the 
c1227_1229delCAC, p.H410del variant in the unaffected father in the heterozygous 
state, confirming that the variants segregate with the disease in this family. Subject 3 
(the proband of family 2) was identified to harbour the novel variant c.253C>T, 
p.Arg85X in the homozygous state; no other family members were available for 
molecular analysis. The proband of family 3, Subject 4, was identified by direct 
screening to harbour the previously reported variant c.961dupA, p.P321TfsX5 in the 
homozygous state [163]. Screening of this variant in other affected family members 
(Subjects 5-8) also identified it in the homozygous state in these individuals. 
Screening of unaffected family members (parents of the affected subjects) confirmed 
that the mutation segregates with the disease in this family as these family members 
were identified to be heterozygous carriers of this variant.  
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Based upon the consanguineous ancestry in family 4, the proband (Subject 9) was 
selected for autozygosity mapping using the Affymetrix SNP 6.0 microarray 
(Affymetrix Inc., California, USA). This identified 11 regions of homozygosity that 
were greater than 10 Mb in length, the smallest of which was present on chromosome 
14 (Table 13). Candidate retinal disease associated genes included ABCA4, C2orf71, 
CNNM4, CNGA3, MERTK, RBP3, CEP290 and SPATA7. Subsequent positional 
screening of SPATA7 identified the novel variant c.253C>T, p.Arg85X in the 
homozygous state. This subject had an affected brother but his DNA was not 
available; segregation analysis in the parents confirmed the variant to segregate with 
the disease in this family, as they were both identified to be heterozygous carriers of 
this mutation. This subject had previously been screened using the LCA chip, with no 
variants identified. 
 
Chromosome From To Size (Mb) Retinal disease associated 
genes 
1 83875590 99936880 16.06 ABCA4 
2 10075000 37675050 36.67 C2orf71 
2 67464630 130110400 62.6 CNNM4, CNGA3, MERTK 
4 84196690 110076800 25.88  
4 162527200 180125700 17.5  
10 35104210 70084230 34.98 RBP3 
11 91493940 103385700 11.8  
12 68292940 92857940 24.56 CEP290 
13 21218200 38110360 16.9  
14 81267210 92342000 11 SPATA7 
16 62435740 81326560 18.9  
 
Table 13 - Augozygosity data, family 4. SPATA7 resides in the eleventh largest region 
of homozygosity. 
 
Based upon the phenotype of Subject 10 (family 5), direct screening of SPATA7 was 
undertaken, which identified the same novel variant that had been identified in 
subjects 3 and 9, c.253C>T, p.Arg85X in the homozygous state. The mother of 
Subject 10 was screened for this mutation, which was identified in the heterozygous 
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state, confirming segregation of the disease in this family. The DNA of the father was 
not available.  
 
The DNA of Subject 11 (family 6) was screened using the LCA chip in 2011, which 
identified the previously described SPATA7 variant c.961dupA, p.P321TfsX5, in the 
homozygous state. Segregation analysis was not performed for this variant as the 
study period had closed shortly after the variant was identified. Of note, the DNA of 
this subject had been screened across the LCA chip in the past, in 2007, by another 
research laboratory in the USA, and no variants had been identified.   
 
The mutations identified in SPATA7 in this study are summarised (Table 14). 
 
Subject Family Mutation 1 Mutation 2 Reference 
1 1 c.265_268delCTCA, 
p.L89KfsX3 
c1227_1229delCAC, 
p.H410del 
Novel to this 
study 
2 1 c.265_268delCTCA, 
p.L89KfsX3 
c1227_1229delCAC, 
p.H410del 
Novel to this 
study 
3 2 c.253C>T, p.Arg85X c.253C>T, p.Arg85X Novel to this 
study 
4 3 c.961dupA, p.P321TfsX5 c.961dupA, p.P321TfsX5 [163] 
5 3 c.961dupA, p.P321TfsX5 c.961dupA, p.P321TfsX5 [163] 
6 3 c.961dupA, p.P321TfsX5 c.961dupA, p.P321TfsX5 [163] 
7 3 c.961dupA, p.P321TfsX5 c.961dupA, p.P321TfsX5 [163] 
8 3 c.961dupA, p.P321TfsX5 c.961dupA, p.P321TfsX5 [163] 
9 4 c.253C>T, p.Arg85X c.253C>T, p.Arg85X Novel to this 
study 
10 5 c.253C>T, p.Arg85X c.253C>T, p.Arg85X Novel to this 
study 
11 6 c.961dupA, p.P321TfsX5 c.961dupA, p.P321TfsX5 [163] 
 
Table 14 - Mutations identified in SPATA7 in this study. 
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4.4.8 Discussion 
The LCA3 locus was identified in 1998 [162] but the causative gene, SPATA7, was 
not determined until 11 years later [163]. Mutations in SPATA7 are associated with a 
severe LCA phenotype. In this study 6 families were identified with pathogenic 
mutations in SPATA7, which were identified using a variety of methods. All affected 
subjects carried a diagnosis of LCA. Visual symptoms began at birth or within the 
first few months of life, with associated nystagmus and initial photoaversion. Visual 
field constriction was severe (less than 10o of the central vision preserved in the 
subject with the mildest disease). The retina displayed widespread RPE atrophy in the 
majority of subjects, with minimal peripheral intra-retinal pigment migration, optic 
disc pallor, arteriolar attenuation and foveal sparing. The fundus autofluorescence 
imaging demonstrated a parafoveal annulus of hyperautofluorescence, which has 
previously been described in RP [344]. OCT imaging suggested preservation of the 
photoreceptor layer at the fovea. However, although the ERG eventually showed 
severe photoreceptor dysfunction, there was a suggestion that this condition may 
present with a cone dysfunction picture, which progresses to cone – rod dysfunction.  
 
The SPATA7 phenotype described in this study correlates with the few published 
reports of families with SPATA7 mutations, and in particular highlights the clinical 
heterogeneity associated with this gene, for which both severe and mild phenotypes 
have been reported [163, 166, 345-347]. Of note, the proband of one of the original 
families identified with SPATA7 mutations had 0.00 LogMAR vision at age 7 years 
and retained only 5o of their central visual field, but had developed nyctalopia at age 2 
years and had an unrecordable ERG [163]. Shortly after the results of the present 
study were published, a consanguineous family was reported with 2 affected 
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individuals and the same mutation identified in the present study, c.253C>T, 
p.Arg85X, in the homozygous state [345]. Interestingly these siblings had much later 
onset of visual symptoms (in one sibling nyctalopia developed at age 25 years, the 
other sibling was asymptomatic at age 26 years), severely reduced scotopic and 
photopic ERG responses in the symptomatic sibling with much milder changes in 
latency and amplitude in the asymptomatic sibling. It is possible that modifier alleles 
are responsible for the clinical heterogeneity associated with this mutation. Wang et 
al. suggested the possibility of a digenic triallelic inheritance pattern causing 
phenotypic heterogeneity, in which the presence of a mutation in a second gene 
contributes to the severity of the phenotype in an individual with two mutations in one 
gene, although this was not demonstrated by their study [163]. There has been a 
report, however, of a family with multiple affected individuals and bi-allelic 
mutations in CRB1 with one sibling harbouring an additional heterozygous missense 
mutation in SPATA7 that was presumed to be damaging by in silico analysis [348]. It 
is possible, though, that this variant is a rare SNP. In this family, the clinical picture 
was the same in all affected individuals leading to the conclusion that there was no 
contribution of the mutant SPATA7 allele to the phenotype seen in this subject.   
 
It has been hypothesised that the differential severity of mutations at a single locus 
may be the cause of the difference in phenotypes [163]. Mutations that occur earlier in 
the SPATA7 coding region might lead to more severe protein truncation with loss of 
function due to nonsense mediated decay, and thus cause a more severe phenotype 
consistent with LCA. Conversely, mutations that occur later in the coding region, 
such as in the last 2 exons, may lead to less severe protein truncation and a less severe 
phenotype that is described as ‘juvenile RP’. Similar observations were made by 
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another group, who identified all six mutations in their study to cause protein 
truncation, and all affected subjects to display a severe phenotype consistent with 
LCA [166]. Of the four mutations identified in SPATA7 in the present study, 3 are 
predicted to lead to premature termination of the protein (p.Arg85X, p.L89KfsX3 and 
p.P321TfsX5), and to be degenerated by nonsense mediated decay. The subjects with 
homozygosity with any of these alleles did indeed have a more severe phenotype. The 
compound heterozygous mutations in family 1, which has a milder phenotype in one 
affected sibling, involves mutations in exon 5 and exon 12, which may lead to some 
residual protein function. However the severity of the phenotype between the siblings 
who harbour the same compound heterozygous mutations is different. The reason for 
this is unclear but it may again be due to the influence of modifier alleles.  
 
At the time that this study was conducted the function of SPATA7 was unknown. 
Spata7 was first cloned in the rat testis and the corresponding human cDNA was 
identified in the human testis [164]. The human protein had been identified to be 
expressed as two transcripts: one that is predominantly expressed in the retina, 
cerebellum and whole brain, and another that is predominantly expressed in the testis 
[166]. Murine Spata7 was observed to be expressed in the mature mouse retina at day 
P21 (postnatal) in multiple layers including the ganglion cell layer, inner nuclear layer 
and inner segments of photoreceptors, and not in the mouse embryo at day E16.5 
[163]. This suggested that Spata7 is required for photoreceptor function rather than in 
photoreceptor development.  
 
Recently the function of Spata7 was further delineated [349]. It has been identified as 
a ciliary protein, which localises to the connecting cilium of photoreceptors. In vitro 
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and in vivo studies identified that a key role of SPATA7 is in its interaction with 
RPGRIP1 and that it binds to the N terminal coiled coil domain of RPGRIP1. In the 
Spata7-/- mouse there is very little RPGRIP1 present at the connecting cilium, 
indicating that Spata7 is necessary for the localisation and assembly of the RPGRIP1 
protein complex, which itself is required for protein trafficking from the IS to the OS. 
Similarly to mutations in other ciliary genes such as Tulp1, Cep290, Rpgrip1 and Rp1 
[243, 305, 350, 351], rhodopsin is seen to accumulate at the ISs and nuclei of 
photoreceptors in the Spata7-/- mouse, leading to photoreceptor apoptosis. The retinal 
defects in Spata7-/- mice are evident shortly after birth with initial thinning of the 
ONL and subsequent shortening and disorganisation of the OSs. Rods die by 6 
months but the cones are better preserved at this age (84% of cones are still present at 
6 months). Subsequent cone loss is presumed to be secondary to rod photoreceptor 
loss. Interestingly, in the present study, ERG testing identified initial loss of cone 
function with eventual rod involvement. In addition, a number of subjects in this and 
other studies reported transient photoaversion initially, suggesting first cone 
photoreceptor dysfunction [166]. 
 
Mutations in SPATA7 have added to the spectrum of conditions known as 
‘ciliopathies’. Photoreceptor dysfunction is due to degeneration rather than 
developmental defects. Further studies will be required to ascertain whether there are 
systemic associations of mutations in SPATA7 such as infertility or hearing loss, 
which was observed in some of the patients in this study. The presence of less severe 
phenotypes and retention of photoreceptor architecture very early in the disease may 
provide a small window of opportunity for therapeutic options as and when they arise.   
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4.5 Tubby and Tubby-Like protein 
Genotype - Phenotype Associations 
 
The tubby-like proteins (TUB, TULP1, TULP2 and TULP3) are a unique family of 
proteins that share a highly conserved C-terminal domain (the ‘tubby domain’) that is 
comprised of around 260 amino acids, and is located at the carboxyl terminus of all of 
the members of the tubby-like protein (TULP) family [352]. TUB is the founding 
member of the TULPs, first identified in the tubby mouse as Tub, which presented 
with a syndrome characterised by late-onset obesity and neurosensory deficits. The 
causative mutation was found in the Tub gene [294, 295, 353]. Although human 
autosomal recessive mutations in TULP1 (MIM 602280) have been identified in 
EORD and ARRP [299-301], no human mutations in TUB (MIM 601197) had been 
identified prior to this study. Through exome sequencing, one family in the Childhood 
Onset Retinal Dystrophy study was identified with a homozygous mutation in TUB. 
The subsequent phenotypic studies, and the results of collaborative studies on this 
family, are reported in this chapter. In addition, the phenotypes of families identified 
with TULP1 mutations are described in a separate section within this chapter.  
 
 
4.5.1 TUB Genotype - Phenotype Association 
The proband of a consanguineous UK Caucasian family had previously been recruited 
to the Childhood Onset Retinal Dystrophy Study. His DNA had been screened across 
the LCA chip by previous researchers in 2008 and no mutations were identified. Due 
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to his consanguineous ancestry, his DNA had been analysed using autozygosity 
mapping by Dr Mackay, UCL, and was subsequently screened using next generation 
sequencing. This identified a homozygous frame-shift mutation in TUB, 
c.1194_1195delAG, p.Arg398Serfs∗9. The proband and his family were invited back 
to MEH for phenotypic studies subsequent to this mutation being identified. 
Collaborators at the University of Cambridge, UK, and the University of Mainz, 
Germany, performed functional studies and immunohistochemistry studies on this 
family, and the work was published in a collaborative paper [330]. Brief descriptions 
of the molecular and functional studies will be presented here, but the main body of 
work into this family to be detailed are the phenotypic studies.  
 
4.5.1.1 Clinical History 
The male proband had reduced vision and nyctalopia from age 9 years. He was 
diagnosed with a unilateral retinal detachment and a retinal dystrophy at 11 years of 
age. Subsequent electrodiagnostic testing demonstrated undetectable full field rod and 
cone responses and severely reduced macular function. He was 18 years old when he 
attended with his parents and 2 siblings for further phenotypic studies.  
 
General health in the proband was good, although he was noted to be overweight in 
his early teenage years and he had mild learning difficulties. In particular, he denied 
any hearing, renal or metabolic abnormalities. He had 4 siblings and there were 
multiple levels of consanguinity within the family (Figure 37). His older brother 
denied any visual symptoms and younger sister, who was obese, had been prescribed 
glasses at 5 years of age and had undergone intermittent occlusion therapy for 
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amblyopia, but had no other visual symptoms. They also denied any other systemic 
abnormalities. There was a family history of unilateral micro-ophthalmos, colobomata 
and extra digits in a male maternal cousin. The parents were asymptomatic.     
 
 
Figure 37 - Pedigree of TUB family. Black symbol = affected with retinal dystrophy; 
red symbol = affected with microophthalmos, colobomatata and extra digits. 
 
4.5.1.2 Clinical Examination 
At 18 years of age BCVA in the proband (VI.11) was 0.2 LogMAR in the right eye 
and NPL in the left eye, with a myopic astigmatic refractive error of -1.25/-4.25, 16o 
in the right eye and -1.00/-4.00, 170o in the left eye. HRR colour vision testing of the 
right eye demonstrated a mild red - green colour deficiency and a strong blue – yellow 
colour deficiency. There was a left relative afferent pupillary defect and left exotropia. 
The anterior segments were normal and cortical lens opacities were present in the left 
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eye. The right fundus had widespread RPE atrophy, generalised retinal pallor, 
arteriolar attenuation, fine peripheral pigmentary mottling and white dots throughout, 
with macular sparing (Figure 38 - A). The optic nerve was normal, with peri-papillary 
atrophy, in keeping with myopia. The left fundus had a total retinal detachment with 
proliferative vitreoretinopathy. He had no syndactyly or polydactyly, although his 
fingers appeared to taper at the distal ends. At age 18 his BMI was 29.5kg/m2, which 
placed him in the ‘overweight’ category. Biochemical investigations into glucose, 
triglycerides and cholesterol were normal. 
 
Unaided visual acuity in the proband’s 21 year old brother (VI.10) was 0.48 LogMAR 
in either eye, with no improvement with pinhole. His myopic astigmatic refractive 
error was -1.00/-2.00, 180o and -0.75/-1.75, 180o in the right and left eyes 
respectively. HRR colour plate testing revealed mild red-green and medium blue-
yellow colour deficiencies. His fundus appearance, which was bilaterally 
symmetrical, was similar to, but less severe, than the proband (Figure 39 - A). His 
BMI at age 21 years was 22.9kg/ m2, which is categorised as being ‘normal’. 
 
The 9-year old sister (VI.12) had a BCVA of 0.18 LogMAR right eye and 0.3 
LogMAR left eye, improving to 0.18 LogMAR with pinhole. Her myopic astigmatic 
refractive error was +0.75/-3.50, 180o in the right eye and +0.25/-3.00, 180o in the left 
eye. HRR colour vision testing was normal. The fundus showed bilateral symmetrical 
mild peripheral RPE atrophy, generalised retinal pallor, inferior retinal pigmentary 
mottling with macular sparing and no retinal pigmentation (Figure 40 - A). Peri-
papillary atrophy was in keeping with her myopia. Her BMI at age 9 years classified 
her as being ‘obese’, falling in the 98th centile for age and gender. 
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Ocular examination in the parents and oldest sister was normal. Unfortunately the 
family did not consent to any further phenotypic studies such as smell acuity, auditory 
testing and metabolic studies. 
 
4.5.1.3 Fundus Autofluorescence Imaging 
In the proband FAF imaging demonstrated an annulus of hyperautofluorescence 
centred on the fovea in the right eye (Figure 38 - B). A normal autofluorescence 
signal was obtained at the fovea in the brother, although there was 
hypoautofluorescent mottling in the posterior pole along the vascular arcades (Figure 
39 - B). FAF imaging in the sister was normal (Figure 40 - B). 
 
4.5.1.4 OCT Imaging 
sd-OCT imaging in the proband demonstrated a preserved photoreceptor inner 
segment outer segment (IS/OS) junction at the fovea, with loss of this layer in the 
parafoveal region, corresponding to the fundus autofluorescence image (Figure 38  - 
C). The inner retinal layers remained intact. In the affected brother (VI.10) the IS/OS 
junction was preserved at the fovea, outer retinal debris was visible at the level of the 
RPE in the parafoveal region, and the inner retinal layers remained intact (Figure 39 - 
C). In the sister (VI.12) OCT imaging was normal (Figure 40 - C). 
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Figure 38 - TUB Family: proband (VI.11): A – right eye fundus; B – right eye fundus 
autofluorescence image; C – right eye sd-OCT. Yellow arrows on image B indicate 
nasal and temporal limits of photoreceptor inner segment outer segment layer at the 
fovea; beyond these arrows this layer is not visible. 
 
 
Figure 39 – TUB Family: brother (VI.10): A – right eye fundus; B – right eye fundus 
autofluorescence image; C – right eye sd-OCT.  
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Figure 40 - TUB Family: sister (VI.12): A – right eye fundus; B – right eye fundus 
autofluorescence image; C – right eye sd-OCT.   
4.5.1.5 Psychophysical testing: Goldmann Visual Fields 
Goldmann visual field analysis was performed only for the right eye of the proband, 
which revealed responses in only the central 15o to the V4e target, the central 10o to 
the III4e target and the central 7.5o to the I4e target (Figure 41). 
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Figure 41 – Goldmann Visual Field, Subject VI.11, TUB. Right eye. V4e – blue line; 
III4e – red line; I4e – green line. 
 
 
4.5.1.6 Electrophysiological Testing 
In the proband, full-field ERGs from both eyes at age 13 years were undetectable. 
There was a residual 30Hz flicker response of 10μV in the right eye suggesting 
residual cone function in this eye. No further electrophysiological studies were 
performed in any subject as the family did not attend for any further studies. 
 
4.5.1.7 Molecular analysis 
Molecular analysis was performed by Dr Mackay and Dr Davidson at UCL, and the 
results briefly described here. More detailed information regarding the molecular 
analysis is available in the paper published on this family [330].  
 
On the basis of the consanguineous ancestry in the proband, his DNA was analysed 
using homozygosity mapping. This identified five chromosomal segments over 5 Mb. 
No genes that had previously been associated with RP were found to be present within 
the identified regions of homozygosity. Four retinal disease associated genes that 
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were identified in the second largest region of homozygosity on chromosome 11 
(CTSD, TPP1, TEAD1, USH1C) were screened in this subject and no disease causing 
variants were identified. In addition, no homozygous pathogenic copy number 
variants were identified. 
 
His DNA subsequently underwent exome capture and high throughput sequencing 
using solution phase Agilent SureSelect 38-Mb exome capture. The average 
sequencing depth on target was 43 with 78.4% of the targeted region covered with a 
minimum read depth of 10. A homozygous frame-shift variant in TUB, 
c.1194_1195delAG, p.Arg398Serfs∗9 was identified (numbered according to 
Ensembl transcript ENST00000299506). This variant was located in the second 
largest region of homozygosity and was identified in the homozygous state in his 
older brother and younger sister. The parents were identified as heterozygous carriers 
of this variant. No additional potentially pathogenic variants in TUB were identified 
on Sanger sequencing in 96 probands with childhood onset ARRP. In collaboration 
with the University of Cambridge Metabolic Research Laboratories, TUB was 
sequenced in 55 subjects with severe obesity and a variety of ocular phenotypes, who 
were part of the Genetics Of Obesity Study, and no potentially pathogenic variants 
were found. The TUB c.1194_1195delAG, p.Arg398Serfs∗9 variant was not 
identified in over 6000 publically available exomes (NHBLI exome variant server).  
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4.5.1.8 Collaborative studies 
In collaboration with the University of Cambridge Metabolic Research Laboratories, 
(Wellcome Trust-MRC Institute of Metabolic Science, Addenbrooke’s Hospital, 
Cambridge) functional studies of the p.Arg398Serfs∗9 variant identified its 
expression in transfected HEK293 cells and its localisation predominantly to the 
nucleus, in contrast to wild type TUB which was detected in the cytoplasm and 
plasma membrane [330]. The Department of Cell and Matrix Biology, Institute of 
Zoology, Johannes Gutenberg, (University of Mainz, Mainz, Germany), performed 
immunohistochemistry studies on retinal cryosections from eyes of a human donor, 
and identified strong TUB expression in the nuclei of the ganglion cell layer and in 
the inner segment of photoreceptor cells. TUB was identified at the base of the 
photoreceptor cilium and ciliary rootlet, which projects through the inner segment of 
the photoreceptor [330]. 
 
4.5.1.9 Summary of TUB phenotype identified in this study 
The results from this study have identified that the phenotype associated with 
mutations in TUB is of a childhood onset rod cone dystrophy characterised by reduced 
vision, nyctalopia and visual field constriction beginning late in the first decade. 
There is associated myopic astigmatism, a mild red - green and a stronger blue – 
yellow colour deficiency, severe visual field constriction and an undetectable full field 
ERG. There may be residual cone function demonstrable by the ERG. The fundus 
displays widespread RPE atrophy, fine peripheral pigmentary mottling, and peripheral 
white dots. The OCT demonstrates preservation of the photoreceptors in the fovea but 
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loss of this layer in the parafoveal region. Autofluorescence imaging correlates with 
the OCT imaging. Systemically there may be obesity in childhood, but no other 
metabolic, auditory or olfactory abnormalities that are found in the tubby mouse can 
be confirmed. Further families will need to be ascertained to determine these features.  
 
 
4.5.2 TULP1 Genotype - Phenotype Association 
Four individuals from 3 families were identified to harbour mutations in TULP1. One 
family with 2 affected siblings (family 1) was recruited in Cohort 1 of this study; one 
family with one affected member had been recruited to the study by a previous 
research registrar (family 2); and the final family with multiple affected individuals 
(family 3) was originally part of a panel of patients with ARRP that underwent 
autozygosity mapping and positional screening of TULP1. The strategies used to 
identify the TULP1 variants in these families varied and will be described in this 
chapter, along with the results of phenotypic studies.  
 
4.5.2.1 Clinical History 
The age of onset of visual symptoms varied in the group of patients identified with 
TULP1 mutations. Two siblings (family 1) were diagnosed with EORD, with onset of 
poor vision and nystagmus within the first year of life; the female proband (IV.4) was 
1 year old when nyctalopia and visual field constriction were first noted but her 
younger brother (IV.5) was 8 months old when nystagmus developed. The probands 
of families 2 (V.5) and 3 (III.3) were 6 years and 12 years old respectively when they 
developed nyctalopia, and carried a diagnosis of rod-cone dystrophy. Current 
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symptoms in all subjects are of reduced vision, nyctalopia and visual field 
constriction. General health was good in all subjects. The children of family 1 were 
classified as being overweight (IV.4) and obese (IV.5) for their age and gender; 
subject V.5 family 2 had a normal body mass index. All 3 families are from the Asian 
subcontinent and are consanguineous (Figure 42 and Table 15).     
 
 
 
Figure 42 - Pedigrees of TULP1 families. A. Family 1; B. Family 2; C. Family 3. 
Black symbols = affected individuals.  
4.5.2.2 Clinical Examination 
Visual acuity ranged from 0.6 LogMAR in the youngest subject at 6.5 years of age to 
1.48 LogMAR in the oldest subject at 36.5 years of age. The refraction, where 
recorded, tended towards a myopic astigmatism (Table 15) and visual fields to 
confrontation in the two oldest subjects were constricted to the central 60o in the third 
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decade and central 10o in the fourth decade. Anterior segments were normal in all 
subjects, and lens opacities were present in the oldest subject.  
 
Funduscopy in the youngest subjects (aged 6.5 years [IV.5 family 1] and 9 years 
[IV.4] family 1) showed mild RPE atrophy in the retinal periphery, vascular 
attenuation, macular preservation and no retinal pigmentation (Figure 43 - A). In the 
older subjects there was a similar picture but with more widespread RPE atrophy (V.5 
family 2, age 24 years) (Figure 44 - A), which progressed to having peripheral bone 
spicule pigmentation and pigment clumping with a pale disc in the oldest subject 
(III.3 family 3, age 36.5 years) (Figure 45 - A). BMI was calculated for families 1 
and 2. The children in family 1 were overweight (IV.4) and obese (IV.5) for their age 
and gender; the proband of family 2 had a normal BMI (Table 15). 
 
Subject 
(Gender) 
Family Ethnicity VA RE, 
LE 
(age, 
years) 
Refraction Visual 
fields 
BMI (kg/m2) 
IV.4 
(F) 
1 Indian 0.6, 0.6  
(9) 
RE -0.75/-1.5, 180 
LE 0/-2.0, 180 
Not 
tested 
24.1 
94th centile 
(over-weight) 
IV.5 
(M) 
1 Indian 0.8, 0.6 
(6.5) 
RE plano 
LE plano 
Not 
tested 
21.1 
98th centile 
(obese) 
V.5 
(F) 
2 Pakistani 0.78, 0.6 
(24) 
RE -5.75/-3.50, 4 
LE -5.50/-4.00, 180 
Central 
65o   
24.2  
(normal) 
III.3 
(M) 
3 Pakistani 1.3, 1.48 
(36.5) 
Not available Central 
10o   
Not available 
 
Table 15 - Clinical features of TULP1 subjects. VA – visual acuity; RE – right eye; 
LE – left eye; M = male; F = female. 
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4.5.2.3 Fundus Autofluorescence Imaging 
FAF imaging at age 9 years (IV.4 family 1) demonstrated an annulus of 
hyperautofluorescence in the macula with a hypoautofluorescent signal at the fovea 
(Figure 43 - B). In the third decade the hyperautofluorescent annulus was more 
diffuse and extended to the fovea (Figure 44 - B). By the fourth decade a 
hyperautofluorescent signal was seen at the fovea with hypoautofluoresence 
corresponding to atrophy and pigmentation throughout the macula and retina (Figure 
45 – B).   
4.5.2.4 OCT Imaging 
In all subjects old enough to be tested, sd-OCT imaging showed preservation of the 
photoreceptor IS/OS layer at the fovea with loss of the layer in the parafoveal area 
(Figure 43, Figure 44 and Figure 45 - C). The inner retinal layers remained intact. 
Debris was visible in the outer retina in the oldest subject.  
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Figure 43 - TULP1 Family 1: subject IV.4: A – right eye fundus; B – right eye fundus 
autofluorescence image; C – right eye sd-OCT. Yellow arrows indicate nasal and 
temporal limits of photoreceptor inner segment outer segment layer at the fovea; 
beyond these arrows this layer is not visible. Images taken at age 9 years. 
 
Figure 44 - TULP1 Family 2: subject V.5: A – right eye fundus; B – right eye fundus 
autofluorescence image; C – right eye sd-OCT. Yellow arrows indicate nasal and 
temporal limits of photoreceptor inner segment outer segment layer at the fovea; 
beyond these arrows this layer is not visible. Images taken at age 24 years. 
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Figure 45 - TULP1 Family 3: Subject III.3. A – right eye fundus; b – right eye fundus 
autofluorescence image; c – right eye sd-OCT. Yellow arrows indicate nasal and 
temporal limits of photoreceptor inner segment outer segment layer at the fovea; 
beyond these arrows this layer is not visible. Images taken at age 36.5 years.  
 
4.5.2.5 Psychophysical Testing: Goldmann Visual Fields 
Goldmann visual fields were performed in the proband of family 2, which showed 
global constriction of the visual fields in each eye. To the V4e target this was reduced 
in the right eye to 40-45o nasally, superiorly and inferiorly, and 60o temporally, and in 
the left eye to 40o nasally and superiorly, 55o inferiorly and 70o temporally (Figure 
46). 
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Figure 46 - TULP1 Family 2: Subject V.5, Goldmann Visual Fields. A – Right eye; B 
– Left eye. V4e – blue line; III4e – red line. 
  
4.5.2.6 Electrophysiological Testing 
Full field and pattern ERGs were markedly reduced in subject IV.5 family 1, the 
youngest subject, and undetectable in 2 others (IV.4 family 1 and V.5 family 2). The 
oldest subject did not undergo electrophysiological testing (III.3 family 3).   
 
4.5.2.7 Molecular analysis 
The DNA of the proband (IV.4) of family 1 was analysed using the LCA chip, which 
identified the exon 15 variant c.1511_1521delTGCAGTTCGGC, p.Leu504fsX140 in 
the homozygous state. This variant had previously been described by den Hollander in 
a Surinamese family with ARRP [312]. This mutation was confirmed by ADB, and 
segregation checked within the family. The affected younger brother (IV.5) was also 
identified to harbour this variant in the homozygous state, and the parents were 
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identified to be heterozygous carriers of the variant, which confirms the segregation 
of this variant with the disease in this family (Figure 47). TULP1 primer sequences 
and PCR conditions are described in the appendix (Appendix 7.2.1). This 11-bp 
deletion causes a frame shift and replaces the 39 C-terminal amino acids with 140 
aberrant amino acid residues.  
 
 
Figure 47 - TULP1 Family 1 Electropherograms. 
 
 
Due to the ancestry of families 2 and 3, autozygosity mapping was performed (family 
2 by Dr Mackay, family 3 by Dr Sergouniotis). In family 2, this revealed 6 
chromosomal segments over 10 Mb (Table 16), in which 4 known retinal disease 
associated genes resided. Based upon the phenotype in the proband of family 2, 
TULP1 was selected as a positional candidate gene, and screened by ADB within a 
panel of 10 patients by direct sequencing. This identified the novel homozygous 
variant c.1035C>G, p.Ser345Arg in exon 10 in the proband. Segregation analysis 
identified that this variant segregates with the disease in this family as her unaffected 
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brother (III.2, family 2) and parents were all heterozygous for this variant (Figure 48). 
This variant was analysed using different in silico analysis programmes. SIFT gave a 
score of 0, indicating that this mutation is damaging (median 2.71); pMUT gave a 
neural network value of 0.70 and reliability value of 4 (predicting the mutation to be 
pathologic); and PolyPhen 2 appraised the mutation to be ‘probably damaging’ with a 
score of 0.992 (sensitivity 0.7, specificity 0.97). This variant was not identified in the 
1000 genomes project or in the exome variant server. 
 
Chromosome From To Size (Mb) Retinal disease 
associated genes 
6 15062945 37547262 22.48 TULP1 
6 130071088 155001410 24.93 AHI1, PEX7 
7 5411296 20831800 15.42  
7 110274772 141816117 31.54  
9 2615553 17987408 15.37 MPDZ 
 
Table 16 - Augozygosity data, TULP1 Family 2. TULP1 resides in the third largest 
region of homozygosity. 
 
 
Figure 48 - TULP1 Family 2 Electropherograms. 
 
The autozygosity mapping data for family 3 are not available, but did identify an area 
of homozygosity on chromosome 6p, in which TULP1 resides. Positional screening 
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(by ADB) of TULP1 in the proband (III.3) of this family identified a novel 
homozygous variant in the intronic sequence as IVS3+1g>a. There were no other 
family members available to check the segregation of this variant, but it was 
confirmed in both the forward and reverse sequence (Figure 49). Splice site in silico 
analysis programmes identified that this mutation abolishes the splice acceptor site at 
this location (www.fruitfly.org). The mutation was not identified in the 1000 genomes 
project or on the exome variant server. 
 
 
Figure 49 - TULP1 family 3 Electropherograms. 
 
A summary of all the TULP1 mutations identified in this study are listed (Table 17). 
 
Subject Family Mutation 1 Mutation 2 Reference 
IV.4 1 c.1511_1521del 
p.Leu504fsX140 
c.1511_1521del  
p.Leu504fsX140 
[312] 
IV.5 1 c.1511_1521del 
p.Leu504fsX140 
c.1511_1521del 
p.Leu504fsX140 
[312] 
V.5 2 c.1035C>G  
p.Ser345Arg 
c.1035C>G  
p.Ser345Arg 
Novel to this study 
III.3 3 IVS3+1g>a IVS3+1g>a  Novel to this study 
 
Table 17 - Mutations identified in TULP1 in this study. 
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4.5.2.8 Summary of TULP1 phenotype identified in this study 
Onset of visual symptoms in subjects with autosomal recessive mutations in TULP1 
can occur in early childhood, giving a clinical picture of an EORD, or later in the first 
decade, giving a clinical picture of a rod-cone dystrophy. Subjects present with poor 
vision, nystagmus, nyctalopia and visual field constriction. The refraction tends 
towards a myopic astigmatism and colour vision is severely reduced. In the early 
stages the retina displays RPE atrophy, vascular attenuation and preservation of the 
macula with no pigmentation; with age, the RPE atrophy becomes more widespread, 
and peripheral retinal pigment clumping and optic disc pallor develop. The OCT 
shows loss of the photoreceptor layer in all areas except at the fovea and fundus 
autofluorescence imaging demonstrates a wide band of hyperautofluorescence around 
the fovea, unlike the autofluorescence imaging seen in other causes of EORD. Visual 
fields are constricted but may remain relatively preserved into the third decade and 
electroretinography shows widespread photoreceptor dysfunction including the 
macula. There may be obesity in childhood as observed in the affected children of 
TULP1 family 1.  
 
 
4.5.3 Discussion 
The TULPs (including TUB) are involved in G-protein coupled receptor trafficking 
pathways in the cilia of neurones, and thus mutations in this family of genes add to 
the growing number of conditions known as ‘ciliopathies’ [354, 355]. Disease 
associated mutations involving the TUB family of proteins have only been identified 
in Tub (in mice) and TULP1 (in humans) to date [294, 295, 353] [299-301]. The first 
human mutation in TUB was identified through this study, in one family, and the 
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phenotype published [330]. Human mutations in TULP1 have been reported to cause 
both EORD and ARRP. The phenotypes associated with mutations in TULP1 
identified in this study are also described. As these genes belong to the same family of 
proteins, the results of the phenotypic and molecular analyses performed in this study 
are being considered together in this chapter.   
 
Humans with loss of function mutations in TUB display a rod-cone dystrophy 
phenotype beginning late in the first decade of life, characterised by nyctalopia and 
visual field constriction. Colour vision is reduced and there is typically a myopic 
astigmatic refractive error. The retinal degeneration is associated with widespread 
atrophy of the RPE, minimal retinal pigmentation and vascular attenuation, with 
preservation of the photoreceptor layer at the fovea. There is associated early onset 
obesity. However, the effects on hearing and further effects on metabolism in humans 
were not determined through this study.  
  
The tubby mouse carries an autosomal recessive loss of function mutation in Tub and 
its phenotype is characterised by neurosensory deficits and metabolic disturbances. 
The neurosensory deficits comprise of retinal and cochlear degeneration. The retinal 
degeneration is secondary to apoptotic death of photoreceptors [293]; the cochlear 
degeneration in the tubby mouse appears to be related to the presence of 
polymorphisms in the microtubule associated protein gene Map1a, but the 
biochemical sequelae of this genetic interaction is unclear [356]. The metabolic 
disturbances consist of obesity and insulin resistance, and are secondary to the effects 
on feeding behaviour and energy homeostasis controlled via the hypothalamus [357], 
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and to the mediating effects of tub on insulin and leptin signalling in the 
hypothalamus [358].   
 
The childhood onset retinal dystrophy and obesity phenotype observed in the TUB 
family in this study is similar to the phenotype seen in the tubby mouse, although the 
obesity in this family was less severe than other genetic forms of obesity. As 
mentioned above, the TULPs (including TUB) are involved in G-protein coupled 
receptor trafficking pathways in neuronal cilia [354, 355]. The method of 
photoreceptor degeneration is likely due to the ineffective transport of rhodopsin to 
the outer segments across the connecting cilium, as observed in mice with loss of 
Tulp1 function, which have an ectopic distribution of rhodopsin prior to photoreceptor 
degeneration [305]. This mechanism has been postulated to occur with the other 
TULPs [355]. The extracellular rhodopsin laden vesicles that are seen to accumulate 
in the interphotoreceptor space in Tub-/- and Tulp1-/-mice occur at a time that 
rhodopsin is usually rapidly synthesised to build up the outer segments, and it was 
hypothesised that the accumulation of these vesicles might be a hallmark of the defect 
of rhodopsin transport to the outer segments, a process in which the TULPs have a 
role [305, 307]. Mice that are doubly mutant for tub and tulp1 display a more severe 
retinal phenotype than either mutant alone, which results in complete failure of 
rhodopsin trafficking and outer segment formation with rapid cell death [307]. 
 
The phenotypes associated with mutations in TULP1 that were observed in this study 
were similar to other reports of TULP1 mutations, which have described widespread 
loss of rod function from a young age, with only residual cone function existing at the 
fovea [258, 309, 311-313, 359]. Onset of visual symptoms can be very early, within 
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the first year of life, and thus the condition is classified as an early onset retinal 
dystrophy, or may begin later in childhood and so be classified as a rod-cone 
dystrophy. Similar to the TUB family, there tends to be a myopic astigmatism. RPE 
atrophy, vascular attenuation and preservation of the macula without pigmentation is 
seen in the early stages but with age, the RPE atrophy becomes more widespread, and 
peripheral retinal pigment clumping and optic disc pallor develop. A recent study has 
identified small islands of preserved RPE that is associated with better visual function 
at these points; these were not identified in the present cohort [359]. Fundus 
autofluorescence imaging in this study identified a wider band of 
hyperautofluorescence than that which is seen in other forms of RP. This has been 
observed in other studies [311]. OCT imaging in the present TULP1 cohort 
demonstrates preservation of the photoreceptors only at the fovea, which may 
represent a small central island of residual foveal cones, but the extracentral loss of 
laminar architecture that has been reported in the literature was not observed [359]. 
Unlike Tub, mutations in TULP1 appear not to be associated with obesity, hearing 
impairment or endocrine dysfunction [311]. Although the children in family 1 in this 
study were classified as being obese for their age and gender, this feature may not be 
related to their TULP1 variant. From the expression profile of TULP1 and the 
phenotype of the Tulp1-/- knockout mouse, systemic features of obesity and endocrine 
dysfunction would not be predicted to occur, and have not been reported in human 
TULP1 mutations [357].  
 
A large number of studies have identified TULP1 mutations in families of Middle 
Eastern or South East Asian descent [201, 258, 311, 313, 314, 360, 361]. Den 
Hollander et al. reported a multiply affected family from Surinam, which has a large 
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South East Asian population, but the ancestry in this family was not defined [312]. A 
small panel of 49 Spanish ARRP families had an incidence of 2% of families affected 
with TULP1 mutations, although the ancestry of these families was also not defined 
[310]. All three families identified in this study were originally from South East Asia 
and were consanguineous, harbouring homozygous mutations in TULP1. This 
suggests the presence of a number of founder mutations in TULP1 in families from 
these regions.  
 
The c.1511_1521delTGCAGTTCGGC, p.Leu504fsX140 variant identified in family 
1 in the homozygous state was first reported in a Surinamese family in the 
heterozygous state by Den Hollander, and causes a frame shift, affecting the TULP1 
C-terminal domain [312]. The novel missense mutation, c.1035C>G, p.Ser345Arg, 
identified in the homozygous state in family 2 is predicted to be pathological and also 
lies within the TULP1 C-terminal domain. It is interesting to note that all missense 
mutations identified in TULP1 and TUB to date affect the highly conserved C-
terminal domain (tubby terminal) of this family of proteins [330, 360]. In the TULP 
family of proteins (including TUB) this domain contains a DNA binding region and a 
phosphatidylinositol-binding region, which anchors the TULPs to the cell membrane 
before they are released by phospholipase Cβ-mediated cleavage of 
phosphatidylinositol bisphosphate [302]. The crystal structure of the C-terminal 
domain in Tub was identified to comprise of a closed β barrel consisting of 12 anti-
parallel strands, surrounded by a central hydrophobic α helix. An important function 
of this domain is in the interaction with phosphatidylinositol bisphosphate, which is 
disrupted in TUB mutations, with subsequent inability of the protein to localise to the 
plasma membrane, and instead remain within the nucleus [303].  
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It remains to be determined whether human mutations in TUB result in other systemic 
abnormalities that resemble the tubby mouse but it is known that TULP1 families 
display a similar phenotype to the loss of function Tulp1 mouse. The conditions 
associated with both of these genes further add to the range of conditions that are now 
classified as ‘ciliopathies’.    
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4.6 LRAT Phenotype 
 
Limited reports of the phenotype associated with mutations in LRAT had been 
published by the time this study was conducted. Rather more extensive phenotypic 
studies of another visual cycle gene, RPE65, had been published, and the first human 
gene therapy studies undertaken into retinal dystrophies were based upon this gene 
[362-364]. In order to understand the phenotype associated with LRAT mutations, 
investigations into 4 families identified with variants in LRAT in this study were 
undertaken. 2 of the 4 families had been recruited to the childhood onset retinal 
dystrophy study by previous researchers, and two by ADB – one who was under 
MEH (Subject 27, cohort 1) and one who was recruited following mutation 
identification by the referring hospital (Subject 28, cohort 1). 3 probands were invited 
back to MEH and the IOO for detailed phenotypic studies. The results of the 
phenotypic studies and the molecular techniques utilised to ascertain the mutations in 
LRAT are described in this chapter. The results of these studies were also published 
[365]. In this chapter, Subject 1 refers to Subject 28 of cohort 1, Subjects 2 and 3 were 
recruited by previous researchers and so are not from cohort 1, and Subject 4 refers to 
Subject 27 of cohort 1. 
 
 
4.6.1 Clinical History 
The onset of visual symptoms in the four probands identified with mutations in LRAT 
was between 1 and 3 years of age (Table 18). All subjects had severe nyctalopia and 
visual field constriction from early childhood. A similar finding to subjects with 
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mutations in RPE65 was of photophilia, which was present in 3 of the 4 LRAT 
subjects (Subjects 1, 3 and 4). Nystagmus was not reported in any subject, indicating 
that some visual function was preserved in infancy. Strabismus was present in 2 
subjects (Subject 3 and Subject 4), with amblyopia affecting the left eye of Subject 3. 
The visual symptoms in all LRAT subjects were progressive, with deterioration of 
visual acuity, visual fields, nyctalopia and colour vision with age. Interestingly, 3 
individuals (Subjects 1 to 3) subjectively reported deterioration of dark adaptation, 
specifically the time required to adapt from photopic to mesopic lighting conditions 
with age. General health was normal in all subjects except Subject 2 who had 
unilateral acquired conductive auditory dysfunction secondary to otosclerosis.  
 
All affected subjects were simplex cases, with no other affected family members. 
Subject 1 (Family 1) was from a multiply consanguineous South East Asian family; 
his parents were first cousins. Subject 2 (Family 2) was British Caucasian whose 
parents were first cousins. Subject 3 (Family 3) was Scandinavian from a non-
consanguineous family. Subject 4 (Family 4) was from the Caribbean, from a non-
consanguineous family.   
 
 
4.6.2 Clinical Examination 
Two of four LRAT subjects were male. They were all examined in adulthood (Subject 
1 – age 27 years; Subject 2 – age 54 years; Subject 3 – age 41 years; Subject 4 – age 
31 years). Best corrected monocular visual acuity ranged from 0.22 LogMAR to hand 
movements (Table 18). Subject 3 had hand movements vision in the left eye, which 
was an amblyopic eye. There was no particular trend to the refractive errors: in the 
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right eye the spherical equivalent ranged from -1.00 DS to +3.63 DS and in the left 
eye it ranged from -1.00 DS to +3.33 DS. Colour vision was severely reduced in all 
subjects: none were able to identify any correct plates on Ishihara testing; low colour 
discrimination was recorded on the Farnsworth-Munsell 100 hue test in Subjects 1, 2 
and 3; and Nagel anomaloscope matches suggested poor red – green colour 
discrimination in Subjects 1, 2 and 3.  
 
Ocular motility examination identified torsional nystagmus in Subject 1; no other 
subjects had nystagmus. Subjects 3 and 4 had a left and right esotropia respectively. 
Anterior segments were normal in all subjects and mild nuclear sclerotic cataracts 
were evident in Subject 2 (unilateral, left eye) and Subject 4 (bilateral). All subjects 
had bilateral widespread RPE atrophy involving the macula, arteriolar attenuation and 
minimal retinal pigmentation, which was confined to the mid-peripheral retina (Figure 
50, Figure 51, Figure 52 and Figure 53 - A). Subject 1 also displayed an annulus of 
retinal pallor extending to the vascular arcades within the macula (Figure 50). In 
Subject 3 the macula appeared relatively spared with hypopigmentation superior to 
the foveae. In Subject 4 there were bilateral epiretinal membranes. Asteroid hyalosis 
was evident in Subject 2 (bilateral) and Subject 3 (unilateral, right eye). A core 
vitrectomy had been performed in the left eye of Subject 2 with the aim of visual 
improvement from symptomatic asteroid hyalosis but there was no subsequent 
subjective or objective improvement in vision following this procedure. 
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4.6.3 Fundus Autofluorescence Imaging 
Fundus autofluorescence imaging revealed a reduced autofluorescence signal in all 
subjects. It had been necessary to utilise a number of frames to obtain a mean image 
at the highest sensitivity of signal detection, which resulted in the optic nerve head 
and large retinal vessels appearing artefactually brighter than normal subjects. In 
those subjects in whom an autofluorescence signal was detected, there was a very 
small hypoautofluorescent signal at the foveolae (Figure 50 - B), poor 
autofluorescence at the macula (Figure 51, Figure 52 and Figure 53 – images B) and a 
diffuse annulus of hyperautofluorescence at the macula (Figure 52 - B). 
 
 
4.6.4 OCT Imaging 
sd-OCT imaging was performed in Subjects 1-3. The quality of the images acquired 
was affected by poor vision, which limited the subjects’ ability to maintain central and 
steady fixation. The inner retinal layers appeared intact in these three subjects and the 
foveal thickness was relatively well preserved, although in the oldest subjects there 
was shallowing and broadening of the foveal depression (Figure 51 and Figure 52 – 
image C). The inner segment outer segment junction appeared to be preserved 
throughout the macula in the youngest subject, Subject 1, with preservation of the 
external limiting membrane and intact retinal lamination (Figure 50 - C). The outer 
retina was disrupted at the fovea in the two oldest subjects, Subjects 2 and 3, and there 
was no clear photoreceptor layer visible (Figure 51 and Figure 52 – images C). In 
these two subjects the outer nuclear layer was absent centrally but was preserved in 
the parafoveal region (Figure 50, Figure 51 and Figure 52 - images C, yellow arrows 
indicate the beginning of the ONL in left eyes). A faint line, presumed to represent the 
247 
external limiting membrane, was visible in these two subjects. In subjects 1-3 the 
nerve fibre layer was irregular but there was no evidence of vitreo-retinal traction. 
Subject 4 had undergone time-domain OCT imaging, which showed loss of the foveal 
inner segment outer segment junction, preserved retinal thickness and bilateral extra-
foveal epi-retinal membranes with no loss of the foveal contour (Figure 53 - C). 
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Subject 
(Gender) 
Family Ethnicity Consanguinity Age at 
Onset 
(years) 
Age at examination (years) LogMAR VA 
RE, LE 
Refraction 
1 (M) 1 Indian Consanguineous 3 27 0.22, 0.90 RE Plano 
LE Plano 
2 (F) 2 British Caucasian Consanguineous 1 54 0.66, HM RE +0.75/+2.63, 162 
LE +2.75/+1.13, 34 
3 (M) 3 Swedish Non-consanguineous 1 41 HM, 1.80 RE +4.25/-1.25, 22 
LE +4.0/-1.75,159 
4 (F) 4 Caribbean Non-consanguineous 2 31 0.80, 0.50 RE plano/-2.00, 20 
LE -0.75/-0.50, 25 
 
Table 18 - Demographic and clinical data of LRAT subjects. M – Male; F – Female; RE – right eye; LE – left eye; HM – hand movements vision.
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Figure 50 - Subject 1, LRAT. A – Left eye fundus image displaying widespread RPE 
atrophy involving the macula but sparing the fovea, arteriolar attenuation and minimal 
retinal pigmentation. There is an annulus of retinal pallor extending to the temporal 
vascular arcade; B – left eye fundus autofluorescence image demonstrating a very 
weak hyperautofluorescent signal at the fovea; C – OCT image of the left macula 
demonstrating intact lamination and retention of a disrupted photoreceptor layer at the 
macula, and of the external limiting membrane. Arrows indicate the outer nuclear 
layer which appears preserved but severely diminished at the fovea. Images taken at 
age 27 years. 
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Figure 51 - Subject 2, LRAT. A – Left eye fundus image displaying widespread RPE 
atrophy involving the macula, arteriolar attenuation and peripheral retinal 
pigmentation. A core vitrectomy has been performed and the vitreous base is visible 
in the inferior retinal periphery; B – left eye fundus autofluorescence image 
demonstrating a very weak autofluorescence signal at the fovea; C – OCT image of 
the left macula demonstrating preservation of the retinal lamination and external 
limiting membrane but severe disruption and loss of the photoreceptor layer. Arrows 
indicate the outer nuclear layer, which is lost at the fovea. The foveal contour is broad 
and shallow. Images taken at age 54 years. 
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Figure 52 - Subject 3, LRAT. A – Left eye fundus image displaying widespread RPE 
atrophy involving the macula but sparing the fovea, arteriolar attenuation and minimal 
retinal pigmentation; B – left eye fundus autofluorescence image demonstrating a 
diffuse hyperautofluorescent signal at the macula; C – OCT image of the left macula 
demonstrating preservation of the retinal lamination and external limiting membrane, 
but severe disruption and loss of the photoreceptor layer. Arrows indicate the outer 
nuclear layer, which is lost at the fovea. The foveal contour is broad and shallow. 
Images taken at age 41 years. 
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Figure 53 - Subject 4, LRAT. A – Left eye fundus image displaying widespread RPE 
atrophy sparing the macula, arteriolar attenuation and peripheral retinal pigmentation; 
B – left eye fundus autofluorescence image demonstrating a very weak 
autofluorescence signal at the fovea; C – OCT image of the left macula demonstrating 
preservation of the retinal lamination and photoreceptor layer at the fovea, and epi-
retinal membranes. Images taken at age 31 years. 
 
 
 
4.6.5 Electrophysiological Testing 
ISCEV standard electrophysiological studies were performed in subjects 1-3. The 
youngest subject, Subject 1, had residual PERGs detectable bilaterally, suggesting 
minimal residual macular function. PERGs were not detectable in Subjects 2 and 3. In 
all 3 subjects, the rod-mediated full field ERGs were undetectable following the 
standard period of 25 minutes of dark adaptation. Following overnight dark adaptation 
of the left eye in Subject 3, no discernable inter-ocular asymmetry was demonstrated 
in the full field ERG responses, indicating no recovery of rod function after prolonged 
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dark adaptation.  Light adapted cone-mediated ERGs were not detectable in Subject 1, 
however in Subjects 2 and 3 they were present but delayed and small.  
 
 
4.6.6 Psychophysical Testing 
4.6.6.1 Goldmann Visual Fields 
Goldmann perimetry was performed in subjects 1-3 but the only reliable responses 
were to the V4e target (Figure 54). Perimetry was difficult and time consuming due to 
variable abilities to maintain central and steady fixation. Circumferentially constricted 
visual fields were present in 2 subjects to between 15o and 40o of central fixation 
(Subjects 1 and 2). Subject 3 had inconsistent responses within the visual field. As has 
been previously described in individuals with RP, in addition to circumferential 
constriction of the visual field, there may be residual ‘islands’ of retained vision 
within apparent ‘non seeing’ areas that can be difficult to plot consistently [57]. All 
three subjects demonstrated this. In Subject 1 the central 30o was retained with 
additional far peripheral crescents of vision in the infero-temporal quadrants 
measuring 10o (Figure 54 – A and B). Subject 2 had retention of the central 15o and 
40o in the left and right eyes respectively, with additional 20o crescents in the inferior 
and temporal quadrants (Figure 54 – C and D). The visual field was difficult to plot in 
Subject 3 and appeared to demonstrate retained fields to 50-55o nasally and 80-90o 
temporally. Although he had small additional islands of visual loss within this area, 
these were not consistently recordable and so are not included in the plots (Figure 54 
– E and F). 
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Figure 54 – Goldmann Visual Field plots, LRAT subjects. A – Left eye, Subject 1 and 
B – Right eye Subject 1, demonstrating retention of the central 15o with additional 
peripheral crescents in the visual fields of both eyes to the V4e target; C – Left eye, 
Subject 2 and D – Right eye, Subject 3, demonstrating retention of the central 15o in 
the visual field of the left eye and central 40o in the visual field of the right eye to the 
V4e target; E – Left eye, Subject 3 and F – Right eye, Subject 3, demonstrating 
retained visual fields across the central 120o to the V4e target, although islands of 
visual loss within these fields are not plotted as they were inconsistent. V4e target – 
blue line; I4e target - red line; hashed areas correspond to islands of reduced vision. 
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4.6.6.2 Dark Adapted Perimetry 
Photopic and dark adapted static threshold perimetry was performed by Professor 
Fitzke’s laboratory at UCL in Subjects 1-3 using a modified Humphrey visual field 
analyser (Allergan Humphrey, Hertford, UK). Dark adapted perimetry was performed 
following pupillary dilatation using guttae tropicamide 1% and guttae phenylephrine 
2.5% in each eye and following 45 minutes of dark adaptation. The Humphrey visual 
field analyser had been modified for dark adapted conditions as previously described 
[366, 367] and controlled by a customised computer programme (PS/2 model 50; 
International Business Machines, Armonk, New York, USA) [368]. Testing was 
performed in the light adapted state with a white light stimulus and, after dark 
adaptation, with red (608 nm) and blue stimuli (506 nm). The blue stimulus reflects 
rod function and red stimulus reflects cone function. 
 
In subjects 1-3 photopic static threshold perimetry demonstrated severely elevated 
thresholds of 10 to 30 decibels (dB) across the central 30o (Figure 55 - A shows an 
example in Subject 3). There was severe loss of sensitivity of 30 dB to 40 dB in all 
subjects with dark adapted perimetry. In subject 1 there were no recordable responses 
to scotopic red and blue stimuli in the dark adapted state, indicating absent rod 
function. Subjects 2 and 3 showed measurable responses in only a few locations in the 
central 9o of fixation, to scotopic red and blue stimuli, indicating severe loss of rod 
function (Figure 55 – B and C show an example in Subject 3). It is likely that the 
sensitivities in these locations are mediated by dark adapted cones, which themselves 
have reduced sensitivity. This is consistent with the findings of abnormal cone 
function from the critical flicker fusion measurements performed in Professor 
Stockman’s laboratory (see section 4.5.6.4). 
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Figure 55 - Full static threshold central 30o photopic and dark adapted perimetry, 
LRAT Subject 3.  A – photopic static threshold perimetry; B – dark adapted static 
threshold perimetry, blue stimulus; C – dark adapted static threshold perimetry, red 
stimulus. Severe threshold elevations are evident throughout with generally some 
central function, but elevated by 20–30 dB even at the most sensitive locations. 
 
4.6.6.3 Dark adapted spectral sensitivities 
The dark adapted spectral sensitivities were measured in Subjects 1-3 by Dr 
Ripamonti in the laboratory of Professor Stockman at UCL. The methods have 
previously been described [369]. Subjects were dark adapted for 40 minutes prior to 
measurements being taken. The target stimulus was 3.5o in visual diameter, presented 
at 10o in the superior retina and sinusoidally flickered at 1 Hz. Target wavelengths of 
400, 500, 550, 600 and 650 nm were used to make the measurements. The observer 
adjusted the radiance of the target at each wavelength, until the flicker at 1 Hz was 
just at threshold.  
 
Evidence of rod function was present in Subjects 2 (green diamonds) and 3 (yellow 
circles), as demonstrated by the dark adapted spectral sensitivity data, which followed 
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the shape of rod, or scotopic, luminosity function (black lines) (Figure 56). However 
in both subjects the rod sensitivity was reduced compared to normal subjects (red 
squares). The data for Subject 1 (blue circles) were more consistent in shape with 
cone, or photopic, luminosity function (dashed red line). They were also reduced in 
sensitivity, which suggested that this Subject had little or no rod function. Compared 
to normal subjects, there was a reduction of cone sensitivity by approximately 3 log 
units, which was consistent with the cone critical flicker fusion loss in this subject. 
 
 
Figure 56 - Dark adapted spectral sensitivities, LRAT subjects. Blue circles - Subject 
1; Green diamonds – Subject 2; Yellow triangles – Subject 3; Red squares – 
normative data. The curves are standard spectral sensitivity functions vertically 
shifted to least squares fit each data set. The continuous black lines are shifted 
versions of the rod or scotopic V0(k) luminosity function, and the red dashed line is a 
shifted version of the cone or photopic V(k) luminosity function adopted by the 
Commission Internationale de l’eclairage (CIE) [370]. Agreement with V0(k) 
indicates rod function in Subjects 2 and 3, but agreement with V(k) suggests mainly 
cone function and no rod function in Subject 1.  
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4.6.6.4 Critical Flicker Fusion 
Defects in light adaptation caused by variants in visual cycle or phototransduction 
genes can be characterised by measuring the changes in temporal sensitivity that 
accompany changes in light levels. This can be undertaken by measuring changes in 
temporal acuity or resolution (also known as the critical flicker frequency, c.f.f.) as a 
function of light level [371]. These tests were performed in Subjects 1-3 by Professor 
Stockman’s laboratory at UCL.  
 
A Maxwellian-view optical system with a 2-mm entrance pupil illuminated by a 900 
W xenon arc lamp was used for the c.f.f. measurements. Wavelengths were selected 
with interference filters with full-width at half-maximum bandwidths of between 7 
nm and 11 nm (Ealing or Oriel). Other details were the same as the spectral sensitivity 
measurements. Fixation was central. A flickering target of 4o in diameter and 650 nm 
in wavelength was presented in the centre of a 9o diameter background field of 481 
nm in order to measure L-cone c.f.f. This background served to suppress the rods, but 
also selectively desensitised the M-cones at lower target radiances. The 650 nm target 
was chosen to favour flicker detection mainly by L-cones over most of the intensity 
range. It was varied in intensity from 6.5 to 11.0 log10 quanta s-1 deg-1 (-0.63 – 3.87 
log10 photopic trolands). At higher target intensities M-cones are also likely to 
contribute to flicker detection. At each target intensity the subject adjusted the flicker 
frequency to identify the frequency at which the flicker just disappeared (the c.f.f.). S-
cone c.f.f. measurements were made by presenting a flickering target of 4o diameter 
and 440 nm wavelength in the centre of a 9o diameter field of background 620 nm, 
which selectively desensitises the M- and L-cones with comparatively little effect on 
the S-cones. In normal subjects a 620 nm field of 11.51 log10 quanta s-1 deg-1 isolates 
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the S-cone response up to a target radiance of approximately 10.5 log10 quanta s-1 deg-
1 [372]. 
 
All 3 subjects had substantially reduced L-cone c.f.f. measurements compared to 
normal subjects (red squares) (Figure 57). Subject 2 (green diamonds) showed the 
best temporal resolution, which suggested reduced but moderately good L-cone 
function. Subjects 1 (blue circles) and 3 (yellow triangles) had devastating loss of 
temporal resolution compared with normal subjects. For these two subjects, flicker is 
seen clearly first at target radiances above 9.0 log10 quanta s-1 deg-1, which is 
approximately 250 times higher than normal subjects. However, resolution reached to 
less than 20 Hz even at the highest radiances, suggesting severely reduced L-cone 
function. No measureable S-cone function was detected in any of these three subjects 
by S-cone cf.f. measurements.  
 
 
Figure 57 - Critical flicker fusion frequencies in LRAT subjects. Blue circles - Subject 
1; Green diamonds – Subject 2; Yellow triangles – Subject 3; Red squares – mean 
data for 12 normal observers. Subjects 1 and 3 show a substantial loss of cone 
temporal sensitivity, while Subject 2 shows more moderate loss. 
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4.6.7 Molecular analysis 
The molecular techniques used to identify LRAT mutations in these 4 subjects varied. 
All direct sequencing was performed by Dr Ocaka, UCL. 
 
Subject 1 (Subject 28, cohort 1), referred by colleagues at the University of 
Manchester, had undergone screening using the LCA chip, which identified the 
previously reported LRAT missense variant c.525T>A, p.Ser175Arg, in exon 2, in the 
homozygous state [285]. The variant was confirmed by direct sequencing and was 
identified to segregate with the disease in the family, as his unaffected parents were 
both heterozygous for this variant.  
 
The mutations in subjects 2-4 were identified by direct sequencing of LRAT in a panel 
of LCA and EORD patients that had previously been screened using the LCA chip, 
without any variants being identified (Table 19). Subject 2 was identified to harbour 
the novel 2- base pair deletion/insertion, c.40-41delGAinsTT, p.Glu14Leu. Both 
unaffected parents were heterozygous for this variant, confirming segregation of the 
disease in this family. Subject 3 harboured the novel variant c.181T>A, p.Tyr61Asp, 
in the homozygous state. His unaffected father was heterozygous for this variant; his 
mother was not available for testing. Subject 4 had previously undergone screening of 
RPE65 as she had some phenotypic similarities to individuals with mutations in this 
gene; this screening did not identify any pathogenic variants. She was subsequently 
identified to harbour the novel LRAT variant c.316G>A, p.Ala106Thr, in the 
homozygous state. No family members were available to check segregation of this 
mutation. 
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Subject Family Mutation 1 Mutation 2 Reference 
1 1 c.525T>A,  
p.Ser175Arg 
c.525T>A,  
p.Ser175Arg 
[285] 
2 2 c.40-41delGAinsTT, 
p.Glu14Leu 
c.40-41delGAinsTT, 
p.Glu14Leu 
Novel to this 
study 
3 3 c.181T>A,  
p.Tyr61Asp 
c.181T>A,  
p.Tyr61Asp 
Novel to this 
study 
4 4 c.316G>A,  
p.Ala106Thr 
c.316G>A,  
p.Ala106Thr 
Novel to this 
study 
 
Table 19 – Mutations identified in LRAT in this study. All are homozygous. 
 
All four variants were not identified in 96 ECACC control DNAs or any other 
probands in the panel of 148 LCA and EORD patients. All four mutations were 
analysed using the in silico analysis programmes SIFT and PolyPhen2. SIFT 
predicted all four mutations to be damaging, with a probability score of 0 for each 
mutation (probability scores less than 0.05 are predicted to be deleterious) and a 
median range between 2.51 and 3.00 (this is used to measure the diversity of the 
sequences used for prediction; this value ranges between 0 and 4.32 and should 
ideally be between 2.75 and 3.5). PolyPhen2 predicted all four mutations to be 
probably damaging (c.525T>A, c.40-41delGAinsTT and c.316G>A in subjects 1, 2 
and 4 respectively) or possibly damaging (c.181T>A in subject 3), with scores 
ranging between 0.95 and 1.00.   
 
 
4.6.8 Discussion 
Mutations in LRAT lead to a severe EORD phenotype that consists of poor vision, 
nyctalopia and visual field constriction from early childhood; photophilia is a 
consistently described feature. With time, visual acuity, contrast sensitivity and colour 
discrimination deteriorate. Electrophysiological data support the clinical findings and 
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are in keeping with severe generalised photoreceptor dysfunction affecting rods more 
severely than cones. At the time that this study was conducted there had only been a 
handful of reports describing the phenotype associated with mutations in LRAT, in 
which in the majority of subjects, poor vision, nyctalopia and nystagmus commenced 
in childhood, the retinal dystrophy was severe with an undetectable ERG, and the 
diagnoses carried were of LCA or juvenile RP [26, 285, 290, 291]. Photophobia had 
been reported in a number of cases [26, 290]. In these studies, visual acuity ranged 
from 0.6 LogMAR (age 6 years) to hand motion vision (age 23 years), with a 
predominantly hypermetropic refractive error. The retinal appearances have been 
reported to be normal in infancy [291], and in adult life to consist of peripheral RPE 
atrophy, optic disc pallor and ‘perimacular retinal surface wrinkling’. In the present 
study, and in agreement with these other studies, RPE atrophy was widespread but 
there was little retinal pigmentation until later age, suggesting that photoreceptor cell 
death occurs late in LRAT mutations [373]. Epi-retinal membranes were present in 
25% of eyes in this study, which is more common than the 1.2% reported prevalence 
of epi-retinal membranes in RP [374]. In addition, asteroid hyalosis was more 
common in LRAT retinopathy, with 37.5% of eyes in this study affected, compared to 
only 3.1% in RP in general [375]. 
 
Detailed retinal imaging in humans with LRAT mutations had not been previously 
reported. Although the ability to acquire clear sd-OCT images in the subjects in this 
study was affected by instability of fixation, reasonable images were obtained. In the 
youngest subject (age 27 years) there was retention of the external limiting 
membrane, the outer nuclear layer was visible throughout the macula but markedly 
diminished in the very centre of the fovea and photoreceptor inner segment outer 
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segment layer was present at the fovea. In the oldest subjects (age 41 and 54 years) 
there was disruption of the outer retina and loss of the outer nuclear layer at the fovea, 
with possible retention of this layer in the extra-foveal region. There was no 
photoreceptor layer discernable in these two subjects, but there was a faint line 
corresponding to the external limiting membrane. An irregular nerve fibre layer, with 
no overlying vitreo-macular traction, was observed in all three subjects, which may 
correspond to early retinal fibrosis. This has not been reported in OCT imaging of 
Lrat-/- mice, however loss of the external limiting membrane and diminution of the 
outer nuclear layer has been observed in these and in Rpe65-/- mice who were treated 
with control compounds (‘vehicle’ and all-trans-retinyl acetate) in a study evaluating 
the effects of prodrugs that generate 9-cis-retinal in vivo [376]. A reduced 
autofluorescence signal was obtained in all LRAT subjects, in keeping with the 
reduced autofluorescence signal seen in mutations in genes encoding other visual 
cycle enzymes [158, 377, 378]. Lrat-/- and Rpe65-/- mice have also been identified by 
scanning laser ophthalmoscopy to have little to no autofluorescence, and reduced 
retinal fluorophore production has also been identified in humans with RPE65 
mutations, however autofluorescence in humans with LRAT mutations has not been 
reported [158, 379, 380]. 
 
The LRAT subjects in this study displayed severe photopic kinetic visual field 
constriction with preserved islands of vision in the mid- and far retinal periphery, and 
elevated thresholds measured by static perimetry, but they were able to maintain 
useful navigational vision that was subjectively reported to be better in daylight or 
ambient lighting conditions. Dark-adapted spectral sensitivity measurements 
demonstrated reduced to undetectable rod function, and perimetric and critical flicker 
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fusion measurements demonstrated severely reduced, but persistent, cone function in 
LRAT mutations. Similar psychophysical analysis using full field stimulus testing of 
subjects with RPE65 related LCA has been undertaken [381]. This identified more 
than half of the subjects tested to have rod mediation of a blue stimulus, indicating 
that there is severely reduced but detectable residual rod function in these subjects. 
The remaining subjects had only residual cone mediated vision. The authors 
suggested that psychophysical methods are able to detect both rod and cone mediated 
vision in these patients. In the present study we were able to identify areas of retina 
with residual but abnormal rod function. In other areas cones were mediating 
responses at threshold. 
 
Phenotypic variability has been reported in disease associated with mutations in visual 
cycle genes, in particular RPE65 [14, 15, 161]. Recently two families have been 
reported with the same homozygous frame-shifting mutation in LRAT, c.12delC, p. 
M5CfsX53, with a phenotype suggestive of retinitis punctata albescens, a slowly 
progressive retinal dystrophy characterised by nyctalopia, tiny yellow-white dots 
throughout the retina, and mutations in RLBP1 [45]. As with the mutations identified 
in the present study, this frame shifting mutation occurs in exon 2, but why it leads to 
a very different phenotype remains unknown. It may be that these white dots are 
present transiently in the disease process and may be replaced by photoreceptor 
degeneration and loss, and thus not be detected if the patient is not examined in time 
[382]. All but one LRAT mutation identified to date reside in exon 2 [26, 45, 285, 290, 
291, 365], suggesting that this exon may be targeted in the screening of this gene in 
LCA and EORD.  
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The N1pC/P60 proteins, of which LRAT is one, are cell-wall peptidases, with 3 
conserved residues: a cysteine, a histidine and a polar residue [383]. As it had not 
been possible to extract and purify full length LRAT, a recombinant truncated form of 
LRAT, t-LRAT, has been expressed in bacteria and purified fully, and has been 
demonstrated to be catalytically active despite it not containing the N- and C- terminal 
hydrophobic segments [384]. The triad of the LRAT-family specific conserved 
residues, cysteine-161, tyrosine-154 and histidine-60, have been identified in this 
truncated protein, and the tyrosine-154 residue has been identified to be essential for 
catalytic activity [385]. It is possible that the novel p.Tyr61Asp mutation identified in 
the present study interferes with the conserved histidine-60 residue and affects the 
catalytic activity of this enzyme. The p.Ser175Arg mutation was originally identified 
by Thompson et al., and it was postulated to cause disease by the loss of an essential 
nucleophillic residue at the catalytically active site of the enzyme [285]. However, the 
effect of this mutation on the function of t-LRAT was recently studied, and although 
no enzymatic activity was found with this mutant, the global tertiary structure of t-
LRAT and its membrane binding properties remained unchanged with this mutation 
[386]. It was suggested instead that as the serine-175 residue lies close to the 
catalytically active site of LRAT, this mutation, resulting in the insertion of an 
arginine residue, could obstruct the entrance of the substrate at this site, leading to 
loss of catalytic activity.  
 
The retinal dysfunction in Lrat-/- and Rpe65-/- murine models is similar, with slow rod 
degeneration, rapid cone degeneration and mislocalisation of cone opsins [288, 289, 
380, 387, 388]. Hypomorphic allele function has been hypothesised to be the reason 
for the continued isomerisation activity in some Rpe65 mutant models and in the 
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milder phenotypes that have been observed in humans [147, 161]. The alternative 
visual pathway involving Müller cells and cone regeneration may be another reason 
for the less severe phenotypes in visual cycle related mutations [139]. 
 
Lrat-/- murine models have led to the identification of two therapeutic interventions 
that restore retinal function: oral pharmacologic treatments with novel retinoid 
compounds such as 9-cis-retinyl acetate and 9-cis-retinyl succinate, and intraocular 
gene therapy [389]. Both of these treatments have resulted in improvements in 
electrophysiological and pupillary responses, and to the levels of visual pigment 
observed in these mice.  
 
The pharmacologic agent QLT091001, manufactured by QLT, Inc. (Vancouver, 
Canada), contains 9-cis-retinyl acetate, a prodrug that generates 9-cis-retinal in vivo 
[390], which has been shown to be safe in mice [376] and humans [391]. In Lrat-/- and 
Rpe65-/- mice administered with prolonged high dose oral QLT091001, retinal 
thickness and morphology were well maintained, no significant increases in 
autofluorescence suggestive of toxic retinoid by-products were seen, and scotopic 
ERG responses were improved compared to wild-type mice who were also treated 
with QLT091001 [376]. Results of the first human oral retinoid trial in patients with 
RPE65 and LRAT mutations were published very recently [392]. In this trial, patients 
received an oral dose of QLT091001 once daily for 7 days. They were examined at 
baseline and followed up over a period of at least 2 months. 10 of 14 patients (71%) 
were reported to have at least 20% improvement in visual field areas, 6 of 14 patients 
(43%) had an improvement in visual acuity of at least 5 letters. No improvements in 
ERG or colour vision were reported and the majority of patients returned to baseline 
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by 2 years. Side effects included headache and photophobia. However, the inter-test 
variability, test-retest variability, wide range of visual field results at baseline due to 
young participant age (64% of patients were under 16 years old) and lack of ERG 
evidence to support the reported large increases in visual field areas in response to 
treatment, mean that the reported improvements following this treatment should be 
taken with caution [58]. Although these results are promising, further more robust 
studies are required.  
 
Advances have been made in the field of retinal gene therapy, with the first human 
trials of RPE65 gene replacement therapy and CHM gene therapy for choroideraemia 
being reported recently [362, 363, 393, 394]. Studies into differentiated RPE cells 
obtained from human induced pluripotent stem cells have identified the expression of 
functional visual cycle enzymes, and transplantation of mouse primary RPE cells into 
Lrat-/- and Rpe65-/- mice has resulted in recovery of the visual function, including 
improvement of visual acuity, improvements in the ERG and endogenous 11-cis-
retinal production [395]. These results are promising and human trials into RPE stem 
cell therapy for Stargardt disease and age related macular degeneration have begun, 
with the results of safety studies recently published [396, 397].  
 
This detailed phenotypic study into families with mutations in LRAT has 
demonstrated residual photoreceptor function in adulthood despite there being 
significant visual dysfunction from early childhood. This suggests that there may be a 
window of opportunity for a variety of therapeutic interventions that can extend into 
late childhood. 
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4.7 RGR Phenotype 
 
The proband of one family was referred for enrolment into the Childhood Onset 
Retinal Dystrophy Study. He had been diagnosed with EORD in Italy and his DNA 
had been sent for screening using the LCA chip by his referring team. He was 
identified to harbour a homozygous mutation in RGR, as follows: c.196A>C, 
p.Ser66Arg [319]. As there had been little description of the phenotype associated 
with mutations in RGR, the family was invited to participate in the Study and the 
proband was extensively phenotyped, along with other family members, at Moorfields 
Eye Hospital (MEH) and at the Institute of Ophthalmology (IOO). 
 
 
4.7.1 Clinical History 
The male proband (Subject 47, Family 45 of Cohort 1) was aged 16 years and 7 
months when he attended for phenotypic studies. He had been diagnosed with an 
EORD at age 13 years following electrophysiological testing in Italy. The family is 
originally from Albania and moved to Italy when the proband was 8 years old. He had 
been noted by his parents to have reduced vision from birth, with nystagmus and a 
convergent squint from 5 months of age. As a toddler he was noted to be clumsy and 
to frequently bump into objects. At age 2 years he was prescribed glasses and 
commenced amblyopia therapy in Albania. A visiting ophthalmologist from Russia 
diagnosed strabismus and ‘a retinal abnormality’ and subsequently performed 
unilateral strabismus surgery in Russia when the proband was 5 years old. This 
improved his ocular alignment and nystagmus, but his symptoms of poor vision and 
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nyctalopia persisted. At age 11 years he noticed significant constriction of his visual 
fields and had difficulty seeing moving objects. He had mild photophobia but no 
photophilia.  
 
His general health was good aside from having renal calculi removed at age 2 years. 
He was born at full term and there had been no problems in pregnancy. There were no 
other affected family members and his younger male sibling and parents denied any 
ocular abnormalities. There is no history of consanguinity in his family.  
 
 
4.7.2 Clinical Examination 
Best corrected visual acuity at age 16 years was 0.48 LogMAR in the right eye, with 
no improvement with pinhole, and 0.30 LogMAR in the left eye, improving to 0.18 
LogMAR with pinhole. Refractive error was right eye +1.00/+2.25, 90o (spherical 
equivalent +2.75D) and left eye +0.75/+1.75, 100o (spherical equivalent +1.3D). The 
right eye is likely to be amblyopic. He failed the screening tests on HRR colour vision 
testing. Pupil examination was normal. He had a mild roving nystagmus and right 
esotropia. 
 
Slit lamp biomicroscopy identified normal anterior segments and clear lenses. 
Funduscopy demonstrated bilateral symmetrical widespread RPE atrophy with 
peripheral retinal white dots, bilateral macular atrophic changes, vascular attenuation 
and minimal retinal pigmentation (Figure 58 - A and B).  
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Visual acuity in his brother and parents was normal (-0.10 LogMAR in each eye), as 
were their retinal examinations. Blood samples were obtained from the proband, his 
brother and parents for molecular analysis. 
 
 
4.7.3 Fundus Autofluorescence Imaging 
Fundus autofluorescence imaging in both eyes demonstrated a ring of diffuse 
hyperautofluorescence in the macula centred on the fovea, which itself had a normal 
autofluorescent signal (Figure 58 - C and D).  
 
 
4.7.4 OCT Imaging 
sd-OCT imaging identified relative preservation of the inner retinal layers and the 
foveal contour. There was loss of the inner segment outer segment layer throughout 
the macula except for a small area at the fovea, which may represent preserved 
photoreceptors in this region. (Figure 58 - E and F, arrows demarcate the preserved 
photoreceptor inner segment outer segment layer at the fovea in right and left eye). 
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Figure 58 - Retinal imaging of Subject 47, RGR with EORD. A - Right eye fundus; B 
- Left eye fundus, both retinas have widespread RPE atrophy, peripheral retinal white 
dots (arrows), minimal retinal pigmentation, bilateral macular atrophy and arteriolar 
attenuation; C - Right eye sd-OCT image; D. Left eye sd-OCT image; OCT images 
demonstrate intact retinal lamination, the arrows demarcate the preserved 
photoreceptor inner segment outer segment layer at the fovea; E - Right eye fundus 
autofluorescence image; F - Left eye fundus autofluorescence image. 
Autofluorescence images demonstrate a diffuse area of hyperautofluorescence at the 
macula in each eye. 
 
 
4.7.5 Psychophysical Testing – Goldmann Visual Fields 
Goldmann visual fields, performed in the proband, were only reliably performed to 
the V4e and III4e targets in each eye. To the III4e target his visual fields were 
constricted to the central 20o although there were additional nasal and peripheral 
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islands of vision present. To the V4e target there was constriction of the superior 
visual field to between 35o to 10o, but the nasal and temporal fields were maintained 
to 60o and 80o respectively. However, there was a mid-peripheral ring scotoma 
bilaterally between 10o to 30o from fixation in the right eye and between 10o to 20o 
from fixation in the left eye to the V4e target (Figure 59).  
 
 
Figure 59 - Goldmann visual fields, Subject 47, RGR. A. Right eye; B. Left eye; V4e 
blue line, III4e stimulus – red line.  
 
 
4.7.6 Electrophysiological Testing 
ISCEV standard electrophysiological studies in the proband carried out at MEH 
demonstrated undetectable full field ERGs, in keeping with severe loss of generalised 
rod and cone function at the level of the photoreceptor. PERGs were poor and 
demonstrated residual function in both eyes, in keeping with bilateral macular 
dysfunction. 
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4.7.7 Molecular analysis 
DNA was obtained for molecular analysis from blood samples provided by the 
proband, his unaffected brother and unaffected parents. All subjects underwent direct 
Sanger sequencing of exon 2 of RGR (by ADB). The primer sequences and PCR 
conditions are listed in the Appendix (Appendix 7.2.2). The pathogenic variant that 
had been identified by the LCA Chip analysis was confirmed in the proband in the 
homozygous state as: c.196A>C, p.Ser66Arg. This variant has been previously 
reported in a family with RP [319]. Sequencing of the DNA in family members 
identified that this variant was present in the heterozygous state in each parent and 
that the unaffected brother was a wild type homozygote, confirming segregation of 
this variant with the disease in this family (Figure 60).  In silico analysis using SIFT 
predicts this mutation to be damaging (SIFT Score 0.04) and using PolyPhen2 to be 
probably damaging (Score 0.984, Sensitivity 0.74, Specificity 0.96). The variant was 
not identified in the exon variant server or in the 1000 genomes project.  
 
 
Figure 60 - RGR sequencing in Family 45. Proband: c.196A>C, p.Ser66Arg 
homozygous; unaffected parents are heterozygous (Het) carriers of the change and 
unaffected brother has the wild type alleles (WT). 
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4.7.8 Discussion 
Mutations in RGR are rare. Only two families have previously been reported with 
bialleic mutations in RGR and both had homozygous c.196A>C, p.Ser66Arg variants 
[292, 319]. Screening of RGR in panels of 331 and 91 RP subjects, respectively, 
identified no other pathogenic variants [320, 321]. The retinal phenotype in the 
original RGR family was of diffuse depigmentation of the RPE involving the macula, 
pigmentation in the retinal periphery and vascular attenuation. The subjects were 
examined in their 4th and 5th decades and had a visual acuity of 1.00 LogMAR or 
worse, severely constricted visual fields and widespread loss of photoreceptor 
function on electrophysiological testing. The individual described by Collin et al. had 
ARRP, diagnosed at age 6 years. He was Serbian in origin and in the 4th decade had 
perception of light vision, RPE atrophy involving the macula, peripheral retinal 
paving stone-like retinal changes, vascular attenuation and pale optic discs. In 
comparison to these two families, the subject described in the present study, who had 
symptom onset from the first few months of age, was examined in his second decade 
and had better preservation of his central vision, although he had severe constriction 
of his visual fields and severe generalised photoreceptor dysfunction on 
electrophysiological testing. The retina had widespread RPE atrophy with white dots 
in the periphery, atrophy at the macula involving the fovea and vascular attenuation. 
There was minimal peripheral pigmentation visible in one eye. His OCT demonstrated 
preservation of the photoreceptor layer at the fovea, but loss of this layer from the 
parafovea and remaining macula, and this could be correlated with the FAF images 
which showed an annulus of hypoautofluorescence corresponding to the loss of 
photoreceptors on OCT, as seen in subjects with RP [344].  
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RGR, retinal G protein-coupled receptor, is an intracellular membrane bound protein 
located in the RPE and Müller cells, that plays a role in the visual cycle [315]. 
However, the specific role of RGR in the visual cycle is not clear. It was initially 
proposed to function in an ‘alternative’ visual cycle, in which is there is regeneration 
of 11-cis-retinal from all-trans-retinal under photopic conditions [316]. This would 
ensure availability of 11-cis retinal under conditions of prolonged light exposure. 
Further studies have suggested that RGR also plays a role in the classical visual cycle 
and that its effects may be independent of light. [317]. It has also been identified that 
RGR mediates the mobilisation of all-trans retinyl esters in RPE cells in response to 
light, and in vitro studies have shown that in the dark, RGR inhibits LRAT and all-
trans-retinyl ester hydrolase, but in the light this inhibition is reversed [318]. Work is 
ongoing but the specific role for RGR remains to be elucidated. 
 
Although the p.Ser66Arg RGR mutation in this and other families has segregated in 
an autosomal recessive manner, an RGR mutation in an autosomal dominant RP 
family has been described, with a phenotype similar to choroidal sclerosis [319]. This 
mutation, a 1-bp insertion at codon Gly275, at the 3’ end of the coding region, creates 
a protein that is 21% longer than that encoded by wild type RGR. The homologous 
region in rhodopsin is a frequent target of mutations in ADRP. It is unclear why 
dominant and recessive mutations in RGR lead to disease, which have different 
phenotypes. However there are also other genes, for example NR2E3, BEST-1, and 
Rhodopsin where both recessive and dominant mutations cause variable retinal 
phenotypes [398-403]. This may be seen to be more common as next generation 
sequencing becomes more available in molecular diagnostic investigation. 
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4.8 Childhood Onset Autosomal 
Recessive Bestrophinopathy  
 
The clinical heterogeneity associated with mutations in the Bestrophin-1 (BEST1) 
gene has recently been expanded and these conditions are now considered under the 
umbrella term: ‘bestrophinopathies’. Autosomal dominant inheritance classically 
leads to the condition ‘Best disease’ (Best’s vitelliform macular dystrophy, BVMD) 
(OMIM 153700) [400], but other rare dominantly inherited conditions also occur, 
including Autosomal Dominant Vitreochorioretinopathy (ADVIRC) (OMIM 193220) 
[404] and retinitis pigmentosa (OMIM 613194) [405]. Recently, autosomal recessive 
inheritance, with bi-allelic mutations in BEST1 was reported in adults, a condition 
termed Autosomal Recessive Bestrophinopathy (ARB) (OMIM 611809) [401].  
 
Subjects recruited into this study presented in childhood with clinical features 
suggestive of a bestrophinopathy, and subsequent molecular analysis of BEST1 was 
performed. A paper has been published with some of the results of this cohort of 
subjects, and since then, further families have been identified [406]. This chapter 
describes the phenotype associated with childhood onset autosomal recessive 
bestrophinopathy (ARB) for those subjects that were phenotyped at MEH, and 
describes the results of the molecular analyses performed in these families.    
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4.8.1 Clinical History 
Six probands of six families were included in this sub-category of the ‘macular 
phenotype’ cohort of subjects in this study. Three of six (50%) probands presented 
with strabismus (Subjects 1, 3 and 5), 2 with reduced vision (Subjects 2 and 6) and 1 
with leucocoria that had been identified on a photograph (Subject 4) (Table 20). Age 
at presentation ranged between 2 years and 6 years. No subjects reported nyctalopia, 
photophobia or ocular pain, and nystagmus was not a feature. Subject 1 was reported 
to be amblyopic in the right eye but she also had macular scarring; Subject 5 
underwent strabismus surgery at age 13 years. General health was unremarkable in all 
subjects.  
 
Of the 11 parents that were available for clinical testing, all were asymptomatic. The 
male cousin of Subject 3 (Family 3) carried a diagnosis of Best disease. There was no 
other family history of ocular disease in the other families. All probands except 
Subject 5 were from non-consanguineous families. The parents of Subject 5 were 
second cousins. Families 1-5 were British Caucasian, and family 6 was Greek.       
 
 
4.8.2 Clinical Examination 
Four of six subjects were male. They were examined at different ages: Subject 1 at 7.7 
years; Subject 2 at 19.0 years; Subject 3 at 12.5 years; Subject 4 at 5.5 years; Subject 
5 at 17.8 years; and Subject 6 at 6.5 years (Table 20). The two subjects that were 
examined in early adulthood (Subjects 2 and 5) had been previously examined in 
childhood. Visual acuity at presentation was generally good, and ranged between 0.00 
LogMAR and 1.10 LogMAR. Subject 1 had amblyopia and macular scarring due to 
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sub-retinal neovascular membrane in the right eye; visual acuity in this eye was 1.10 
LogMAR. If this measurement is excluded, the worst visual acuity at presentation was 
in the left eye of Subject 2, at 0.48 LogMAR. No subjects showed deterioration of 
vision over time unless there was choroidal neovascularisation (Subject 1). As with 
adults with ARB, hypermetropia predominated; the spherical equivalent ranged 
between +1.50 dioptres and +8.00 dioptres. Anterior segments were normal in all 
subjects. 
 
The affected subjects all had bilateral symmetrical macular changes with 
characteristic sub-retinal yellow deposits that either had the appearance of ‘classical’ 
Best disease (Subject 1), or a variable multi-focal pattern (Subjects 2-6), or a 
combination of the two (Subject 6, left eye). In subject 1 the macular lesions extended 
to the inferior vascular arcades and contained, bilaterally, a para-foveal cicatricial 
component (Figure 61 - A and B). This subject developed a right sub-retinal 
neovascular membrane by age 7.5 years. The multi-focal yellow deposits were more 
subtle in subject 2, and appeared on a background of macular oedema and confluent 
yellow sub-retinal change located along and beyond the temporal vascular arcades 
(Figure 62 - A and B). In subjects 3 to 6 the multi-focal round yellow deposits were 
more prominent, surrounding an area of neurosensory detachment, with similar 
additional areas superior to the optic discs (Figure 63, Figure 64, Figure 65 and Figure 
66 - A and B). Subject 3 had a similar area inferior to the discs of approximately 1 
disc diameter. Subject 5, at age 17.8 years additionally had bilateral macular scarring 
which spared the foveae, and very fine yellow dots in the peripheral retina at the 
equators. In Subject 6 there was a foveal yellow lesion that resembled the vitelliform 
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lesion classically seen in Best disease – this was more prominent in the left macula 
than in the right.  All parents examined (11 of 12) had normal fundi. 
 
 
4.8.3 Fundus Autofluorescence Imaging 
Fundus autofluorescence imaging displayed marked hyperautofluorescence 
corresponding to the round yellow lesions seen on funduscopy (Figure 61, Figure 62, 
Figure 63, Figure 64, Figure 65 – images C and D, and Figure 66 - C). In Subject 1 
the hyperautofluorescence corresponded to the focal macular lesions, which extended 
to the inferior vascular arcades. In subject 2 the hyperautofluorescence was more 
diffuse but there were additional foci of hyperautofluorescence corresponding to the 
yellow lesions.  
 
 
4.8.4 OCT Imaging 
sd-OCT imaging demonstrated sub-retinal hyporeflective areas in the maculae of all 
subjects (Figure 61, Figure 62, Figure 63, Figure 64, Figure 65 – images E and Figure 
66 - D). Discrete hyperreflective dome-shaped sub-retinal elevations were present in 
all subjects except Subject 2. A prominent photoreceptor outer segment layer 
bordering the sub-retinal hyporeflectivity was seen in Subjects 1, 3, 4 and 6, but in the 
two oldest subjects this layer appeared to be disrupted and more irregular (Subjects 2 
and 5). The inner retinal layers were intact with normal laminar architecture in 
Subjects 1, 3, 4 and 5. Multiple intra-retinal hyporeflective areas were present in 
Subject 2; in Subject 6 there was one focal intra-retinal hyporeflective spot.  
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Table 20 - Clinical Features of Paediatric ARB subjects. F – Female; M – Male; VA – Visual Acuity; RE – Right Eye; LE – Left Eye; yr – year; 
DS – Dioptre Sphere; EOG – Electro-Oculogram; PERG – Pattern Electroretinogram; ffERG – full field Electroretinogram.   
a. ERGs performed using paediatric protocol and peri-orbital skin electrodes with non-Ganzfeld stimulation. 
 
 
Subject, 
Family 
(Gender) 
Presenting 
symptoms 
Presenting VA, 
LogMAR 
(RE; LE) 
(Age, yr) 
Latest VA, 
LogMAR 
(RE; LE) 
(Age, yr) 
Refraction 
(RE; 
LE) 
EOG light rise 
(RE; 
LE) 
PERG 
(RE; 
LE) 
(Age, yr) 
ffERG 
(RE; 
LE) 
(Age, yr) 
1, 1 (F) Strabismus 1.10; 0.10 (4.8) 1.18; 0.18 (7.7) +8.00 DS; 
+7.00/-1.00, 20 
Undetectable; 
Undetectable 
Normal; 
Subnormal (7.5) 
Normal; Normal  
(7.5) 
2, 2 (F) Reduced vision 0.18; 0.48 (6) 0.00; 0.30 (19) +2.50/-0.75, 170; 
+2.50/-0.75, 170 
Undetectable; 
Undetectable 
Normal (9.5), 
Subnormal (17.5);  
Normal (9.5), 
Subnormal (17.5) 
Normal (9.5), 
Subnormal (17.5);  
Normal (9.5), 
Subnormal (17.5) 
3, 3 (M) Strabismus 0.40; 0.00 (2) 0.4; 0.00 (12.5) +7.00/-0.25, 90; 
+5.00/-0.50, 90 
Undetectable; 
Undetectable 
Normal; Normal  
(12.5) 
Normal; Normal  
(12.5) 
4, 4 (M) Leucocoria  
(on photograph) 
0.12; 0.12 (2) 0.12; 0.08 (5.5) +5.25/-0.75, 10; 
+4.25/-0.75, 170 
Not tested; 
Not tested 
Normal; Normal  
(3.5)a 
Normal; Normal  
(3.5)a 
5, 5 (M) Strabismus 0.3; 0.2 (12) 0.2; 0.2 (17.8) +3.50/-3.00, 180; 
+2.50/-2.00, 15 
Undetectable; 
Undetectable 
Not tested;  
Not tested 
Normal; 
Normal 
(13) 
6, 6 (M) Reduced vision 0.1; 0.1 (6.5) 0.1; 0.1 (6.5) +3.00/+3.00, 100; 
+3.25/+2.50, 80 
Undetectable; 
Undetectable 
Normal;  
Normal  
(6.5) 
Normal; 
Normal  
(6.5) 
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Figure 61 - Subject 1 ARB. A – Right eye fundus; B – Left eye fundus; C – Right eye 
fundus autofluorescence image; D – Left eye fundus autofluorescence image; E – 
Right eye OCT image. 
 
 
 
 
 
Figure 62 - Subject 2 ARB. A – Right eye fundus; B – Left eye fundus; C – Right eye 
fundus autofluorescence image; D – Left eye fundus autofluorescence image; E – 
Right eye OCT image. 
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Figure 63 - Subject 3 ARB. A – Right eye fundus; B – Left eye fundus; C – Right eye 
fundus autofluorescence image; D – Left eye fundus autofluorescence image; E – 
Right eye OCT image. 
 
 
 
 
 
Figure 64 - Subject 4 ARB. A – Right eye fundus; B – Left eye fundus; C – Right eye 
fundus autofluorescence image; D – Left eye fundus autofluorescence image; E – 
Right eye OCT image. 
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Figure 65 - Subject 5 ARB. A – Right eye fundus; B – Left eye fundus; C – Right eye 
fundus autofluorescence image; D – Left eye fundus autofluorescence image; E – 
Right eye OCT image. 
 
 
 
 
 
Figure 66 - Subject 6 ARB. A – Right eye fundus; B – Left eye fundus; C – Left eye 
fundus autofluorescence image; D - Left eye OCT image. 
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4.8.5 Electrophysiological Studies 
Electrophysiological testing was undertaken in all subjects using ISCEV standards or 
using a modified paediatric protocol with peri-orbital skin recording electrodes. Flash 
or full-field ERGs (ffERGs), pattern ERGs (PERGs) and electro-oculograms (EOGs) 
were performed where possible. All available parents underwent EOG testing. 
 
There was no light rise in either eye on EOG in all subjects who underwent testing 
(Subjects 1-3, 5 and 6). Subject 4 was too young to perform the test reliably. These 
findings are in keeping with severe generalised RPE dysfunction. Both of the parents 
of Subjects 1, 2, 4 and 5 had normal EOG light rises. Only the mother of Subject 3 
was available and she also had a normal EOG light rise. The mother of Subject 6 had 
a normal EOG light rise but his father had a mildly subnormal light rise at 155% in 
both eyes (a light rise less than 150% is considered abnormally low and above 200% 
is considered to be normal; between 150% and 200% is considered to be borderline). 
The EOG result in the father of Subject 6 was considered not to be typical of a carrier 
of autosomal dominant Best disease, as in asymptomatic gene carriers there is 
minimal light rise, if any.  
 
Except for Subject 2, the ffERGs were normal in all probands (age 7.5 years, Subject 
1; 12.5 years, Subject 3; 4.0 years, Subject 4; 13.0 years, Subject 5; 6.5 years, Subject 
6). Longitudinal ffERG data were available for Subject 2. At age 9.5 years she had 
normal flash ERGs but at age 17.5 years full field ERG abnormalities were evident, 
consistent with mild generalised rod and cone dysfunction. 
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The pattern ERG (PERG), a measure of macular function, was mildly subnormal in 
the eye with a subretinal neovascular membrane, but normal in the fellow eye, of 
Subject 1. In subject 2, at age 9.5 years, the PERG was normal but at 17.5 years the 
P50 component of the PERG was reduced, consistent with macular involvement. In 
Subjects 3, 4 and 6 the PERGs were normal. PERGs were not performed in Subject 5.  
 
In summary, the electrophysiology findings in subjects 1-3 and 5-6 are of severe 
generalised dysfunction at the level of the RPE / photoreceptor interface. There is 
additional generalised photoreceptor dysfunction with macular involvement in the 
oldest subject, in whom serial electrophysiology demonstrates progression over an 8-
year period. An important finding is that all but one parent of the affected children 
had normal EOGs. 
 
 
4.8.6 Molecular Analysis 
Molecular analysis of BEST1 was performed by Dr Davidson, University of 
Manchester, in Families 1-4 and by ADB in Families 5 and 6. All ten coding exons 
and flanking intronic boundaries were analysed by direct sequencing from PCR 
amplicons for subjects 1,2,3,5 and 6. DNA was only available for the parents of 
Subject 4 and was screened for mutations in BEST1. Otherwise, only the relevant 
exons containing sequence alterations were sequenced in the parents (Table 21). PCR 
conditions and primer sequences are listed in the Appendix (Appendix 7.2.3). 
 
Subject 1 harboured one previously reported heterozygous missense mutation 
c.422G>A p.Arg141His [401, 407] [408] and one novel heterozygous nonsense 
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mutation, c.475C>T p.Gln159X, in BEST1. Her father carried the c.422G>A 
p.Arg141His variant in the heterozygous state and mother carried the c.475C>T 
p.Gln159X variant in the heterozygous state.  
 
Subject 2 harboured a novel missense mutation, c.533A>C p.His178Pro, and a novel 
duplication mutation, c.1038dupC p.Tyr347LeufsX54, in BEST1. Her father carried 
the c.533A>C p.His178Pro variant in the heterozygous state and mother carried the 
c.1038dupC p.Tyr347LeufsX54 variant in the heterozygous state. 
 
Subject 3 had one novel heterozygous missense mutation and one novel heterozygous 
nonsense mutation in BEST1: c.550C>T p.Pro184Ser and c.1066C>T p.Arg356X. His 
mother carried the c.550C>T p.Pro184Ser variant in the heterozygous state. His father 
was not available for testing. 
 
DNA was unavailable from subject 4. However, both of the unaffected parents of this 
subject carried the following previously reported heterozygous missense mutations in 
BEST1: c.584C>T, p.Ala195Val [409, 410] (mother) and c.974T>C, p.Met325Thr 
[401] (father). 
 
Subject 5 harboured the novel intronic homozygous mutation c.1740-3t>g, 
p.Asp581SerfsX85 in BEST1 (mutation identified by direct sequencing by ADB, 
protein change identified by RT-PCR by Dr Davidson). This was the only 
consanguineous family in this cohort. His unaffected parents and unaffected sister 
were each identified to carry this mutation in the heterozygous state (Figure 67). This 
mutation occurs 3 nucleotides before the first base of exon 11. In silico prediction 
287 
software (www.fruitfly.org) predicts that this mutation abolishes the acceptor splice 
site. It is likely that the transcript does not undergo nonsense mediated decay, but that 
it produces a non functional isoform of bestrophin-1 that may affect the function of 
the calcium channel (direct communication from Dr Davidson, UCL).  
 
 
 
Figure 67 – Electropherograms ARB Family 5. BEST1 c.1740-3t>g, 
p.Asp581SerfsX85.  
 
 
Subject 6 harboured the novel duplication c.171-172dupAC, p.Glu58GlufsX4  and the 
previously reported missense mutation c.653G>A, p.Arg218His [410-412] in BEST1 
(Figure 68). His mother harboured the c.171-172dupAC, p.Glu58GlufsX4 variant in 
the heterozygous state and father harboured the c.653G>A, p.Arg218His variant in 
the heterozygous state. The frame shifting mutation is likely to be a null variant as it 
occurs early in the protein. 
 
288 
 
 
Figure 68 - Electropherograms ARB Family 6. BEST1 c.171-172dupAC, 
p.Glu58GlufsX4  and c.653G>A, p.Arg218His. 
  
 
 
Screening of DNA from the unaffected parents of subjects 1, 2, 3, 5 and 6 
demonstrated that, in each instance, the BEST1 mutations identified in the children 
were present in trans, one being inherited from each parent on separate alleles (Table 
21). The absence of the putative novel pathogenic sequence alterations that had been 
found in families 1-4 in 210 control chromosomes was confirmed by either single 
stranded conformation polymorphism analysis or by direct sequencing (Dr Davidson). 
Five of 7 novel mutations identified in this study (c.475C>T p.Gln159X, c.533A>C 
p.His178Pro, c.550C>T p.Pro184Ser, c.1038dupC p.Tyr347LeufsX54 and c.1066C>T 
p.Arg356X) were absent from 210 ethnically matched control chromosomes. The 
novel variants c.1740-3t>g, p.Asp581SerfsX85 and c.171-172dupAC, 
p.Glu58GlufsX4, identified in subjects 5 and 6 respectively, were not identified on 
different variant databases including dbSNP (http://www.ncbi.nlm.nih.gov/), the 
exome variant server (http://evs.gs.washington.edu/EVS/), the 1000 genomes variant 
database (http://browser.1000genomes.org/index.html) or the Leiden Open Variation 
Database (http://www-huge.uni-regensburg.de/BEST1_database/).  
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Table 21 - BEST1 molecular analysis in affected Subjects and unaffected parents in ARB families. WT – Wild Type; NA – Not Available. 
Compound heterozygous and homozygous mutations identified in the probands are indicated in bold. 
Family Subject BEST1 Allele 1 BEST1 Allele 2 Nucleotide Amino Acid Type Ref. Nucleotide Amino Acid Type Ref. 
1 1 
Mother 
Father 
c.422G>A 
WT 
c.422G>A  
p.Arg141His 
WT 
p.Arg141His 
Missense [401, 
407, 
408, 
410] 
c.475C>T 
c.475C>T 
WT  
p.Gln159X 
p.Gln159X 
WT 
Nonsense Novel to 
this study 
2 2 
Mother 
Father 
c.533A>C 
WT  
c.533A>C 
p.His178Pro 
WT 
p.His178Pro 
Missense Novel 
to this 
study 
c.1038dupC 
c.1038dupC 
WT  
p.Tyr347LeufsX54 
p.Tyr347LeufsX54 
WT 
Duplication, 
Frame shift, 
Null 
Novel to 
this study 
3 3 
Mother 
Father 
c.550C>T 
c.550C>T 
NA  
p.Pro184Ser 
p.Pro184Ser 
NA 
Missense Novel 
to this 
study 
c.1066C>T  
WT 
NA 
p.Arg356X 
NA 
WT 
Nonsense Novel to 
this study 
4 4 
Mother 
Father 
NA 
c.584C>T 
WT 
NA 
p.Ala195Val 
WT 
Missense [408, 
410] 
NA 
WT 
c.974T>C 
NA 
WT 
p.Met325Thr 
Missense [401] 
5 5 
Mother 
Father 
c.1740-3t>g 
c.1740-3t>g 
WT  
p.Asp581SerfsX85 
p.Asp581SerfsX85 
WT 
Frame shift,  
Null 
Novel 
to this 
study 
c.1740-3t>g 
WT 
c.1740-3t>g 
p.Asp581SerfsX85 
WT 
p.Asp581SerfsX85 
Frame  
shift,  
Null 
Novel to 
this study 
6 6 
Mother 
Father 
c.171-172dupAC 
c.171-172dupAC 
WT 
p.Glu58GlufsX4 
p.Glu58GlufsX4 
WT 
Duplication, 
Frame shift, 
Null 
Novel 
to this 
study 
c.653G>A 
WT 
c.653G>A  
p.Arg218His 
WT 
p.Arg218His 
Missense [410-412] 
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4.8.7 Discussion 
At the time that this study was conducted, ARB had been a recently described 
disorder caused by bi-allelic, or compound heterozygous, mutations in BEST1 [401, 
405, 413]. Most of the reports were of individuals who were diagnosed in adulthood, 
and only 12 molecularly confirmed individuals from 7 families had been reported. An 
additional family reported with ‘atypical’ Best disease with compound heterozygous 
mutations was also likely to have ARB [407]. The phenotype associated with ARB 
had predominantly been described in adults who had central visual loss, 
hypermetropia, irregularity of the RPE and deep scattered hyperautofluorescent sub-
retinal deposits [401]. The BEST1 gene was initially mapped to chromosome 11q13 in 
1992 [414, 415] and was later characterised in 1998 [400]. BEST1 encodes a 585 
amino acid protein product, bestrophin-1, which is thought to function as a calcium 
activated chloride channel in the basolateral plasma membrane of RPE cells [405, 
416]. An additional role of bestrophin-1 as a regulator of voltage dependent calcium 
channels has been suggested [417]. The reduced/absent EOG light rise in conditions 
caused by mutations in BEST1, which are grouped under the umbrella term 
‘bestrophinopathies’, is believed to be generated by a reduced influx of chloride ions 
into the RPE [417-420]. 
 
In this study the paediatric phenotype of ARB was sought in order to expand 
understanding of this condition in a young age group. In all affected subjects 
compound heterozygous mutations in BEST1 were identified, with symptoms or signs 
being present by 6 years of age. Hypermetropia was frequent, in keeping with other 
disorders associated with mutations in BEST1 [401, 404]. Overall, visual loss was 
mild and there was little change in the visual acuity unless choroidal 
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neovascularisation developed. Sub-retinal yellow deposits with sub-retinal fluid were 
evident in the posterior pole of all subjects. Similar changes were reported in adults 
with ARB [401, 407, 413], but the fundus appearances were more variable in the 
present paediatric cohort, ranging from subtle multi-focal deposits to a more 
‘classical’ Best disease appearance. In addition to the macular deposits, similar 
lesions could be seen to extend beyond the vascular arcades or to localise to the peri-
papillary regions, predominantly superior to the optic discs. The deposits were highly 
autofluorescent and appeared as discrete hyper-reflective dome-shaped sub-retinal 
elevations. It is unclear whether these elevations lie above, below or within the RPE. 
Similar appearances were described in a previous report and were thought to localise 
to within the RPE [413]. In multi-focal vitelliform macular dystrophy [421] and Best 
disease [76], similar lesions have been proposed to lie at the level of the 
RPE/photoreceptor complex.    
 
Sd-OCT imaging in the younger subjects (5 subjects, age range 5.5 – 17.8 years) 
suggested that the inner retinal layers remain intact, but with age, intra-retinal 
hyporeflective areas, presumed to be intra-retinal cysts, may develop (demonstrated 
by Subject 2, age 19 years). Comparison of the OCT imaging in this older subject 
with time domain OCT images obtained in other adult series’ suggests that in ARB, 
intra-retinal cystic changes develop with age [401, 407]. The neurosensory retina was 
detached in all affected subjects, with sub-retinal hyporeflective areas that are 
presumed to represent sub-retinal fluid. The photoreceptor layer appeared more 
prominent than normal, giving the appearance of extensions into the sub-retinal space. 
These extensions may represent an unmasking of the normal tight inter-digitations 
that exist between the photoreceptor outer segments and the RPE apical microvilli 
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[422]. They may also represent prolongations of the photoreceptor outer segments that 
do not become phagocytosed by the RPE due to the neurosensory detachment. 
Thickening and elongation of the photoreceptor outer segments with small filament-
like bridges connecting the outer segment layer and the RPE, proposed to represent 
unshedded outer segment discs that in turn may lead to outer segment elongation, 
have been reported in ARB [413]. Such bridges were not identified in the present 
study. 
 
Electrophysiological investigation is paramount to the diagnosis of ARB. The absent 
EOG light rise suggests that the defect localises to the RPE. However, EOG testing is 
difficult to perform in young children and may not be possible. In dominant BEST1 
disease the EOG is abnormal in heterozygotes. Thus, investigation of other family 
members may help distinguish dominant from recessive disease, allowing clinicians 
to provide appropriate genetic counselling to the family. If both parents have a normal 
EOG light rise, the disease is almost certainly recessive in inheritance.  
 
In the present study the EOG light rise was undetectable in all subjects that were old 
enough to comply with the test. In the younger subjects, PERGs were normal in all 
but one eye of one child (subject 1, age 7.5 years), who clinically had a sub-retinal 
neovascular membrane and strabismus that could account for the subnormal PERG. In 
the oldest subject the PERG became subnormal at an older age (subject 2, at age 17.5 
years), having been normal at a younger age, suggesting progressive macular 
dysfunction. All subjects tested in childhood had normal flash or full-field ERGs (age 
3.5 to 13 years).  
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Of the previously described cases in the literature, all adults were identified to have 
abnormal full-field ERGs with mild to severely reduced PERGs, in keeping with 
generalised retinal dysfunction with macular involvement [401]. Of the data published 
in children, full-field ERGs were reported to show reduced rod and cone b-waves, and 
multi-focal ERG responses were reduced and delayed within the central 10o [401] 
[413]. The limited longitudinal data available suggest that there is deterioration of the 
full-field ERG with time [401].  
 
Molecular analysis of the 6 ARB families in this study, performed by Dr Davidson 
and ADB, identified 5 families to harbour compound heterozygous mutations and 1 
consanguineous family to harbour a homozygous mutation in BEST1. Of the seven 
novel mutations identified, 2 were missense mutations (c.553A>C p.His178Pro and 
c.550C>T p.Pro184Ser), 2 were nonsense mutations (c.475C>T p.Gln159X and 
c.1066C>T p.Arg356X), 2 were duplications that lead to frameshifts and premature 
stop codons that are presumed to produce transcripts that are degraded by nonsense 
mediated decay (c.1038dupC p.Tyr347LeufsX54 and c.171-172dupAC, 
p.Glu58GlufsX4), and one was an intronic variant occurring 3 bases before the start 
of exon 11, causing a frame shift that produces a non-functioning isoform of 
bestrophin-1 (c.1740-3t>g, p.Asp581SerfsX85). The novel missense mutations 
identified lie in highly conserved regions of the protein product, suggesting that these 
regions have an important functional role. 
 
The original paper describing ARB proposed that the phenotype results from null 
BEST1 mutations, with affected individuals having either null or missense mutations 
that are non-functional [401]. Three subjects in the present cohort had compound 
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heterozygous null mutations (Subjects 2, 5 and 6), 2 had a combination of nonsense 
and missense mutations (Subjects 1 and 3) and 1 had two missense mutations (Subject 
4). Three variants were present that have been described in both autosomal dominant 
Best disease and ARB (p.Arg141His, p.Ala195Val and p.Arg218His) [407, 408, 410, 
412]. However, an affected subject reported with the p.Arg141His mutation had a 
further nonsense mutation in trans and it is likely that they have ARB [407]. 
Moreover, a p.Arg141His / wild type heterozygous parent of a subject with ARB 
reported by Burgess et al. had a normal examination and electrophysiology [401] and 
the p.Arg141His heterozygote reported by Schatz et al. also had a normal EOG light 
rise (although the ERG was reported to be reduced at age 59 years) [407], suggesting 
that the variants in these two reports are more likely to be recessive mutations. There 
have been further reports of the bestrophin-1 codon 141 being affected in ARB 
indicating that the p.Arg141His mutation is predominantly an ARB mutation and that 
it is likely to be the most frequently identified mutation associated with ARB to date 
[401, 406, 407, 423-427]. The probands with p.Ala195Val reported by Lotery et al. 
and Kramer et al. have no family or clinical data described in either study, leaving 
open the possibility that these, too, had ARB, in which a second allele was 
undiscovered [408, 410].  
 
Interestingly, family 6 in the present cohort harboured compound heterozygous 
mutations, one of which has been reported in a number of families with [autosomal 
dominant] Best disease (c.653G>A, p.Arg218His) [411] [410, 412, 428]. In fact, 
codon 218 has been implicated in a number of unrelated families with Best disease, 
and the Arginine that normally resides in this position has been mutated to Histidine 
and Cysteine in different families [410, 412]. This residue is highly conserved and 
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codon 218 is a key residue in the bestrophin-1 protein that may represent a mutational 
‘hotspot’ in Best disease. In a number of French studies this codon was the target of 
various missense mutations in unrelated families, leading the authors to conclude that 
this may correspond to a founder effect in French and other western European 
families [411, 412]. The clinical data in reports of mutations affecting the 218 codon 
are variable, and the cases included are both isolated and familial [410, 412]. In one 
family with a p.Arg218His mutation, the phenotype was described to be highly 
heterogeneous within the family, with the proband being severely affected and her 
father having very mild disease [412]. Although this may represent variable 
expressivity within this family, it is possible that this family had recessive disease in 
which the second allele was not found in the proband and that the father was an 
unaffected heterozygous carrier [411].  
 
Alternatively, the mutations identified in family 6 in the present study may indicate 
both dominant and recessive inheritance within the same family. Aside from in the 
proband, there is no clinical history of BEST1 related disease in this family. However, 
his father, who carried the p.Arg218His mutation in the heterozygous state had 
normal fundi and very mild reduction in the EOG. It can be postulated that either he 
has a mild phenotype of dominant disease (detectable only on EOG testing), or that he 
is phenotypically normal, and that the variant he carries is truly recessive. If this 
mutation behaves in a dominant manner, then when inherited along with the variant 
inherited from the mother, the combination may lead to a mixed inheritance pattern. If 
this mutation behaves in a recessive manner then the affected child has truly recessive 
disease and the clinical picture in the child is due to bi-allelic mutations. The correct 
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inheritance pattern is important to distinguish in this family, as it will help towards 
genetic counselling if other offspring are planned. 
 
Around the time that some of the data from this study were published, a number of 
other reports of ARB families were also published, with descriptions made of the 
phenotype in both adults and children [406, 423, 424, 426, 429-435]. There is general 
agreement with the present study regarding the clinical features and 
electrophysiological findings in ARB. The phenotype is milder in children unless sub-
retinal neovascularisation develops, and the full field ERG remains normal until late 
childhood / early adulthood, when the flicker (cone) ERG and PERG (macular) first 
become reduced and delayed, with eventual full field rod and cone dysfunction 
developing in adulthood [423, 426, 429, 430, 433, 434]. In agreement with the 
findings of the present study, the deterioration in the ERG appears to occur when 
intra-retinal cysts or neovascularisation develop [401, 413, 426, 430, 433]. More 
recently, further families have been described and the phenotype widely recognised to 
be associated with choroidal neovascularisation and angle closure glaucoma, that may 
be resistant to conventional treatment with laser iridotomy due to a plateau iris 
configuration and peripheral anterior synechiae [425, 427, 428, 436-441]. 
 
There is currently no treatment available for the bestrophinopathies, although 
complications such as choroidal neovascularisation and angle closure glaucoma do 
benefit from therapeutic intervention. As with all conditions affecting young children, 
management of amblyopia is important. There have been recent reports of success 
with anti-vascular endothelial growth factor (anti-VEGF) treatment for individuals 
with choroidal neovascularisation in ARB, with improvement of the visual acuity 
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(especially if combined with amblyopia therapy) [426, 427, 437]. Other options for 
management of intra-retinal fluid include carbonic anhydrase inhibitors, although 
there has been a recent report of reduction of the dose of this treatment leading to sub-
acute angle closure [425, 439]. The management of angle closure in ARB may be 
difficult due to the configuration of the iris; the options include laser peripheral 
iridotomy and lens extraction. 
 
A naturally occurring dog model of ARB exists (a disorder termed canine multi-focal 
retinopathy, cmr) [442]. Multi-focal areas of retinal elevation containing sub-retinal 
serous or pink-tan fluid occur, which are more clearly visible superiorly in the canine 
retina. In the more densely pigmented inferior canine retina the lesions are fewer and 
appear white, lying adjacent to the inferior retinal vessels. Histopathologic 
examination of cmr revealed autofluorescent cytoplasmic granules within 
hypertrophic RPE cells. As there are phenotypic similarities with humans, the study of 
cmr may help improve understanding of the disease mechanism and serve as a useful 
model for the future testing of novel therapies, including gene replacement therapy. 
Most recently, advances have been made in the recombinant adeno-associated virus 
based gene augmentation therapy of BEST1 in dogs, which may pave the way for 
future human therapies for bestrophinopathies [443]. 
 
To conclude, the childhood phenotype of ARB has been determined in this study, 
demonstrating that the clinical features, results of electrophysiological studies and 
retinal imaging distinguish ARB from Best disease. The normal ERG in childhood 
suggests that there may be a window of opportunity for gene replacement therapy or 
other therapeutic intervention at an early age. 
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4.9 Benign Yellow Dot Dystrophy 
 
A subset of individuals in Cohort 2 had been identified with an unusual phenotype 
that affected the macula, which was associated with good visual function. This subset 
was comprised of 18 individuals (Subjects 7 – 24 from Cohort 2) from 14 families 
(Families 7 – 20 from Cohort 2). Their phenotypes were ascertained and the results 
reported in this chapter. Molecular analysis is outstanding on this group of patients. 
The condition has been termed ‘Benign Yellow Dot Dystrophy’. 
 
 
4.9.1 Clinical History 
Of the 18 subjects identified with this phenotype, 16 were asymptomatic (88.9% of 
subjects with yellow dot dystrophy; 66.7% of subjects of cohort 2). Subjects were 
either referred from a community optometrist (13/18), from another ophthalmologist 
(1/18) or following screening due to a positive family history (4/18). Reduced vision 
was the presenting complaint in the two symptomatic subjects (Subjects 7 and 14). No 
cause was found for the reduced vision in Subject 7, who presented at age 16 years, 
and in whom multiple electrophysiological studies over a number of years were 
normal. A diagnosis of ‘functional’ visual loss was subsequently made. In Subject 14, 
who presented to another ophthalmologist at age 4 years but whose macular yellow 
dots were not apparent until age 6 years, the reduced vision was attributed to bilateral 
ametropic amblyopia due to hypermetropic astigmatism; there was also a partially 
accommodative esotropia. His vision eventually improved with spectacle wear and 
occlusion therapy. 
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Refractive error (identified in 5 subjects) was the predominant feature in the 7 
subjects who had any past ocular history (Table 22). One of these 7 subjects had been 
treated for strabismus and 3 of 7 had been treated for amblyopia. One subject was 
diagnosed with functional visual loss (Subject 7). One subject had bilateral optic 
neuropathy of unknown cause 4½ years after presentation with the maculopathy; the 
optic neuropathy resolved spontaneously (Subject 16). General health was good in all, 
except for subject 24, who was taking antidepressants. 
 
Of the 14 families identified in this sub-group, 2 families had multiple affected 
members (Family 7 and Family 8) and 12 families had only one affected member. 
Family 7 had 4 affected members in 2 successive generations. Family 8 had 2 affected 
members in 2 successive generations. The ethnic distribution was as follows: 12 
families were British Caucasian; 1 was West African (Subject 21, Family 17); and 1 
was South East Asian (Subject 24, Family 20). There was no history of consanguinity 
in any family.  
 
 
4.9.2 Clinical Examination 
Five subjects in the yellow dot dystrophy sub-group of cohort 2 were male, 13 were 
female. The age at presentation ranged between 5 years and 45 years, median 14.5 
years.  Visual acuity at presentation was 0.00 LogMAR or better in both eyes in 13 of 
18 subjects (72.2% of yellow dot dystrophy subjects) (Table 22). Subject 7, with 
functional visual loss, had a presenting visual acuity of 0.78 LogMAR in either eye at 
age 15 years. Pattern appearance VEPs were consistent with normal visual acuity. 
Amblyopia affected subjects 14 (bilateral), 18 (unilateral right eye) and 19 (unilateral 
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left eye), whose acuities are listed (Table 22). Colour vision was normal in 12 of 13 
subjects examined using Ishihara or HRR colour plates. Only in subject 7 was the 
colour vision abnormal - she failed the HRR screening plates II and III at age 16 
years. Anterior segments and ocular mediae were normal in all patients.  
 
Characteristic bilateral macular changes consisting of yellow dots at the level of the 
retinal pigment epithelium, concentrated around the fovea, were present in all subjects 
(Table 23). These were symmetrical between each eye and resembled drusen-like 
deposits. In the majority of subjects these were fine discrete lesions (Figure 69, Figure 
70 and Figure 71), however, in 7 subjects some of the dots were confluent (subjects 7, 
9, 10, 12, 13, 19, 22) (Figure 69 and Figure 72). In 11 subjects the yellow dots were 
distributed evenly around the fovea (Figure 70); in 7 subjects they were concentrated 
in the nasal parafoveal region (Figure 71). In subjects 13 and 15 dots were visible 
outside the temporal vascular arcades in the right eye. These were minimal in number. 
In all but 1 subject (subject 14) for whom detailed images were available, a yellow 
crescent was visible to varying degrees around the optic disc, which was otherwise 
normal in all (Table 23). In some cases this took on the appearance of a ‘yellow halo’ 
around the disc; in others the change was more consistent with peri-papillary atrophy. 
The retinal periphery and vasculature were otherwise normal in all subjects. In all 
parents of the sporadic cases that were examined, funduscopy was normal. 
 
301 
 
Subject 
(Gender) 
Family Ethnicity Relation to 
Proband 
Age at 
presentation 
(years) 
Presenting 
symptoms 
Family 
history 
Visual Acuity 
(LogMAR) 
RE, LE 
(Age, years) 
Past Ocular History 
7 (F) 7 British Caucasian Proband 15 Reduced vision Dominant 0.78, 0.78 (15) Functional visual loss 
8 (F) 7 British Caucasian Sister 18 Asymptomatic1 Dominant 0.00, 0.00 (18) Nil 
9 (F) 7 British Caucasian Mother 45 Asymptomatic1 Dominant 0.18, 0.18 (45) Nil 
10 (M) 7 British Caucasian Maternal first cousin 10 Asymptomatic1 Dominant -0.08, -0.08 (10) Nil 
11 (F) 8 British Caucasian Proband 22 Asymptomatic2 Dominant -0.08, -0.08 (22) Myopic astigmatism 
12 (F) 8 British Caucasian Mother Unknown Asymptomatic1 Dominant 0.00, 0.00 Nil 
13 (F) 9 British Caucasian Proband 8 Asymptomatic2 Sporadic 0.00, 0.00 (8) Nil 
14 (M) 10 British Caucasian Proband 6 Reduced vision, 
strabismus 
Sporadic 0.18, 0.26 (14) Hypermetropic astigmatism, 
Partially accommodative ET, 
bilateral amblyopia 
15 (F) 11 British Caucasian Proband 10 Asymptomatic2 Sporadic 0.00, 0.00 (10) Nil 
16 (F) 12 British Caucasian Proband 5 Asymptomatic2 Sporadic 0.00, 0.00 (10) Bilateral optic neuropathy 
17 (F) 13 British Caucasian Proband 10 Asymptomatic2 Sporadic 0.00, 0.00 (10) Nil 
18 (F) 14 British Caucasian Proband 12 Asymptomatic2 Sporadic 0.40, 0.00 (14) Hypermetropia, RE amblyopia 
19 (M) 15 British Caucasian Proband 14 Asymptomatic2 Sporadic 0.08, 0.14 (14) Hypermetropia, LE amblyopia 
20 (F) 16 British Caucasian Proband 15 Asymptomatic2 Sporadic 0.00, 0.00 (15) Hypermetropia 
21 (M) 17 West African Proband 15 Asymptomatic2 Sporadic 0.00, 0.00 (15) Nil 
22 (M) 18 British Caucasian Proband 28 Asymptomatic2 Sporadic 0.00, 0.00 (29) Nil 
23 (F) 19 British Caucasian Proband 28 Asymptomatic2 Sporadic -0.08, -0.08 (29) Nil 
24 (F) 20 South East Asian Proband 29 Asymptomatic2 Sporadic 0.00, 0.00 (29) Nil 
 
Table 22 - Clinical features of subjects with Benign Yellow Dot Dystrophy. M – Male; F – Female, RE – right eye; LE – left eye; ET – 
Esotropia. 1Family history; 2Referred from the Community.  
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Subject 
 
 
Family 
 
Appearance of yellow dots at the macula 
 
Autofluorescence 
7 7 Discrete, drusen-like, some confluent Even distribution HyperAF dots Crescent not visible 
8 7 Discrete, fine, drusen-like Even distribution HyperAF dots HypoAF crescent 
9 7 Discrete, drusen-like, large Even distribution HyperAF dots Crescent not visible 
10 7 Discrete, drusen-like, some confluent Even distribution HyperAF dots HyperAF crescent 
11 8 Discrete, fine, drusen-like Nasal parafovea N/A N/A 
12 8 Discrete, drusen-like, some confluent Nasal parafovea N/A N/A 
13 9 Discrete, drusen-like, some confluent Even, some outside macula HyperAF dots Crescent not visible 
14 10 Discrete, fine, drusen-like Even distribution HyperAF dots Crescent not visible 
15 11 Discrete, fine, drusen-like Even, some outside macula HyperAF dots HypoAF crescent 
16 12 Discrete, fine, drusen-like Even distribution N/A N/A 
17 13 Discrete, fine, drusen-like Nasal parafovea HyperAF dots HyperAF crescent 
18 14 Discrete, fine, drusen-like Nasal parafovea HyperAF dots HyperAF crescent 
19 15 Discrete, drusen-like, many confluent Nasal parafovea HyperAF dots HyperAF crescent 
20 16 Discrete, fine, drusen-like Even distribution HyperAF dots Crescent not visible 
21 17 Discrete, fine, drusen-like Nasal parafovea HyperAF dots HypoAF crescent 
22 18 Discrete, drusen-like, some confluent Nasal parafovea HyperAF dots HyperAF crescent 
23 19 Discrete, fine, drusen-like Even distribution N/A N/A 
24 20 Discrete, fine, drusen-like Even distribution N/A N/A 
 
Table 23 - Features of yellow dots at the fundus in Benign Yellow Dot Dystrophy Subjects. 
HyperAF – hyperautofluorescent; HypoAF – hypoautofluorescent; N/A – not available.
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Figure 69 - Subject 10, Family benign yellow dot dystrophy. A – right eye fundus; B 
– left eye fundus. Discrete, fine drusen-like yellow dots are distributed evenly at each 
fovea. Some are confluent. Arrows indicate the location of the dots. A faint yellow 
crescent is seen around the optic discs in both eyes. 
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Figure 70 - Subject 15, Sporadic benign yellow dot dystrophy. A – right eye fundus; 
B – left eye fundus. Discrete, fine drusen-like yellow dots are distributed evenly at 
each fovea. Arrows indicate the location of the dots. Some dots are evident outside the 
macula area in the right eye. A faint yellow crescent is seen around the optic discs in 
both eyes. 
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Figure 71 - Subject 17, Sporadic benign yellow dot dystrophy. A – right eye fundus; 
B – left eye fundus. Discrete fine drusen-like yellow dots are concentrated in the nasal 
parafoveal regions of both eyes. Arrows indicate the location of the dots. A faint 
yellow crescent is seen around the optic discs temporally in both eyes. 
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Figure 72 - Subject 19, Sporadic benign yellow dot dystrophy. A – right eye fundus; 
B – left eye fundus. The discrete drusen-like yellow dots are more confluent and are 
concentrated in the nasal parafoveal region in both eyes. Arrows indicate the location 
of the dots. A faint yellow crescent is seen around the optic discs resembling peri-
papillary atrophy in both eyes. 
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4.9.3 Fundus Autofluorescence Imaging 
Fundus autofluorescence imaging, available for 13 of 18 subjects, revealed foci of 
hyperautofluorescence corresponding to the yellow dots, on an otherwise normal 
background autofluorescence signal in all (Figure 73). In 5 of these there was a 
hyperautofluorescent signal corresponding with the crescent seen around the optic 
disc (Subjects 10, 17, 18, 19 and 22). In 3 subjects this crescent displayed a 
hypoautofluorescent signal (Subjects 8, 15 and 22). In no subjects did the fundus 
autofluorescence imaging identify further yellow dots than were visible on 
funduscopy. 
 
 
4.9.4 OCT Imaging 
Sd-OCT imaging performed in 7 of 18 subjects identified no subretinal hyper- or 
hypo-reflectivity, and the inner retinal layers remained intact. OCT imaging in 3 
subjects was normal (Subjects 13, 15 and 18). In 3 subjects a slight irregularity of the 
inner segment / outer segment junction was seen (Subjects 10, 14 and 17), which 
corresponded with the locations of the yellow dots, as observed on the infra-red 
reflectance image taken during OCT image acquisition (Figure 74). In 1 subject 
(Subject 19) only a slight irregularity of the RPE layer was seen (Figure 74).  
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Figure 73 - Fundus autofluorescence images of benign yellow dot dystrophy Subjects. 
A – subject 10; B – Subject 15; C – Subject 17; D – Subject 19. In all subjects the 
yellow dots are hyperautofluorescent. In subjects 10, 17 and 19 there is 
hyperautofluorescence corresponding to the yellow crescent at the optic disc (A, C 
and D) and in subject 15 there is hypoautofluorescence corresponding to the yellow 
crescent (B). 
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Figure 74 - OCT of Subjects with benign yellow dot dystrophy. A – Subject 15, 
normal OCT; B – subject 17 – slight irregularity of the inner segment outer segment 
line, indicated by the arrow; C – subject 19 – slight irregularity of the RPE layer, 
indicated by the arrow. 
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4.9.5 Electrophysiological Studies 
Electroretinography was performed in 13 subjects. In 12, the PERG and full field 
ERGs were normal (age range 6-45 years). In subject 19 the PERG and cone ERGs 
were slightly delayed and of reduced amplitude. This was attributed to his 
hypermetropic refractive error. Of the 2 subjects with subjectively reduced vision 
(subjects 7 and 14), the PERGs and ffERGs, were normal. In subject 14 the pattern 
reversal VEP was slightly reduced in the left eye, consistent with strabismus. EOGs 
performed in 4 of 5 subjects demonstrated a normal light rise. In subject 19 the EOG 
was mildly subnormal in both eyes, at age 18 years. 
 
 
4.9.6 Discussion 
The subjects in this group were identified to have a previously unreported macular 
phenotype that is associated with excellent visual function. The condition is 
commonly sporadic, although it may also segregate in an autosomal dominant 
manner. In the majority of subjects, identification is an incidental finding or 
discovered after examination of family members of affected individuals. 
 
Macular dystrophies may occur in isolation or in association with a variety of 
systemic abnormalities. Considerable clinical and genetic heterogeneity exists for this 
group of disorders and all of the Mendelian inheritance patterns have been described, 
as well as mitochondrial inheritance [444, 445]. A rare sub-group of disorders 
presenting in infancy have also been described, termed ‘developmental macular 
dystrophies’, which may be further sub-classified to include a condition known as 
North Carolina Macular dystrophy (NCMD) [446]. 
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There are a number of conditions with systemic associations that have been identified 
with drusen-like deposits at the macula. These include: membranoproliferative 
glomerulonephritis type 2, in which there are electron dense deposits in glomerular 
basement membranes and in Bruch’s membrane, with associated renal failure [447]; 
Alport’s syndrome, a predominantly X-linked condition associated with renal failure, 
deafness, anterior lenticonus and macular flecks [448]; Sjögren-Larsson syndrome, 
associated with a ‘crystalline’ maculopathy, spastic diplegia / tetraplegia and 
congenital icthyosis [449]; and hereditary oxalosis due to multi-system calcium 
oxalate crystal deposition including the retina [450]. However, none of the subjects in 
this study had any such systemic associations. Purely ocular conditions with drusen-
like deposits include: autosomal dominant drusen [451]; Bietti’s crystalline 
maculopathy, characterised by crystalline deposits at the macula with areas of 
geographic atrophy; and Sorsby dystrophy which has autosomal dominant inheritance 
and marked loss of vision with extensive macular drusen and choroidal 
neovascularisation [452]. However the macular appearances described in this study 
appear quite different to these.    
 
The phenotype associated with benign yellow dot dystrophy shares some similarities 
with the mildest cases of NCMD. This autosomal dominant condition, with variable 
expressivity, was first described by Lefler et al, who reported a single family that 
settled in North Carolina in the early 19th century, with amino aciduria and a macular 
dystrophy [453]. A number of families with NCMD without systemic associations 
have subsequently been reported and the phenotype extensively documented [454-
462]. The macular appearances associated with NCMD demonstrate both inter- and 
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intra-familial variability, and have been categorised into 3 grades: Grade 1 - 
bilaterally symmetrical central macular yellow ‘specks’ less than 50 microns in 
diameter, associated with good visual acuity of 0.00 to 0.18 logMAR; Grade 2 – 
bilaterally symmetrical confluent yellow specks at the central macula with vision of 
0.10 to 0.48 logMAR; Grade 3 – bilaterally symmetrical large colobomatous central 
macular lesions with visual acuity of 0.30 to 1.00 logMAR [67, 454, 463]. Grade 1 
NCMD patients bear the most resemblance to the benign yellow dot dystrophy 
subjects reported in this study. However, the majority of the subjects in this study 
were sporadic. Those that were familial displayed none of the other clinical 
characteristics associated with NCMD.  
 
The phenotype described here is mild and associated with excellent visual function.  
Fine hyperautofluorescent yellow dots, similar to drusen, are visible at the macula, 
which rarely extend beyond this area, unlike in NCMD [462]. The dots are distributed 
in the parafoveal areas, and may concentrate in the nasal parafovea. The underlying 
RPE and vasculature appear normal. In all subjects the optic disc appearance was 
within normal limits. However, in 96% of patients a yellow ‘halo’ surrounding the 
optic disc was observed, which in some resembled peripapillary atrophy, and which 
was associated with both hyper- and hypoautofluorescence on fundus 
autofluorescence imaging. Although myopia is associated with peripapillary atrophy, 
it was not a feature identified in these subjects. OCT imaging showed a subtle 
irregularity of the IS/OS junction. The inner retinal layers were normal, no drusen 
were seen and no serous detachments between the RPE and Bruch’s membrane were 
visible. Electrophysiologial studies of macular and full field retinal function were 
normal. 
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Through linkage analysis two loci have been identified that segregate with NCMD. 
Chromosome 6q was the first region identified to harbour the MCDR1 locus, the first 
area to be mapped to NCMD families [144, 464, 465]. Further refinement has 
identified a 1.86 million bp region between D6S1716 to D6S1671 [459] and a second 
locus, MCDR3, has been identified on chromosome 5p in subjects with a phenotype 
typical of NCMD [378, 466]. Despite a vast amount of work performed into this 
condition, the causative gene(s) remains to be identified.  
 
It is possible that benign yellow dot dystrophy represents a variation of the phenotypic 
spectrum that has been described in NCMD. However, due to the sporadic nature of 
the majority of patients that have been identified and the fact that in the familial cases 
there are no cases with an atrophic macular phenotype, it is considered to be a 
separate clinical entity. Although two families identified in this study suggested an 
autosomal dominant mode of inheritance to their ocular condition, their phenotypes 
are not typical of NCMD. The precise aetiology for the condition described in this 
study remains to be determined. However, subjects can be reassured of the excellent 
visual function that is associated with this phenotype. 
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5.0 Discussion and Conclusions 
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5.1 The Childhood Onset Retinal 
Dystrophy Study 
 
The aims and objectives of this study were to recruit subjects with childhood onset 
retinal dystrophies to an on going investigation into the molecular genetic basis and 
phenotypic characteristics of inherited retinal disease in childhood. This study 
specifically aimed to characterise the phenotypes associated with variants in specific 
genes identified in these cohorts and of those previously recruited into the study, and 
to characterise any novel phenotypes among the subjects included in these cohorts. 
The overall aim was to undertake genotype – phenotype studies in order to enable 
more accurate information for prognostic and genetic counselling, that may, in turn, 
identify potential candidates who may be amenable to future therapeutic options.  
 
Over a 3-year period, I recruited 201 subjects from 186 families into the Study. 
Subjects were categorised into two cohorts: (i) Cohort 1 - generalised retinal 
dystrophies that encompassed Leber congenital amaurosis (LCA), Early Onset Retinal 
Dystrophy (EORD), rod-cone dystrophies, cone-rod dystrophies and cone 
dystrophies, and (ii) Cohort 2 - childhood onset macular phenotypes that included 
Autosomal Recessive Bestrophinopathy (ARB) and benign Yellow Dot Dystrophy. 
177 subjects from 166 families were recruited into cohort 1 and 24 subjects from 20 
families into cohort 2. Access was also available to a database of patients that had 
been previously recruited into the study in order to re-investigate them if their 
molecular cause was identified. A number of subjects were recalled for phenotypic 
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studies based upon their molecular diagnosis, and this project succeeded in its aim of 
exploring, expanding and refining our understanding of the phenotypes associated 
with variants in specific genes. 
 
The genetic heterogeneity that is associated with LCA and EORD was evident from 
the phenotypic and molecular studies undertaken in this project. The predominant 
molecular strategies utilised in this study were apex microarray using the Asper 
Biotech LCA chip and direct sequencing of candidate genes. These techniques were 
in widespread use at the time that this study was conducted, although they have now 
been surpassed by the next generation sequencing technologies. Apex microarray via 
the LCA chip was a used as a ‘first pass’ screen in 107 subjects in cohort 1, which 
identified the causative gene in 29.9% of subjects that were sent from UCL to be 
screened with this technique. Of all the subjects in cohort 1 whose causative gene was 
identified using a variety of techniques, the LCA chip was responsible for 52.5%. It 
was a useful strategy to ascertain previously reported variants in genes that have been 
identified to cause LCA and EORD. New mutations in these genes would be missed 
using this technique. The efficacy of this technique has previously been investigated, 
with mutation identification in approximately 30% – 35% of patients analysed, and a 
higher rate of identification in LCA than EORD [109, 110, 122]. Despite a newer 
generation of this chip being used in this study, the overall success rate of gene 
identification was slightly less than these reports, and this is likely to reflect the 
higher percentage of EORD subjects analysed with this technology than LCA (47 
LCA and 51 EORD subjects from UCL). However, in agreement with Henderson et 
al., the chip was more informative for those carrying a diagnosis of LCA than EORD.  
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Molecular analysis using a variety of techniques identified the causative gene in 
34.5% of all subjects in cohort 1. These genes were all previously known to be 
associated with LCA and EORD. However, using next generation sequencing, a 
family that had been previously recruited to the study was found to harbour a 
pathogenic mutation in a gene previously unreported in humans to cause early onset 
retinal dystrophy: TUB. The phenotype associated with this gene was investigated in 
detail in this study and adds to the clinical heterogeneity observed in LCA and EORD. 
To date it remains the only family in the literature with mutations in this gene [330]. 
The gene had long been thought to be a strong candidate for human retinal disease as 
there is a well characterised mouse model that has a severe retinal dystrophy [293, 
295]. This thesis also reports the results of detailed phenotypic studies in a number of 
other genes including LRAT, SPATA7, RGR and BEST1; some of which only had 
limited descriptions prior to this study. In addition, this study revealed some new 
insights into the phenotype associated with other causative genes such as LCA5 and 
RDH12. This will help inform affected individuals of their prognoses, aid clinicians in 
reaching diagnoses and provide information to aid in genetic counselling. 
 
A large proportion of the families identified with mutations in this study were from 
consanguineous pedigrees. From some of the earliest studies into inherited diseases, 
the increased incidence of autosomal recessive disease in consanguineous families has 
been recognised [8, 467]. Molecular techniques have evolved to analyse regions of 
autozygosity that are presumed to harbour causative genes [104] and inbred 
populations are recognised to be very informative for gene identification in recessive 
diseases [468]. Four families reported in this study underwent autozygosity mapping 
that subsequently led to successful candidate gene screening in LCA5, TULP1 and 
318 
SPATA7. The incidence of consanguinity was high in this study, with 10 families in 
cohort 1 whose mutations were identified and 7 other families who were recalled for 
phenotyping being consanguineous. In one consanguineous family (Subject 16, family 
16), compound heterozygous mutations in CRB1 were identified, highlighting the 
importance of avoiding the presumption that individuals will be homozygous if they 
have a consanguineous ancestry [469]. This individual underwent autozygosity 
mapping which failed to identify the causative gene. This was eventually identified to 
be CRB1, in the compound heterozygous state, by exome sequencing. On revisiting 
the phenotype in this individual, the clinical characteristics were typical of a rod-cone 
dystrophy due to mutations in CRB1. The incidence of consanguinity in the 
molecularly identified families was higher in those from South East Asia (11 families) 
and Middle Eastern countries (2 families), which reflects the high proportion of first 
and second cousin marriages that are traditional in these communities [103]. 
Consanguinity was also observed in European families, with 3 British Caucasian and 
1 Irish consanguineous family among the molecularly identified families in this study. 
 
 
 
5.2 Phenotypic heterogeneity in 
childhood onset retinal dystrophies 
 
Phenotypic heterogeneity was identified in 5 genes that were identified in this study: 
RDH12, RPE65, LCA5, AIPL1 and BEST1. The largest sub-group of subjects 
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identified had RDH12 mutations (17 subjects, 15 families in cohort 1). This may be 
due to the easily recognisable fundus features, which allowed direct selection for 
RDH12 screening. The phenotype varied with respect to the age of symptom onset, 
and therefore diagnosis, with 14 affected with EORD (symptom onset less than 5 
years of age) and 3 with a rod cone dystrophy (symptom onset of at least 5 years of 
age). This heterogeneity was evident within families, with one family carrying two 
diagnoses based on the age of symptom onset. Although the retinal features were 
similar amongst those with RDH12 retinopathy, with severe pigment clumping, dense 
macular atrophy and yellowing of the macula, some variability was present, such as 
para-arteriolar sparing of the pigmentation and a ‘colobomatous’ appearance to the 
macular atrophy. No genotype phenotype correlation was identified for the retinal 
features or age of symptom onset in RDH12.  
 
RPE65 was also well represented in cohort 1. Again, this is likely to be due to the 
recognisable clinical signs, such as photophilia and minimal retinal changes, and the 
subsequent selective screening of RPE65. However, a spectrum of retinal features was 
noted in RPE65, including some with normal fundi, some with RPE atrophy and only 
one (the oldest subject) with retinal pigmentation and white dots at the macula. One 
subject displayed hypomorphic features with nyctalopia, normal vision, full visual 
fields and essentially normal retinas aside from peripheral RPE disturbance. He was a 
compound heterozygote, as were 5 of the 7 families identified with RPE65 mutations, 
but the only subject to harbour a duplication on one allele. His c.1543C>T, 
p.Arg525Trp variant occurs late in the transcript, and his duplication, c.1067dupA, 
p.Asn356Lysfs*8 occurs beyond halfway in the transcript. Presumably this compound 
heterozygous mutation leads to some functional protein product. However, 
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comparison of the location of these variants to the other milder cases reported in the 
literature, which have occurred much earlier in the transcript, do not identify any true 
correlation between the location of the mutations and the severity of the phenotype 
[151, 161].  
 
The small numbers of cases identified with mutations in both AIPL1 and LCA5 mean 
that no generalisations should be made from this study regarding the phenotypes 
associated with mutations in these genes. However, both of the subjects affected with 
mutations in each of these genes displayed quite different phenotypes to each other. In 
the two LCA5 subjects this difference in retinal appearance may have been due to the 
different ages at which the subjects were examined – one was 8 years and the other 18 
years old. Although LCA5 mutations are frequently associated with widespread RPE 
atrophy, white dots in the retinal periphery and macular atrophy, other cases reported 
in the literature have also suggested that there is some degree of variability to the 
phenotype, with a similar disparity between young and older individuals to those 
individuals in this study [185, 339]. The fundi of both of the AIPL1 subjects identified 
in this study were essentially normal, but their clinical features were quite different – 
one had typical LCA, the other was much more mildly affected with an EORD with 
cone rod dysfunction, again reflecting the clinical heterogeneity associated with 
EORDs. 
 
The studies of subjects with mutations in LRAT, RGR and SPATA7 have made a 
significant contribution to our knowledge of the phenotypes associated with these 
genes. Prior to this there were few detailed descriptions of these phenotypes. 
Mutations in the visual cycle gene LRAT are associated with a severe EORD with 
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poor vision, visual field constriction and nyctalopia from early childhood. Similarly to 
RPE65, there is photophilia in childhood. With age, there is deterioration in visual 
acuity, colour vision and contrast sensitivity. The retina is characterised by 
widespread RPE atrophy but little pigment migration, suggesting that photoreceptor 
cell death is a late feature [373]. Epi-retinal membrane formation and asteroid 
hyalosis are also more common. There is a severely reduced autofluorescence signal, 
which is a feature of retinal dystrophies due to visual cycle genes [158, 377, 378]. At 
a young age the OCT can identify a preserved photoreceptor layer and outer nuclear 
layer at the fovea, but these are lost with age. The nerve fibre layer is frequently 
irregular without any overlying vitreo-retinal traction. Kinetic perimetry identifies 
severe visual field constriction with preserved islands of vision. Dark-adapted 
psychophysical testing demonstrates reduced to undetectable rod function, with 
reduced but better preserved, cone function. The results of such detailed 
investigations had not been reported in LRAT retinopathy prior to this study. This 
study has demonstrated that the phenotype associated with mutations in LRAT is 
similar to that associated with mutations in RPE65, with an extended window for 
therapeutic intervention. LRAT and RPE65 are both key proteins in the visual cycle 
that are both expressed in the RPE. Successful gene replacement therapies have been 
carried out in RPE65 disease, which suggests that LRAT retinopathy is also a good 
candidate for gene replacement therapy [362, 363, 392, 393].  
 
The phenotype in a family with mutations in another visual cycle gene, RGR, was 
investigated in this study. Mutations in this gene are very rare and there are only 2 
reported families in the literature to date with mutations in this gene [292, 319]. This 
study has identified that RGR mutations are characterised by an EORD with 
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nyctalopia and visual field constriction, but with preservation of the central vision 
until the second decade. The retina displays widespread RPE atrophy with white dots 
in the periphery, minimal retinal pigmentation and macular atrophy involving the 
fovea. The OCT demonstrates preservation of the photoreceptor layer only at the 
fovea, and this correlates with the autofluorescence images, which show an annulus of 
hyperautofluorescence typical of RP [344].  
 
This study identified that mutations in SPATA7, a cilial gene, usually display a severe 
LCA phenotype, although milder features can occur [165, 166]. This heterogeneity 
was evident in this study within the same family, in which 2 brothers were affected to 
different degrees, with one displaying better preservation of his central vision, albeit 
with severe visual field constriction. The vision is generally extremely poor from 
infancy and progressively deteriorates. The retina displays widespread RPE atrophy, 
minimal retinal pigmentation and foveal sparing. The OCT can identify preserved 
photoreceptors at the fovea and autofluorescence imaging reflects this by 
demonstrating a hyperautofluorescent annulus. SPATA7 represents another LCA / 
EORD gene that is associated with phenotypic variability as differences between 
individuals within a family harbouring the same mutation were observed. Although 
the cause for this was not clearly identified, it may be due to the influence of modifier 
alleles.   
 
A number of genes identified in this study are important in the structure or function of 
cilia, and thus mutations in them contribute to the spectrum of conditions known as 
‘ciliopathies’. Of the subjects that were phenotyped more closely, these included 
TUB, TULP1 and SPATA7. The TUB family had systemic features of childhood 
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obesity, but no other systemic effects that have been identified in the Tubby mouse 
were identified in the affected family members. Unfortunately no other studies were 
possible in this family to ascertain smell acuity, hearing and other metabolic 
abnormalities. Further families will need to be identified and studied for this to be 
ascertained. The TULP1 individuals in this study, in agreement with other studies, did 
not display any systemic features. This is to be expected, as the TULP1 expression 
profile is purely retinal. The individuals with SPATA7 mutations might have been 
expected to have infertility as the human protein has been identified as two transcripts 
– one predominantly expressed in the retina, cerebellum and whole brain, and another 
that is predominantly expressed in the testis. Although there were 3 affected males in 
the SPATA7 group who had planned to have children, two did not have any 
difficulties conceiving, and only one had infertility due to a low spermatozoa count. It 
is possible that this may be due to a wider ‘ciliopathy’ secondary to his SPATA7 
mutations. Further studies would be required to ascertain this. The association of the 
ocular phenotype with fertility in these individuals is important to ascertain as this 
may influence choices to plan for families in the future. Clearly the association with 
systemic abnormalities in different ciliopathies, such as renal and neurological 
function in CEP290 mutations, is important to recognise, manage and counsel patients 
about, once their causative mutation has been identified.  
 
The ARB phenotypes in children identified in this study were interesting. Although 
there was some variability in the retinal features in that some displayed characteristic 
multifocal yellow sub-retinal deposits on a background of confluent sub-retinal 
change, and some had a more ‘classical’ Best disease appearance, the phenotype was 
clearly identifiable and differed from adults reported with the condition. The 
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electrodiagnostic findings observed in ARB children and their parents are 
fundamental to their diagnosis and allow distinction between the different BEST1 
related conditions, which will provide information both for prognosis and for accurate 
genetic counselling to these families.    
 
One novel phenotype associated with fine drusen-like deposits at the macula was 
identified in this study, and the condition termed ‘benign yellow dot dystrophy’. As 
the name suggests, this condition appears to have a benign course and ocular function 
remains normal. Although it is predominantly a sporadic condition, some families 
have been identified, in whom the condition appears to segregate in an autosomal 
dominant manner. Although the condition bears some resemblance to mild North 
Carolina Macular Dystrophy, there are a number of differences that suggest that the 
phenotype described in this study is a novel entity. The causative gene is yet to be 
determined in these families. 
 
 
 
5.3 Therapeutic options for childhood 
onset retinal dystrophies 
 
One aim of this study was to identify subjects that may be amenable to new therapies 
for retinal dystrophies. These diseases, until recently, have been considered to be 
incurable. During the past few years exciting progress has been made into new 
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therapeutic techniques, predominantly into gene augmentation therapies, but also into 
oral pharmacologic therapies. As discussed in chapter 4.6, the first human phase 1b 
trials of an oral retinoid replacement therapy have been undertaken and promising 
initial results of improvements in visual fields and visual acuity were reported by the 
trial authors [392]. Two of the four LRAT subjects identified in the present study took 
part in this trial and their results are due to be published in a subsequent report. It will 
be interesting to see whether these compounds have an effect and are sustainable in 
these subjects, in whom the retinal degeneration is well established with significant, 
potentially irreversible, retinal damage. 
 
Gene augmentation therapies in humans have become possible due to animal models 
of recessive retinal disease, through which proof-of-concept, safety and efficacy 
studies have been performed. In this regard, rodents provide a useful model as the 
effects of therapy can be ascertained fairly rapidly. The primary disadvantages of 
mouse models compared to humans are that they lack a well-defined cone dominated 
central retinal region, and due to the small size of the murine eye, different surgical 
approaches are required for gene delivery. Large animal models such as dogs and 
cats, many of which have naturally occurring mutations in retinal dystrophy genes, 
such as the Briard dog with an RPE65 mutation and the Abyssinian cat with a 
CEP290 splice defect, serve as useful models as they are anatomically more similar to 
humans than rodents [46]. Gene augmentation therapies utilise vectors to deliver 
DNA to target tissues, and a number of viral and non-viral vectors have been used in 
retinal gene therapy proof-of-concept studies [470]. Viral vectors include recombinant 
adeno-associated viruses (rAAVs) and lentiviruses. rAAVs generally target 
photoreceptors more efficiently than other vectors and induce a relatively benign 
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immune response; they are non-integrating and the transgene expression persists only 
for a few months. Lentiviruses are integrating vectors and mediate stable transgene 
expression, but there is a risk of insertional mutagenesis [46].  
 
The first human gene augmentation therapies were carried out in subjects with LCA 
and RPE65 mutations [362-364, 393, 471]. Subjects demonstrated both objective and 
subjective improvements in vision, and the extent of recovery was age dependent, 
with children having the greatest improvement. Further trials into RPE65 gene 
therapy are on going, and human gene therapy trials into MERTK have begun 
(ClinicalTrials.gov Identifier: NCT01482195) [472]. However, one challenge is in 
ascertaining the stage of the disease process that intervention is most likely to be 
beneficial. In this regard, detailed phenotyping of the different genes that underlie 
retinal dystrophies is important as it can identify the extent of the degeneration and 
the age at which this degeneration occurs – if the gene is involved in photoreceptor 
differentiation then therapy may be required in infancy to maximise the chance of 
restoring and preserving vision [46]. In fact, treatment might be optimal in children 
below 3 years of age as the plasticity of the retinal and neurological pathways 
deteriorates beyond this age. It is predicted that the less severe the retinal phenotype 
in terms of structural damage, the more chance that gene therapy would be successful. 
However, promisingly, studies into gene therapy for other causes of retinal dystrophy, 
for example into AIPL1, have suggested that there may be rescue of photoreceptor 
degeneration in a more severe phenotype [335]. 
 
Another approach to gene augmentation therapy is in stem cell therapy for retinal 
degenerative disease, and a number of trials are currently recruiting subjects [473]. In 
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pre-clinical studies, both embryonic stem cells and induced pluripotent stem cells 
have been used to guide differentiation into cells that display many similarities to 
RPE cells, that can be transplanted to replace this monolayer which is frequently 
damaged in retinal diseases such as RP, Stargardt disease and age related macular 
degeneration. Childhood onset retinal dystrophies caused by genes that reside in the 
RPE, such as RPE65, LRAT, RGR and BEST1 may be amenable to treatment with 
stem cell derived RPE in the future. The results from the first human clinical trials 
into RPE stem cell transplantation, including those using autologous human induced 
pluripotent stem cells, and the subsequent applications, are keenly anticipated.     
 
 
 
5.4 Advances since this study was 
conducted 
The most significant advances since this study was conducted have been in molecular 
analysis. Next generation sequencing technology has surpassed the molecular 
techniques that were routinely utilised to identify the molecular cause of disease in 
individuals with childhood onset retinal dystrophies. This has led the genetic cause 
being ‘solved’ in a number of families, and has identified novel genes.  
 
The causative gene at the LCA9 locus remained undiscovered for many years, but was 
eventually identified in 2012, simultaneously by different groups using whole exome 
sequencing, to be NMNAT1 [236-239]. NMNAT1 encodes a rate-limiting enzyme that 
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generates NAD+ both in a biosynthetic pathway from nicotinic acid mononucleotide, 
and in a salvage pathway from nicotinamide mononucleotide [236]. It is involved in 
the nuclear NAD+ homeostasis that is necessary for both DNA metabolism and cell 
signalling. The phenotype is of severe LCA, with vision in the majority of patients of 
between hand movements and nil perception of light. There is dense pigmented 
macular atrophy, widespread RPE atrophy and peripheral pigment migration. Nine 
subjects from the childhood onset retinal dystrophy study from UCL were 
subsequently identified with mutations in NMNAT1, of which 4 were from cohort 1 in 
this study, and they contributed to one of the original NMNAT1 LCA publications 
[236].  
 
A second gene, KCNJ13, was also recently identified using a combination of 
homozygosity mapping and exome sequencing, to cause LCA in two families [327]. 
The proband of one of these families was in cohort 1 of the present study. KCNJ13 
encodes an inwardly rectifying potassium channel subunit, Kir7.1, which localises to 
the plasma membrane of a number of ion-transporting epithelia [327]. In the retina it 
primarily localises to the apical membrane of the RPE. Mutations in this gene have 
also been reported to cause another retinal dystrophy known as ‘snowflake vitreo-
retinal degeneration’, but the phenotype associated with this and that associated with 
KCNJ13 related LCA are quite different, once again highlighting the clinical 
heterogeneity associated with genes causing childhood onset retinal dystrophies.  
 
The next generation sequencing technologies have vastly improved the ability and 
speed of identification of the molecular causes of genetic disease. As the costs of 
these technologies are rapidly falling they will lead to the discovery of a number of 
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novel genes and will quickly ‘solve’ many undetermined cases. Despite these 
predicted advances, accurate phenotyping of affected families still remains very 
important in these conditions. 
 
The other major advance has been in therapeutics for retinal dystrophies. Some of the 
advances in gene augmentation therapy have been discussed in the previous section. 
However it is important not to ‘oversell’ the potential of gene therapy to patients who 
may wish to participate in future studies of gene therapy for retinal degeneration [46]. 
The successes of the RPE65 trials were influenced by the mild retinal changes, 
presence of some useful vision early in life in some of these individuals and the 
location of the defective gene; in the future, gene augmentation therapy may not be as 
successful if the defect leads to severe functional and/or structural retinal changes or 
if it primarily affects the photoreceptors. In this situation, there is a fine balance 
between effective ‘dosage’ and toxicity, and the target therapy needs to involve as 
many photoreceptors as possible, which may prove to be technically challenging.  
 
As the landscape of molecular technologies continues to evolve, next generation 
sequencing will provide many answers and lead to many more families having their 
molecular cause identified. In addition, advances in gene augmentation therapy are 
entering an exciting era in which effective treatments will become available for these, 
previously ‘incurable’ blinding conditions. 
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5.5 Conclusions and further work 
Since Donders’ and Leber’s first descriptions of childhood onset retinal dystrophies, a 
vast body of work has been conducted to elucidate the molecular causes, clinical 
features and possible therapies for this heterogeneous group of conditions. Although 
the specific conditions that comprise this spectrum of diseases have been, and 
continue to be, characterised, confusion can lie in the specific clinical diagnoses, as 
there is often significant overlap between them. It is likely that, as the molecular 
causes are being identified, the classification of these conditions will progress to 
reflect the genetic cause, such as that which has occurred for the bestrophinopathies. 
Phenotypic studies have become invaluable at characterising these conditions, and 
allow accurate prognostic and genetic counselling to affected individuals and their 
families. Careful phenotyping is also very important in ascertaining disorders that 
may be suitable for clinical trials of novel therapies, and in identifying the optimal 
point in the disease process for which intervention is likely to have the greatest 
success.  
 
Future research and clinical diagnostic work on the childhood onset retinal 
dystrophies will undoubtedly involve next generation sequencing technologies. These 
technologies, including whole exome sequencing, will identify novel mutations in 
known genes, novel genes for isolated retinal dystrophies and for retinal dystrophies 
with systemic associations. Although expected to be higher, it has been predicted that 
whole exome sequencing will lead to the molecular diagnosis in 55% of non-
syndromic retinal dystrophies and 80% of syndromic retinal dystrophies [474]. Whole 
genome sequencing is likely to be adopted as the gold standard as costs come down. 
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This technique has better read depths of exomes and allows the identification of 
intronic variants that affect gene transcription. Phenotypic studies will become 
necessary once these genes have been identified. Detailed phenotyping, or ‘deep 
phenotyping’, involving conventional phenotypic techniques utilised in the present 
study, along with additional psychophysical testing such as microperimetry and 
adaptive optics, will be useful for selecting subjects for therapeutic trials and in 
identifying treatment effects. Such future molecular and phenotypic investigations are 
likely to benefit from large-scale collaborations, such as those that are currently 
underway into rare genetic diseases.   
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7.1 Patient Documents 
 
7.1.1 Patient Information Leaflet 
 
A clinical and molecular genetic investigation of childhood retinal 
dystrophies  
INFORMATION LEAFLET 
 
PLEASE CONTACT US IF YOU WOULD LIKE THIS LEAFLET IN LARGER 
TYPE OR THE INFORMATION PROVIDED ON AUDIO CASSETTE TAPE 
 
You are invited to take part in this research study. Before you decide it is important 
for you to understand why the research is being done and what’s involved. Please take 
time to read the following information carefully and discuss it with your family, 
friends, hospital specialist or GP if you wish. If you need more information please 
contact the research team whose telephone number is at the end of this leaflet. 
 
Why the study is being done? 
Inherited retinal disorders are an important cause of childhood visual impairment and 
this research study aims to discover the causes of the retinal problem and to 
understand the reasons why the retina fails to function normally. Vision is dependent 
upon the functioning of the cone and rod cells of the retina, a thin membrane at the 
back of the eye. There are two groups of cells in the retina that detect light. The cones 
cells are used when light levels are high, and the rods are used when light levels are 
low. From the way in which night vision, colour vision, central vision and the 
electrical responses from the retina are changed we can learn how a condition has 
affected the cells in the retina. We are able to use this information together with 
knowledge of the genetic faults causing an eye disorder to build up a picture of what 
is causing the retinal dysfunction and which approach would be best used in the future 
to slow down disease progression.  
 
Research has shown that genetic factors have an effect on the risk of someone 
developing this group of disorders. In other words, some people are at higher risk than 
others because of their genetic make-up.  
 
This research study is being carried out for two important reasons: 
1. We want to find out more about the genetic factors in childhood retinal dystrophies 
2. We want to find the genes that affect the risk of developing childhood retinal dystrophies 
 
If we can find which genes affect the risk of childhood retinal dystrophies it would 
help us understand why the disease occurs and could in the longer term lead to better 
treatment. 
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How will the study be carried out? 
To find out more about genetic factors in childhood retinal dystrophies we need the 
help of patients with childhood retinal dystrophies and their relatives. By comparing 
the genetic make-up of those with childhood retinal dystrophies we can see what 
genes they have in common and start to work out which genes affect the risk of 
developing childhood retinal dystrophies. We can also obtain additional information if 
we have the opportunity of studying unaffected relatives as well. 
 
Why you are being invited to take part 
You are being invited to take part because you or your relative has a childhood retinal 
dystrophies. To give us a good chance of success, we need to study a large number of 
cases. We hope to recruit at least 60 patients with the disorder and their close 
relatives. 
 
Do I have to take part? 
It is up to you to decide whether or not to take part.  If you do decide to take part you 
will be given this information sheet to keep and be asked to sign a consent form. If 
you decide to take part you are still free to withdraw at any time and without giving a 
reason. A decision to withdraw at any time, or a decision not to take part, will not 
affect the standard of care you receive. 
 
What will happen to me if I take part? 
If you decide to take part and have signed a consent form you will be asked to give a 
30 ml blood sample (that’s about 6 teaspoon-fulls) which will be used to extract DNA 
(the chemical containing your genetic information) which will be used to try and 
identify genes causing eye disorders.  The results of these tests will be kept strictly 
confidential. You will also be asked to undergo a routine eye examination and have 
some images taken of the back of your eye using several imaging techniques. The 
imaging techniques are similar to having a photograph taken of the back of your eyes. 
You may also have the length of your eye measured with ultrasound (a small probe 
will touch your eye after a local anaesthetic drop has been instilled).  For the imaging 
we will need to dilate your pupils. This procedure is conducted routinely in eye 
clinics.  The use of these drops causes some temporary blurring of vision especially 
for near and as they increase the size of the pupil, they may be associated with 
increase sensitivity to light.  It is advisable that you bring along sunglasses to wear on 
your journey home.   For most people, it takes around 8 hours for the pupil of the eye 
to return to its normal size following dilation although vision recovers sooner.  It is 
advisable not to drive for 5-6 hours after the drops have been instilled. We will pay 
your travel expenses to and from London.  The tests are quite simple and last 
approximately 90 minutes although the length of the examination varies from person 
to person.   
 
In some cases we will ask you to return for additional tests.  These tests will involve 
either the examination of your ability to see targets in your peripheral vision , or 
measurement  of your vision at low light levels (these tests last approximately 2 
hours) 
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What will happen to the blood sample?  
The laboratory will extract the genetic material DNA from the cells in the blood 
sample so that this can be used to study the genes that we think may have an effect on 
the risk of developing childhood retinal dystrophy. 
 
 
 
What will happen to the results of the research study? 
All the information from the study will be published in medical journals and 
presented to relevant health professionals at meetings and conferences. We would also 
be pleased to provide information about the results of the study to anyone who has 
taken part. Individual patients will not be identified in any reports or publications 
arising from the study. 
 
Will information from the study be kept confidential? 
All information collected for the study will be kept strictly confidential. The research 
team will not pass on your personal details to anyone else. The samples will be coded 
and scientists working in the laboratory will be provided with relevant medical 
information relating to the samples but will not be given the names of the people from 
whom the samples were obtained.  
 
Working with other research groups to speed things up 
Finding the genes that are important in childhood retinal dystrophy is a major 
challenge and may take many years. To speed up the research, we may join forces 
with other research teams in this country or abroad, in which case we may want to 
provide them with some of the sample stored from yourself and others for them to 
work on. In order to make this possible, on the consent form you are asked to agree to 
donate your sample to the research team as a gift. This means that you give up all 
rights to the sample and cannot at a later date ask for the sample to be destroyed or 
returned to you. It also means that at the discretion of the research team your sample 
can be used by others for research on the causes of childhood retinal dystrophy.  
 
 
What are the possible benefits of taking part? 
It is unlikely that you will benefit personally from helping with this research project, 
but the results of the research should be of benefit to patients affected by childhood 
retinal dystrophy in the future.  
 
 
Will you be told the results of the eye examination or genetic testing? 
The purpose of the eye examination is to obtain information we need for the research 
study. This sort of technical information is unlikely to have any implications for 
yourself. It is possible but unlikely that in the course of examining your eyes we may 
discover a problem with your eyes that you were not aware of. Please let us know if 
you would prefer not to be told if this situation arises. Otherwise we will assume that 
you would like us to bring it your attention, and with your permission, pass on 
information to your general practitioner. If you are a car driver, one reason you may 
choose not to be told about unexpected findings might be the implications this could 
have for holding a driving licence. 
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The genetic testing that we will be carrying out will have the aim of identifying the 
changes in a specific gene which is causing your eye disorder.  It may take months or 
even years before the specific change causing your eye disease is identified.  We will 
inform you if we identify the change in your case.  Please let us know if you do not 
wish to know the result.  We will not inform your GP of the result unless you 
specifically ask us to. 
 
 
What are the possible disadvantages of taking part? 
Your eyes will be photographed, which requires having drops put in your eyes to 
dilate the pupils. This may cause brief discomfort and some temporary blurring of 
your near vision so you will not be able to drive a car for the rest of the day. Dilating 
the pupils is a routine procedure in hospital eye clinics which doesn’t usually cause 
any problem, but you should be aware that a painful rise in the pressure in the eye 
(acute glaucoma) is a rare but treatable complication. You will be asked to provide a 
blood sample for the study. This will be done with care by qualified staff but may 
cause some discomfort and occasionally bruising.  
 
 
Who is organising and funding the research? 
The Special Trustees on Moorfields Eye Hospital using funding donated by the 
Eranda foundation 
 
 
What if something goes wrong? 
If you are harmed by taking part in this research project, there are no special 
compensation arrangements.  If you are harmed due to someone’s negligence, then 
you may have grounds for a legal action but you may have to pay for it.  Regardless 
of this, if you wish to complain or have any concerns about any aspect of the way you 
have been approached or treated during the course of this study, the normal National 
Health Service complaints mechanisms would be available to you. 
 
 
Contact for Further Information: 
Professor AT Moore Moorfields Eye Hospital, City Road, London EC1V  2PD 
Tel 0207 566 2260 
Dr Arundhati Dev Borman, Research Fellow, Genetics Office, Professorial Unit, 
Moorfields Eye Hospital NHS Trust, 162 City Road, London EC1V 2PD 
Tel:  0207 566 2265  Email:  a.dev-borman@ucl.ac.uk 
 
 
 
 
Thank you for reading this information leaflet and for considering taking part in 
this study 
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7.1.2 Consent form – Adult 
Title of Project: A clinical and molecular genetic investigation of childhood 
retinal dystrophies 
 
Name of Researcher: Professor A T Moore 
           
 
1. I confirm that I have read and understand the information sheet dated January 
2004 for the above study and have had the opportunity to ask questions. 
 
2. I understand that my participation is voluntary and that I am free to withdraw at 
any time, without giving any reason, without my medical care or legal rights being 
affected  
 
3. I understand that sections of any of my medical notes may be looked at by the 
research team or individuals from regulatory authorities where it is relevant to my 
taking part in research.  I give permission for these individuals to have access to 
my records. 
 
4. I understand that the results of any new genes or novel alterations in these 
genes that are discovered to be responsible for inherited eye disorders will be 
published in scientific and medical journals. This information and any results 
obtained from the analysis of a blood sample will not be used by 
pharmaceutical companies in the future.  In addition, I understand that I will 
not benefit financially if the results of this research lead to the development of 
new treatments, tests, or patents. 
 
5. I give permission for clinical images and information gained from this study 
to be published in the scientific literature as long as all personal identifying 
information is removed. 
 
 
6. I agree to take part in the above study.  
  
  
Name of Patient Date Signature 
 
 
 
Name of Person taking consent Date Signature 
(if different from researcher) 
 
 
 
Researcher  Date Signature 
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7.1.3 Consent form – Child 
Title of Project: A clinical and molecular genetic investigation of 
childhood retinal dystrophies 
 
Name of Researcher: Professor A T Moore 
 
1. I confirm that I have read and understand the information sheet dated January 
2004 for the above study and have had the opportunity to ask questions. 
 
2. I understand that the participation of my child is voluntary and that I may 
withdraw my child at any time, without giving any reason, without his/her care or 
legal rights being affected. 
 
3. I understand that sections of any of my child’s medical notes may be looked at by 
the research team or individuals from regulatory authorities where it is relevant to 
his/her taking part in research.  I give permission for these individuals to have 
access to my child’s records. 
 
4. I understand that the results of any new genes or novel alterations in these genes 
that are discovered to be responsible for inherited eye disorders will be published 
in scientific and medical journals. This information and any results obtained from 
the analysis of a blood sample will not be used by pharmaceutical companies in 
the future.  In addition, I understand that neither I, nor my child, will benefit 
financially if the results of this research lead to the development of new 
treatments, tests, or patents. 
 
5. I give permission for clinical images and information gained from this study to be 
published in the scientific literature as long as all personal identifying information 
is removed. 
 
6. I agree that my child may take part in the above study.  
 
 
Name of Patient 
 
Name of Parent/Guardian giving consent       Date Signature 
 
 
Relationship to child  
 
Name of Person taking consent                   Date Signature 
(if different from researcher) 
 
Researcher                    Date Signature 
 
[1 for patient;  1 for researcher;  1 to be kept with hospital notes] 
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7.1.4 Data Protection Consent Form 
Data Protection Consent Form 
 
 
1. I agree to my/my child’s personal identifying details (name, address, telephone 
number) being kept on a secure electronic database. 
 
2. I agree to information regarding my family pedigree (who is related to who) 
being kept in a secure electronic database 
 
3. I agree to clinical and genetic information about my condition being kept on 
this database. 
 
4. I understand that this information will be held on a database located at the 
Institute of Ophthalmology (& Moorfields Eye Hospital). The personal 
information gathered will only be accessed by the principal researcher and 
team. Any results published from this information will not contain any 
personal identifying data. 
 
 
 
Name of Patient: …………………………………………………  
Date…………………. 
 
Signature of patient: …………………………………………….. 
 
 
Name of Parent (if child)…………………………………………. 
Date………………… 
 
Signature of Parent………………………………………………. 
 
Relationship to child…………………………………………...... 
 
 
Name of researcher……………………………………………..   
Date…………………. 
 
Signature of researcher…………………………………………. 
 
 
1 copy in notes  
1 copy to patient/parent 
1 copy to researcher 
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7.2 Primer Sequences 
 
7.2.1 TULP1 Primers 
 
Exon Primer Tm 
(oC) 
PCR 
annealing 
temperature 
(oC) 
Size of 
fragment 
(bp) 
Exon 1F TCGTGGGCTGTAGCACCTCCC 72.6 63 381 
Exon 2R CTACCCTGCGTGGGTTTACGC 69.4 
Exon 3F TAATCTGCGGTTATTTCTGGCGG 69.3 63 257 
Exon 3R TCAAGCCCCTCCCTTCCGCAGC   77.8 
Exon 4F TGGGAGAAGTGTTGAAAGTGG 64.0 58 457 
Exon 4R TACCTGGCTCAAAGATAAGGCC 65.1 
Exon 5F TGGTGCCCATGCACCACTTCC 74.6 60 348 
Exon 5R TGAGGCCTCAATCGCTGTGTC 69.9 
Exon 6F TGTCAAGCTTTCAGCCTCCCTG 69.7 58 514 
Exon 7R TCTGGCAAACTCCTTACCTAGC 63.3 
Exon 8F TCCAAGTGAGACATGGGTGTTGG 70.2 61 289 
Exon 8R TAACCTCAAGTGGCTCCAAGCC 68.3 
Exon 9FA TAAATCACAGAGCTCCCCAGAG   
 
 
 Exon 11RA TATGTACATCAAAGCGAGAGGC  
Exon 9F (old) TGTCTCAGCACTGGGACCTGC   70.2 63 593 
Exon 10R (old) TCTACCAGGCACAGCAGGACAG 68.8 
Exon 12F (old 11F) TGAATTGCTCAGTCCTAACTCACC 65.3 58 514 
Exon 13R (old 12R) TGGATGTGCTCAGGGAGTTGG 69.6 
Exon 14F (old 13F) TACCCTAATGGATGAAGATGTCC 62.7 58 424 
Exon 14R (old 13R) TCCCAGCTCTCGGGATAAAGGC 71.2 
Exon 15F (old 14F) TGTTGAGTAACTGAGATGGTG 57.7 53 736 
Exon 15R (old 14R) TACCGCTCCGCTTGGCCAAGG 75.8 
 
Table 24 - Primers and PCR conditions for TULP1. 
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7.2.2 RGR Primers 
 
Exon Primer Tm 
(oC) 
PCR annealing 
temperature 
(oC) 
Size of 
fragment 
(bp) 
Exon 1F ATAACCTGCATGTGCCTCCA 65.4 64 246 
Exon 1R GTGGCCTGGGTCCTCAGA 66.6 
Exon 2F CCCCACACACACTGTTCTGA 64.9 60 329 
Exon 2R TGTAAGTAGTAAAAATGCCCTTGG 61.8 
Exon 3F CAAGCTGTACTTGGCAGGTG 63.4 61 298 
Exon 3R TGGGAAACACGGAGCAGTAG 65.1 
Exon 4F TCTTCGATCAGGAAGTCCA 63.8 61 299 
Exon 4R GGAGTTCAAAGCCAAGATTCC 63.7 
Exon 5F CCACAACCGATCATCTAGGC 64.2 62 288 
Exon 5R ATTCTTTGTTCGGGACACCA 64.2 
Exon 6F CTTGGCCACATAGGCTGT 65.0 61 248 
Exon 6R TGAGATGAGATGAGACAGAGA 62.9 
Exon 7.1R CAGAGAGAGGATCAGTGGCTTT 63.7 62 398 
Exon 7.1R CTTGAGTGTAGGGGGCTGTG 64.6 
Exon 7.2F TGGATAGATTGCCTAGTGGTG 61.5 60 444 
Exon 7.2 R TCAAAAAGAAACCTGCACTTG 61.7 
 
Table 25 - Primers and PCR conditions for RGR. 
 
 
 
7.2.3 BEST1 Primers 
 
Exon Primer PCR annealing 
temperature 
(oC) 
Exon 2F CACCTGCTGCAGCCCACTGCC 61 
Exon 2R CTTGTAGTGAACTGGTACACTGGCC 
Exon 3F GGACAGTCTCAGCCATCTCCTCG 59 
Exon 3R GCAGCTCCTCGTGATCCTCCCCTGG 
Exon 4F CTAGGCCCGCTCGCAGCAGAAAGC 60 
Exon 4R CTTCCATTCCTGCCGCGCCCATCTC 
Exon 5/6F CATCCCTTCTGCGGTTCTC 59 
Exon 5/6R CTTGGTCCTTCTAGCCTCAGTTTC 
Exon 7F CTGGAGCATCCTGATTTCAGGGTTC 59 
Exon 7R CTCTGGCCATGCCTCCAGC 
Exon 8/9F GCTGGCTTTGAGGAGTTCTGCCTG 59 
Exon 8/9R GTGCTATTCTAAGTTCCTAGGCAG 
Exon 10F GTAAGGGAGAAGTAAGGCCAGGTG 59 
Exon 10R GTAGGTCCAGTGTGCTCTGGCAG 
Exon 11F GAAGGGACCTTCCATACTTATG 59 
Exon 11R CATTAAAGGCTGAAGTAGTCTGGG 
 
Table 26 - Primers and PCR conditions for BEST1. 
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